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Abstract  
 
Although proof-of-principle for non-viral gene transfer to the airways of cystic fibrosis 
patients has been established the efficiency is comparatively low. Two strategies related 
to further improving gene transfer were studied in this PhD. First, bacteria-mediated 
gene transfer (bactofection) and second, the ability of tight junction openers to enhance 
liposome-mediated gene transfer to murine lung in vivo were assessed.  
 
A genetically engineered E. coli strain was used to assess bactofection. Successful in 
vitro bactofection was demonstrated. In vivo data indicated that E. coli-mediated lung 
bactofection does not lead to easily detectable eukaryotic gene expression, and is less 
efficient than well established GL67-mediated gene transfer. A narrow toxicity/efficacy 
window was identified and, furthermore, reporter gene expression in the bacterial host 
complicated interpretation of the data.  
 
The ability of ethyleneglycol-bis-(β-aminoethyl ether)-N,N‟-tetraacetic acid (EGTA), 
lysophosphatidylcholine (LPC), sodium caprate (C10) and sodium laurate (C12) to 
enhance GL67-mediated gene transfer in vivo by modulating tight junctional 
permeability was assessed. EGTA had no effect. Pre-treatment with C10, C12 and LPC 
significantly enhanced gene transfer to murine lung and nose after careful optimisation 
of drug doses and delivery. C10 proved most efficient and potential difference 
measurements indicated that C10 altered tight junction permeability in the murine nasal 
epithelium. However, pre-treatment with C10 did not allow correction of the ion 
transport defect in CF mice or enhance CFTR mRNA expressions levels. A higher 
concentration of C10 was also assessed in the murine nose; tissue damage was 
observed, indicating a narrow efficacy/toxicity window. Finally, in a human airway ex 
vivo model, C10 pre-treatment resulted in a significant decrease in transepithelial 
resistance indicating an opening of tight junctions, but no enhancement of GL67-
mediated gene transfer was observed.  
 
In conclusion, bactofection does not provide any advantages over lipid-mediated gene 
transfer. Lipid-mediated gene transfer can be enhanced through administration of tight 
junction openers and, therefore, may warrant further assessment in large animal models. 
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RT-    no-reverse transcriptase 
SCID   severe combined immune deficiency  
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Chapter 1: Introduction 
 
 
1.1 Cystic fibrosis overview 
 
Cystic fibrosis (CF) is the most common lethal autosomal recessive gene disease among 
Caucasians, affecting approximately 1 in 2500 newborns [1]. The disease, caused by a 
single gene defect, is inherited in an autosomal recessive manner with approximately 1 
in 20 people being a carrier. Although several organs are affected by the disease, 
leading to pancreatic insufficiency, malabsorption, male infertility and raised sweat 
chloride secretions, severe lung disease is the main cause of morbidity and mortality in 
CF individuals. An abnormal water and ion transport across the airway epithelium 
caused by mutations in the CF gene, is responsible for CF lung disease and will 
eventually result in accumulation of mucus, chronic bacterial infections and 
inflammation. Currently, the average life expectancy of CF individuals is approximately 
37 years [2]. 
 
 
1.2 Clinical manifestations 
 
1.2.1 Respiratory disease 
CF lung disease is characterised by progressive cycles of infection and inflammation 
culminating in respiratory failure. At birth, the lungs of CF patients appear normal, 
however, mucus plugging of the airways and inflammatory cells in the bronchi have 
been detected in infants even in the absence of apparent bacterial infection [3,4]. The 
lungs quickly become infected and although the infections initially can be cleared by 
antibiotic treatment permanent bacterial colonisation eventually occurs. Common 
bacteria early in the course of the disease are Staphylococcus aureus and Haemophilus 
influenza. However, later on Pseudomonas aeruginosa becomes the most common 
pathogen, infecting approximately 80% of CF patients [5] Furthermore, the volume of 
glands and secretory cells in the epithelium is increased (hypertrophy) and mucociliary 
clearance is decreased, which results in mucus accumulation in the bronchioles 
promoting the establishment of bacterial colonisation [5]. In addition, mucus viscosity is 
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increased by deoxyribonucleic acid (DNA) derived from bacteria and inflammatory 
cells, which further complicates mucociliary clearance and hereby enhances bacterial 
colonisation. Bacterial infections provoke a persistent inflammatory response with 
inflammatory cells infiltrating the airways. More precisely, neutrophils are 
chemotactically attracted to the site of infection from the vascular space and activated. 
Activation results in release of the enzyme neutrophil elastase (proteinase) and due to an 
inactivation of proteinase inhibitors, excess levels of the enzyme is present in the 
airways leading to epithelial cell damage, which in later stages of the disease develops 
into bronchiectasis [6]. 
 
1.2.2 Gastrointestinal disease 
In the majority of patients with CF, pancreatic insufficiency (PI) is present from birth or 
develops during the first year of life. However, the severity of the pancreatic disease 
varies greatly among patients. Thick viscous mucus, resulting from impaired function of 
the CF gene, is responsible for obstruction of the pancreatic ducts preventing the flush 
of enzymes, involved in absorption of fat and nutrients, into the duodenum [7]. 
Importantly, pancreatic insufficiency can lead to failure to thrive. However, pancreatic 
enzyme replacement therapy has made malnutrition manageable in developed countries, 
but remains a problem in underdeveloped countries. Mucus plugging is also observed in 
the intestine and approximately 15% of infants with CF are born with meconium ileus 
(MI), an intestinal obstruction, which is normally treated successfully with surgery. In 
older patients, distal intestinal obstruction syndrome (MI equivalent) can produce 
intermittent, recurrent episodes of partial small bowel obstruction [5]. Furthermore, the 
intra-hepatic bile duct gets obstructed with mucus, similar to the pancreatic ducts, 
resulting in focal biliary cirrhosis in more than 70% of patients, and in addition 
approximately 25% of patients show liver disease within the first 20 years of life [8]. 
 
1.2.3 Endocrine disease 
As patients live longer, CF-related diabetes (CFRD) is becoming more common. The 
chance of developing diabetes is approximately 50% in patients over 30 years whereas 
children between 5 and 9 years only have a 9% chance of CFRD. Patients who develop 
CFRD appear to have an accelerated decline in lung function and suffer from higher 
mortality than patients without CFRD and the disease is, therefore, often treated 
aggressively with insulin from the onset [5]. The underlying defect appears to be a 
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reduction in the number of β-cells due to pancreatic autolysis and loss in insulin 
secretion and is only seen in patients with PI.  
 
Low bone mineral density (BMD) is observed in almost all patients with severe disease. 
The underlying cause of BMD is not fully understood but may be related to steroid use, 
delayed puberty, mal-absorption of vitamins (especially K and D), inactivity, poor 
nutritional status and chronic pulmonary inflammation resulting in elevated cytokine 
levels which increase bone reabsorption and decrease bone formation [9]. 
 
1.2.4 Fertility and urinary incontinence 
95% of all male CF patient are infertile due to structural abnormalities of the 
reproductive tract, the most common being congenital absence of the vas deferens. 
Females are fertile and in those individuals with a normal body mass index (BMI), 
menstruation and ovulation are likely to occur normally [10]. Approximately 40% of CF 
females and 5% of males suffer from urinary incontinence as a result of chronic 
coughing which raises the pressure on the pelvic floor [10].  
 
 
1.3 The CF gene  
 
1.3.1 CFTR gene  
Identification of polymorphic DNA markers found to be genetically linked to the gene 
responsible for CF resulted in localisation of the gene to chromosome 7 in 1985 [11,12]. 
A few years later, in 1989, the gene was cloned and characterised [13]. It spans a 
genomic region of approximately 250,000 base pairs on chromosome 7q31.2 and 
contains 27 exons [14]. The messenger ribonucleic acid (mRNA) transcript consists of 
6.5 kb and encodes the cystic fibrosis transmembrane conductance regulator (CFTR) 
protein containing 1480 amino acids [13,14].  
 
The CFTR protein is a chloride channel located on the apical cell surface of epithelial 
cells. It belongs to the adenosine triphosphate-binding cassette (ABC) superfamily of 
transport proteins. It consists of two repeated motifs; each consisting of a membrane 
spanning domain and a nucleotide binding domain (NBD). Each of the two membrane 
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spanning domains consists of six transmembrane hydrophobic segments, which form 
the channel in the apical membrane of epithelial cells. Both NBDs are located in the 
cytoplasm and are responsible for adenosine triphosphate (ATP) binding and hydrolysis. 
Finally, the two protein halves are linked by the intracellular R domain containing 
multiple phosphorylation sites, which in conjunction with NBD ATP hydrolysis is 
essential for CFTR channel activation [15] (Figure 1).  
 
1.3.2 CFTR gene mutations 
Over 1700 mutations have been identified in the CFTR gene, of which the majority 
occur within the exons or at the boundaries of the introns and exons 
(http://www.genet.sickkids.on.ca/Home.html). However, the functional consequences of 
many of these mutations are poorly understood and the majority of them are rare. In 
fact, less than 10 mutations occur with a frequency of more than 1% [17]. Mutations 
observed include missense, frameshift, splice-site and nonsense mutations in addition to 
amino acid deletions and substitutions. The most common mutation worldwide is a 
deletion of a cytosine/thymidine/thymidine (CTT) nucleotide triplet in exon 10, 
resulting in the loss of a phenylalanine residue at position 508 (∆F508) in the first NBD 
of the CFTR protein [18]. The ∆F508 mutation accounts for approximately 70% of 
mutant CFTR alleles seen worldwide [19], however its frequency varies among ethnical 
groups, with the highest rate in Caucasians descending from Northern Europe.   
 
CFTR gene mutations have been divided into five classes based on the effect on the 
CFTR protein (Figure 2). Class I mutations cause defects in CFTR synthesis resulting in 
no full length protein being made. These are nonsense, frameshift and splice-site 
mutations leading to creation of premature termination codons. Class II mutations, such 
as ∆F508, are missense mutations that interfere with correct posttranslational processing 
in the endoplasmic reticulum. The ∆F508 mutation results in CFTR being synthesised, 
but the protein is abnormally folded. Consequently, it is retained in the endoplasmic 
reticulum, where the protein is degraded. Class III mutations result in protein being 
expressed and processed to reach the apical membrane, but the channel function is not 
properly regulated. Class IV mutations are mutations in the membrane spanning 
domains, which lead to a reduced chloride conductance of the CFTR channel.  
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Figure 1: CFTR protein 
The CFTR protein contains two repeated motifs, each consisting of a membrane spanning 
domain and a nucleotide binding folds (NBF). The two proteins halves are linked by the 
intracellular R domain. The figure is taken from Alton et al [16]. 
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Figure 2: CFTR mutations 
The five classes (I-V) of CFTR mutations and their effects on protein synthesis. The figure is 
taken from Pier et al [21]. 
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Finally, Class V mutations refer to splicing mutations or point mutations in the promoter 
region, which interfere with correct transcription or translation resulting in reduced 
levels of functional CFTR protein [19,20].  
 
1.3.3 Polymorphisms and genotype-phenotype correlations  
The clinical manifestation of CF as described above varies greatly among patients, 
ranging from the classical severe CF where the patients are pancreatic insufficient and 
exhibit early lung disease, to patients with a much milder disease pattern, such as a 
single-organ disease or symptoms presenting much later in life than average.   
 
The CF genotype-phenotype correlation is relatively high for the pancreas and intestine. 
Generally, class I, II and III mutations (also called “severe” mutations) cause pancreatic 
insufficiency in the vast majority of cases, whereas classes IV and V are associated with 
normal pancreatic function and are generally classified as „milder‟ mutations [22].  
 
For the lung, correlation between the genotype and phenotype has been much harder to 
establish; patients with the same mutation, including siblings, can have very different 
disease severity. This makes it hard to predict the prognosis for CF patients as the vast 
majority of patients die due to lung failure. A few specific mutations, including A455E 
and R117H, have been described as „mild‟ mutations [23,24] and furthermore an 
extensive retrospective study by McKone et al has reported that class II homozygotes 
generally have lower lung function and increased mortality compared to those patients 
carrying a class II mutation plus a Class IV or V mutation [25].  
 
The poor genotype-phenotype correlation in the lung is likely to be due to a significant 
contribution of other genes and/or the environment. The search for genetic 
polymorphisms in other genes outside the CFTR locus (so-called modifier genes), 
which may influence disease severity has, therefore, intensified. Polymorphisms in pro-
inflammatory cytokines have been particularly studied as these proteins may play a role 
in regulating lung inflammation in CF. Tumour necrosis factor α (TNF-α), a cytokine 
found in high concentrations within the CF airways, was studied by Hull et al and 
Yarden et al . Both studies found that specific, although different, polymorphisms in the 
TNF-α gene was linked to a significantly lower forced expiratory volume in 1 second 
(FEV1) in CF patients [26,27]. However, other studies have not been able to find similar 
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association [28,29]. Furthermore, polymorphisms in the gene encoding mannose-
binding lectin (MBL), a liver-derived serum protein, which is involved in the innate 
immune defence, have been linked to impaired lung function [30,31] and so have 
polymorphisms in the transforming growth factor β1 (TGFβ1) gene, assessed together 
with 9 other candidate modifier genes in one of the largest studies to date [32]. 
Polymorphisms in the β-adrenergic receptor linked to impaired responsiveness to 
bronchodilator treatment have also been associated with impaired lung function in CF 
patients [33]. Finally, polymorphisms in the genes, encoding the pro-inflammatory 
cytokines interleukin (IL) 1β and IL-8, have been associated with CF lung disease in CF 
patient populations [34,35]. Although modifier genes have been described in a number 
of studies, some of them mentioned here, it can be difficult to obtain conclusive results 
in these kinds of studies, which is mainly due to small sample sizes, heterogeneous 
patient population and inadequately characterised phenotypes.  
 
Polymorphisms that affect the CF phenotype have not only been found in non-CFTR 
genes. Approximately, 200 polymorphisms have been identified within CFTR itself 
[36]. These do not cause CF but may alter CFTR protein production and/or function, 
which may be tolerated in individuals without additional CFTR gene mutations, but 
could influence disease phenotype in CF patients. An example is a polymorphism in 
intron 8, in which the number of thymidine residues is 5, 7 or 9. The 9T polymorphism 
is associated with the most efficient splicing of exon 9. However, the efficiency 
decreases with lower numbers of T residues, which result in lower then normal level of 
full-length CFTR mRNA and presumably a decrease in functional CFTR protein [37]. 
Approximately 10% of the general population carry the 5T polymorphism and they 
have reduced amounts of functional CFTR. However, when this specific polymorphism 
is found in trans (on the second CFTR allele) with a severe CFTR mutation, it can result 
in a normal phenotype, male infertility due to congenital bilateral absence of the vas 
deference (CBAVD) or nonclassic CF, in which the patients only exhibit a subset of the 
classical CF symptoms and may only have mild lung disease [38,39]. Furthermore, the 
number the number of thymidine/guanine (TG) repeats next to the 5T polymorphism 
itself also affects the severity of the polymorphism and hereby the phenotype [38]. 
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1.4 The function of CFTR and how it relates to CF lung disease 
 
1.4.1 CFTR protein 
The CFTR protein is expressed on the apical membrane of epithelial cells lining the 
pancreatic duct, the crypts in the small and large intestine, the reabsorptive duct of 
sweat glands and the interlobular ducts in salivary glands. In the lung CFTR is found in 
the surface epithelium and in the submucosal glands. In epithelial cells the CFTR 
protein functions as a chloride channel regulating transmembrane chloride permeability. 
The mechanism by which chloride ion transport is governed by CFTR is still not fully 
understood but it is known that activation of CFTR requires two distinct events; 
phosphorylation of the R domain and binding of ATP to NBDs. The two membrane 
spanning domains are believed to represent the pore of the chloride channel, which is 
initially activated by cyclic adenosine-3',5'-monophosphate (cAMP)-mediated 
phosphorylation of the R domain through protein kinase A and possible protein kinase 
C. Phosphorylation of the R domain is thought to be obligatory for subsequent 
activation of the channel by binding of ATP to both NBDs, which results in a 
conformational changes in the CFTR structure, allowing the channel to go from a 
„closed‟ to an „open‟ state. Conversely, ATP hydrolysis drives a CFTR conformation 
change leading to closure of the channel [15,40].  
 
CFTR is in normal functioning airway epithelial cells believed to have an inhibitory 
effect on the epithelial sodium channel (ENaC), found on the apical surface of these 
cells, hereby regulating sodium absorption [41]. See Section 1.4.2 and 1.4.3 for further 
details. 
 
1.4.2 Regulation of the airway fluid volume in non-CF airways 
Normal CFTR function is essential in maintaining the appropriate conditions for 
efficient trapping and subsequent clearing of inhaled particles and microorganisms from 
the airways. A process, which is mediated by cilia, hair-like structures present on the 
apical membrane of airway epithelial cells. More precisely, cilia are responsible for 
transporting overlying mucus, in which inhaled particles and microorganisms are 
trapped, to the oropharynx, by beating in a coordinated fashion (a mechanism named 
mucociliary clearance). At the oropharynx the mucus is either swallowed or 
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expectorated [41,42]. For the cilia to beat effectively, they are submerged in a 
periciliary liquid (PCL) layer, which has a depth that equals that of an extended cilium 
(~ 7 μm). Importantly, CFTR plays a significant role in maintaining the effective height 
(~ 7 μm) of the PCL.  
 
Maintenance of the effective height of the PCL layer by airway epithelial cells is done 
by regulating the ion and water transport across the epithelium. When excess fluid is 
present, the basolateral Na
+
-K
+
- ATPase pump generates the driving force for sodium 
absorption across the apical membrane, which is mediated by ENaC. This is followed 
by passive chloride absorption via paracellular pathways. The ion flux results in water 
absorption from the lumen leading to a reduced PCL layer [41]. To rehydrate the PCL 
layer, when necessary, sodium absorption through ENaC is inhibited by CFTR. 
Furthermore, chloride is taken up by the Na
+
-K
+
- 2Cl
-
 co-transporter on the basolateral 
membrane and subsequently secreted, via CFTR, into the lumen leading sodium to 
diffuse passively (paracellularly) in the same direction. This is followed by water 
secretion to restore the PCL layer [41]. 
 
1.4.3 Abnormal regulation of the airway fluid volume - reduced airway clearance 
in CF 
As described, the airway surface liquid (ASL), which consist of the PCL layer and the 
overlying mucus layer, is a major constituent of the innate lung defence mechanism. 
Reduction of the ASL volume appears to be the most likely hypothesis, linking CFTR 
dysfunction to sustained bacterial infection in CF. This hypothesis is known as the „low 
volume‟ hypothesis and was initially suggested by Boucher and colleagues, who 
showed that one of the primary defects in CF is depletion of the PCL layer [41,43]. In 
CF, chloride transport through the CFTR channel is eliminated. In addition, CFTR-
mediated inhibition of ENaC is abolished leading to increased sodium absorption. This 
is followed by increased chloride and water absorption through paracellular and 
transcellular pathways, which eventually depletes the PCL layer and allows a viscous 
dehydrated mucus layer to collapse onto the cilia resulting in impaired mucociliary 
clearance of potential pathogens (Figure 3). This scenario ultimately results in mucus 
obstruction and chronic infections, the hallmarks of CF phenotype [41,43].  
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Figure 3: Low volume hypothesis 
In wild-type epithelial cells Na
+ 
absorption is limited due to CFTR inhibiting ENaC (left 
diagram). In CF, inhibition of ENaC is lost leading to increased Na
+
 absorption. This is 
followed by increased Cl
-
 and water absorption through paracellular and transcellular pathways, 
resulting in depletion of the periciliary liquid layer (TJ: tight junction). The figure is taken 
from Wine et al [54]. 
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To support the „low volume‟ hypothesis, Boucher and colleagues have demonstrated 
that the ASL height is significantly reduced in fully differentiated airway cultures 
originating from CF bronchial specimens compared to non-CF, leading to impaired 
mucociliary clearance and mucus accumulation. They also found no difference in 
chloride concentration between the two groups indicating an isotonic hyperabsorption 
of water across the epithelium [44]. Similar results were found in vivo by Tarran et al, 
who showed a reduced but isotonic PCL layer in the nasal epithelium of CF mice [45]. 
In addition, a number of other studies strongly support the „low volume‟ hypothesis [46-
48].  
 
As described above as part of the „low volume‟ hypothesis, the lack of CFTR-mediated 
inhibition of ENaC leads to sodium hyperabsorption in CF. To prove this Mall et al 
generated a transgenic CF-like mouse model by over expressing ENaC in the lower 
airway epithelium. ENaC consists of three individual subunits (α, β, γ). Overexpressing 
the β subunit under control of the airway specific Clara cell secretory promoter (CCSP) 
resulted in increased absorption of sodium together with a reduced PCL height, when 
transgenic mice were compared to their wild-type (WT) littermates. Furthermore, PCL 
depletion was associated with impaired mucociliary clearance, increased amounts of 
mucus, mucus obstruction and inflammation, all features of CF lung disease [49]. 
Importantly, CFTR functioned normally in the ENaC-overexpressing mice, suggesting 
that ENaC plays an important role in CF lung disease. In addition, a patch-clamp study 
by Mall et al showed, that ENaC is inhibited by CFTR in Xenopus laevis oocytes when 
the two proteins are co-expressed, and similar results have been demonstrated in Madin 
Darby canine kidney (MDCK) epithelial cells [50,51]. However, others were unable to 
reproduce these results in comparable systems (Xenopus laevis oocytes and MDCK 
epithelial cells) [31,52,53] emphasising the need to resolve this issue and thereby clarify 
the role of ENaC in CF lung disease.  
 
1.4.4 Abnormal regulation of the airway fluid salt concentration - reduced 
bacterial killing in CF 
Welsh and colleagues proposed an alternative hypothesis to explain the relation between 
defective CFTR and CF disease. According to this „high salt‟ hypothesis, both chloride 
and sodium absorption via CFTR and ENaC, respectively, are reduced in CF (Figure 4).  
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Figure 4: High salt hypothesis  
According to this hypothesis, wild-type epithelial cells absorb Na
+
 and Cl
-
 via ENaC and CFTR, 
respectively (left diagram). In CF, Na
+
 and Cl
-
 absorption is reduced due to the absence or 
dysfunction of CFTR, leading to an elevated salt concentration in the periciliary liquid layer 
(TJ: tight junction). The figure is taken from Wine et al [54]. 
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This results in an elevated salt concentration in the PCL layer, which is believed to 
cause inhibition of antimicrobial factors present in PCL and hence facilitate bacterial 
colonisation [55]. The striking differences between the two hypotheses are the lack of 
ENaC inhibition by CFTR in the „high salt‟ hypothesis and the transport of chloride 
through paracellular pathways to maintain the isotonic properties of PCL in the „low 
volume‟ hypothesis.  
 
In support of  the „high salt‟ hypothesis, Welsh and colleagues have shown a 
significantly lower PCL salt concentration in fully differentiated non-CF cultures of 
human airway epithelia compared to CF cultures. Furthermore, they found no difference 
in the ASL height between the two cultures [55]. To further support the „high salt‟ 
hypothesis, Smith et al demonstrated that bacterial recovery from CF cultures could be 
eliminated by CFTR gene transfer and raising the salt concentration in the medium of 
non-CF cultures showed enhanced bacterial recovery [56]. The antibacterial β-defensin 
may play a part in this mechanism, as it has been shown that it is salt sensitive and 
furthermore inactivated in CF [57].  
 
The „high salt‟ hypothesis is today not widely accepted. Instead, the „low volume‟ 
hypothesis appears to be the most likely link between CFTR dysfunction and sustained 
bacterial infection in CF. 
 
1.4.5 Post-translational modification of proteins and mucins - increased bacterial 
binding in CF 
CFTR is not only present on the apical membrane of epithelial cells but is also found in 
intracellular compartments such as the endoplasmic reticulum, Golgi and endosomes 
[58]. Several studies have suggested, that the absence of CFTR causes 
hyperacidification of the trans-golgi network (TGN) thereby interfering with the 
regulation of enzymes responsible for glycosylation and sulfation of cell-surface 
glycoconjugates and mucins. The exact mechanism is not understood but it is currently 
believed to involve the loss of ENaC inhibition [59,60]. The raised pH level in the TGN 
may cause changes to the activity levels of sialyltransferases, fucosyltransferases and 
sulfortransferases resulting in decreased sialylation and increased fucosylation and 
sulfation. 
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The initial connection between cell-surface glycosylation defects in CF and 
predisposition of patients to colonization Pseudomonas aeruginosa was reported by 
Krivan and colleagues [61]. They showed that the bacterium, which was isolated from 
CF patients, preferably bound to the unsialylated form of cell-surface glycolipids, such 
as asialoganglioside M1 and M2 (aGM1 and aGM2) than the sialylated form (GM1 and 
GM2). These findings suggested that aGM1 and aGM2 function as receptors for 
Pseudomonas aeruginosa and facilitate bacterial binding. Furthermore, it has been 
demonstrated that binding of Pseudomonas aeruginosa to primary CF airway cells 
could be competitively inhibited by the addition of aGM1 [62] and, interestingly, 
Davies et al have shown that the increased Pseudomonas aeruginosa adherence to 
primary CF airway epithelial cells was reduced after CFTR gene transfer [63] All 
together these studies support the hypothesis that decreased sialylation of 
glycoconjugates promotes bacterial binding and hence CF lung disease.  
 
In contrast to decreased sialylation seen on cell-surface glycoconjugates in CF, an 
increased sialylation has been observed in airway mucins secreted by CF patients [64]. 
It is likely that this is due to a secondary defect, and therefore not directly related to 
mutations in the CFTR gene, as the expression of CFTR in cells synthesizing mucins 
(goblet cells and submucosal glands) is very low. Inflammation may modify 
glycosylation and also sulfation of mucins. TNF-α, an inflammatory cytokine and 
important factor in airway mucosal inflammation, has been shown to increase the 
activity of sialyltransferases and sulfortransferases resulting in increased sialylation and 
sulfation of secreted mucins [65]. The changes in mucin sulfation and glycosylation are 
then thought to promote binding of Pseudomonas aeruginosa in the CF airways by 
enhancing the affinity of the bacteria to CF mucins [66,67]. 
 
In order to assess if a primary defect (mutated CFTR gene) could be responsible for the 
changes in mucin sulfation in CF, Zhang and colleagues used a xenograft model in 
which cells from human primary airway cultures were seeded onto denuded rat tracheas 
and transplanted into flanks of mice to generate fully differentiated mucus secreting 
airway epithelium [68]. Using this model secondary effects, such as bacterial infection, 
inflammation and goblet cell hyperplasia, were eliminated. The study found, in the 
absence of secondary CF defects, an increased level of sulfation in mucins from CF 
xenografts compared to controls, which were believed to be directly linked to mutations 
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in the CFTR gene. The enhanced sulfation level in CF xenografts was reduced to normal 
after non-viral mediated CFTR gene transfer in a subsequent study by the same group, 
which further supports the belief that CFTR gene mutations can cause changes in the 
composition of mucoglycoproteins [69]. 
 
1.4.6 Altered acidification in macrophages - reduced bacterial killing in CF 
Epithelial cells are not the only cell type expressing CFTR; human and murine 
machrophages have also been shown to express functional CFTR at their plasma 
membrane and within the phagosomes and lysosomes [70]. Interestingly, Di et al have 
shown that macrophages from Cftr-/- mice have a reduced ability to kill bacteria 
compared to wild-type macrophages, which was not related to a reduction in 
macrophage-mediated bacterial uptake (phagocytosis). Instead, Cftr-/- macrophages had 
a reduced ability to kill ingested microorganisms, which is believed to be linked to the 
finding that both lysosomes and phagosomes in macrophages from Cftr-/- mice failed to 
acidify [70].  The authors hypothesised that the lack of CFTR resulted in alterations in 
intracellular compartmental chloride concentrations, which then impeded H
+ 
accumulation, thus inhibiting phagolysosomal acidification. The failed acidification 
resulted in a phagolysosome with a suboptimal pH for proteolytic enzymes normally 
ensuring destruction of internalised bacteria. This led to the reduced bactericidal activity 
observed in Cftr-/- macrophages.  
 
1.4.7 CFTR as a bacterial receptor - reduced bacterial clearance in CF 
CFTR itself may also function as a specific receptor for Pseudomonas aeruginosa in the 
airways. It is thought that the outer-core oligosaccharide of the lipopolysaccharide 
(LPS) layer is the ligand responsible for binding to CFTR and triggering bacterial 
internalisation and apoptosis [21]. The absence of CFTR may therefore lead to 
increased bacterial airway colonisation. However, the hypothesis does not explain why 
CF patients with class III and IV mutations, in which CFTR reaches the airway 
epithelial cell surface, are just as vulnerable to Pseudomonas aeruginosa infections as 
are patients that lack CFTR on the cell surface [71]. Contradictory results have also 
been published in another study showing no direct correlation between levels of CFTR 
expression and bacterial clearance or association of bacteria with epithelial cells in vitro 
[72]. 
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1.4.8 Immune response - increased inflammation and reduced bacterial killing in 
CF 
Infection and inflammation are critical in the progression of CF lung disease and are the 
cause of death of most patients. An excessive and persistent inflammatory response due 
to bacterial infection is generally believed to be the major cause of lung tissue damage 
in CF. However, proinflammatory cytokines and inflammatory cells have been observed 
prior to demonstrable infection in a number of studies thereby questioning whether 
airway inflammation is a primary or secondary event in CF [3]. CF mouse models do 
not develop chronic bacterial infections, and hence do not exhibit lung disease similar to 
humans and cannot be used to solve the above mentioned issues. However, the recent 
development of CF pigs [73,74], which spontaneously develop many features of the CF 
multi-organ disease including lung pathology will hopefully provide opportunities to 
address the persistent questions regarding CF pathogenesis [75,76]. 
 
CF inflammation is characterised by a neutrophilic infiltration. Neutrophils are recruited 
by elevated cytokine production by pre-existing neutrophils and epithelial cells in the 
small airways [3]. Human studies have shown that the ratio of neutrophils and IL-8, a 
pro-inflammatory cytokine, to bacteria was significantly elevated in bronchoalveolar 
lavage fluid (BALF) of CF children compared to controls [77,78]. Furthermore, 
additional studies have reported increased levels of IL-8 as well as other pro-
inflammatory mediators such as IL-1, IL-2, IL- 9 and TNF-α in BALF in CF patients 
[3]. Despite the high levels of other cytokines, IL-10, an anti-inflammatory cytokine, 
was found to be significantly reduced in CF [79]. Interestingly, IL-10 knockout mice 
showed prolonged inflammatory response after bacterial challenge, similar to those 
observed in CF mice and humans [80]. 
 
Interaction of epithelial cells with pathogens and the resulting activation of the immune 
system occur via toll-like receptor (TLR) molecules, which activate intercellular 
signalling pathways resulting in production of pro-inflammatory cytokines. TLR-5 and 
TLR-4 have, for example, been implicated as important in initial recognition of 
flaggelin and LPS from Pseudomonas aeruginosa, respectively [81]. In CF, the airways 
are rich in TLR agonists (bacteria and endogenous molecules) and it has been suggested 
that the chronic inflammatory profile is probably due in large part to activation of TLR 
molecules [82]. 
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Epithelial cells, in addition to macrophages, are major producers of nitric oxide (NO) 
and the enzyme responsible for NO production is called nitric oxide synthase (NOS). In 
CF airway epithelial cells, an isoform of the enzyme, NOS-2, is reduced, which is 
believed to be directly linked to CFTR dysfunction. The diminished NO production 
seen in CF is thought to lead to reduced bacterial killing and hence facilitates bacterial 
colonisation [71]. Support for a link between NO production and CFTR was obtained in 
vivo. In CF mice, in which human CFTR was expressed in the gut under control of the 
fatty acid binding protein (FABp) promoter, NOS-2 expression was restored in the gut 
epithelium but not in the airways. Furthermore, human CFTR gene transfer in CF mice 
showed CFTR staining in the same cells that had NOS-2 activity restored [71]. The 
reduction of NOS-2 expression in CF is caused by inhibition of STAT-1 (signal 
transducer and activator of transcription 1), which is required for NOS-2 transcription. 
Other mediators affected by the down-regulation of STAT-1 are IRF-1 (anti-
inflammatory cytokines interferon regulatory factor 1) and RANTES (regulated on 
activation normal T cell expressed and secreted) [3,71]. 
 
 
1.5 Treatments 
 
1.5.1 Established treatments 
Although there is no cure for CF, the outlook for patients diagnosed with the disease has 
improved steadily over many years, mainly due to earlier diagnosis, more aggressive 
treatments and improved care in specialised centres. 
 
Antibiotics 
Antibiotics, the main treatment for lung disease, can be administered prophylactically 
(with the aim of preventing Staphylococcus aureus or Pseudomonas aeruginosa), as 
eradication treatment (commonly for Pseudomonas aeruginosa), as chronic suppressive 
therapy (for Pseudomonas aeruginosa) and for the treatment of pulmonary 
exacerbations [83]. Staphylococcus aureus is often the first bacterium to be encountered 
in infants and children with CF and prophylactic treatment with flucloxacillin or 
cephalosporins are today standard leading to fewer children having isolates of 
Staphylococcus aureus. However, worryingly several studies have associated long-term 
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use of prophylactic antibiotic treatment with an increased frequency of Pseudomonas 
aeruginosa infection in children [84,85]. Treatment in the early stages of infection with 
Pseudomonas aeruginosa is aimed at eradication and delaying the onset of chronic 
infection. Eradication therapy with oral ciprofloxacin and nebulised colomycin has been 
shown to delay chronic infection in 75% of patients during a 3.5 year follow up. 
Additionally, inhaled tobramycin treatment has resulted in early eradication of the 
bacterium [86]. Long-term suppressive therapy is used when Pseudomonas aeruginosa 
infection has become chronic. Chronic infection develops as a result of bacterial 
resistance, normally due to a shift from the non-mucoid to the mucoid form of the 
bacterium. The mucoid form is able to establish biofilms (clusters of bacteria) which 
become impossible to eradicate. Treatment consists of inhaled colomycin to improve 
lung function. However, administration is time consuming and adds to the therapeutic 
burden [83]. Finally, exacerbations are treated intermittently with either oral or 
intravenous antibiotics (e.g. β-lactam aminoglycosides, tobramycin) [83,86]. 
 
Macrolide antibiotics 
Marcrolide antibiotics are believed to have anti-inflammatory effects. It has been 
reported that they suppress the production of pro-inflammatory cytokines including IL-
6, IL-8 and TNF-α and reduce neutrophil infiltration [87]. Furthermore, they inhibit 
alginate production by Pseudomonas aeruginosa, which among other factors is 
responsible for bacterial biofilm formation [88]. Three clinical trials have studied 
azithromycin, a macrolide antibiotic, in CF patients and a review of these studies has 
concluded that there is clear evidence of a small but significant positive effect on lung 
function [89]. Based on these clinical trials, many patients with CF with or without 
Pseudomonas aeruginosa are now on regular macrolide antibiotic therapy. However, as 
these trials only lasted for 6 months, it is unclear whether there are longer term benefits 
or adverse effects from the treatment and more work is, therefore, needed [90,91].  
 
Recombinant human DNase 
In addition to antibiotic treatment there are many techniques used by CF patients to 
augment clearance of airway secretions, such as physiotherapy, high-frequency chest 
wall oscillation, positive expiratory pressure and β-adrenergic agonists of which the 
latter is intended to relax airway smooth muscles. Furthermore, recombinant human 
DNase (rhDNase), which cleaves neutrophil- and bacterial-derived DNA in airway 
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mucus and thereby reduces mucus viscosity, is extensively used to improve mucus 
clearance [92]. Interestingly, rhDNase treatment has also been suggested to have a pro-
inflammatory effect. This is due to breakdown of DNA, which otherwise binds and 
thereby inactivates pro-inflammatory cytokines and neuthrophil elastase [88]. However, 
a study comparing the level of BALF neutrophils in CF patients receiving long-term 
therapy with rhDNase to untreated patients, showed that the level of neutrophils 
stabilised in patients receiving treatment, whereas increased levels were observed in 
untreated patients [93]. This important study, therefore, provide evidence that rhDNase 
treatment should be given long term to appropriate CF patients.  
 
Hypertonic saline 
Inhaled hypertonic saline has attracted great interest over the last few years and is now 
used clinically. This treatment enhances mucociliary clearance and improves lung 
function in CF patients [83]. It is an osmotically active substance that works by pulling 
water from the submucosa through paracellular pores between epithelial cells, thereby 
re-hydrating the PCL and subsequently allowing normal mucociliary clearance. A study 
by Elkins and colleagues in 164 patients reported more than 50% fewer excerbations in 
the group treated with hypertonic saline (7%) compared to controls receiving 
physiological saline (0.9%) and, in addition, the excerbations observed in treated 
patients were of a shorter duration and less severe, with fewer needing intravenous 
antibiotic [94]. However, no changes was seen in the primary endpoint; the rate of 
change in lung function. A further study has, although on a much smaller scale, 
supported the previous findings [95]. CF patients receiving hypertonic saline (7%) in 
this study had increased mucociliary clearance and improved lung function.  
 
Lung transplantation 
The final therapeutic option for patients with end-stage lung disease is lung 
transplantation. However, the shortage of organs limits this option and as a result many 
patients die on the waiting list. In an attempt to overcome this problem „living lobe 
donor lung transplantation‟ has emerged. Using this technique, lobes from different 
donors are removed and transplanted into the CF recipient. Follow-up data, assessing 
the effect of this technique have shown survival rates at 70% and 45%, 1 year and 5 
years post transplantation, respectively. These data are comparable with survival rates 
(80% and 50%) obtained following complete lung transplant and so are pulmonary 
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function and exercise capacity [92,96]. To obtain the relatively high survival following 
transplant, patients are carefully chosen based on fitness level, CFRD diagnosis and 
presence of Burkholderia cenocepacia, a bacterium know to cause increased mortality 
and morbidity post transplantation [96]. 
 
Pancreatic enzyme replacement  
Although, treatments have mainly focused on reducing lung infection and inflammation 
in CF, others are now available addressing some of the secondary clinical phenotypes. 
Pancreatic insufficiency (i.e. deficiency of pancreatic lipolytic and proteolytic enzymes) 
is the major cause of malabsorption in CF affecting approximately 85% of CF patients. 
Malabsorption is treated with pancreatic enzyme replacement, which greatly enhances 
fat and protein digestion in the majority of patients [97]. In addition, fat-soluble vitamin 
deficiency is common in untreated pancreatic insufficient patients and should, therefore, 
be given as supplementation from diagnosis [98]. 
 
1.5.2 Research into novel treatments 
In addition to established treatments, great effort has been made to develop new novel 
treatments for patients with CF. The following sections describe such possible 
treatments. 
 
Mutation-specific treatments 
A novel therapeutic approach, named „protein repair therapy‟, has emerged in an 
attempt to therapeutically improve the function of mutant CFTR in a mutation specific 
fashion. Generally, protein repair strategies are directed at restoring protein production 
for class I mutations, correcting abnormal intracellular trafficking for class II mutations 
and improving function and/or regulation of chloride transport for class III and IV 
mutations.  
 
As previously described, class I mutations abolish protein synthesis by creating 
premature termination codons (e.g. nonsense mutations). This type of mutation has been 
shown to be at least partly corrected following treatment with aminoglycoside 
antibiotics (e.g. gentamicin) in vitro, in animal models in vivo and in humans [99-103]. 
The compounds induce ribosomes to read through a premature mRNA stop codon 
resulting in incorporation of an amino acid and continuation of translation to produce a 
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complete protein [100]. Despite these promising results, long-term systemic use of 
aminoglycosides is limited by the toxicity profile [104]. The need for compounds that 
can provide safe and convenient suppression of class I mutations led to the development 
of PTC124, a non-aminoglycoside compound, by Welch and colleagues [105]. PTC124 
was found to be well tolerated in humans and when tested in a mouse model of stop-
mutation-mediated CF, PTC124 generated production of full length, functional CFTR 
[106,107]. Furthermore, PCT124 has been assessed in a phase II clinical trial [108]. 
Many of the patients in the trial responded to treatment with an increase in total chloride 
transport and normalisation of nasal potential difference, which has led to an ongoing 
multi-centre phase III clinical trial. However, although promising this treatment will 
only be suitable for a small percentage of CF patients with class I CFTR mutations.  
 
Several pharmacological agents have also been developed to correct abnormal 
intracellular trafficking observed in class II mutants. These agents are so-called 
„correctors‟ because they have been reported to allow trafficking of ∆F508 CFTR from 
the endoplasmic reticulum to the apical cell membrane. „Correctors‟ assessed in vitro 
and in animal models in vivo include Sildenafil (Viagra
®
), phenylbutyrate and Miglustat 
(Zavesca
®
) whereas curcumin (compound contained in tumeric) and a compound named 
VX-809 have been taken into phase I and II clinical trials [83,109-111]. However, 
although curcumin was initially shown to correct chloride conductance in vitro and in 
∆F508 homozygous mice, an additional replicate in vivo study and the clinical trial 
reported negative results [83,112,113]. Interestingly, a phase II clinical trial in patients 
with the ∆F508 gene mutation showed a reduction in sweat chloride levels following 
treatment with VX-809, which suggests that the compound may improve the function of 
CFTR (http://www.cff.org). 
 
Potentiators of CFTR channel activity, including genistein, alkylxanthines, 
phosphodiesterase-5-inhibitors and VX-770, could benefit patients with class III and IV 
mutations. VX-770, a compound which acts directly on defective CFTR to restore 
chloride transport in patients carrying the G551D mutation (class III), has been assessed 
in a phase II clinical trial. Although numbers were low, improved lung function and 
reduced sweat chloride levels were observed; however, lung function also improved in 
the placebo group [114]. A phase III clinical trial is currently ongoing to determine the 
efficacy of VX-770.  
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Purinergic receptor agonist treatment 
Another novel strategy for the treatment of CF is to target and activate other epithelial 
chloride channels and, thereby, compensating for the CFTR defect. Airway epithelial 
cells compensate for the decrease in ASL by releasing ATP, which activates luminal 
purinergic receptors (including P2Y2) resulting in inhibition of sodium absorption and 
activation of calcium-mediated chloride secretion. However, this mechanism will only 
partially compensate for loss of ASL volume due to active ATP metabolism. P2Y2 
agonists have been shown to activate an alternative non-CFTR chloride channel leading 
to an increase in ASL height, ciliary beat frequency and enhanced mucociliary clearance 
[115]. Placebo controlled phase II studies with denufosol, a P2Y2 agonist, suggest that 
treatment with denufosol for up to 28 days in patients with relatively normal lung 
function (FEV1 greater than or equal to 75% of predicted), result in improved lung 
function [115]. Furthermore, treatment with denufosol for a total of 48 weeks (24 weeks 
blinded + 24 weeks open label) in the first phase III clinical trial resulted in significantly 
improved lung function in denufosol treated CF patients compared to patients receiving 
placebo. The promising results led to the currently ongoing 48 weeks placebo controlled 
phase III clinical trial with an open label extension study to follow [116]. 
 
New antibiotics and anti-inflammatory treatments  
Very few new antibiotic molecules have in recent years entered clinical trials in CF 
patients. Instead there has been a focus on developing inhaled forms of antibiotics 
which are normally given orally or intravenously. By directly delivering the antibiotic to 
the site of infection, the local drug concentration will be higher and there is a reduced 
risk of systemic side-effects. Azetreonam lysine, tobramycin and colistemethate are 
some of the antibiotics which have been assessed in phase III inhalation clinical trials. 
The results were promising for azetreonam lysine showing improved lung function in 
the treated group compared to placebo and furthermore, the drug was well tolerated 
[117]. The data from the other trials are still awaited.  
 
Furthermore, cysteinyl leukotrines (LTC4, LTD4, LTE4) may contribute to the 
pulmonary destruction seen in CF, as they result in bronchi constriction and mucus 
hypersecretion [83]. Montelukast is a selective antagonist of LTD4, which has been 
assessed in CF patients. However, the trials have resulted in conflicting findings 
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highlighting the need for further clinical research to determine the effect of montelukast 
in CF [83]. 
 
ENaC inhibition treatments 
As previously mentioned, the lack of ENaC inhibition in CF results in hyperabsorption 
of sodium, which contributes to reduced airway clearance in CF (see Section 1.4.3 for 
further details). Inhibiting ENaC would, theoretically, result in enhanced mucociliary 
clearance and better lung function. However, clinical trials with amiloride, a specific 
blocker of ENaC, showed disappointing results, which was likely to be related to the 
rapid clearance of amiloride in the airways following nebulisation [118-120]. 
Interestingly, novel longer-acting and more potent blockers of ENaC have recently been 
developed. One of them, 552-02, has in comparison with amiloride shown to be more 
potent, more selective and showed slower transepithelial absorption in vitro. When 
administered to sheep by nebulisation, 552-02 produced a sustained increase in 
mucociliary clearance [121].  With novel compounds, like 552-02, it will be possible in 
future studies to address whether ENaC directed therapy can be beneficial in established 
CF lung disease. 
 
 
1.6 Gene therapy  
 
CF is an obvious target disease for gene therapy for several reasons.  It is a single gene 
disorder with insufficient treatment options and the target organ, the lung, is accessible 
via topical administration, without the need for invasive surgical procedures. 
 
In the UK this research is undertaken by the UK Cystic Fibrosis Gene Therapy 
Consortium. This consists of groups at the University of Edinburgh, Oxford University 
and Imperial College London, which have all undertaken CF gene therapy clinical trials. 
The aims of this collaboration are to avoid duplication and competition, to develop core 
facilities and assays in order to identify a potential therapeutic product which could be 
taken into a clinical trial [122]. Currently, the Consortium is undertaking a clinical trial 
programme in CF patients to assess if cationic liposome-mediated gene transfer can 
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alter clinically relevant endpoints in the CF airways when the vector is repeatedly 
administered over a long-term period. 
 
1.6.1 CFTR gene therapy  
Since cloning of the CFTR gene a total of approximately 25 clinical trials have been 
carried out with viral and non-viral gene transfer agents, in which the gene has been 
delivered to either nasal or bronchial epithelial cells. Most trials have demonstrated 
proof-of-principle for gene transfer to the airways and in addition shown that partial 
correction of the chloride transport defect in CF is achievable [123]. However, gene 
expression was transient indicating the need for repeated administration to treat this life-
long chronic disease. Furthermore, gene expression was generally low, which raises the 
question whether the gene transfer efficacy obtained with currently available vectors is 
sufficient to change clinical relevant endpoints, such as decline in lung function, 
inflammation or bacterial colonisation. 
  
1.6.2 How much CFTR expression is required to achieve clinical benefit? 
Clearly, CFTR function to levels nearing 100% of non-CF levels would be expected to 
have clinical benefit. However, gene transfer is currently not efficient enough to achieve 
this. In addition to the absolute level of gene expression per cell, it is also important 
how many cells and which cells have been transfected. Importantly, a number of pre-
clinical studies and theoretical considerations based on levels of CFTR expression in 
patients with milder phenotypes indicate that only low level gene expression may be 
needed to achieve an improvement in CF lung disease.  
 
As mentioned above, the amount of CFTR expressed per cell plays a role in CF disease. 
Heterozygotes carriers of CF mutations (i.e. the parents of CF patients), for example, 
have generally normal lung function and no other signs of CF despite that fact that they 
only have 50% of CFTR expression and function. Furthermore, patients with so-called 
„milder‟ mutations (class IV and V) who have some residual CFTR function, generally 
have less severe lung disease [25]. Finally, males with CFTR mutations that give rise to 
about 10% of the non-CF levels of CFTR mRNA have generally normal sweat chloride 
concentrations, normal lung and pancreatic function, but suffer from CBAVD [92]. In 
addition to these observations, a murine study assessed the amount of CFTR per cell 
required to obtain normal chloride transport in intestinal epithelium [124]. Intercrossing 
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of mice carrying different CFTR mutations allowed the authors to produce mice with 
CFTR expression levels varying from 0-100% in the intestinal tract. They then reported 
that only 5% of normal CFTR expression per cell resulted in a disproportionately large 
correction of chloride transport (50% of non-CF) and completely prevented intestinal 
disease in the mouse model. Based on these observations there is evidence that lung 
disease only becomes severe if CFTR function drops below 5-10% of non-CF levels per 
cell. This nonlinear relationship between the amount of residual CFTR expression and 
function and the severity of lung disease may indicate that low levels of CFTR 
expression after gene transfer may result in a significant improvement in disease 
severity (Figure 5). 
 
With regards to the number of cells that need to be corrected, Johnson et al mixed CF 
and non-CF cells at different ratios and showed that as few as 6-10% of non-CF within 
a cell monolayer generated a chloride conductance similar to monolayers containing 
100% of corrected cells [125]. However, Johnson and colleagues used a strong 
promoter to drive CFTR expression in the study, thereby generating higher CFTR 
expression levels than those endogenously observed. A more recent study also assessed 
the number of corrected cells needed to restore chloride conductance [126]. Freshly 
isolated wild-type and CF airway epithelial cells were mixed in varying proportions, 
which showed that 20% wild-type cells expressing CFTR at the endogenous level 
generated 70% of the wild-type chloride conductance. These results indicate that the 
expression of normal level CFTR, i.e. endogenous level, in a relatively small fraction of 
cells is sufficient to correct the chloride transport defect. Finally, Zhang et al have 
assessed how many epithelial cells require CFTR expression in order to restore the 
mucus transport defect seen in CF [127]. They reported that CFTR protein delivery, via 
a viral vector engineered to express CFTR, to approximately 25% of CF airway 
epithelial cells in air liquid interface cultures restored normal levels of airway surface 
hydration and mucus transport. Interestingly, this study also showed that expression of 
CFTR in 60% of CF ciliated cells fully corrected the ENaC hyperabsorption defect 
characteristic of the CF airway epithelium in vitro and in vivo. This finding is in 
contrast to data reported by Johnson et al, which suggest that almost all cells (>90%) 
are required to express CFTR in order to correct ENaC hyperabsorption [128]. 
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Figure 5: Correlation between CFTR function and disease severity 
There appears to be a nonlinear relationship between CFTR function and disease severity, 
suggesting that low levels of CFTR expression after gene transfer may result in a significant 
change in disease severity. CF patients with severe lung disease (e.g. ∆F508 homozygotes) 
retain no or very low levels of CFTR function. However, patients with 10% CFTR function 
have, generally speaking, normal lung function as is the case for heterozygote carriers (50% 
CFTR function) and individuals with no CFTR mutations (100% CFTR carriers). The figure is 
adapted from E. Alton, Department of Gene Therapy, Imperial College London, UK. 
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The reason for the discrepancy may be that a differentiated human airway epithelium 
was used in the recent study by Zhang et al, whereas polarised cultures of human 
primary nasal epithelial cells were used in the other study. A fully differentiated human 
airway epithelium is likely to be more representative and relevant to CFTR gene transfer 
efficiency in human airway epithelium in vivo. Importantly, none of the clinical gene 
therapy trials carried out has shown correction of sodium hyperabsorption in CF 
patients. 
 
Despite these studies, it is still debatable whether low level CFTR is needed in all cells 
or if a few cells expressing either low or normal levels are sufficient to restore chloride 
function in CF and hence improve disease severity. Furthermore, it is currently unclear 
whether correction of the sodium transport is required to improve lung disease. 
 
1.6.3 Endpoint assays - assessment of CFTR gene therapy 
Suitable pre-clinical and clinical endpoint assays are vital when the effect of CFTR gene 
transfer is to be assessed. Several endpoint assays have already been established which 
are used both in pre-clinical and clinical studies [129]. 1) CFTR mRNA can be 
measured by reverse transcriptase-polymerase chain reaction (RT-PCR) in murine nasal 
brushings and human nasal and bronchial brushings. 2) CFTR channel function can be 
quantified by measuring potential difference (PD) across the murine nasal epithelial. In 
a clinical setting PD measurements are performed either in the nose or in the lung. 3) 
Immunohistochemistry has been used with some success to detect CFTR protein 
expression. However, in general anti-CFTR antibodies are not very good and their lack 
of sensitivity and specificity has limited the use of this assay. Although, these assays are 
useful their clinical relevance is debatable. Lung function measured by FEV1 is 
currently the most used and relevant endpoint assay clinically. However, FEV1 only 
changes by approximately one percent per patient per year and is, therefore, less than 
ideal for early phase clinical trials, because long (several years) or large (several 100 of 
patients) clinical trials are likely to be required to power this endpoint. The UK Cystic 
Fibrosis Gene Therapy Consortium is, therefore, spending a significant amount of time 
and resources on developing and refining novel and existing surrogate endpoint assays, 
which may be more suitable to predict clinical status following gene therapy.  
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1.6.4 Viral vectors for airway gene therapy 
Adenovirus 
The use of viral vectors for airway gene therapy has attracted great interest as they 
possess natural mechanism for cell entry. One of the first viral vectors to be assessed 
was adenovirus (AdV), a double-stranded DNA virus with a natural tropism for airway 
epithelial cells. Proof-of-principle of AdV-mediated gene transfer was established in 
xenograft models of human airway epithelium [130] and, additionally, subsequent 
studies have produced encouraging result in the nasal and pulmonary tissue in pre-
clinical models [131,132]. Several clinical trials have also been carried out in both the 
nose and lung of CF patients. Most trials reported expression of vector-specific CFTR 
complementary deoxyribonucleic acid (cDNA) and/or mRNA or partial correction of 
chloride transport after just one administration of AdV-CFTR [133-136]. However, in a 
trial by Zabner et al a diminished effect with subsequent vector administration was 
reported, and after the fifth dose efficacy was completely abolished [135]. Furthermore, 
serum-neutralising antibodies against the vector were detected suggesting that immune 
responses against the vector were responsible for loss of efficacy. Supportive results 
were published from a subsequent clinical trial by Harvey and colleagues [137]. They 
delivered three doses of AdV-CFTR to the lungs of CF patients three months apart and 
showed that after the final administration vector-specific CFTR mRNA was no longer 
detectable. Finally, transduction efficiency in humans has been relatively low [138]. 
 
Overall, adenoviral vectors are severely hampered by low transduction efficiency in 
airway epithelium and development of neutralising antibodies against the virus which 
prevent re-administration of this vector. The low transduction efficiency is mainly due 
to the distribution of adenovirus receptors. Coxsackie-adenovirus receptor (CAR) and 
the integrin receptors (αvβ3 and αvβ5) are predominately located on the basolateral 
membrane of human airway epithelial cell [139]. To overcome this problem tight 
junction openers have been used to gain access to the receptors on the basolateral 
membrane. More precisely, agents such as sodium caprate and ethyleneglycol-bis-(β-
aminoethyl ether)-N,N‟-tetraacetic acid (EGTA) have been shown to increased 
adenovirus-mediated gene transfer in the lungs of animal models [140,141]. 
Interestingly, Waddington et al have recently shown that the CAR receptor is not 
needed for liver transduction following intravascular delivery of adenovirus serotype 5. 
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Instead, coagulation factor X binds directly to the adenovirus capsid protein, hexon, and 
thereby „bridges‟ the virus to alternative receptors in the liver [142]. 
 
Attempts have also been made to overcome the induction of the immune response to 
allow repeat administration of adenoviral vectors and the use of this virus in CF gene 
therapy. Administration of immunosuppressants and corticosteroids and treatments 
aimed at transiently blocking CD
4+
 T cells, allowed re-administration of the vector 
[143,144]. However, ultimately transgene expression was reduced and finally absent 
after repeated administration of the vector. Kolb and colleagues are so far the only 
group, who have successfully have been able to re-administer (a total of 5 times) 
adenovirus to the lungs of mice without loss of transfection efficiency. They achieved 
this by administration of the steroid budenoside intranasally at the same time as 
delivering the first dose of adenovirus [145]. 
 
Finally, helper-dependent (“gutted”) adenoviral vectors, which are depleted of all viral 
genes, may be less immuno-stimulatory and have improved safety profiles compared to 
previous generations of viruses, which have only a subset of viral genes deleted [146]. 
Encouragingly, re-administration of low titre helper-dependent virus did not reduce 
gene expressions levels in a study by Koehler et al [147]. However, the immune system 
may not be fully activated after just two doses of the virus and the virus does therefore 
need to be re-administered more times before a conclusion regarding repeat 
administration can be drawn.  
 
Adeno-associated virus 
Adeno-associated virus (AAV) is a single-stranded DNA virus, which has also been 
used for CFTR gene transfer. The virus has a good safety profile, tropism for respiratory 
epithelium and, in contrast to AdV, offers longer-term duration of gene expression for 
reasons that are not yet fully understood. However, a major concern is the limited 
packaging capacity as the virus only barely holds the CFTR gene. AAV serotype 2 was 
the first and to date most studied serotype. It has been shown to transduce the rabbit 
lung with mRNA being detected for up to 7 months [148]. However, a subsequent 
study, also in rabbits, reported low transduction efficiency and a noticeably decrease in 
reporter gene positive cells after 60 days probably due to turn-over of the airway 
epithelial cells initially transfected. Moreover, gene expression did not persist following 
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re-administration of the virus, which correlated with development of an immune 
response [149]. In contrast, several studies have been published which suggest that 
AAV can be re-administered [150-152]. Auricchio et al delivered the AAV2/5 to the 
lungs of mice and reported that the second dose of virus, delivered 5 months after the 
first, was just as efficient as the first dose [150]. AAV2/5 is a „hybrid‟ virus consisting 
of different serotypes of AAV. AAV2 binds preferably to receptors on the basolateral 
membrane, but by packaging the genotype of AAV2 into the capsid of AAV5, which 
binds to sialic acid found on the apical membrane of airway epithelial cells, a more 
efficient transducing vector is generated. Furthermore, „hybrid‟ virus AAV2/9 has been 
re-administrated successfully to murine airway epithelial cells as early as 1 month after 
the initial exposure despite high levels of serum-circulating neutralizing antibodies 
[152]. However, attempts at repeatedly administering AAV5 to the mouse lung, as part 
of the UK CF Gene Therapy Consortium‟s gene therapy programme, have not been 
successful due to production of neutralising antibodies against the AAV5 capsid [153]. 
More recently, AAV2 genomes with capsids from additional serotypes (1 and 6) have 
also been assessed in vivo in terms of airway gene transfer efficiency and Lui et al have 
recently shown that AAV serotype 1 and 5 vectors may be able to transduce progenitor 
cells in the mouse lung, which if efficient may help to solve the problem [154,155].  
 
Several AAV clinical trials have been carried out in CF patients, all using the AAV2-
CFTR vector, originally developed by Targeted Genetics Corporation, which employs 
the weak AAV long-terminal repeat (LTR) promoter to drive expression [123]. Moss et 
al have assessed safety and repeat administration in a phase II trial [156]. Three doses 
of the virus were aerosolised to the lungs of CF patients one month apart. Interestingly, 
the study showed a small improvement in lung function (FEV1) and reduction in sputum 
IL-8 (pro-inflammatory cytokine) after the first dose but not after the following 
administrations. However, although antibodies against the virus were detected, vector 
administration was safe. Based on this study Targeted Genetics Corporation initiated a 
large repeat administration study in 100 subjects, powered to detect significant 
improvement in lung function [157]. However, the study did not meet its endpoint 
which could be due to (1) inefficiency of AAV2 to transduce airway epithelial cells 
from the apical membrane, (2) the LTR promoter being too weak to drive expression or 
(3) repeat administration is not possible due to immune responses against the virus as 
previously mentioned.  
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As previously mentioned the limited packaging capacity of the virus is a major 
drawback. However, to allow incorporation of stronger promoters in addition to the 
large CFTR gene, strategies have been developed which are based on packaging 
therapeutic cDNA and promoter elements into two separate viruses, which when 
transfecting the same cell may recombine and generate full-length CFTR gene 
[158,159]. Another approach is to shorten the CFTR cDNA. Studies have shown that 
truncated CFTR cDNA partially can correct chloride transport in vitro and result in 
mRNA and protein expression in vivo [160,161]. However, although truncated CFTR 
cDNA leads to protein expression and chloride transport function, deletion of coding 
sequences may result in other functions of the protein being eliminated.   
 
Negative strand RNA viruses 
Although, AAV and AdV are the only viral vectors which have been used in CF clinical 
trials, other viruses have been studied for airway gene transfer. Sendai virus (SeV), 
human respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (PIV3) 
have all been shown to efficiently transfect airway epithelial cells via sialic acid and 
cholesterol, abundantly expressed on the apical membrane [123]. They are negative-
strand RNA viruses and do not enter the nucleus as they replicate in the cytoplasm (no 
DNA intermediate occurs). Therefore, these viral vectors carry no risk of insertional 
mutagenesis. Of the three viruses, SeV is the only one which has been assessed in vivo. 
In the ferret lung, SeV has been shown to transfect up to 80% of airway epithelial cells 
and in the nasal epithelium of CF knockout mice the chloride transport defect was 
partially restored following SeV-CFTR gene transfer [162,163]. However, SeV-
mediated gene expression is transient, lasting for about 7 days and repeat 
administration, which is required for a life-long disease, such as CF, is not feasible due 
to immune responses [123,164]. 
 
Lentivirus 
Retro- and lentiviruses are positive-strand RNA viruses, which after infection use the 
enzyme reverse transcriptase to produce DNA from the RNA genome. The viral DNA is 
then incorporated into the host‟s genome by an integrase enzyme, theoretically allowing 
expression to last for the lifetime of the cell. In contrast to retroviruses, lentiviruses can 
transfect non-dividing cells, and, therefore seem better suited for transfection of fully 
differentiated airway epithelial cells [123]. However, cell-surface receptors used for cell 
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entry are low in the airway epithelium [139]. To enhance vector uptake via the apical 
membrane, envelope proteins from other viruses have, therefore, been incorporated into 
lentiviral vectors (a process called pseudotyping), thereby allowing the viruses to target 
receptors present on the apical membrane of airway epithelial cells. Simian 
immunodeficiency virus pseudotyped with SeV-derived F and HN envelope proteins 
have been shown to transduce murine airway epithelial cells in vivo and interestingly 
gene expression persisted for 17 months [165]. Additionally, Sinn et al reported gene 
expression for up to 12 months in the mouse nose following transfection with a feline 
immunodeficiency virus pseudotyped with baculovirus GP64 envelope protein [166]. It 
is unclear, whether the prolonged expression observed is due to vector integration into 
airway stem cells or long-term expression in airway epithelial cells, recently reported to 
have a half-life expectancy of up to 17 months [167]. However, as re-administration of 
lentiviral vectors will eventually be needed if gene expression originates from 
transfected airway epithelial cells, several studies have shown that, in contrast to other 
viral vectors, lentiviruses can be repeatedly administered to the airway epithelium of 
mice [165,166]. The prolonged expression profile and the fact that the virus can be 
repeatedly administered in vivo make lentiviral vectors attractive candidates for CF gene 
therapy. However, the safety of these viruses has to be carefully assessed following the 
development of leukaemia, which occurred as a result of insertional mutagenesis in 
several patients treated with retroviruses in a X-linked severe combined immune 
deficiency (SCID) trial [168]. 
 
1.6.5 Non-viral vectors for airway gene therapy 
The three main types of non-viral vectors for airway gene therapy are cationic 
liposome/plasmid DNA (pDNA) complexes (lipoplexes), cationic polymer/pDNA 
complexes (polyplexes) and DNA nanoparticles. In comparison to viral vectors, these 
non-viral vectors are generally less efficient in the context of lung gene transfer, which 
are mainly due to the lack of cellular uptake and nuclear entry mechanisms. However, 
non-viral vectors are less likely to be immunogenic, a major obstacle for viral vectors, 
and therefore offer the potential advantage of repeat administration. Below, the leading 
non-viral formulations for CF gene therapy are described.  
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Cationic liposomes 
A cationic lipid gene delivery complex (lipoplex) normally consist of three components; 
a cationic lipid, a neutral co-lipid and pDNA. Cationic lipids are composed of (1) a 
positively charged head group interacting with negatively charged pDNA, (2) a 
hydrophobic anchor group responsible for the interaction with membranes and (3) a 
linker molecule, linking the head and anchor group together and, furthermore, affecting 
the stability of the lipid. Neutral colipids can increase transfection activity of the 
complex, probably by (1) destabilizing cell membrane bilayers and thereby enhancing 
cellular entry and (2) facilitating pDNA endosomal escape.  
 
Several lipoplexes have shown proof-of-principle for airway gene delivery in preclinical 
models. Hyde et al demonstrated that human CFTR complexed to Lipofectamine and 
delivered to the lungs of CFTR null mice via tracheal instillation corrected both chloride 
and sodium transport defects [169]. Furthermore, nebulisation of liposome/CFTR 
complexes, consisting of cationic liposome DC-Chol (3β[N-(N‟, N‟-
dimethylaminoethane)-carbamoyl]) and the co-lipid DOPE (dioleoyl phosphatidyl-
ethanolamine), restored airway chloride transport to 50% of wild-type levels in a 
different strain of null mice [170]. DC-Chol/DOPE has subsequently been assessed in 
clinical trials. Liposome/pDNA complexes were delivered topically to the nose of CF 
patients resulting in partial correction (20%) of the chloride defect. However, as 
expected, the effect was transient; peaking by day 3 and undetectable by day 7 [171]. 
Importantly, Hyde et al demonstrated that three doses of DC-Chol/DOPE complexed to 
CFTR could be repeatedly administered to the nose of CF patients without loss of 
efficacy, a necessity if non-viral vectors are to be used to treat a life-long disease, such 
as CF [172].  
 
One of the most efficient lipids for airway gene transfer is cationic lipid GL67 
(Genzyme lipid 67). It was generated by Genzyme after extensive optimisation of the 
promising DC-Chol structure and co-formulated with the neutral lipid DOPE and small 
amounts of polyethylene glycol (PEG) containing lipid (dimyristoyl 
phosphatidylethanolamine (DMPE)-PEG5000) in order to stabilise the formulation for 
aerosol delivery to the human lung [173,174]. In the mouse lung, GL67/pDNA 
complexes were shown to enhance gene transfer by more than a 1000-fold when 
compared to pDNA administered alone. However, gene expression was transient, 
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peaking between 1-4 days post-administration, when complexed to a plasmid containing 
the eukaryotic cytomegalovirus (CMV) immediate-early promoter/enhancer [174]. 
Recently, the effect of GL67 complexed to plasmid CFTR was assessed in the nasal 
epithelium of approximately 400 mice. Although, CFTR mRNA was detected in the 
majority of mice no significant correction of the CF phenotype (chloride transport, 
periciliary liquid height and bacterial adherence) was observed. This is likely to be 
linked to the fact that the assays used in the study were only powered to detect changes 
of more than 50% even though a comparatively large number of mice were assessed 
[175]. The comparative low efficiency of non-viral vectors compared to viral vectors 
may also explain why no correction of the CF phenotype was observed.  
 
The efficacy of GL67 has also been assessed in clinical trials and, to date, it is the only 
non-viral vector which has been aerosolised to the lungs of CF patients [176,177]. In the 
study by Ruiz et al vector-derived transgene mRNA was detected in four out of nine 
bronchoscopic lung samples [177]. Importantly, partial correction of the chloride defect 
was reported by Alton et al in the nose and lower airways of CF patients also treated 
with GL67 [176]. Interestingly, both studies reported mild, transient flu-like symptoms 
post administration, which are thought to be related to the unmethylated 
Cytosine/Guanine dinucleotides (CpG) in the bacterial pDNA, creating an inflammatory 
response.  
 
Recently, a clinical trial programme has been initiated in CF patients by the UK CF 
Gene Therapy Consortium to evaluate further the effect on GL67 in the lung when 
complexed to a novel CpG-free plasmid in which the CFTR cDNA is under control of a 
hybrid promoter consisting of a human CMV enhancer and the elongation factor 1α 
promoter (hCEFI). More precisely, the programme will assess if GL67-mediated gene 
transfer can alter clinically relevant endpoints in the CF airways when the non-viral 
vector is repeatedly administered over a long-term period. GL67 was chosen for the 
clinical trial programme as this vector performed best out of a number of available non-
viral GTAs when these were screened pre-clinically, employing the following criteria; 
(1) efficient gene transfer into airway epithelial cells in vivo, (2) repeated administration 
without provoking an immune response, (3) stability in a clinically-used nebuliser, (4) 
low toxicity and (5) good manufacturing practice (GMP) for vector production (G. 
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McLachlan, CF Gene Therapy Group, Edinburgh University, UK - manuscript in 
preparation). 
 
Cationic polymers 
Polyethylenimine (PEI), a cationic polymer, has also been used as a non-viral vector to 
transfect airway epithelial cells. PEI binds negatively charged pDNA via electrostatic 
forces, resulting in complexation of DNA into small particles which is a necessity for 
efficient delivery of the DNA into cells. Furthermore, complexation of DNA with PEI 
protects the DNA against degradation. However, an excess of polycation, leading to an 
overall positive charge, is essential not just for sufficient solubilisation of the complex, 
but also for efficient cell transfection [178,179]. Unmodified cations interact with 
negatively charged proteoglycans located on the surface of cell membranes, which 
facilitates cellular uptake of the complex predominately via endocytosis [178]. 
Additionally, the high content of nitrogen atoms that can be protonated allows PEI to 
act as a „proton sponge‟, which induces osmotic swelling of the endosome and 
eventually rupture, leading to release of the vector into the cytoplasm.   
 
Two forms of PEI have been investigated for airway gene transfer, linear 22 kDa PEI 
and branched 25 kDa PEI [180,181]. Instillation of linear PEI complexed to pDNA via 
the trachea resulted in efficient lung gene transfer in the lungs of rabbits. In addition, the 
authors showed that the complex could be repeatedly administrated without eliciting an 
immune response to PEI. However, lack of expression was observed at consecutive 
instillations due to a neutralising response against the reporter gene [180]. Wiseman et 
al have compared linear and branched PEI in vitro and in vivo following intranasal 
instillation of the complex to the murine lung and showed that in both cases linear PEI 
resulted in higher levels of reporter gene transfer. However, expression was short-
lasting and repeat dosing with linear PEI failed to give gene expression at the level 
observed after the initial dose [181]. 
 
In contrast to linear PEI, significant expression following nebulisation, a clinically 
relevant delivery method, has only been reported for branched PEI [182]. 25 kDa 
branched PEI complexed to pDNA has been delivered to the mouse lung via whole 
body nebulisation without losing its transfection efficiency and, importantly, without 
causing significant inflammation [183,184]. In contrast, moderately to severe 
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inflammation has been observed after PEI bolus instillations in vivo indicating that 
aerosol delivery of the non-viral vector is a safer delivery method [185,186]. 
Furthermore, a direct comparison between linear and branched PEI resulted in a 
significant higher expression level in the murine lung following nebulisation of 
branched PEI [187]. 
 
One limitation of PEI/pDNA complexes is that they have proven difficult to prepare at 
high concentrations, relevant for clinical application. Preparation of these complexes at 
pDNA concentrations exceeding 0.5 mg/ml is normally associated with precipitation 
and loss of efficacy. However, recently, Davies et al have generated a more 
concentrated formulation by incorporation of a simple filtration step, allowing 
preparation of stable 25 kDa branched PEI at concentrations at 8 mg/ml pDNA, which 
lead to more efficient gene transfer in the murine lung [185]. 
 
DNA nanoparticles 
DNA nanoparticles are formed by condensing pDNA with a poly-lysine peptide 
substituted with PEG. The size of the particles are <20 nm and they are believed to be 
small enough to allow efficient cellular and, more importantly, nuclear entry. In 
addition, they are charge-neutral, non-immunogenic and can transfect non-dividing cells 
[188,189]. Moreover, DNA nanoparticles have shown to bind to the cell surface protein 
nucleolin, which is believed to function as a receptor, thereby facilitating cellular uptake 
of the particles. Nucleolin is also known to shuttle between the cell surface, cytoplasm 
and the nucleus and this protein may, therefore, also facilitate the transport of the 
particles from the cell surface to the nucleus [190]. 
 
Ziady et al have compared transfection efficiency in the mouse lung following 
intranasal and intratracheal instillation of DNA nanoparticles and naked pDNA. 
Administration of DNA nanoparticles resulted in a 200-fold increase in gene transfer 
compared to naked pDNA, however, as expected expression was transient and lasted 
approximately 3 days [189]. Importantly, DNA nanoparticles have already been 
prepared at concentrations and to a standard which is suitable for clinical application. In 
addition, preliminary results suggest that the vector retains integrity following 
nebulisation [182]. In the clinic, DNA nanoparticles have been delivered to the nasal 
epithelium of CF patients. The formulation proved to be safe and a partial correction of 
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the chloride transport defect was observed in some patients, however, some cross-
contamination was observed as the active agent and the placebo were delivered into 
contralateral nostrils [191]. 
 
1.6.6 Bacterial vectors for gene therapy 
Over the last decade bacterial vectors have emerged as an alternative to the commonly 
used viral and non-viral vector systems. Several studies have shown that bacteria-
mediated gene transfer is feasible in vitro and in vivo using a broad range of attenuated, 
intracellular bacteria such as Shigella flexneri, Salmonella typhimurium, Listeria 
monocytogenes, Salmonella typhi and recombinant invasive Escherichia coli (E. coli) 
[192,193]. 
 
Most in vitro studies assessing bacteria-mediated gene transfer have been performed on 
poorly differentiated immortalized cell lines such as HeLa or macrophage-like cell lines 
which have no direct relevance for airway gene therapy. However, Fajac et al have 
recently assessed uptake and intracellular trafficking of a recombinant invasive 
Escherichia coli into human tracheal /bronchial cell lines and explant outgrowth of non-
CF bronchial tissue [194]. The study has shown efficient uptake of invasive E. coli into 
cells at the periphery of the outgrowth and in all airway cell lines tested and, albeit low 
efficiency, bacteria-mediated gene transfer. Attempts at bacteria-mediated gene transfer 
in vivo have mainly been directed at genetic vaccination targeting macrophages and 
dendritic cells [195-198]. One study has assessed bacteria-mediated gene transfer into 
non-phagocytic cells with Castagliuolo et al demonstrating that recombinant invasive E. 
coli can efficiently deliver therapeutic genes to the intact intestinal mucosa in mice 
[199]. However, bacteria-mediated gene transfer into the airway epithelium in vivo has 
not been assessed yet (see Chapter 3 for a more detailed description). 
 
1.6.7 Ways to enhance non-viral airway gene transfer 
As outlined above, non-viral vectors are attractive candidates for CF gene therapy due 
to their safety profile and ability to be repeatedly administered. However, compared to 
viral vectors these vectors are generally less efficient and, therefore, ways to enhance 
efficiency are attracting attention.  
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Receptor-mediated vector uptake  
Viral vectors can efficiently infect airway epithelium via receptor-mediated uptake or 
cell fusion. However, for non-viral gene transfer agents, vector uptake is a rate-limiting 
step and, furthermore, nuclear entry is also known to be a significant barrier for 
liposome/pDNA complexes [200]. 
 
In an attempt to enhance efficiency, peptide ligands have been attached to non-viral 
vectors, which specifically target receptors found on the apical membrane of airway 
epithelial cells thereby facilitating receptor-mediated vector uptake. Ziady et al have 
complexed plasmid CFTR to the polymer poly-L-lysine and a peptide ligand consisting 
of 17 amino acids, which is known to target the serpin-enzyme complex receptor (sec-
R) [201]. The complex not only partially corrected chloride transport in the nasal 
epithelium of CF mice but also restored NOS-2 expression. However, the formulation 
was not stable, which made it difficult to develop it for clinical use. Similar, an integrin-
targeting peptide has been used to enhance cellular uptake of the cationic liposome, 
Lipofectin, complexed to pDNA in the rat lung [202].  Sugar moieties have also been 
used for receptor targeting. Both lactosylated poly-L-lysine and PEI have been shown to 
enter airway epithelial cells in vitro via receptor-mediated endocytosis and, furthermore, 
enhanced gene transfer efficiency was observed following lactosylated PEI/pDNA gene 
transfer in vitro [203,204]. However, compared to non-glycosylated linear and branched 
PEI, lactosylated PEI delivered via nasal instillation to the murine lung did not increase 
gene transfer efficiency, emphasising the need to assess vectors primarily in vivo [204]. 
Although various strategies have been assessed to enhance non-viral vector uptake as 
described above, none of these result in higher levels of gene expression compared to 
GL67.  
 
Physical methods 
The addition of physical energy is also an interesting approach to increase non-viral 
gene transfer. Electroporation involves the application of electrical pulses to enhance 
gene delivery by transiently permeabilising the cell membrane. By placing electrodes 
onto the chest, this approach has successfully been applied in mice and rats and as a 
result pDNA gene delivery to the lung has increased [205-207]. However, translation of 
lung electroporation into larger animal models, such as the sheep, has been difficult. In 
preliminary experiments, an electrode was placed into a large airway via a 
58 
 
bronchoscope while the second electrode was placed on the chest. Although gene 
expression increased modestly the effect was restricted to a very small part of the 
airways (I. Pringle, Gene Medicine Group, University of Oxford, UK - personal 
communication) and therefore not suitable for translation into clinical trial. 
  
Coupling of magnetic particles to plasmid DNA makes the DNA responsive to a 
magnetic field, a process called magnetofection. This approach has successfully been 
used to transfect primary airway cells in vitro [208]. However, when assessed in vivo in 
murine nasal epithelium, by placing a magnetic rod externally directly onto the mouse 
nostril, gene transfer efficiency decreased following delivery of naked pDNA or 
GL67/pDNA complexes coupled to magnetic particles [209]. This may be due to 
alteration of the physiochemical properties of the non-viral vector when coupled to 
magnetic particles.  
 
Finally, ultrasound (sonoporation) can cause transient pore formation in the cell 
membrane, thereby increasing vector uptake, a process which is enhanced by the 
addition of gas-filled microbubbles. Proof-of-principle that ultrasound increases gene 
transfer in the air-filled lung has been established despite the fact that this type of 
physical energy is greatly attenuated when travelling through air/tissue interfaces [210]. 
Low-frequency ultrasound, which has greater potential for sonoporation in the air-filled 
lung, was shown to increase naked pDNA gene transfer in the mouse lung in vivo [211]. 
However, ultrasound-based methods were reported to cause haemorrhage to the mouse 
lung, at high exposures, showing that there is a narrow efficacy - toxicity window in this 
animal model. There was an attempt to test this method in the sheep lung, in vivo, in 
order to assess its potential clinical relevance. However, these attempts were hindered 
by small n numbers and severe technical limitations, as the ultrasound equipment 
available was not suitable for large animal studies.   
  
Although, proof of principle has been established that physical methods can be used to 
enhance non-viral gene transfer in pre-clinical in vitro and in vivo models, these 
methods are unlikely to be suitable for translation into clinical trials.  
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Tight junctions  
As previously mentioned, the concept of opening tight junctions (TJ) to increase gene 
transfer to airway epithelial cells has been explored in the context of adenovirus-
mediated gene transfer. Importantly, pre-administration of tight junction openers has 
enhanced access of adenovirus to its receptors, which are predominately expressed on 
the basolateral membrane of airway epithelial cells, and has greatly improved gene 
transfer in pre-clinical models [140,212-214]. 
 
Opening of tight junctions may also increase non-viral gene transfer efficiency as it is 
believed that non-viral GTAs enter cells via endocytosis and this process may be more 
efficient at the basolateral compared to the apical membrane [215,216]. However, only 
a limited number of studies have been carried out to assess this approach. In vitro 
EGTA has been shown to enhance GL67-mediated gene transfer [215]. In vivo the 
effect of EGTA has been assessed using PEI and the non-viral vector system LID 
(lipofectamin, integrin-targeting peptide, plasmid DNA). PEI failed to enhance gene 
transfer to the murine lung whereas LID had a positive effect on gene transfer efficiency 
[187,215,217]. These studies are discussed in more details in Chapter 4. To date, the 
effect of tight junction openers on GL67-mediated gene transfer to the airways in vivo 
has not been assessed.  
 
Plasmid improvements 
Although, non-viral vectors are less likely to be immunogenic compared to viral 
vectors, inflammatory responses were observed in two CF clinical trials after 
administration of GL67/pDNA complexes to the lung [176,177]. As previously 
mentioned, the inflammatory response was thought to be related to the presence of 
unmethylated CpG sequences in the plasmid DNA. Unmethylated CpG dinucleotides 
are present in high frequency in bacterial DNA and, therefore, in most pDNA 
molecules. Their presence can activate the innate immune system via toll-like receptor 9 
and lead to production of proinflammatory cytokines [182]. Recently, Hyde et al have 
shown that the presence of even a single CpG in a plasmid could induce an 
inflammatory response in the murine lung following delivery of GL67/pDNA [218]. 
However, generation of completely CpG-depleted plasmids reduced the inflammatory 
response to backgrounds levels and led to longer lasting gene expression in the mouse 
lung [218]. Importantly, CpG-depleted plasmids may prevent the inflammatory 
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responses previously observed in CF patients transfected with GL67/pDNA complexes. 
However, this is still to be assessed.  
 
Viral promoters such as the CMV promoter, which have been used in most pre-clinical 
and clinical studies, generally result in a high level of expression but fail to generate 
persistent gene expression [219]. A persistent expression level is needed to ensure 
maximal gene expression between repeated GTA/pDNA administrations, required for 
treatment of chronic CF lung disease. The human polyubiquitin C (UbC) promoter and 
the elongation factor 1α (EF1α) promoter have led to persistent gene expression in the 
mouse lung [220]. More recently, the generation of the hybrid promoter hCEFI, which 
combined CpG-free enhancer/promoter sequences, resulted in sustained gene expression 
in the mouse lung 84 days post delivery [218]. As previously mentioned, a CpG-free 
plasmid containing this hybrid promoter has been selected for the clinical trial 
programme conducted by the UK CF Gene Therapy Consortium. 
 
1.6.8 Other approaches - gene repair, gene silencing and stem cells 
Gene repair 
In addition to the standard gene therapy strategies described above, gene repair is 
another approach which has been assessed. This involves the induction of gene repair at 
the genomic level using oligonucleotides. It offers the theoretical advantage that the 
‟corrected‟ CFTR gene expression is under control of the endogenous CFTR promoter 
[221]. However, oligonucleotide-mediated gene repair for CF is currently very 
inefficient as shown in a study by De Semir and colleagues in which gene repair was 
attempted in CF airway epithelial cells [222]. To date no successful pre-clinical in vivo 
studies have been published.  
 
Gene silencing 
Gene silencing through RNA interference (RNAi) is a process in which translation of 
mRNA is prevented due to the presence of small  double-stranded RNA molecules 
which bind to the target mRNA thereby inducing its degradation and prevent 
translation. RNAi is a natural mechanism taking place in cells, however, the term RNAi 
can also be used to describe the introduction of small interference (si) RNA into a cell 
to inhibit the expression of a particularly gene. The approach has been used to inhibit 
candidate proteins with the aim of attenuating CF lung disease. A reduction in the 
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expression of nuclear factor kappa B, which regulates the transcription of many pro-
inflammatory cytokines, may be beneficial [223]. A more specific target maybe ENaC, 
which is known to be upregulated in CF and contributes to the imbalanced water 
movement in CF lung. Recently, Caci et al have reported that down-regulation of ENaC 
in human bronchial epithelial cells in vitro by siRNA resulted in reduced transepithelial 
fluid transport [224]. However, a previous publication has shown that although siRNA 
reduced the level of ENaC mRNA in vivo, this was too inefficient to translate into a 
reduction in protein, which is thought to be linked to the inefficient cellular uptake of 
the non-viral vector used [225]. Further improvements in non-viral gene transfer 
efficiency, may perhaps make gene silencing a realistic treatment option in the future.  
 
Stem cell therapy 
Stem cell therapy is another approach for the treatment of CF. The technique, which 
involves ex vivo transfection of bone-marrow derived stem cells with integrating retro- 
and lentiviral vectors followed by systemic re-administration, is well established. These 
vectors are chosen as they offer the advantage of integration and thereby providing 
expression for the life-time of the cell. Furthermore, bone-marrow derived stem cells 
may have the capacity to differentiate into airway epithelial cells making this approach 
very interesting in the context of CF [123]. However, regeneration of the airway 
epithelium by re-administration of bone-marrow derived stem cells is very inefficient 
and seems to require lung damage for engraftment to take place. One study reporting 
<1% of tracheal epithelial cells were bone-marrow derived after detergent damage in a 
mouse model [226]. A slightly different approach which may hold more promise is to 
target resident pulmonary stem cells with for example integrating lentiviral vectors. 
Certain cell types have been shown to have stem cell properties in the mouse lung, 
thereby being able to differentiate into other pulmonary cells. In the airway epithelium 
for example, Clara and basal cells have a regenerative capacity and, by targeting these 
cells with integrating vectors, life-long expression in airway epithelial cells is a 
possibility [123]. However, the safety profile of this approach has to be carefully 
studied and, in addition, proof-of-principle in animal models established. 
 
62 
 
1.7 Aims 
 
Many interesting strategies have been assessed in pre-clinical models. However, none 
has proven immediate suitability for translation into clinical trial. Therefore, further 
optimisation of existing non-viral GTAs and the development of novel GTAs may be 
important to make gene therapy a viable option for treatment of cystic fibrosis and other 
lung diseases. The aim of this thesis was to further assess strategies to increase gene 
transfer to the lung. Two separate approaches both related to CF gene therapy were 
studied.  
 
1. Optimisation and assessment of bacteria-mediated gene transfer to the murine lung 
and comparison of efficiency to the current “gold-standard” non-viral GTA, cationic 
lipid GL67, which is currently used in clinical trials. This project involved optimisation 
of bacterial constructs, determination of bacteria deposition in the mouse lung and 
quantification of reporter gene expression.   
 
2. Assessing the effects of various tight junction openers on GL67-mediated gene 
transfer to the airway epithelium of mice and in a human ex vivo model. This project 
involved careful optimisation of drug doses and delivery, identification of the most 
effective tight junction opener and assessment of efficacy in CF knockout mice, as 
measured by the correction of the chloride transport defect characteristic for CF 
animals.  
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Chapter 2: Materials and Methods 
 
The following chapter is a description of generic materials and methods used in this 
thesis. Specific materials and methods used in individual experiments are described in 
detail in the relevant chapter.  
 
 
2.1 Plasmids and gene transfer agents 
 
2.1.1 Plasmid DNA (pDNA) 
Varies plasmids carrying prokaryotic or eukaryotic regulatory elements were used in 
this thesis (details below). DNA was either purified from commercial suppliers (Bayou 
Biolabs, New England Biolabs Ltd.) or produced in house using standard plasmid 
Qiagen-based extractions (www.qiagen.com).  
 
 pCIKLux: The pCIKLux plasmid used in theses studies was obtained from Dr. 
Deborah Gill (Gene Medicine Group, University of Oxford, UK) and carries the 
Firefly luciferase (lux) reporter gene under control of the eukaryotic CMV 
immediate-early promoter/enhancer. Expression is transient (approximately 7 days) 
with maximum reporter gene expression obtained 24-48 hrs after transfection.  
 
 pCIKLux-mod: The modified pCIKLux (pCIKLux-mod), in which two copies of the 
transcription terminator sequence of gene 32 from bacteriophage T4 were inserted 
downstream of the hybrid intron, was developed by Dr. Catherine Grillot-Courvalin 
(Unité des Agents Antibactériens, Institut Pasteur, France). In brief, to obtain 
pCIKLux-mod, a NheI linker containing the T4 terminator was created by 
hybridization of two complementary linkers, T4-F (5‟CTA GCG GTA CCA TTA 
TAT TAC TAA TTA ATT GGG GAC CCT AGA GGT CCC CTT TTT TAT TTT 
AAA AAG-3‟) and T4-R (5‟CTA GCT TTT TAA AAT AAA AAA GGG GAC 
CTC TAG GGT CCC CAA TTA ATT AGT AAT ATA ATG GTA CCG-3‟) and the 
fragment obtained was cloned into the NheI site of the pCIKLux as described by 
Larsen et al [227]. 
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 pCIKCFTR: The pCIKCFTR plasmid was provided by Dr. Deborah Gill (Gene 
Medicine Group, University of Oxford, UK) and carries the human CFTR cDNA 
under control of the eukaryotic CMV immediate-early promoter/enhancer.  
 
 pCIKempty: The plasmid obtained from Dr. Deborah Gill (Gene Medicine Group, 
University of Oxford, UK) harboured the eukaryotic CMV immediate-early 
promoter/enhancer but no transgene or reporter gene was inserted into the plasmid. 
 
 pAT505: Plasmid pAT505 in which the gfpmut1 gene was under the control of the 
prokaryotic Plac (lactose) promoter was provided by Dr. Catherine Grillot-Courvalin 
(Unité des Agents Antibactériens, Institut Pasteur, France) [228]. GFPmut1 is a 
mutated green fluorescence protein (GFP), which exhibits ~35 times higher 
fluorescence intensity than wild-type GFP at 488 nm [229]. 
 
 pEGFP-N1: The pEGFP plasmid carries the gfpmut1 gene encoding the GFPmut1 
protein, also called enhanced green fluorescent protein (EGFP), under control of the 
eukaryotic CMV immediate-early promoter/enhancer. The plasmid was cloned by 
Dr. Deborah Gill (Gene Medicine Group, University of Oxford, UK) and 
subsequently amplified by Bayou Biolabs (Bayou Biolabs, Harahan, USA).  
 
 pGM144: The pGM144 plasmid was generated by a member of the UK CF Gene 
Therapy Consortium [218] and carries the Firefly luciferase reporter gene under 
control of the human CEFI promoter/enhancer. The CEFI promoter/enhancer 
consists of the CMV enhancer coupled to the human elongation factor 1 alpha 
(EF1α) promoter. The plasmid, including the promoter/enhancer sequence and the 
reporter gene, was completely CpG depleted. 
 
 pGM169: The pGM169 plasmid was generated by a member of the UK CF Gene 
Therapy Consortium [218] and contains the same plasmid backbone as pGM144. 
Instead of the reporter gene it carried the human CFTR transgene.  
 
 pCMV-GLux: The pCMV-GLux plasmid carries the secreted Gaussia luciferase 
reporter gene under control of the eukaryotic CMV immediate-early 
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promoter/enhancer. The plasmid was obtained from New England Biolabs Ltd. (New 
England Biolabs Ltd., Hitchin, UK). 
 
2.1.2 Cationic liposomes and generation of lipid/pDNA complexes 
The non-viral gene transfer agent used in these studies was cationic lipid GL67 
consisting of GL67 / DOPE (dioleoylphophatidylethanolamine) / DMPE 
(dimyristoylphosphatidylethanol- amine)-PEG5000 (polyethylene glycol) at molar ratios 
of 1:2:0.05 [173]. This GTA was optimised for airway gene transfer and obtained from 
OctoPlus (Leiden, Holland). GL67 was resuspended in water for injection (WFI) (B. 
Braun Medical Ltd., Sheffield, UK) to a final concentration of 11.4 mM and vortexed 
for approximately 45 min at 2400 rpm (revolutions per minute) (DVX-2500 Multi-Tube 
Vortexer, VWR International, Lutterworth, UK). In this thesis, GL67 refers to the 
cationic lipid resuspended in WFI. GL67/pDNA complexes were administered to mice 
by nebulisation, nasal instillation („sniffing‟) and nasal perfusion (see Section 2.4). 
Generation of the gene transfer complexes varied slightly with the delivery method used 
in vivo. In addition, the gene transfer complexes were generated at different molar ratios 
for transfections in human airway air liquid interface (ALI) cultures. 
 
 Nebulisation: Resuspended GL67 (11.4 mM) and pDNA (15.2 mM, 5 mg/ml) were 
equilibrated at 30ºC for 5 min and equal volumes were mixed to achieve a molar 
ratio of 6:8 (GL67:pDNA) as previously described [173]. The complexes were then 
left for 15 min at room temperature before use. 
 
 Nasal instillation/perfusion: Resuspended GL67 (11.4 mM) was diluted to a final 
concentration of 1.2 mM in WFI. GL67 and pDNA (4.8 mM, 1.6 mg/ml) were 
equilibrated (30ºC, 5 min) and equal volumes were mixed to achieve a molar ratio of 
1:4 (GL67/pDNA) as previously described [173]. Before use, complexes were 
incubated at 30ºC for a further 15 min.  
 
 Air liquid interface culture: GL67 was complexed to pDNA at molar ratios of 1:4 or 
6:8. These complexes were generated as described above for „Nasal 
instillation/perfusion‟ and „Nebulisation‟.  
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2.1.3 Virus 
Recombinant Sendai virus (SeV), obtained from DNA VEC Research Inc. (DNA VEC 
Research Inc., Tsukuba, Japan) carrying Firefly luciferase as a reporter gene was used 
for ex vivo studies to transfect differentiated respiratory epithelium (see Chapter 8). The 
virus transfects most cell types, including respiratory epithelia, efficiently and did, 
therefore, function as a positive control in these studies.   
 
 
2.2 Cell lines and air liquid interface cultures 
 
2.2.1 Cell lines  
 CFTE29o-A:  The human CF tracheal epithelial cell line (CFTE29o-) was obtained 
from D. Gruenert, California Pacific Medical Center Research Institute, University of 
California, USA. CFTE29o- cells were cultured in minimum essential medium 
(MEM) (Sigma-Aldrich Com. Ltd., Poole, UK) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Sigma-Aldrich Com. Ltd., Poole, UK) and 1% 
penicillin/streptomycin (Sigma-Aldrich Com. Ltd., Poole, UK). Cells were 
maintained at 37ºC in a 5% CO2 atmosphere. 24 hrs prior to bacterial infection 
CFTE29o- cells were seeded in 6-well and 8-well plates at a density of 2x10
5
 
cells/well and 8x10
3
 cells/well, respectively, in order to achieve 100% confluence on 
day of infection. 
 
 293T: The human embryonic kidney cell line (293T) (LGC Standards, Middlesex, 
UK) was cultured in Dulbecco‟s modified Eagle‟s medium (DMEM) (Sigma-Aldrich 
Com. Ltd., Poole, UK), supplemented with 10% heat-inactivated FBS and 1% 
penicillin/streptomycin. Cells were maintained at 37ºC in a 5% CO2 atmosphere. 24 
hrs prior to bacterial infection 293T cells were seeded in 6-well and 8-well plates at a 
density of 1x10
5
 cells/well and 6x10
3
 cells/well, respectively, in order to achieve 
100% confluence on day of infection. 
 
2.2.2 Air liquid interface cultures (MucilAirTM) 
Human pseudostratified respiratory epithelia maintained at ALI (MucilAir
TM
) were 
obtained from Epithelix Sarl (Epithelix Sarl, Geneva, Switzerland) and used in these 
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studies. Briefly, primary human airway epithelial cells (AEC) isolated from nasal 
polyps were grown into differentiated respiratory epithelia by seeding the AECs onto 
semi-permeable supports (Transwell insert, 6.5 mm in diameter, 0.4 µm pore size). 
Following proliferation in submerged conditions, differentiation was induced by 
culturing the cells at an ALI [230]. Fully differentiated ALI cultures were ordered from 
the company. On arrival, inserts were maintained at 37ºC in a 5% CO2 atmosphere. 
Culture medium (MucilAir
TM
 Culture Medium) (Epithelix Sarl, Geneva, Switerland) in 
the basolateral compartment (500 µl) was changed every 2-3 days according to 
manufacturer‟s recommendations. 
 
 
2.3 Animals and anaesthesia 
 
For in vivo studies, the wild-type C57Bl/6 mouse (Harlan UK Ltd. Bicester, UK) and a 
gut-corrected CF-knockout mouse were used. The gut-corrected CF knockout mouse 
carries the human CFTR transgene under the control of the rat intestinal fatty acid 
binding protein gene promoter (FABp), which means that CFTR is expressed only in 
the murine intestinal epithelium [231]. Generally, CF knockout mice have a high 
mortality and gut disease is normally the cause of death, making these animals hard to 
breed and work with. However, gut-corrected CF-knockout mice (FABp mice) exhibit 
no gut disease and furthermore, they have a normal lifespan and breeding pattern. The 
gut-corrected CF knockout mice were bred at Imperial College London. All animal 
procedures were carried out with the approval of appropriate local Ethics Committees 
and adhered to the UK Home Office Animals (Scientific Procedures) Act 1986. 
 
Group sizes of approximately 8 mice were used in each experiment to allow for reliable 
statistical comparison combined with what is ethically justifiable. 
 
In the majority of in vivo experiments, Metofane (Medical Developments International 
Ltd., Springvale, Australia) was used as an anaesthetic. In brief, the mouse was fixed 
inside a tube containing holes which allowed inhalation of the anaesthetic from soaked 
cotton wool. The anaesthesia was short lived as the mouse recovered within minutes. 
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For longer lasting anaesthesia the following anaesthetics were used (all animals were 
carefully monitored until the „righting‟ reflex had recovered): 
 
 Ketaset (Ketamine), Domitor (Medetomidine) (National Veterinary Services, Stoke-
on-Trent, UK) and sterile water were mixed at a ratio of 0.38:0.5:4.12 (volume) and 
given intraperitoneally (i.p.) (100 µl were administered per 10 g mouse). As antidote 
Antisedan (Atipamezole) (National Veterinary Services, Stoke-on-Trent, UK) was 
diluted (9:1) and given i.p. (20 µl were administered per 10 g mouse).  
 
 Hypnorm (Fetanyl citrate and Fluanisone), Hypnovel (Midazolam) (National 
Veterinary Services, Stoke-on-Trent, UK) and sterile water were mixed at a ratio of 
1:1:2 and 1:1:4 (volume) and administered i.p. (100 µl were administered per 10 g 
mouse). The antidote Naloxone hydrocloride (National Veterinary Services, Stoke-
on-Trent, UK) was given i.p. (30 µl were administered per 10 g mouse) undiluted. A 
combination of Hypnorm, Hypnovel and sterile water at a ratio of 1:1:4 were also 
given to exsanguinate the mouse (100 µl were administered per 10 g mouse).  
 
 Pentobarbital (15 mg/ml) (Sigma-Aldrich Com. Ltd., Poole, UK) was administered 
i.p. (80 µl were administered per 12 g mouse). Importantly, real care was taken to 
administer the exact dose of pentobarbital to avoid overdosing and hereby killing the 
mouse. No antidote was available for this anaesthetic.  
 
 Euthatal (Sodium pentobarbital) (50 mg/ml) (National Veterinary Services, Stoke-
on-Trent, UK) was administered i.p. (200 µl were administered per 20 g mouse) to 
cull the mouse.  
 
 
2.4 Procedures for in vivo gene and drug delivery in mice 
 
2.4.1 Delivery to nasal epithelium by nasal perfusion  
Delivery of the gene transfer complex by nasal perfusion leads to selective transfection 
of the nasal epithelium. For nasal perfusion, mice were anaesthetised i.p. with 
Ketaset/Domitor, Hypnorm/Hypnovel or Pentobarbital (see Section 2.3) and placed on 
69 
 
to heated boards in the supine position. A fine catheter approximately 0.5 mm in 
diameter (Portex polythene tubing, Jencons, Forest Row, UK) was inserted 2.5 mm into 
the left nostril by marking the catheter at 2.5 mm and the appropriate solution was 
perfused at a rate of approximately 6.7 µl/min using a syringe pump (Cole-Parmer, 
Illinois, USA) (Figure 6). Perfusion time and volume varied for each experiment, but 
the same amount of DNA (80 µg) was administered; 15 min perfusion (100 µl), 1 hr 
perfusion (400 µl) and 6 hrs perfusion (2.4 ml). The generated GL67/pDNA complexes 
(see Section 2.1.2) were used undiluted for 15 min nasal perfusion. However, to deliver 
the same amount of plasmid (80 µg) over a longer period of time, GL67/pDNA 
complexes were diluted 1:4 and 1:24 (v/v) in WFI for 1 hr and 6 hrs perfusion, 
respectively. During the procedure, the mice were placed at a 45º angle, a paper wick 
was placed into the mouths to prevent swallowing the solutions and a paper pad was 
placed on to the nose to absorb excess solution. Immediately after the procedure, mice 
were given the appropriate antidote if available and placed in a box on a heat board until 
fully recovered. Nasal perfusion was also used to deliver tight junction openers to the 
mouse nasal epithelium (Chapter 7). Nasal perfusions with the tight junction openers 
were performed as described above. 
 
2.4.2 Delivery to nasal and lung epithelium by nasal instillation 
Mice were anaesthetised with Metofane as described in Section 2.3. For nasal 
instillation („sniffing‟), the mouse was positioned upright and their mouth was held 
closed between the thumb and forefinger. A single bolus (25 µl, 50 µl or 100 µl) was 
then applied to the nose, using a standard pipette, and rapidly „sniffed‟ into the lung 
(Figure 7).  
 
2.4.3 Delivery to nasal and lung epithelium by whole body nebulisation 
Mice were placed in a nebulisation box (30 cm x 21.5 cm x 20.5 cm) in which the 
bottom was lined with paper towels. A PARI LC PLUS nebuliser (PARI Medical Ltd, 
West Byfleet, UK) was connected to the box and 10 ml of GL67/pDNA complexes (2.5 
mg/ml) or a tight junction opener was nebulised at 22 pounds per square inch (PSI) (1.5 
bar) using compressed air (BOC, Guildford, UK) taking approximately 1 hr (Figure 8). 
Following nebulisation, mice were left in the box for a further 5 min before 
disconnecting the nebuliser.  
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Figure 6: Delivery to nasal epithelium by nasal perfusion 
For nasal perfusion, the mouse was anaesthetised and placed on to a heated board in the supine 
position. A fine catheter (~0.5 mm in diameter) was inserted 2.5 mm into the left nostril and the 
appropriate solution was perfused onto the nasal epithelium using a syringe pump (~6.7 µl/min). 
During the procedure, the mouse was placed at a 45º angle, a paper wick was placed into the 
mouth to prevent swallowing the solution and a paper pad was placed on to the nose to absorb 
excess solution. 
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Figure 7: Delivery to nasal and lung epithelium by nasal instillation 
For nasal instillation („sniffing‟), the mouse was anaesthetised and positioned upright. The 
mouth was held closed between the thumb and forefinger. A single bolus (25 µl, 50 µl or 100 
µl) was then applied to the nose, using a standard pipette, and rapidly „sniffed‟ into the lung.  
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Figure 8: Delivery to nasal and lung epithelium by whole body nebulisation 
For whole body nebulisation, mice were placed in a nebulisation box (30 cm x 21.5 cm x 20.5 
cm) in which the bottom was lined with paper towels. A PARI LC PLUS nebuliser was 
connected to the box and 10 ml solution was nebulised at 22 pounds per square inch (PSI) 
taking approximately 1 hr. 
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2.5 Quantification of reporter gene expression 
 
2.5.1 Preparation of cell lysates and tissue homogenates  
 Cell line: To prepare for quantification of Firefly luciferase gene expression, cell 
pellets derived from 6-well plates were resuspended in 100 µl Reporter Gene Assay 
Lysis Buffer (1x) (Roche, Welwyn, UK) freeze-thawed three times to break up cells 
further, spun for 10 min at 13 793 g (4ºC) and the supernatant assayed for Firefly 
luciferase gene expression. For 96-well plates, 100 µl lysis buffer was added directly 
to each well, followed by 30 min incubation at room temperature. The plates were 
then freeze-thawed (3x) and the cells removed and spun, as described above, before 
assaying the supernatant. The supernatant was either analysed immediately or stored 
at -80ºC for later analysis.  
 
 Air liquid interface culture: Cells grown on inserts and maintained at an ALI were 
harvested by adding 100 µl lysis buffer onto the apical surface and scraping the insert 
without piercing it. After 30 min incubation at room temperature, 3 cycles of freeze-
thawing were performed before spinning the cell lysate for 10 min at 13 793 g (4ºC) 
and assaying the supernatant for Firefly luciferase gene expression. The supernatant 
was either analysed immediately or stored at -80ºC for later analysis.  
 
 Nasal tissue: The mouse was exsanguinated as previously described (Section 2.3). 
Before harvesting the nasal septum, lined with airway epithelium, the mouse head 
was trimmed for hair and the thin bone covering the nasal septum was gently 
removed. The nasal septum, lined with airway epithelium, was then cut loose, gently 
removed with a pair of forceps, snap-frozen in liquid nitrogen and stored at -80ºC 
until homogenisation was performed. The nasal septum was homogenised with fine 
scissors in 100 µl lysis buffer. Nasal homogenates went through 3 cycles of freeze-
thawing before spinning for 10 min at 13 793 g (4ºC). The supernatant was then 
assayed for Firefly luciferase gene expression.  
 
 Lung tissue: The mouse was culled using the appropriate anaesthetic and the chest 
cavity opened by cutting through the rib-cage. The lungs were gently cut free while 
holding on to the trachea with a pair of forceps and finally removed from the body. 
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Lungs were snap-frozen in liquid nitrogen and stored at -80ºC until lung 
homogenisation was carried out. Lung homogenisation was performed in 200 µl or 
300 µl lysis buffer for the left and right lung, respectively, using either a handheld 
homogeniser (Ultra-Turrax, Sceince Lab, Houston, TX, USA) or a FastPrep machine 
(FastPrep FP120, Qbiogene, Cambridge, UK). Lung homogenates, prepared using 
the Ultra-Turrax homogeniser went through 3 cycles of freeze-thawing before 
spinning for 10 min at 13 793 g (4ºC). The supernatant was then assayed for reporter 
gene expression. Lung tissue prepared using Fastprep was transferred into lysing 
matrix D tubes (Qbiogene, Cambridge, UK) and homogenised for 45 sec (4.0 m/s). 
After 15 min incubation time, the homogenised tissue was transferred to a 
QIAshredder spin column (Qiagen Ltd., Crawley, UK) and centrifuged for 1 min (13 
793 g, 4ºC). The lysates was centrifuged for further 5 min (13 793 g, 4ºC) prior to 
quantification of Firefly luciferase gene expression.  
 
2.5.2 Quantification of Firefly luciferase expression 
In most experiments Firefly luciferase was the chosen reporter gene. It is sensitive, easy 
to assay which allows for high throughput and linear over a large range of 
concentrations. The sample supernatant, prepared as described in the previous section, 
was assayed for luciferase activity according to manufacturer‟s recommendations 
(Luciferase Assay Kit, Promega, Southampton, UK). The assay is based on measuring 
the light produced when the substrate benzothiazole (beetle luciferin) is converted into 
oxy-luciferin by Firefly luciferase. Briefly, 100 µl Luciferace Assay mixture 
(Luciferace Assay Substrate + Luciferase Assay Buffer) was added to 20 µl sample and 
the activity was measured using a single-tube luminometer (TD-20e, Turner, Steptech 
Instruments, Arleysey, UK). Some samples required additional dilution with lysis buffer 
to ensure they fell within the linear detection range of the equipment. Samples were 
assayed in duplicate and luciferase activity expressed as relative light units (RLU). In 
addition, total protein concentration was photometrically measured in all supernatants 
according to manufacturer‟s recommendations (Bio-Rad DC-Protein Assay Kit, Bio-
Rad, Hemel Hempstead, UK). Total protein concentration was measured at 750 nm 
(Appliskan) (Termo Fisher Scientific, Basingstoke, UK). Some samples required 
additional dilutions to ensure they fell within the linear range of the standard curve. 
Reporter gene expression was expressed as luciferase activity (relative light unit (RLU)) 
per mg total protein. 
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2.5.3 Quantification of Gaussia luciferase expression  
The apical culture medium from ALI cultures was assayed for Gaussia luciferase 
(GLux) activity according to manufacturer‟s recommendations (Gaussia Luciferase 
Assay Kit, New England BioLabs Inc. Herts, UK). The assay is based on measuring the 
blue light emitted when Gaussia luciferase, secreted into the culture medium, catalyses 
the oxidation of the substrate coelenterazine. Briefly, 50 µl Gaussia Luciferase Assay 
solution (50 µl GLuc Substrate + 5 ml GLuc Assay Buffer) was added to 15 µl culture 
medium in a 96 well plate and luciferase activity was measured at 470 nm using a 
luminometer (Appliskan) (Termo Fisher Scientific, Basingstoke, UK). All samples were 
assayed in duplicate and reporter gene expression expressed as GLux activity (RLU) per 
µl medium. 
 
 
2.6 Statistical analysis 
 
Data are expressed as mean ± standard error of the mean (SEM). A normality test 
(Kolmogorov-Smirnov) was performed. For normal distributed data, an independent 
sample t-test for two groups or one-way analysis of variance (ANOVA) with Bonferroni 
correction for more than two groups was carried out unless otherwise stated. Where 
necessary, raw data were log10 transformed to ensure normal distribution and equal 
variances between groups. When the assumptions were not met after transformation of 
the data, a non-parametric Mann-Whitney test for two group comparison or a Kruskal-
Wallis with Dunn‟s correction for more than 2 group comparison was carried out. The 
null hypothesis was rejected at p<0.05. 
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Chapter 3: Bactofection in vitro and in vivo using a genetically 
modified E. coli  
 
The introduction below is split in to two parts. The first part describes the general 
principles and applications of bactofection and the second part specifically describes E. 
coli-mediated bactofection. 
 
 
3.1 General introduction to bactofection    
   
3.1.1 Bacterial vectors and principles of bacteria-mediated transfer of eukaryotic 
expression plasmids into host cells 
Over the last decade, delivery of plasmid DNA into mammalian cells using virulence-
attenuated bacteria has emerged as an alternative approach for gene therapy and genetic 
vaccination. The term „bactofection‟ has been applied to describe bacteria-mediated 
gene transfer into mammalian cells. A broad range of intracellular bacteria such as 
Shigella flexneri, Salmonella typhimurium, Listeria monocytogenes, Salmonella typhi 
and recombinant invasive E. coli have been used as bacterial vectors to transfer 
eukaryotic expression plasmids into both phagocytic and non-phagocytic cells 
[228,232-235]. These bacteria, with the exception of E. coli which is a normal part of 
the intestinal flora, are intestinal pathogens causing a range of symptoms in infected 
individuals such as diarrhoea, vomiting, fever and abdominal cramps.  
 
To understand how these bacteria mediate plasmid transfer into eukaryotic cells one has 
to understand the mode of uptake and the fate of the bacteria in the cell. Apart from E. 
coli, the above mentioned bacteria are all facultative intracellular pathogens, i.e. they 
are capable of adapting to different conditions and thereby surviving intracellularly. 
However, access to non-phagocytic host cells is gained using different mechanisms. For 
certain genera, such as Shigella and Salmonella, contact between the bacteria and the 
host cell results in secretion of a number of invasion proteins. These proteins trigger 
intracellular signalling events, leading to cytoskeletal rearrangement, membrane ruffling 
and thereby bacterial uptake into, for example, epithelial cells [192,193]. For bacteria 
such as Listeria monocytogenes and Yersinia species (Y. pseudotuberculosis and Y. 
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enterocolitica) binding of a single protein to a receptor present on the host cell surface 
is sufficient to initiates bacterial entry into non-phagocytic cells. The proteins 
responsible for uptake into cells are internalins (A and B) and invasin for Listeria 
monocytogenes and Yersinia, respectively. The receptor for internalin A, the product of 
the inlA gene, is E-cadherin, which is expressed at the basolateral membrane domain of 
polarised epithelial cells and is part of the junctional complex linking neighbouring cells 
together. As E-cadherin is not readily accessible to Listeria monocytogenes, which 
naturally invade the intestinal lumen, other ligand-receptor pairs may be responsible for 
the initial bacterial uptake. As an example, internalin B (the gene product of the inlB 
gene) and its receptor gC1qR have been identified as the ligand-receptor pair 
responsible for bacterial entry into a variety of other cells (e.g. hepatocytes, endothelial 
cells and fibroblasts) and other pairs, not yet identified, could therefore also play a role 
in bacterial uptake [193,236]. In contrast to internalins, bacterial invasin binds to the β1-
integrin receptor, which belongs to a wide family of integrin receptors, present on many 
mammalian cell types (e.g. platelets, lymphocytes, fibroblasts, endothelial cells, 
epithelial cells). Importantly for the initial bacterial uptake, β1-integrin has been found 
in the polarised intestinal epithelium where the receptor is expressed on the apical 
membrane of so-called M cells, which are special epithelial cells associated with 
lymphoid follicles that actively take up material from the intestinal lumen [237,238]. 
Overall, β1-integrin is involved in a variety of cellular activities, including cell-cell 
adhesion, cell-matrix adhesion and cell signalling [193]. 
 
Naturally, intake of food contaminated with the above mentioned bacteria (Shigella, 
Salmonella, Listeria monocytogenes and Yersinia) leads to food poisoning with 
symptoms such as diarrhoea and vomiting. However, the bacteria are also capable of 
infecting other organs in addition to the colonic mucosa. Upon ingestion of 
contaminated food they are naturally capable of translocating across the intestinal 
epithelium, most likely via M cells. The translocation provides the bacterium with an 
entry portal into the lymphoid system, where it moves to the mesenteric lymph nodes 
and spreads via the lymph to the liver and spleen, thereby causing infections in other 
organs [192,237]. 
 
The natural uptake mechanisms describe above are exploited when the above mentioned 
bacteria are used for gene transfer purposes. However, the fate of the bacteria within the 
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target cell is partly altered in order to achieve optimal plasmid delivery to the cell 
nucleus. Following invasion, bacterial vectors such as Shigella flexneri, Listeria 
monocytogenes and recombinant invasive E. coli escape from the phagocytic vacuole 
into the cytosol due to their own, or in the case of E. coli, engineered virulence factors 
[239]. Listeria monocytogenes for example naturally secretes a pore-forming toxin 
named listeriolysin O (LLO) which literally creates pores in the phagocytic vacuole, 
thereby allowing the bacteria to move into the cell cytosol [240]. Entry into the cytosol 
is then followed by auxotroph bacterial lysis as these bacteria have been engineered to 
require essential components for protein (aromatic amino acids), nucleotide (guanine) or 
cell wall (diaminopimelic acid) metabolism not supplied by the target cell (Figure 9a). 
However, auxotrophic strains of Listeria monocytogenes, which can efficiently invade 
host cells, are not currently available. Therefore, an autolytic strain that expresses a 
phage-derived lysin under control of a promoter activated in the cytosol has been 
engineered in order to achieve efficient bacterial lysis [241]. Finally, antibiotic 
treatment can be employed to lyse bacteria intracellularly. As a result of bacterial lysis, 
expression plasmids are released into the cell cytosol from where they can move into 
the nucleus. Alternatively, bacteria such as Salmonella remain in the phagocytic vacuole 
after uptake and bacterial lysis of these engineered auxotrophic strains occurs within 
this compartment. By an unknown mechanism expression plasmids then cross the 
vacuolar membrane and reach the nucleus where they are expressed [239] (Figure 9b). 
 
3.1.2 Applications of bactofection in the context of DNA vaccination 
Vaccination has proven to be the most efficient and cost-effective way to prevent a wide 
variety of infectious diseases. However, while humoural immune responses (Th2: T 
helper type 2 response)  can easily be achieved by immunisation with killed pathogens 
or antigens from these, induction of the cell-mediated immune responses, i.e. the T 
helper type 1 (Th1) and especially the cytotoxic T cell (CTL) response, is rather limited 
[242]. Bacteria are promising candidates for the elicitation of both humoural and cell-
mediated immune responses. Foreign antigens from, for example, influenza and measles 
virus can efficiently be expressed by bacterial carriers, phagocytosed and presented by 
antigen presenting cells (APCs). However, these antigens may not be presented in their 
native, active form in the bacteria which can lead to lack of protective immunity 
[196,233,242].  
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Figure 9: Mechanisms used by different bacteria to transfer eukaryotic expression 
plasmids into host cells 
During bactofection, bacteria enter cells by phagocytosis. a: Bacteria such as Shigella flexneri, 
Listeria monocytogenes and engineered E. coli carrying the virulence plasmid (pWR110) of 
Shigella flexneri escape the phagocytic vacuole after invasion. Once in the cytosol bacterial 
lysis occurs due to either metabolic attenuation (auxotrophy), expression of autolysins or 
addition of antibiotics. The eukaryotic expression plasmids are then released and able to enter 
the nucleus. b: Bacteria such as Salmonella typhimurium, Salmonella typhi and genetically 
engineered E. coli expressing invasin (inv) from Yersinia pseudotuberculosis remain in the 
phagocytic vacuole after invasion. Auxotroph bacterial lysis takes place within the vacuole and 
expression plasmids cross the vacuolar membrane by an unknown mechanism. Plasmids in the 
cytosol can then move into the cell nucleus to be transcribed. The figure is taken from Weiss et 
al [239]. 
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Bacterial delivery of eukaryotic antigen expression plasmids to APCs which then 
express the antigen (bacteria-mediated DNA vaccination) offers an attractive alternative 
as this method allows for expression of post-translationally modified antigens [243].  
 
Bacterial strains used for vaccination purposes are mainly Salmonella, Shigella and 
Listeria monocytogenes. These are enteric bacteria which have the ability to infect 
human colonic mucosa after oral administration thereby stimulating both mucosal and 
systemic immune responses. After crossing the intestinal barrier via M cells, bacteria 
are taken up by APCs in local lymphoid tissues and in spleen, liver and lymph nodes 
after systemic spread. The ability of bacterial carriers such as Salmonella, Shigella and 
Listeria monocytogenes to deliver their eukaryotic expression plasmids to the host 
cytosol where they have the capacity to enter the nucleus and be transcribed allow the 
encoded antigen to gain access to the endogenous antigen presentation pathway and 
thereby be presented via MHC (major histocompatibility complex) class I molecules. 
MHC class I presentation triggers CD8
+ 
(cluster of differentiation) CTLs and stimulates 
the all important cell-mediated immune responses [243,244]. Humoural immune 
responses are achieved via cross-presentation where neighbouring APCs take up dying 
macrophages and re-present the antigens expressed by these cells via MHC class II 
molecules thereby triggering CD4
+
 Th2 cells to stimulate B cell-mediated antibody 
production [245]. 
 
A vast number of studies have been undertaken to assess bacteria-mediated DNA 
vaccination in vivo. Most of these studies have focussed on vaccination of animal 
models against a variety of infectious diseases of both bacterial and viral origin such as 
Mycobacterium tuberculosis (M. tuberculosis), measles virus, hepatitis B virus and HIV 
(human immunodeficiency virus). Immunisation against measles using an attenuated 
Shigella flexneri vector was carried out by Fennelly et al. This study demonstrated both 
Th1- and Th2-type immune responses against structural proteins of the measles virus 
when the bacterial vector harbouring a eukaryotic expression plasmid encoding measles 
antigens was delivered to mice intranasally. In addition, bacterial delivery was safely 
tolerated in mice receiving an inoculum one million-fold higher than the dose of the 
wild-type parent strain that would have killed more than 90% of mice [195]. Passetti et 
al have also shown an elicitation of neutralising antibodies against measles virus when 
attenuated strains of both Shigella and Salmonella were used to deliver the DNA 
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vaccine. This subsequently led to protection when rats were challenged with the virus 
[196]. Moreover, mucosal immunisation with Shigella and Salmonella strains 
harbouring DNA vaccines has also been shown to induce humoural and cell-mediated 
immune responses against HIV and hepatitis B in mice [197,198]. Although, the 
antibody response observed after oral delivery of Salmonella typhimurium carrying a 
plasmid encoding hepatitis B surface antigen was relatively weak compared to a 
recombinant protein vaccine and a naked DNA vaccination [198] the strong CD8
+
 CTL 
response associated with administration of both Salmonella typhimurium and Shigella 
flexneri containing HIV and hepatitis B DNA vaccines, respectively, was comparable to 
that elicited by a naked DNA intramuscular vaccination [197,198]. These results 
suggest that mucosal bacteria-mediated DNA vaccination may be a viable alternative to 
naked DNA vaccination which is limited by the extremely expensive production and 
purification of large amounts of DNA. In contrast to most studies assessing bacterial 
vaccination against viral infections, Miki et al used attenuated Listeria monocytogenes 
to deliver a DNA vaccine against M. tuberculosis. They showed that Listeria 
monocytogenes was able to induce Th1 cellular immune responses in mice and 
inoculation with this vaccine could confer protective immunity against infection with 
M. tuberculosis [246] indicating a role for bacteria-mediated DNA vaccination against 
bacterial as well as viral infections.  
 
3.1.3 Applications of bactofection in the context of gene therapy 
As previously described in Section 1.6.4 and 1.6.5, the use of viral and non-viral vectors 
are hampered mainly by host immune responses and low level of gene transfer due to 
inefficient cellular and nuclear uptake respectively. Further optimisation of these 
existing vector systems and the development of novel GTAs would therefore be useful. 
Bacterial vectors may be an alternative to the commonly used vector systems as they 
exhibit several unique properties as outlined by Weiss et al [245]:  
 
 They are controllable by common antibiotics and virulence attenuated strains are 
widely available. 
 
 Some bacteria exhibit tissue tropism which can be used to target genes to specific 
tissue types. Salmonella and Shigella, for example, show a natural tropism for the 
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intestinal epithelium which is directly exploited when these bacteria are used for 
oral DNA vaccination purposes.  
 
 The bacterium Listeria monocytogenes has the ability to spread from cell to cell via 
recruitment of the host actin cytoskeleton which allows it to move around within the 
cell cytosol, randomly forming finger-like protrusions containing the bacterium at 
the tip. These protrusions can then be engulfed by the neighbouring cell resulting in 
a newly formed vacuole from where the bacterium rapidly escapes into the cell 
cytosol [247]. Such bacterial characteristic may make delivery of expression 
plasmids to cells in deeper tissue layers possible which are not accessible to 
standard viral and non-viral vectors.  
 
 Bacterial vectors have an almost unlimited capacity which should allow transfer of 
large genomic fragments including not only cDNA but also large regulatory 
elements and untranscribed regions of the gene.  
 
 
Although bacteria-mediated gene transfer has mainly been directed at genetic 
vaccination targeting macrophages and dendritic cells in vitro and in vivo, a limited 
number of studies have also assessed bactofection into non-phagocytic cells. Thus, 
Krusch et al assessed Listeria monocytogenes-mediated gene transfer of human CFTR 
(hCFTR) cDNA into chinese hamster ovary (CHO) cells in vitro [249]. These cells were 
chosen as they do not express detectable levels of endogenous CFTR. They 
demonstrated a significant increase in GFP gene transfer, which was caused by bacterial 
escape from the phagocytic vacuole and entry into the cytosol and nucleus. However, 
the level of gene transfer was low (2.6% of cells expressed GFP), likely due to 
inefficient intracellular lysis of the bacterium and plasmid transfer to the nucleus. The 
corresponding CFTR gene transfer experiment resulted in functional CFTR function, 
measured by patch-clamp recordings. However, fewer cells were transfected compared 
to GFP transfection. The reason for the difference in expression levels remains unclear, 
but could be related to a lower sensitivity of the CFTR detection system or interference 
by CFTR-containing plasmids with the transfer process. Furthermore, Zelmer et al have 
showed comparable in vitro gene transfer levels when Listeria monocytogenes carrying 
either a GFP plasmid or a GFP-CFTR plasmid (encoding a fusion protein between GFP 
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and CFTR) was employed as a bacterial vector [250]. The authors concluded that low 
levels of bacteria-mediated transfection were not due to poor bacterial invasion, 
insufficient lysis or plasmid degradation but were linked to association of plasmid DNA 
to high molecular weight components following lysis of the bacteria which eventually 
inhibited nuclear entry and transgene transcription. GFP gene transfer into cell lines 
such as Caco-2 (human colonic adenocarcinoma cells) and COS-1 (cell line derived 
from african green monkey kidney cells) was greatly improved when an optimised 
Listeria monocytogenes vector system expressing a phage-derived lysin was used to 
lyse intracellular bacteria instead of antibiotic [232]. Although some of these in vitro 
studies assessed bacteria-mediated CFTR gene transfer the direct relevance for airway 
gene therapy is uncertain as these studies were performed on poorly differentiated 
immortalized cell lines. Fajac et al, however, have assessed uptake and intracellular 
trafficking of a recombinant invasive E. coli into a human CF tracheal cell line and, 
importantly, into an explant outgrowth of non-CF bronchial tissue [194]. The study has 
shown efficient uptake of invasive E. coli into cells at the periphery of the outgrowth 
and in the airway cell line tested and, albeit at low efficiency, bacteria-mediated gene 
transfer was reported. Recombinant invasive E. coli has also been used to deliver the 
therapeutic gene, TGFβ1, to intact intestinal mucosa in mice [199]. Although, 
preliminary data demonstrated low levels of bacteria-mediated gene transfer into 
colonic epithelial cells in vitro the delivery of the therapeutic gene in vivo significantly 
reduced the severity of induced colitis indicating a role for recombinant invasive E. coli 
in the treatment of colitis. Bactofection has also shown to be an effective treatment 
against cancer in vivo. However, in most of these studies macrophages and dendritic 
cells were targeted to express either specific cytokines with antitumor effect or tumor 
antigens which generated a protective immune response against development of specific 
tumors (cancer DNA vaccination) [251-253]. In contrast, Lee et al have demonstrated 
that Salmonella choleraesuis carrying a eukaryotic expression plasmid encoding the 
angiogenic inhibitor thrombospondin-1 (TSP-1) has a tumor-targeting effect resulting in 
reduced tumor growth and enhanced survival in a murine melanoma model [254].  
In summary, bacteria-mediated gene transfer into non-phagocytic cells has proven 
feasible and although further research is needed to enhance efficiency, bactofection may 
be a valuable tool for the treatment of not only monogenetic diseases such as CF but 
also for the treatment of cancer. 
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3.2 Introduction to E. coli-mediated gene transfer  
   
3.2.1 Principles of E. coli-mediated transfer of eukaryotic expression plasmids 
into host cells 
In this thesis, recombinant E. coli was the chosen bacterial vector to be assessed as it 
was well characterised, the genetics were well established, the receptor for the 
recombinant bacterium was expressed on murine airway epithelial cells and, finally, 
good links to the collaborator, who had developed the vector, was in place.  
 
The use of E. coli as a bacterial vector for gene transfer into non-phagocytic cell 
requires genetical engineering of the bacteria as wild-type E. coli is not invasive and 
does, therefore, not enter non-phagocytic cells, such as lung epithelial cells, naturally. 
Originally, the virulence plasmid of Shigella flexneri (pWR110) was introduced into E. 
coli which not only enabled the bacteria to infect epithelial cells but also allowed 
bacterial escape from the phagocytic vacuole into the cytosol [255]. However, in order 
to design a genetically better defined system and to improve recipient cell viability, a 
genetically engineered E. coli expressing the inv and hly gene, encoding invasin from 
Yersinia pseudotuberculosis and LLO from Listeria monocytogenes, was generated 
[228]. Invasin expressed by the bacteria binds to β1-integrin receptors present on the cell 
surface and is hereby responsible for bacterial entry into non-phagocytic cells. β1-
integrin has been shown to be expressed in airway epithelial cells in murine lung [256], 
which makes this recombinant invasive E. coli a relevant bacterial vector to assess 
airway gene transfer in vivo (Figure 10). Following internalisation and uptake into the 
phagolytic vacuole recombinant E. coli undergo lysis due to diaminopimelic acid (dap) 
auxotrophy and LLO is released into the vacuole. As previously mentioned, LLO is 
capable of binding and perforating vacoular membranes and is, thereby, responsible for 
the escape of plasmids into the cytosol of the mammalian cell where they have the 
capacity to enter the nucleus [228] (Figure 11). 
 
3.2.2 E. coli-mediated gene transfer 
A limited number of studies have assessed E. coli-mediated gene transfer into non-
phagocytic cells in vitro and in vivo.  
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Figure 10: Expression of β1-integrin in mouse lung 
a: β1-integrin expression in airway epithelial cells in the bronchiolar region of the murine lung. 
The secondary conjugated antibody, Alexa
TM
 488, was used to determine β1-integrin expression. 
b: Negative control, in which the primary antibody was not included. The images are taken from 
Blundell et al [256]. 
a 
 
b 
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Figure 11: Recombinant E. coli-mediated transfer of eukaryotic expression plasmids into 
non-phagocytic cell 
Recombinant invasive E. coli express the inv and hly gene, encoding invasin from Yersinia 
pseudotuberculosis and LLO from Listeria monocytogenes, respectively. The invasin protein 
binds to the β1-integrin receptor expressed on the surface of the target cell and is hereby 
responsible for bacterial entry into non-phagocytic cells. Following internalisation and uptake 
into the phagolytic vacuole recombinant invasive E. coli undergo lysis due to dap auxotrophy 
and LLO is released into the vacuole. LLO is then capable of binding and perforating vacoular 
membranes and is, hereby, responsible for the escape of plasmids into the cytosol of the 
mammalian cell where they have the capacity to enter the nucleus. The figure is adapted from 
Weiss et al [239]. 
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At first, Courvalin et al described the development of an invasive E. coli by 
introduction of the virulence plasmid pWR110 of Shigella flexneri into the bacteria 
[255]. This study showed for the first time that E. coli was capable of transferring DNA 
to a number of cell lines such as HeLa (cell line derived from cervical cancer cells), 
CHO and COS in vitro. Gene transfer efficiencies were found to be equal or greater 
than those obtained by lipofection, ranging from 2‰ to 5% when β-galactosidase was 
used as reporter gene. In a follow-up study, bacterial uptake and GFP reporter gene 
transfer efficiency were assessed in vitro using recombinant invasive E. coli expressing 
invasin and LLO [228]. Expression of invasin had a significant effect on bacterial 
invasion with an increase in the number of bacteria per cell and, albeit low efficiency 
(5-20% of cells expressed GFP), bacteria-mediated gene transfer was observed. 
Interestingly, gene transfer efficiency did not always correlate with the number of 
internalised bacteria in the cell lines assessed. For example, gene expression was higher 
in HeLa cells compared to CHO cells, although the latter displayed the highest number 
of internalised bacteria. Co-expression of LLO and invasin increased gene transfer 
efficiency compared to expression of invasin alone, although this occurred mainly at 
lower multiplicities of infection (MOI). For example, in HeLa and CHO cells gene 
transfer efficiency increased from 5.9% to 7.1% and from 0.7% to 5.8%, respectively. 
Hardly any difference in transfer rates was detected at higher MOIs (MOI 250 and MOI 
500) suggesting that plasmid DNA may also gain access to the cell cytoplasm via 
leakage from the phagocytic vacuole by an LLO independent mechanism.  
 
In contrast to above in vitro studies performed on poorly differentiated immortalised 
cell lines Fajac et al provided the first evidence that recombinant invasive E. coli was 
able to transfer genes into airway epithelial cell in vitro and ex vivo thereby suggesting 
the relevance of E. coli-mediated gene transfer in the context of CF gene therapy [194]. 
However, bactofection efficiencies into human CF and non-CF airway epithelial cell 
lines were relatively low with approximately 2% of cells expressing the reporter gene. 
In an explant outgrowth of non-CF bronchial tissue ex vivo, gene transfer was limited to 
the periphery of the outgrowth and resulted in bactofection of poorly differentiated cells 
expressing β1-integrin. As previously mentioned this study also assessed bacterial 
uptake. Invasive E. coli was, as expected, shown efficiently to invade a β1-integrin 
expressing CF tracheal epithelial cell line. In the explant-outgrowth model, cells 
expressing β1-integrin were located only at the periphery of the outgrowth and as a 
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result bacterial uptake was mostly observed in these cells. Overall, these result link the 
binding of bacterial invasin and β1-integrin receptors to gene expression in airway 
epithelial cells.  
 
Laner et al have demonstrated that recombinant invasive E. coli can also be used to 
transfer artificial chromosomes containing a large fragment of the CFTR locus into a 
cell line, thereby taking advantage of the almost unlimited carrier capacity of bacterial 
vectors which allows them to carry large genomic fragments such as bacterial artificial 
chromosomes (BACs) and P1-based artificial chromosomes (PACs) (~150-200 kb) 
[257]. Briefly, PAC was employed to deliver a large portion of the CFTR gene to a 
human lung sarcoma cell line and, although, the protein encoded did not have CFTR Cl
-
 
channel function the authors showed a correctly spliced transgene in approximately two 
thirds of the analysed clones and suggested that a functional CFTR could be obtained by 
inserting the entire CFTR locus into the artificial chromosome.  
 
In vivo assessment of E. coli-mediated gene transfer is limited to one study which has 
no direct relevance for airway gene therapy [199]. As previously mentioned 
Castagliuolo et al demonstrated that invasive E. coli could efficiently deliver a 
therapeutic gene to the intestinal mucosa of mice following a single oral administration 
and thereby reduce the severity of artificially induced colitis in vivo. Bacteria-mediated 
airway gene transfer has not yet been assessed in vivo and further research is needed to 
study the efficiency and behaviour of bacterial vectors in pulmonary tissue in vivo. 
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3.3 Aims 
 
The aim of this part of the thesis was to assess bactofection into murine lung in vivo 
using a genetically engineered E. coli K12 strain. In contrast to previously published 
first generation bacteria, which carry a plasmid encoding the inv and hly genes, this 
second generation strain, E. coli BM4570, carries chromosomal copies of the genes (C. 
Grillot-Courvallin, Unité des Agents Antibactériens, Institut Pasteur, France - 
manuscript in preparation). Prior to assessing bactofection in vivo, in vitro experiments 
were carried out using the second generation E. coli strain with the aim of reproducing 
previous published results generated with first generation E. coli. In vivo, distribution 
and uptake of invasive E. coli BM4570 expressing GFP under the control of the 
prokaryotic Plac promoter were assessed in murine lungs. Subsequently, bactofection 
was assessed in pulmonary tissue using invasive E. coli carrying a eukaryotic 
expression plasmid encoding a luciferase reporter gene. In addition, bacterial gene 
transfer efficiency was compared to an already established non-viral GTA, cationic lipid 
GL67.  
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3.4 Materials and Methods  
 
3.4.1 Bacterial strains and transformation 
Non-invasive E. coli BM2710 and invasive E. coli BM4570, kindly supplied by Dr. 
Catherine Grillot-Courvalin, were generated as previously described
 
[255] (C. Grillot-
Courvallin, Unité des Agents Antibactériens, Institut Pasteur, France - manuscript in 
preparation). Invasive E. coli BM4570 carries chromosomal copies of inv and hly genes 
in addition to the ampicillin resistant gene, whereas the non-invasive E. coli BM2710 
only carries a chromosomal copy of the ampicillin resistant gene. Invasive E. coli 
BM4570 and non-invasive E. coli BM2710 were transformed with pCIKLux, pCIKLux-
mod and pAT505 (see Section 2.1.1 for description of plasmids). In brief, heat shock 
bacterial transformation was carried out as follows; E. coli were mixed with 
approximately 50 ng plasmid DNA and incubated on ice for 30 min. Heat shock 
treatment was then performed for 45 sec at 42ºC followed by an additional incubation 
on ice for minimum 2 min. Medium was added and the bacteria were incubated at 37ºC 
for 1 hr prior to centrifugation (9875 g, 4ºC). The supernatant was removed and the 
resuspended pellet was plated an agar plates containing ampicillin (50 µg/ml) and 
incubated overnight at 37ºC. Colony forming units (CFU) were then selected. 
 
3.4.2 Bacterial amplification in culture medium 
Five ml of brain heart infusion (BHI) medium (Sigma-Aldrich Com. Ltd., Poole, UK)  
containing 0.5 mM dap (Sigma-Aldrich Com. Ltd., Poole, UK) and 50 µg/ml ampicillin 
(Sigma-Aldrich Com. Ltd., Poole, UK) were inoculated with a single bacteria colony 
and grown for 8 hrs at 37ºC while shaking. The starter culture was used to inoculate 250 
ml of BHI containing dap and ampicillin. Overnight cultures were harvested by 
centrifugation (2504 g, 4°C) in the middle logarithmic phase of growth (Optical density, 
OD600 = 1-2) and resuspended at a final concentration of 5x10
9
- 5x10
10
 CFU/ml (OD600 
= 0.75 is approximately equivalent to 5x10
8
 CFU/ml) in the appropriate culture medium 
containing 0.5 mM dap and 10% FBS or phosphate buffered saline (PBS) (Sigma-
Aldrich Com. Ltd., Poole, UK) containing 0.5 mM dap.  
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3.4.3 Validation of spectrophotometer 
In order to convert an OD value to bacteria per ml (CFU/ml), the spectrophotometer 
(Unicam UV1, Unicam Ltd. Cambridge, UK) used in these studies was validated. Four 
separate E. coli BM4570 cultures were grown as described in Section 3.4.2. Serial 
dilutions were performed using the stock cultures and bacterial concentration was first 
determined photometrically. Subsequently, serial dilutions were plated (100 µl/plate) in 
triplicate on to BHI agar plates containing ampicillin (50 µg/ml) and dap (0.5 mM). 
Plates were incubated at 37ºC overnight and CFUs counted. 
 
3.4.4 Bactofection in vitro  
To assess bactofection efficiency, CFTE29o- and 293T cells, seeded in 6-well plates, 
were first washed with serum-free MEM and DMEM, respectively. E. coli BM4570 and 
E. coli BM2710 carrying pCIKLux or pCIKLux-mod were then added at multiplicity of 
infections (MOIs) ranging from 50 to 5000 in 2 ml MEM or DMEM containing 0.5 mM 
dap and 10% FBS (n=5 wells/dose). As a positive control, cells were transfected with 
pCIKLux complexed to Lipofectamine 2000 (Invitrogen Ltd., Paisley, UK) according to 
manufacturer‟s recommendations. Briefly, 4 µg pCIKLux and 10 µl Lipofectamine 
2000 were each diluted in 250 µl Opti-MEM (Invitrogen Ltd., Paisley, UK), gently 
mixed and incubated for 20 min at room temperature. 0.5 ml Lipofectamine 2000-
pCIKLux complex in a total volume of 2 ml Opti-MEM was then added. Cells were 
incubated with liposome complexes or bacterial suspension for 5 and 2 hours at 37ºC, 
respectively. The medium was then removed and cells were washed three times with 
culture medium. Cells were then cultured in complete medium containing gentamicin 
(20 µg/ml) to kill the remaining extracellular bacteria. In contrast, intracellular bacteria 
are protected from degradation by gentamicin. 48 hrs after transfection, cells were 
washed, trypsinised, centrifuged twice for 10 min at 9875 g (4ºC) and the supernatants 
were discarded. The pellets were assayed for luciferase activity as described in Section 
2.5.1 and 2.5.2.  
 
In order directly to compare E. coli and Lipofectamine-mediated transfection efficiency 
the number of plasmids used to transfect the cell lines were calculated for each of the 
two gene transfer agents, respectively:  
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 E. coli MOI 5000: 
Plasmids for transfection = 1.5 x 10
9
 CFU x 500 plasmid copies/CFU = 7.5x10
11
 
plasmids 
 
 Lipofection: 
Plasmids for transfection = 7.3x10
11 
plasmids (based on the molecular weight of double 
stranded nucleotides being 660 g/mol). 
 
3.4.5 Bacterial localisation in mouse lung  
Invasive E. coli BM4570 (5x10
7
-5x10
9
 CFU/mouse) harbouring pAT505, in which GFP 
expression is under control of the prokaryotic Plac promoter, were delivered to the 
lungs of gut-corrected CF-knockout mice (approximately 12 weeks old females, n=4 per 
group) by nasal instillation (100 µl) as described in Section 2.4.2. One hr post infection 
mice were exsanguinated using Hypnorm:Hypnovel:water (1:1:4). The trachea was 
exposed and lungs were inflated with 4% paraformaldehylde (PFA) (Sigma-Aldrich 
Com. Ltd., Poole, UK). The inflated lungs were excised, submerged overnight in 4% 
PFA and then cryopreserved in 15% sucrose at 4ºC for a period of 12 hours before 
embedding the left lobe in optimal cutting temperature (OCT) compound (Bayer PLC, 
Newbury, UK). The embedded lobe was trimmed to the point where the airways were 
fully branched and 7 µm sections were cut, mounted on to glass slides and stained with 
0.1% Evans blue prior to mounting in Vectashield containing 4,6-diamidino-2-
phenylindole (DAPI). Localization of GFP-expressing fluorescent bacteria was 
examined using a confocal microscope (LEICA TCS SP) equipped with a 20-63x/1.32-
0.6 NA oil immersion objective. 10 fields of views per section were analysed for each 
mouse. 
 
3.4.6 Bactofection of mouse lung tissue 
The lungs of CF-knockout mice were transfected, by nasal instillation (see Section 
2.4.2), with 5x10
8
-5x10
9
 invasive E. coli BM4570 carrying pCIKLux (approximately 12 
weeks old females/males, n=6-8 per group) or with invasive E. coli BM4570 or non-
invasive E. coli BM2710 (2.5x10
9
 CFU/mouse, n=8-12/group) carrying the original 
pCIKLux or the modified plasmid pCIKLux-mod in a total volume of 100 µl. Control 
groups received PBS and GL67/pCIKLux complexes as described in Section 2.1.2. 48 
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hrs after infection, all mice were culled. Lungs were harvested, snap-frozen in liquid 
nitrogen and stored at -80ºC for detection of luciferase activity (Section 2.5.1 and 2.5.2).  
 
3.4.7 Bactofection of mouse nasal tissue 
The nasal epithelium of CF-knockout mice were transfected, by nasal perfusion as 
described in Section 2.4.1, with 5x10
9
 E. coli BM4570/pCIKLux (approximately 12 
weeks old females, n=4 per group) for 15 min or 6 hrs. Controls groups were perfused 
with GL67/pCIKLux complexes for 15 min or with PBS for 15 min and 6 hrs, 
respectively. 48 hrs post transfection, mice were culled and the nasal epithelium 
removed, snap-frozen in liquid nitrogen and stored at -80ºC prior for detection of 
luciferase activity.  
 
3.4.8 Bacterial uptake in vitro 
CFTE29o- cells seeded on chamber slides were first washed with serum-free MEM and 
then incubated with invasive E. coli BM4570 and non-invasive E. coli BM2710 
carrying plasmid pAT505 (GFP expression under control of the prokaryotic Plac 
promoter) for 2 hours at 37ºC at MOI 500 in 100 µl MEM containing 0.5 mM dap and 
10% FBS (n=8 wells/dose). After infection, the cells were washed and fixed in 4% PFA 
for 30 min at room temperature and then stained with 0.1% Evans blue (Sigma-Aldrich 
Com. Ltd., Poole, UK) prior to mounting in Vectashield containing DAPI (Vector 
Laboratories, Peterborough, UK). Uptake of GFP-expressing fluorescent bacteria into 
the cell cytosol was examined using a confocal microscope (LEICA TCS SP) equipped 
with a 20-63x/1.32-0.6 NA oil immersion objective.  
 
3.4.9 Prokaryotic reporter gene expression  
Although, E. coli BM4570 carrying luciferase expression plasmids was not expected to 
generate luciferase expression as the lux reporter gene was under control of the 
eukaryotic CMV promoter, prokaryotic luciferase expression from the eukaryotic CMV 
promoter was assessed. E. coli BM4570 carrying the eukaryotic lux expression plasmids 
pCIKLux-mod and pCIKLux (1.5x10
7
, 1.5x10
8
 and 1.5x10
9
 E. coli corresponding to 
MOI 50, 500 and 5000 in vitro) were lysed according to manufacturer‟s 
recommendation (Luciferase Assay Kit, Promega, Southampton, UK) and the lysates 
assayed for luciferase activity. Briefly, 300 µl bacteria were centrifuged for 10 min at 
3137 g (4ºC), resuspended in 0.1 M K2HPO4/2 mM EDTA (Sigma-Aldrich Com. Ltd., 
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Poole, UK) in PBS (25 µl total volume) and incubated for 10 min at room temperature 
in 75 µl freshly prepared lysis mix (1.25 mg/ml lysozyme, 2.5 mg/ml bovine serum 
albumin, 1x cell culture lysis reagent) (Sigma-Aldrich Com. Ltd., Poole, UK). The 
lysate was centrifuged for 10 min at 13 793 g (4ºC) and 20 µl of the supernatant was 
assayed for luciferase activity according to the manufacturer‟s recommendations. E. coli 
BM4570/pAT505 expressing GFP (1.5x10
10 
E. coli) under the control of a prokaryotic 
promoter were included as a negative control. 
 
3.4.10 Intracellular survival of E. coli in vitro 
To assess if E. coli survive intracellularly, 293T cells were transfected with invasive E. 
coli BM4570 carrying pCIKLux. Briefly, 293T cells were seeded in 6-well plates and 
then transfected as described in Section 3.4.4 at MOI 50 and 500 (n=4 well/group). 48 
hrs after transfection, cells were washed and 1 ml DMEM containing 0.5 mM dap was 
added to each well prior to lysing the cells with 26 µl 10% sodium deoxycholate 
(Sigma-Aldrich Com. Ltd., Poole, UK) per well. The cells were incubated for 1 min at 
room temperature before plating the lysate on BHI agar plates containing ampicillin (50 
µg/ml) and dap (0.5 mM). Plates were incubated at 37ºC overnight and CFUs counted. 
Negative control groups were infected with non-invasive E. coli BM2710/pAT505 or 
medium. Furthermore, a positive control group was included by treating cells with E. 
coli BM4570/pCIKLux and incubating them for 30 min after infection before treating 
them with 10% sodium deoxycholate.  
 
3.4.11 Plasmid purification from E. coli 
Prior to assessing if incorporation of transcription terminator sequences into pCIKLux 
(i.e. generation of pCIKLux-mod) alters eukaryotic gene expression, the plasmids 
(pCIKLux and pCIKLux-mod) were purified from E. coli BM4570. Bacteria (250 ml) 
were grown as described in Section 3.4.4, overnight cultures were harvested by 
centrifugation (2504 g, 4ºC) and plasmids were purified according to manufacturer‟s 
recommendations (Qiagen Plasmid Maxi Kit, Qiagen Ltd., Crawley, UK). To 
precipitate purified DNA, isopropanol (Sigma-Aldrich Com. Ltd., Poole, UK) was 
added. Precipitated pDNA was centrifuged (13 793 g, 4ºC) for 30 min and the pellet 
was washed in 70% ethanol (Sigma-Aldrich Com. Ltd., Poole, UK) and centrifuged 
before re-dissolving the pDNA in DNase-free water. Finally, the pDNA concentration 
95 
 
was determined by spectrophotometry at 260nm (OD260 = 50 µg DNA/ml) (Unicam 
UV1, Unicam Ltd. Cambridge, UK). 
 
3.4.12 Lipofection in vitro using pCIKLux and pCIKLux-mod 
To assess if the generated pCIKLux-mod alters eukaryotic gene expression compared to 
the original pCIKLux, CFTE29o- cells were seeded and transfected with Lipofectamine 
2000 complexed to pCIKLux or pCIKLux-mod as previously described (Section 3.4.4) 
(n=6 well/group). 48 hrs after transfection, cells were washed, trypsinised and 
centrifuged before assaying the pellets for luciferase activity.  
 
3.4.13 Statistical analysis 
Results are expressed as mean ± SEM. Normal distribution was assessed by 
Kolmogorov-Smirnov normality test. Data were compared using ANOVA plus Dunnett 
analysis (for comparison of more than two groups) or independent sample t-test (for 
comparison of two groups) when data were normally distributed. Where necessary, raw 
data were log10 transformed to ensure normal distribution and equal variances between 
groups. A non-parametric Mann Whitney test (for comparison of two groups) or a 
Kruskal-Wallis with Dunn‟s correction (for comparison of more than two groups) was 
carried out when the assumptions were not met after transformations. The null 
hypothesis was rejected at p<0.05.  
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3.5 Results  
 
3.5.1 Validation of the spectrophotometer  
Before any experiments were carried out, the spectrophotometer was validated in order 
to assess if the concentration of bacteria in any given culture matched with the 
calculated concentration (OD600 = 0.75 is approximately equivalent to 10
8
 CFU/ml) (C. 
Grillot-Courvallin, Unité des Agents Antibactériens, Institut Pasteur, France - personal 
communication). Four separate bacterial cultures were grown and stock solutions 
generated based on the OD readings (OD600 = 1-2). Serial dilutions to an estimated 1, 10 
and 100 CFU per plate were then carried out, plated on to agar plates and 24 hrs after 
the number of CFUs on each plate was determined. As shown in Figure 12, the actual 
number of bacteria present on the plates was approximately 5 times the expected 
number. This was the case for each of the 4 cultures and for each dilution too. The 
results therefore indicate that the spectrophotometer used in these studies is 
approximately 5-fold out which was taken into account in all subsequent experiments.  
 
3.5.2 E. coli mediated gene expression in vitro  
Prior to assessing bactofection in vivo, in vitro luciferase gene transfer experiments 
were carried out with the second generation E. coli strain with the aim of reproducing 
previously published results generated with first generation E. coli and to ensure that the 
second generation E. coli works as expected. CFTE29o- and 293T cells were chosen for 
these experiments as CFTE29o- cells resemble the target cell for CF gene therapy and 
293T cells are easy to work with. The cell lines were incubated with invasive E. coli 
BM4570 carrying pCIKLux, a plasmid in which the luciferase gene is under control of 
the eukaryotic CMV promoter, for 2 hrs at MOIs ranging from 50-5000. 48 hrs after 
infection the cells were harvested and luciferase activity determined. In CFTE29o- cells, 
all MOIs led to significant (p<0.01) dose-related lux activity compared to untreated 
cells (Figure 13). As shown in Figure 14, a slightly different pattern was seen for 293T 
cells as all MOIs led to approximately the same level of lux activity (p<0.01). However 
for both cell lines, lux activity even at the highest MOI was significantly (p<0.05) lower 
than after Lipofectamine 2000-mediated gene transfer, despite the fact that a similar 
number of plasmid molecules were added to the cell preparation in each case.  
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Figure 12: Validation of spectrophotometer 
The spectrophotometer was validated in order to assess if the concentration of bacteria in any 
given culture matched up with the calculated concentration (OD600 = 0.75 is approximately 
equivalent to 10
8
 CFU (colony forming unit)/ml) Four separate bacterial cultures were grown 
and stock solutions generated based on the OD readings. Serial dilutions were carried out, 
plated on to agar plates and bacterial growth was determined after 24 hrs. Data are expressed as 
mean ± SEM (n=3/dilution). 
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Figure 13: Luciferase expression after infection of CFTE29o- cells with invasive E. coli 
CFTE29o- cells were infected with invasive E. coli BM4570 carrying the eukaryotic expression 
plasmid pCIKLux at MOI 50 to 5000. 48 hrs post infection cells were harvested and luciferase 
activity assayed. Bacteria-mediated expression was compared to cells transfected with pCIKLux 
complexed to Lipofectamine 2000 (Lipo/pCIKLux) or untransfected cells. Data are expressed as 
mean ± SEM (n=5/group), * = p<0.05 E. coli / pCIKLux (MOI 5000) compared to 
Lipofectamine 2000 and ** = p<0.01 E. coli / pCIKLux compared to untransfected (medium). 
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Figure 14: Luciferase expression after infection of 293T cells with invasive E. coli 
293T cells were infected with invasive E. coli BM4570 carrying the eukaryotic expression 
plasmid pCIKLux at MOI 50-5000. 48 hrs post infection cells were harvested and luciferase 
activity assayed. Bacteria-mediated expression was compared to cells transfected with pCIKLux 
complexed to Lipofectamine 2000 (Lipo/pCIKLux) or untransfected cells. Data are expressed as 
mean ± SEM (n=5/group), * = p<0.05 E. coli / pCIKLux (MOI 5000) compared to 
Lipofectamine 2000 and ** = p<0.01 E. coli / pCIKLux compared to untransfected (medium). 
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Due to toxicity, bacteria-mediated gene transfer efficiency could not be enhanced 
further by increasing dose. Overall, these results indicate that invasive E. coli was able 
to mediate lux expression, defined as luciferase protein generated after bacterial 
infection, in both an „easy to work with‟ human embryonic kidney cell line and in the 
more appropriate human CF tracheal epithelial cell line (CFTE29o-).  
 
3.5.3 Bacteria were mainly localised in the alveoli after nasal instillation in mouse 
lung 
To visualise bacterial localisation in vivo, the lungs of mice (n=4) were inoculated via 
nasal instillation with 100 l of invasive E. coli BM4570 carrying the pAT505 plasmid 
at 5x10
7
 to 5x10
9 
CFU/mouse. 5x10
10
 CFU/ml was the most concentrated stock solution 
achievable and the maximum dose chosen (5x10
9
 CFU/mouse) was therefore the 
highest feasible dose to deliver to the mice, when 100 l was to be instilled. Following 
instillation, mice treated with E. coli were hunched and immobile and these mice did 
not recover before harvesting (1 hour post infection). 
 
The pAT505 plasmid contains the gfpmut1 gene encoding GFP under the control of the 
prokaryotic Plac promoter, resulting in GFP-expressing bacteria. The animals were 
sacrificed 1 hr post infection as the bacteria at this time point have infected the cells but 
have not yet lysed due to dap deficiency. Lung sections were examined for green 
fluorescent E. coli using confocal microscopy (see inserted image in Figure 15d for 
green fluorescent E. coli). A total of 16 mice were assessed (n=4/group), and at all 
doses studied the majority of bacteria were concentrated around the alveoli possibly 
indicating bacterial pooling in this part of the lung, which was probably related to the 
bolus administration (Figure 15a-d). Bacteria associated with the epithelium were 
quantified in mice exposed to the highest dose (5x10
9
 CFU/mouse, n=4 mice) and 
showed that 16%±3 of airway epithelial cells were associated with bacteria. 
Importantly, for the vast majority of these cells only one bacterium (as judged by size 
and shape), was associated with each cell (Figure 16a-b). Overall, bacterial association 
and uptake into airway epithelial cells, the target for CF gene therapy, was inefficient.  
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Figure 15: GFP-expressing invasive E. coli in the alveolar epithelium of mouse lung 
Lungs of mice were infected with invasive E. coli BM4570 carrying the prokaryotic expression 
plasmid pAT505 (GFP expressed under the control of the prokaryotic plac promoter, see 
inserted image for green fluorescent E. coli, original magnification x63) with doses ranging 
from 5x10
7
 to 5x10
9
 CFU/mouse. The lungs were harvested 1 hr post infection. Invasive E. coli 
are associated with the alveoli in a dose-dependent manner (a: 5x10
7
 CFU/mouse, b: 5x10
8
 
CFU/mouse, c: 5x10
9
 CFU/mouse, d: PBS control, Original magnification x20). GFP 
expressing bacteria appear in green, alveoli in red and DAPI-stained nuclei are shown in blue. 
Arrows indicate E. coli associated with alveoli. Images are representative of 10 fields of views 
per section.  
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Figure 16: GFP-expressing invasive E. coli in the respiratory epithelium of mouse lung 
Lungs of mice were infected with invasive E. coli BM4570 carrying the prokaryotic expression 
CFU/mouse. The lungs were harvested 1 hr post infection. Bacteria associated with airway 
epithelial cells were detected for approximately 16% of cells (a: 5x10
9
 CFU/mouse, b: PBS 
control, original magnification x63). GFP expressing bacteria appear in green and DAPI-stained 
nuclei are shown in blue. Arrows indicate E. coli associated with airway epithelial cells. Images 
are representative of 10 fields of views per section. 
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3.5.4 E. coli mediated luciferase expression in mouse lung  
To assess whether plasmids can be transferred from the bacteria to the nucleus of lung 
cells in vivo, mice were inoculated intra-nasally with invasive E. coli BM4570 
harbouring pCIKLux at doses ranging from 5x10
8 
to 5x10
9
 CFU/mouse. Importantly, 
this delivery method, i.e. bolus administration to the lung, only achieves a relatively 
short contact time between the respiratory epithelium and the bacteria, which will affect 
transfection efficiency in AECs. 
 
All mice (n=8) receiving the highest dose died within 2 hrs and 4 out of 8 mice treated 
with 2.5x10
9
 E. coli died the following day. All remaining mice were culled 48 hrs post 
infection and the lungs were harvested and assayed for luciferase activity. Figure 17 
shows that lux expression was undetectable in mice that had received 5x10
8
 CFU (n=8), 
but was significantly (p<0.01) increased in mice inoculated with 2.5x10
9 
CFU (n=4), 
suggesting that E. coli-mediated gene transfer may have occurred in the murine lung. 
However, when compared to an already established non-viral gene transfer agent, 
cationic lipid GL67, bacteria-mediated gene transfer was 10-fold less efficient (p<0.01) 
in this model. 
 
3.5.5 E. coli mediated luciferase expression in mouse nose  
Bolus administration to the nose does not allow extended contact time between airway 
epithelium and bacteria. Therefore, the nasal epithelium of mice were perfused with 
invasive E. coli BM4570 harbouring pCIKLux at 5x10
9
 CFU/mouse for either 15 min 
or 6 hrs (n=4/group) in order to assess if longer contact time would enhance E. coli-
mediated luciferase expression. 2 of the mice perfused for 15 min died within 1 hr. 48 
hrs post infection, the remaining mice were culled, the nasal epithelium harvested and 
luciferase activity determined. As shown in Figure 18 luciferase expression was 
increased in both cohorts of mice perfused with E. coli BM4570 compared to PBS 
treated mice (p<0.05 for cohort of mice perfused for 6 hrs, n=4). However, prolonging 
the contact time between the epithelium and the vector from 15 min to 6 hrs did not 
increase lux expression. Furthermore, when compared to cationic lipid GL67 bacteria-
mediated gene transfer was approximately 15-fold less efficient (p<0.05).  
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Figure 17: Luciferase expression in mouse lung after infection with invasive E. coli  
The lungs of mice were infected with invasive E. coli BM4570 carrying the eukaryotic 
expression plasmid pCIKLux (5x10
8
 and 2.5x10
9
 CFU/mouse). Lungs were harvested 48 hrs 
post infection and luciferase activity assayed. Bacteria-mediated lux expression was compared 
to mice transfected with pCIKLux complexed to the cationic lipid GL67 (GL67/pCIKLux) or 
PBS controls. Data are expressed as mean ± SEM (n=4-8/group), ** = p<0.01 E. coli / 
pCIKLux (2.5x10
9
) compared to PBS and ** = p<0.01 E. coli / pCIKLux (2.5x10
9
) compared to 
GL67/pCIKLux. 
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Figure 18: Luciferase expression in mouse nose after infection with invasive E. coli  
The murine nasal epithelium was infected by nasal perfusion, with invasive E. coli BM4570 
carrying pCIKLux (5x10
9
 CFU/mouse) for 15 min and 6 hrs. 2 of the mice perfused for 15 
min died within 1 hr. The nasal epithelium of the remaining mice was harvested 48 hrs post 
infection and luciferase activity assayed. Bacteria-mediated lux expression after 15 min and 6 
hrs perfusion was compared to mice perfused for the same length of time with PBS and 
GL67/pCIKLux, respectively. Data are expressed as mean ± SEM (n=2-4/group), * = p<0.05 E. 
coli / pCIKLux (6 hrs) compared to PBS (6 hrs) and * = p<0.05 E. coli / pCIKLux (15 min) 
compared to GL67/pCIKLux (15 min). 
B 
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Prolonging contact time via nasal perfusion did not, therefore, offer advantages 
compared to delivering the vector by nasal instillation to the lung tissue.  
 
3.5.6 Invasive, but not non-invasive, E. coli entered CFTE29o- cells efficiently 
To determine more accurately, if lux expression in the mouse lung is due to bactofection 
or prokaryotic read through of the eukaryotic CMV promoter, I compared the efficiency 
of invasive and non-invasive bacteria in vivo (see Section 3.5.7). In preparation for 
these experiments, I repeated in vitro experiments previously published by Fajac et al 
[194] to ensure that the invasive and non-invasive bacteria behaved appropriately in my 
hands. I first compared the uptake of invasive E. coli BM4570 and its non-invasive 
counterpart BM2710, each carrying the prokaryotic expression plasmid pAT505 
(resulting in GFP-expressing green fluorescent bacteria) in CFTE29o- cells (MOI 500) 
in vitro. Cells were harvested 2 hours post infection, fixed and slides examined for 
GFP-expressing E. coli via confocal microscopy. In contrast to the invasive strain, the 
non-invasive E. coli strain lacks the inv gene from Yersinia pseudotuberculosis and 
hence does not express invasin, which is responsible for bacterial uptake into non-
phagocytic cells. This strain would, therefore, not be expected to enter CFTE29o- cells. 
Figure 19a shows that the vast majority of invasive E. coli BM4570 were taken up into 
the cytoplasm of CFTE29o- cells at MOI 500, whereas non-invasive E. coli BM2710 
did not enter the cells (a few residual bacteria remained attached to slides after fixing) 
(Figure 19b). These results support previous published data showing that invasin is 
required for the uptake of E. coli into non-phagocytic epithelial cells [194,228]. 
 
3.5.7 Invasive and non-invasive E. coli led to similar levels of luciferase 
expression in mouse lung 
The efficiency of invasive and non-invasive bacteria in vivo was compared to determine 
if lux expression in the mouse lung was due to bactofection or potentially generated by 
the bacteria from the eukaryotic CMV promoter. The murine lung was infected with 
invasive E. coli BM4570 and non-invasive E. coli BM2710 carrying pCIKLux (2.5x10
9
 
CFU/mouse). Mice were culled 48 hours post infection and luciferase activity was 
determined in lung homogenates. Similar levels of lux expression were observed when 
comparing the invasive E. coli to its non-invasive counterpart (Figure 20).  
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Figure 19: Uptake of GFP-expressing invasive and non-invasive E. coli into CFTE29o- 
cells 
CFTE29o- cells were infected with (a) invasive E. coli BM4570 (MOI 500) and (b) its non-
invasive counterpart E. coli BM2710 (MOI 500) carrying the prokaryotic expression plasmid 
pAT505 (GFP expressed under the control of the prokaryotic plac promoter). The cells were 
harvested 2 hrs post infection. GFP expressing bacteria appear in green, the cytosol and DAPI-
stained nuclei are shown red and blue, respectively. Original magnification x63. Arrows 
indicate GFP-expressing E. coli. 
a 
b 
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Figure 20: Luciferase expression in mouse lung after infection with invasive and non-
invasive E. coli 
The lungs of mice were infected with invasive E. coli BM4570 and its non-invasive counterpart 
E. coli BM2710 carrying pCIKLux (2.5x10
9
 CFU/mouse). Lungs were harvested 48 hrs post 
infection and luciferase activity assayed. Luciferase expression from non-invasive E. coli and 
invasive E. coli was compared to PBS controls. Data are expressed as mean ± SEM (n=8-
9/group), *** = p<0.001 non-invasive E. coli / pCIKLux compared to PBS and *** = p<0.001 
invasive E. coli / pCIKLux compared to PBS. 
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This may suggest that the eukaryotic CMV promoter may be partially active in E. coli 
and lux expression observed in vivo may, therefore, not be entirely due to plasmid 
transfer from the bacteria to the nuclei of the lung, but rather due to expression of lux in 
the bacteria. 
 
3.5.8 Incorporation of prokaryotic termination sequences into pCIKLux reduced 
prokaryotic reporter gene expression 
In an attempt to abolish luciferase expression potentially generated by E. coli via 
prokaryotic read through, a new plasmid (pCIKLux-mod) was created by inserting two 
copies of the transcription terminator sequence of gene 32 from bacteriophage T4 
downstream of the hybrid intron (Figure 21a), a procedure that was previously 
successful for E. coli and Salmonella [258]. To assess if prokaryotic lux expression was 
reduced after generation of the modified plasmid (pCIKLux-mod), invasive E. coli 
BM4570 carrying the eukaryotic lux expression plasmids pCIKLux-mod or pCIKLux 
(1.5x10
7
, 1.5x10
8 
and 1.5x10
9 
CFU) were lysed and the lysates assayed for luciferase 
activity. As shown in Figure 21b, insertion of the transcription terminator sequences 
lead to an approximately 20-fold reduction in luciferase activity. However, luciferase 
activity from invasive E. coli/pCIKLux-mod was still considerably higher than 
background levels (control plasmid; 0.0025 RLU/1.5x10
10 
CFU) indicating that the 
CMV promoter still had some residual activity in E. coli.  
 
3.5.9 Intracellular survival of E. coli was limited in vitro 
Prior to assessing E. coli-mediated gene transfer using the modified plasmid (pCIKLux-
mod), I attempted to ensure that lux expression observed in vitro was not generated by 
E. coli, but due to bacteria-mediated gene transfer. I determined if bacteria survive 
intracellularly in vitro at the time point where gene transfer efficiency was assessed. 
Cells were transfected with the invasive E. coli harbouring pCIKLux (MOI 50 and 500). 
The engineered E. coli strain is dap deficient and hence is not expected to survive 
intracellularly for a longer period of time. The infected cells were lysed 48 hrs post 
infection and the lysate plated on agar plates to determine bacterial growth. Only a very 
small number of invasive bacteria survived intracellularly at both MOIs assessed 
(Figure 22). At an MOI of 50 the number of invasive bacteria surviving (~15 bacteria) 
corresponded to approximately 0.0001% of the initial dose.  
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Figure 21: Modification of pCIKLux to abolish CMV-driven luciferase expression in E. 
coli 
a: A new plasmid (pCIKLux-mod) was created by inserting two copies of the prokaryotic 
transcription terminator of gene 32 from bacteriophage T4 downstream from the hybrid intron 
of pCIKLux. b: Invasive E. coli BM4570 carrying the eukaryotic lux expression plasmids 
pCIKLux-mod, pCIKLux (1.5x10
7
-1.5x10
9
 CFU) or the prokaryotic GFP expression plasmid 
pAT505 (NC) (1.5x10
10
 CFU) were lysed and the lysates were assayed for luciferase 
expression. 
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Figure 22: Total number of bacteria surviving intracellularly 48 hrs post infection 
293T cells were infected with invasive E. coli BM4570 and non-invasive E. coli BM2710 
carrying pCIKLux and pAT505, respectively, at MOI 50 and 500. 48hrs post infection cells 
were lysed and lysate plated on to agar plates to determine bacterial growth 24 hrs later. At MOI 
50 a mean of 15 invasive E. coli survived intracellularly, which corresponds to ~0.0001% of the 
initial dose administrated. Data are expressed as mean ± SEM (n=4/group). 
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These results support my expectations that the engineered invasive E. coli has limited 
survival intracellular in vitro. As a negative control cells were also infected with non-
invasive E. coli. At an MOI of 50 approximately one non-invasive bacterium survived 
intracellularly (<0.0001%), which corresponds with the evidence that these bacteria do 
not enter cells efficiently. As a positive control, cells treated with the invasive E. coli 
were harvested 30 min post infection. At this time point, large numbers of bacteria 
survived intracellularly which was expected as this is a relative short time after bacterial 
uptake. 
 
3.5.10 The modified plasmid did not alter eukaryotic gene expression 
Prior to assessing E. coli-mediated gene transfer in vitro and in vivo using the modified 
plasmid (pCIKLux-mod), I assessed whether incorporation of transcription terminator 
sequences into pCIKLux altered eukaryotic gene expression. CFTE29o- cells were 
transfected with Lipofectamine 2000 complexed to pCIKLux or pCIKLux-mod and 48 
hrs later, cells were harvested and luciferase activity determined. Figure 23 shows that 
there was no significant difference (p>0.05) between cells treated with the modified 
plasmid compared to the original plasmid. Incorporation of transcription terminator 
sequences into pCIKLux did, therefore, not change eukaryotic gene expression.   
 
3.5.11 Low level bactofection occurred in vitro and in vivo following transfection 
with E. coli carrying modified pCIKLux  
Bactofection in vitro and in vivo was then assessed using invasive E. coli carrying the 
modified plasmid pCIKLux-mod. CFTE29o- cells were transfected with invasive E. coli 
BM4570 or its non-invasive counterpart E. coli BM2710 carrying the modified 
pCIKLux-mod at MOI 50. The cells were harvested 48 hours post infection, lysed and 
assayed for luciferase activity. Cells treated with the invasive E. coli carrying pCIKLux-
mod showed high levels of luciferase activity (Figure 24). At an MOI of 50, 
approximately 15 bacteria/well would have survived intracellular 48 hrs post infection 
based on a previous experiment (Section 3.5.9). In addition, it was shown in Figure 21b 
that 1.5x10
7
 bacteria generated approximately 50 RLU lux activity when bacteria were 
lysed. It is, therefore, unlikely that the low level of prokaryotic lux expression derived 
from the small number of bacteria (~15 bacteria), surviving 48 hours after bactofection, 
generated the high levels of luciferase activity observed in this experiment.  
 
113 
 
 
 
 
 
Li
po
/p
S
G
16
2-
7
Li
po
/p
C
IK
Lu
x
100
101
102
103
104
105
106
Lipo/pCIKLux-mod                      Lipo/pCIKLux
ns
L
u
x
 (
R
L
U
/m
g
 p
ro
te
in
)
 
Figure 23: Luciferase expression after lipofection of CFTE29o- cells with pCIKLux and 
modified pCIKLux 
CFTE29o- cells were transfected with Lipofectamine 2000 complexed to pCIKLux or CIKLux-
mod. 48 hrs post transfection cells were harvested and luciferase activity assayed. Luciferase 
expression from the modified plasmid was compared to pCIKLux. Data are expressed as mean 
± SEM (n=6/group). 
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Figure 24: Luciferase expression after infection of CFTE29o- cells with invasive and non-
invasive E. coli carrying modified pCIKLux  
CFTE29o- cells were infected at MOI 50 with invasive E. coli BM4570 and non-invasive E. 
coli BM2710 carrying the modified pCIKLux (pCIKLux-mod). 48 hrs post infection cells were 
harvested and luciferase activity assayed. Luciferase expression from non-invasive E. coli was 
compared to the negative control (Medium). Data are expressed as mean ± SEM (n=6/group), * 
= p<0.05 non-invasive E. coli / pCIKLux-mod compared to untransfected (medium). 
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The data, therefore, suggest that bacteria-mediated gene transfer into the nuclei of 
CFTE29o- cells has occurred.  
 
Surprisingly, lux expression in cells treated with non-invasive E. coli carrying 
pCIKLux-mod was significantly higher than cells treated with medium (p<0.05). As 
non-invasive E. coli do not enter cells, these data indicate that, although gentamicin was 
added to kill extracellular bacteria, a small fraction of the initial administered E. coli 
survive  extracellularly for 48 hours, thereby generating prokaryotic lux expression.  
 
For the in vivo corollary of these studies, mice were infected by nasal instillation with 
invasive E. coli BM4570 and non-invasive E. coli BM2710 carrying the modified 
pCIKLux-mod (2.5x10
9
 CFU/mouse). Mice were culled 48 hrs post infection and lux 
activity was determined in lung homogenates. A small but significant (p<0.05) increase 
in lux expression was observed in mice treated with invasive E. coli when compared to 
mice treated with non-invasive E. coli (Figure 25), suggesting that low level 
bactofection had occurred in vivo. However, the relatively high luciferase activity in 
mice treated with non-invasive E. coli compared to mice treated with PBS (p<0.001) 
confirms that prokaryotic luciferase expression has not been completely abolished.  
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Figure 25: Luciferase expression in mouse lung after infection with invasive and non-
invasive E. coli carrying modified pCIKLux  
The lungs of mice were infected with invasive E. coli BM4570 and non-invasive E. coli 
BM2710 carrying the modified pCIKLux (pCIKLux-mod) (2.5x10
9
 CFU/mouse). 48 hrs post 
infection mice were culled and lux activity was determined in lung homogenates. Luciferase 
expression from non-invasive E. coli was compared to invasive E. coli and the negative control 
(PBS). Data are expressed as mean ± SEM (n=8-9/group), * = p<0.05 non-invasive E. coli / 
pCIKLux-mod compared to invasive E. coli / pCIKLux-mod and *** = p<0.001 non-invasive 
E. coli / pCIKLux-mod compared to PBS. 
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3.6 Discussion 
 
Here, the distribution and uptake of invasive E. coli BM4570 expressing green 
fluorescent protein under the control of the prokaryotic Plac promoter was assessed in 
the murine lung after topical administration via nasal instillation. In addition, 
bactofection was assessed in pulmonary tissues using E. coli carrying an eukaryotic 
expression plasmid encoding a luciferase reporter gene under the control of a CMV 
immediate-early promoter/enhancer. Bacteria were mainly located in the alveolar 
epithelium and only rarely associated with respiratory epithelial cells. Bacteria-
mediated luciferase expression was detected in the murine lung, but was less efficient 
than GL67-mediated gene transfer. 
 
To date, attempts at using bacteria as vectors have mainly concentrated on delivering 
DNA for the purpose of genetic vaccination. More recently, the use of bacteria as gene 
transfer vectors for gene therapy applications has been suggested. Finally, the ability of 
some bacteria to spread from cell to cell, in addition to the absence of insert size 
restrictions, make bacteria an interesting vector for gene therapy. Proof-of-principle for 
bactofection in a range of non-phagocytic cell lines, including airway epithelial cells, 
has been established in vitro. [194,228,232,259]. These studies have mainly focused on 
transfer of the GFP reporter gene. However, more relevant to CF gene therapy, 
recombinant E. coli and Listeria monocytogenes were recently used to transfer artificial 
chromosomes carrying the CFTR gene locus [257] or a pCMV-CFTR plasmid, 
[249,250] respectively, to cell lines in vitro.  
 
Prior to starting any experiments, the spectrophotometer was validated in order to assess 
if the concentration of bacteria in any given culture matched up with the calculated 
concentration. The calculated concentration was based on recommendations from Dr. 
Catherine Grillot-Courvalin, my collaborator, who had developed the E. coli vector. 
Interestingly, the spectrophotometer was approximately 5-fold out compared to the 
calculated concentration, which was originally based on measurements using a 
spectrophotometer at my collaborator‟s laboratory. This result emphasises the 
importance of validating the equipment before starting a set of experiments.  
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E. coli-mediated bactofection of the luciferase reporter gene was first assessed in 293T 
and CFTE29o- cells in vitro to ensure that all bacterial proteins required for 
bactofection are efficiently produced and that the eukaryotic expression plasmid 
pCIKLux is fully functional. 293T cells were chosen as they are extremely easy to 
culture and transfect. In contrast, CFTE29o- cells were used because they resemble the 
target cell for CF gene therapy more closely than 293T cells and are known to express 
β1-integrin, which is required for efficient E. coli uptake into non-phagocytic cells 
[194]. Bactofection into CFTE29o- cells was dose-related, whereas 293T cells reached a 
transfection plateau at the lowest MOI used. This is likely to be due to the ease with 
which 293T cells transfect, thereby allowing even a relatively low dose to produce 
maximum expression level. Although cell survival decreased with increasing MOI, even 
at an MOI of 5000 a small proportion of the cells survived to allow luciferase detection 
48 hrs after bactofection. Other studies often use a MOI of 500 to circumvent significant 
toxicity (C. Grillot-Courvalin, personal communication). Bacterial LPS may induce a 
cellular inflammatory response resulting in production of cytokines, which may lead to 
cell death [260]. In contrast to previously published in vitro studies FBS was included 
during bactofection in this study, which may to a degree have protected the cells from 
bacteria induced toxicity and may explain why cell survival at MOI of 500 was higher 
than expected based on published data.  
 
Lux expression detected in both cell lines is likely to be a combination of prokaryotic 
and eukaryotic gene expression as the subsequent in vivo experiment revealed that the 
CMV promoter in combination with the luciferase gene was leaky in E. coli. However, 
only a very small number of bacteria survive inside 293T cells (approximately 0.0001% 
of the initial dose) after 48 hours, suggesting that a significant proportion of luciferase 
measured at this time-point must have been generated by plasmid DNA reaching the 
nuclei of the cultured cells. This point is further supported by the fact that luciferase has 
a short half-life of approximately 3 hours, which means that luciferase expression is not 
likely to originate from bacteria dying intracellulary during the 48 hours. As proof-of-
principle that bactofection can occur in the more appropriate human CF tracheal 
epithelial cell line, Fajac et al recently demonstrated bacteria mediated gene transfer in 
CFTE29o- cells using E. coli carrying a plasmid in which GFP expression was under 
the control of the eukaryotic CMV promoter. Importantly this expression plasmid used 
was not leaky in bacteria [194], implying that the combination of the CMV immediate-
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early promoter/enhancer with the luciferase cDNA presented a unique nucleotide 
combination for bacterial read-through. As this is the first study using a luciferase 
plasmid for bactofection, comparisons of absolute lux expression with other studies 
were not possible. Although, compared to standard Lipofectamine 2000-mediated 
transfection, which has been extensively optimised for in vitro gene transfer, 
bactofection was less efficient in both cell lines. I concluded that E coli BM4570 was 
fully functional and, therefore, suitable for subsequent in vivo studies.  
 
Although a dose-related deposition of bacteria was observed within the alveolar region, 
there was little evidence for bacterial contact with conducting airways, and the limited 
number of bacteria associated with airway epithelial cells did not appear to be inside the 
cell. As noted above invasive E. coli requires β1-integrin expression. Blundell et al have 
shown that β1-integrin is expressed in murine airways [256] and, the absence of bacteria 
in cells lining the conducting airways may, therefore, not be due to the absence of the 
appropriate receptor. The nasal instillation method has been widely used for transfecting 
murine lungs [164,225] because the method is fast, non-invasive and well tolerated. 
However, using this technique contact between the bacteria and the airway epithelium is 
comparatively short, and may have been insufficient for binding of the bacteria to β1-
integrin. Nasal instillation leads to pooling of liquid in the alveolar region, possibly 
ensuring longer contact time between the bacteria and cells and, therefore, leading to 
increased deposition of bacteria in this region. Alternative methods such as prolonged 
nebulisation may be more appropriate in targeting the airways and maybe worth 
evaluating in the future. However, the commonly used whole body nebulisation method, 
which exposes mice in a nebulisation box is inefficient. More advanced murine 
nebulisation set-ups, based on administration of the aerosol via a nose cone, are more 
efficient. These are commonly used by contract research organisations, but not easily 
available in a laboratory setting. In addition, it is unknown if the bacteria would 
withstand the shear forces and heat generated in jet and ultrasonic nebulisers 
respectively, although the new single-pass mesh nebulisers may help overcome 
potential problems. Here, I opted to initially assess proof-of-principle for increased 
bactofection after prolonged contact time, by using nasal perfusion (see below), which 
additionally targets the nasal airway epithelial cells.  
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In vivo infection with invasive E. coli generated dose-related lux expression in the lung. 
The toxicity of E. coli BM4570 at high doses (>2.5x10
9
 CFU/mouse), likely related to 
septic shock, restricted the use of higher titres and highlighted a narrow toxicity/efficacy 
window. In order to assess if longer contact time between the airway epithelium and 
vector would enhance E. coli-mediated luciferase expression the vector was delivered 
via perfusion to the murine nasal epithelium. The nasal epithelium was used as contact 
time can be tightly regulated by changing the time it takes to perfuse the vector onto the 
nasal airway epithelium. Prolonging the contact time between host cells and vector had 
no effect on gene expression suggesting that perfusion for even a relatively short period 
of time is likely to allow for sufficient binding of the bacteria to β1-integrin receptors.  
 
Total protein levels, measured after tissue homogenisation and cell lysis, were generally 
higher in bacteria and lipid-treated mice when compared to PBS-treated animals. This 
may be a reflection of higher tissue cellularity due to inflammatory cells entering the 
lung. In addition, bacterial proteins may contribute to total lung protein. However, 
increasing the bacterial load delivered to the mice by 5-fold (from 5x10
8
 CFU to 
2.5x10
9
 CFU) did not affect the total protein content and, therefore, it is unlikely that 
bacterial proteins contribute to total protein content. Importantly, normalisation of 
luciferase expression for total lung protein may have slightly underestimated gene 
expression in bacteria-treated mice.  
 
To determine more accurately, if luciferase expression observed in vivo was due to 
bactofection, expression levels in lung tissue following infection with invasive and non-
invasive E. coli were compared. In contrast to the invasive strain, the non-invasive 
bacteria lack both the inv and hly genes and do not, therefore, enter non-phagocytic 
cells. Surprisingly, similar levels of lux expression were detected implying that lux 
expression may not be due to bactofection, but may more likely be due to CMV 
promoter-mediated expression of lux in the bacteria.  
 
Proof-of-principle for low level CMV promoter-driven reporter gene expression in 
gram-negative bacteria such as E. coli and Salmonella typhimurium has previously been 
reported for β-galactosidase and GFP reporter genes, and techniques to reduce the 
inappropriate expression have been described. Goussard et al inserted a prokaryotic 
termination sequence from bacteriophage T4 downstream of the CMV promoter, which 
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successfully abolished both β-galactosidase and GFP expression in those bacterial 
species [258]. Transcription termination sequences from bacteriophage T4 are likely to 
prevent bacterial polymerase from transcribing the plasmid DNA. I inserted the 
transcription terminator sequences from T4 into pCIKLux. This reduced lux expression 
from the bacteria (~ 475-fold), but did not completely abolish expression. These results 
were surprising, considering that the strategy had been successful in the context of β-
galactosidase and GFP expression plasmids. Prokaryotic recognition of the CMV 
promoter and the phage termination sequences may be context-dependent and may in 
part depend on the sequence of the reporter gene. These results may have implications 
for future studies, underlining that the degree of bacteria-derived gene expression in the 
context of bactofection studies has to be carefully monitored and controlled. 
Additionally, this study emphasises the use of bacteria in so-called „alternative gene 
therapy‟. „Alternative gene therapy‟ is characterised by expression of therapeutical 
proteins by genetically modified bacteria, which following delivery persist in the target 
tissue [261].  
 
Despite the incomplete inhibition of prokaryotic lux expression, luciferase expression in 
vitro was assessed after infection with the invasive and non-invasive bacteria carrying 
the modified plasmid (pCIKLux-mod). I first transfected CFTE29o- cells with 
pCIKLux-mod or the unmodified pCIKlux complexed to Lipofectamine 2000 to ensure 
that incorporation of transcription terminator sequences had not altered eukaryotic gene 
expression. Importantly, no difference in lux expression was found between the two 
plasmids. In vitro bactofection with invasive E. coli harbouring pCIKLux-mod 
generated high levels of lux activity suggesting that bacteria-mediated gene transfer into 
the nuclei of CFTE29o- cells had occurred, as I and others have shown [228] that only a 
very small number of dap deficient E. coli survive intracellular 48 hours post gene 
transfer due to a lack of intracellular dap. The low numbers of intracellular surviving 
bacteria are unlikely to be responsible for the high transfection level seen. In addition, 
the short half-live of luciferase (approximately 3 hours) means that luciferase expressed 
by a possible larger number of initial intracellular surviving bacteria will not be present 
48 hours post transfection, which further indicate that the high levels of lux activity 
observed in vitro is due to bacteria-mediated gene transfer.  
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The non-invasive and invasive E. coli carrying the modified pCIKLux was then 
compared in vivo and a modest, but significant increase in lux expression was detected 
in mice treated with the invasive strain. This indicated that low level bactofection may 
have occurred in vivo, which was masked by high levels of prokaryotic lux expression 
in experiments using the unmodified pCIKLux plasmid. However, overall the efficiency 
of E. coli-mediated bactofection in the mouse lung was low and gene expression was 
significantly lower than after transfection with the gold-standard non-viral GTA lipid 
GL67.  
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3.7 Summary and future directions 
 
In summary, successful in vitro bactofection using luciferase as a reporter gene was 
demonstrated as part of this study. In vivo data indicated that E. coli-mediated lung 
bactofection, at least in my model, does not currently lead to easily detectable 
eukaryotic gene expression, and is less efficient than well established liposome-
mediated gene transfer. In addition, this study highlighted a narrow toxicity/efficacy 
window restricting the dose-range which could be used. Furthermore, inappropriate 
CMV promoter-driven reporter gene expression in E. coli complicated interpretation of 
the data and, importantly, could not be completely overcome by incorporation of 
transcription terminator sequences.   
 
Additional modification of the plasmid backbone is, therefore, required to abolish 
recognition of eukaryotic promoter and enhancer sequences in E coli.  One option may 
be to include an intron into the coding sequence of the luciferase gene. In contrast to 
bacterial genes the coding regions of eukaryotic genes are often discontinuous with non-
coding introns separating coding exon sequences. Eukaryotes contain splicing 
machinery which removes the introns from pre-mRNA, thereby generating the mature 
mRNA used for translation into the actual protein. In contrast, prokaryotes are not able 
to generate protein from mRNA containing introns. Incorporation of an intron into 
pCIKLux may therefore abolish inappropriate expression within E. coli.  
 
However, even if prokaryotic luciferase expression could be completely abolished the 
low efficiency in vivo and the narrow toxicity/efficacy window of E. coli-mediated gene 
transfer remain significant problems. I have, therefore, considered the use of other 
bacteria for lung bactofection. Shigella flexneri, Salmonella typhimurium or Listeria 
monocytogenes are currently mainly used for vaccination purposes. Listeria 
monocytogenes for example has the ability to spread from cell-to-cell making delivery 
of expression plasmids to neighbouring cells possible which could increase the overall 
gene transfer efficiency. However, similar to E. coli the above bacteria are enteric 
strains with a natural tissue tropism for the intestinal epithelium and there is currently 
no evidence that uptake of alternative enteric bacteria into AECs would be more 
efficient than of recombinant invasive E. coli.  
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Alternatively, the insertion of genes encoding for additional cell adhesion molecules 
suitable for airway epithelial cells may increase E. coli-mediated bactofection. For 
example, peptide ligands attached to non-viral vectors, have been shown specifically to 
target receptors found on the apical membrane of airway epithelial cells thereby 
facilitating receptor mediated vector uptake. Ziady et al complexed pCFTR to a 
polymer and a peptide ligand consisting of 17 amino acids, which is known to target the 
serpin-enzyme complex receptor [201]. The study showed that sec-R was expressed on 
airway epithelial cells and, importantly, the complex partially corrected chloride 
transport in nasal epithelium of CF mice whereas mice treated with non-targeted vector 
or DNA alone showed no changes in chloride transport.  
 
I also considered the use of obligate intracellular pulmonary bacteria such Legionella, 
Mycoplasma pneumoniae, Chlamydia pneumoniae or Coxiella burnetti as vectors for 
lung bactofection, as these bacteria may have developed more efficient mechanisms for 
uptake into lung epithelial cells. However, extensive consultations with an expert in the 
field (C. Grillot-Courvalin, Unité des Agents Antibactériens, Institut Pasteur, France) 
revealed that the genetics and bacteriology of these bacteria are currently not well 
enough understood to make them useful vectors for bactofection and further 
development with the aim to generate bacterial vectors would, therefore, take 
approximately 3 to 5 years, which was beyond the timeline for this PhD.  
 
Considering the limitations of bactofection for lung gene therapy, I decided to publish 
the results described above [227] and further assess alternative methods to improve non-
viral airway gene transfer. The cationic lipid GL67 is the most effective non-viral vector 
for airway gene transfer and is currently being assessed in clinical studies in CF 
patients. The remaining thesis, therefore, concentrates on assessing strategies aimed at 
further improving GL67-mediated airway gene transfer. I next assessed the effect of 
opening tight junctions on lipid-mediated gene transfer in vivo (Chapter 4 to 7).  
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Chapter 4: The effect of the Ca
2+
-chelator EGTA on lipid-mediated 
gene transfer in vivo  
 
The introduction below is split in to two parts. The first part describes the general 
functions of the tight junctional complex and the applications of tight junction openers 
in the context of gene transfer to the airways. The second part focuses on EGTA, which 
belongs to the class of tight junction openers called Ca
2+
-chelators. The mechanisms by 
which EGTA opens tight junctions, its clinical applications and the use of this TJ opener 
to enhance airway gene transfers are described. 
 
 
4.1 General introduction to tight junctions and tight junction 
openers 
 
4.1.1 Intercellular junctional complex and its general function 
Polarised epithelial and endothelial cells act as a barrier between different environments 
and enable transport of solutes and water across the cellular layer. These functions are 
mediated by the intercellular junctional complex consisting of several well defined 
structures; gap junctions, desmosomes, adherens junctions and tight junctions (Figure 
26). Desmosomes, adherens junctions and tight junctions contribute to cell-cell 
adhesion whereas gap junctions are required for intercellular communication.  
 
Gap junction 
Gap junctions contain channels which consist of proteins called connexins. These 
channels connect neighbouring cells and mediate communication between cells by 
allowing movement of inorganic ions (Na
+
, Ca
2+
, K
+
) and small molecules, such as the 
second messengers cAMP and inositol-triphosphate (IP3), through the channels by 
passive diffusion [262]. Although channel permeability is relative non-specific it has 
been suggested that expression of different connexins may lead to changes in 
permeability which may be important in maintaining normal physiological processes in 
different organs [262]. 
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Figure 26: The intercellular junctional complex 
Epithelial cells attach to adjacent cells via the intercellular junctional complex consisting of 
tight junctions (TJ) (purple rectangles), adherens junctions (AJ) (green rectangles) and 
desmosomes (yellow rectangles) and to the basement membrane by focal contacts (blue 
rectangles). Tight junctions and adherens junctions are linked to the actin cytoskeleton where as 
desmosomes are connected to intermediate filaments. Tight junctions create a „fence‟ between 
apical (red lines) and basolateral (blue lines) membrane domains. The figure is taken from 
Miyoshi et al [267]. 
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Desmosome 
Desmosomes contain two types of transmembrane glycoproteins, desmocollins and 
desmogleins. They belong to the cadherin superfamily of adhesion molecules and their 
adhesion properties are dependent on the extracellular Ca
2+
 concentration [263]. The 
desmogleins and desmocollins are linked to the intermediate filament network by 
several cytoplasmic proteins (desmoplakins and plakoglobin). The linkage between 
desmosomes and the intermediate filament network is likely to play a role in tissue 
integrity and the high abundance of desmosomes in the epidermis suggests that this is 
probably most significant in tissues that must withstand high levels of mechanical stress 
[264]. 
  
Adherens junction 
Adherens junctions, present immediately below the tight junctions, consist of two 
separate adhesive components; the nectin-afadin complex and the classical cadherin-
catenin complex. The nectin family of immunoglobulin G (IgG)-like adhesion 
molecules consist of nectin 1-4 and they are all linked to the actin cytoskeleton via the 
actin binding molecule afadin. Cadherins, of which the best studied is E-cadherin, are 
transmembrane Ca
2+
-dependent molecules belonging to the cadherin superfamily. They 
form a basic complex with α-, β- and p120 catenin. The latter two bind directly to 
cadherin whereas α-catenin, an actin binding protein, connects via β-catenin hereby 
linking the cadherins to the actin cytoskeleton (Figure 27) [265]. The extracellular 
domain of nectins and cadherins are responsible for adhesion between adjacent cells and 
the interaction between these transmembrane proteins and the actin cytoskeleton, via 
cytoplasmic molecules, plays a part in regulation of the junctional permeability. Direct 
modification of the extracellular domain of nectins and cadherins can result in 
disassembly of adherens junctions leading to increased paracellular permeability. In 
addition, it is believed that disassembly of adherens junctions - as well as tight junctions 
- is regulated indirectly through phosphorylation of myosin light chain (MLC) by Ca
2+
-
calmodulin dependent MLC kinase. Phosphorylation of MLC results in the classical 
myosin-actin cross bridging, which generates a contractile force pulling the 
transmembrane molecules inwards thereby forcing them to disassociate from each other. 
The gap generated between neighbouring cells by disruption of the junctional integrity 
results in increased paracellular permeability [266]. 
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Figure 27: Adherens junction 
The adherens junctional transmembrane proteins cadherins and nectins are linked to the actin 
cytoskeleton via cytosolic proteins. Cadherins form a basic complex with α-, β- and p120 
catenin (p120ctn). The latter two bind directly to cadherin whereas α-catenin, an actin binding 
protein, connects via β-catenin hereby linking the cadherins to the actin cytoskeleton. Nectin 
binds to the actin cytoskeleton via the actin binding molecule afadin, also known as AF6. The 
figure is taken from Niessen et al [265]. 
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Tight junction 
The tight junction is the most apical component of the junctional complex. It functions 
as a gatekeeper of the paracellular pathway, forming in association with the adherens 
junction, a regulated barrier which controls movement of water and solutes. Tight 
junctions also act as a fence separating the apical and basolateral membrane domains 
and prevent diffusion of lipids and membrane proteins from one domain to the other 
[267]. Many tight junction proteins have been identified and the majority of these are 
located in the cytosol playing a part in regulation of the junctional permeability. 
However, the first tight junction protein to be discovered, occludin, was one of the 
transmembrane proteins, which extend into the paracellular space (Figure 28). Occludin, 
a single gene product consists of four transmembrane spanning domains and two 
extracellular loops and both the amino- and the carboxy terminals are located in the 
cytoplasm. The exact physiological function of occludin is still unclear. However, the 
very few charged amino acids in the extracellular loops suggest that occludin may play 
a role in cell adhesion through hydrophobic interactions between loops on adjacent 
cells. In addition, the extracellular domain of occludin is predicted to have no net charge 
at physiological pH making it unlikely that occludin regulates the paracellular ion 
selectivity [266,268]. The observation that transgenic occludin-deficient mice do not 
have tight junction abnormalities further questioned the exact role of occludin and 
ultimately led to the discovery of claudins [269]. 
 
Claudins are transmembrane proteins consisting of four transmembrane domains and 
two extracellular loops. Similar to occludin the N- and C-terminals are cytoplasmic, 
however, the amino acid composition of the extracellular loops of claudins varies 
significantly among different claudins resulting in a wide range of isoelectric points. In 
different epithelial, different claudins with different isoelectric points will at 
physiological pH be charged or uncharged thereby forming specific ion-selective 
channels in different epithelia [268]. Claudins play a vital role in cell adhesion but 
recent studies also suggested that claudins are the main regulator of paracellular 
permeability, not only controlling paracellular ion selectivity but also discriminating 
between molecules varying in size [270,271]. More than 20 members of the claudin 
family have been identified and different claudins dominate in different tissues which 
might explain the variability in paracellular permeability observed in different tissues 
[267].  
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Figure 28: Tight junction 
The tight junctional transmembrane proteins claudins, occludin and junction adhesion molecules 
(JAM) are linked to the actin cytoskeleton via cytosolic scaffolding proteins, such as zonula 
occludens 1 (ZO-1), ZO-2, ZO-3 and cingulin. Other scaffolding proteins (MUPP1, MAGI) 
have also been identified. The figure is taken from Niessen et al [265]. 
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For examples, the claudins expressed in the airway epithelium (claudin-1, -3, -4, -5, -7, 
-8, -10, -14 and -16) are different from the ones expressed in the kidneys possible 
explaining the higher paracellular permeability in the this organ [272]. 
 
Junction adhesion molecules (JAMs) are the third group of transmembrane proteins, 
forming a complex with occludin and claudins. They belong to the IgG superfamily and 
consist of two extracellular immunoglobulin (Ig) domains and a single transmembrane 
domain [265,268]. The extracellular domain is responsible for adhesion between 
neighbouring cells and as JAMs are also found on leukocytes they facilitate migration 
of inflammatory cells between endothelial cells through adhesion to counter JAMs in 
the tight junctions [273]. Recently CAR, which like JAMs is a transmembrane protein 
with an extracellular region consisting of two Ig domains, was shown to be a tight 
junction protein. CAR mediates cell adhesion and also functions as a receptor for 
pathogens [274]. 
 
The tight junctional transmembrane proteins are linked to the actin cytoskeleton via the 
so-called scaffolding proteins; zonula occludens 1 (ZO-1), ZO-2, ZO-3 and cingulin. In 
addition to structures and proteins described here a vast number of other proteins have 
been identified which are likely to play a regulatory role in tight junctional 
permeability. As for the adherens junctions, tight junctional permeability may be 
regulated directly through modification of tight junctional proteins or indirectly through 
effects on the cytoskeleton. It has, for example, been suggested that activation of protein 
kinase C (PKC) by the second messenger system diacylglycerol (DAG)/IP3 causes 
phosphorylation of occludin and ZO proteins resulting in enhanced tight junctional 
permeability. In addition to the classical contraction of the actin cytoskeleton by 
phosphorylation of MLC, PKC has also been suggested to stimulate internalisation of 
transmembrane spanning proteins via reorganisation of the cytoskeleton thereby 
increasing paracellular permeability [270,275]. Although the exact mechanisms remain 
unclear it is evident that multiple signalling pathways are responsible for regulation of 
the paracellular permeability.  
 
4.1.2 The role of tight junctions in the lung   
The presence of fluid in the airway lumen of the correct amount, the right ionic 
composition and with the appropriate visco-elastic properties is crucial to the normal 
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functioning of mucociliary clearance and mucus secretion. Epithelial tight junctions 
help maintain homeostasis by selectively controlling the movement of ions and solutes 
through the paracellular channel. For example tight junctions play a part in the „low 
volume‟ hypothesis (Section 1.4.3) by controlling the amount of chloride and water, 
which are absorbed from the airway lumen through the paracellular channel and they 
thereby regulate the height of the airway surface liquid. Furthermore, water, ions and 
small molecules can „escape‟ from the relatively leaky endothelial cells, pass through 
the basement membrane of the airway epithelium and into the paracellular channel. 
Here the tight junctions restrict their passage into the airway lumen [276].  
 
Tight junctions play a role in different lung diseases. It has, for example, been shown 
that the airway epithelial barrier function in asthma is impaired, which is due to severely 
disrupted tight junctions. The disruption of the epithelial barrier does not just allow 
pollutants and infectious agents to penetrate the airway wall, which facilitates immune 
and inflammatory responses and eventually tissue damage, but it also result in a flux of 
inflammatory cells into the airway lumen [276]. Another example is acute respiratory 
distress syndrome (ARDS), which is a severe lung disease caused by a variety of direct 
and indirect issues. It is characterised by inflammation of the lung parenchyma leading 
to impaired gas exchange with concomitant systemic release of inflammatory mediators 
causing inflammation, hypoxemia and frequently resulting in multiple organ failure.  
 
Inhalation of allergens such as house dust mite faecal pellet (HDMFP) proteins has been 
linked to the development of allergic sensitisation and asthma. Amongst these allergens, 
Der p 1 (Dermatophagoides pteronyssinus), found in high concentration in HDMFP, is 
the most extensively studied. In vitro studies have shown that Der p 1, an enzyme with 
proteolytic activity, causes increased permeability in bronchial epithelial cells via 
cleavage of the tight junctional transmembrane proteins occludin and claudins [277-
279]. Disruption of tight junctions is believed to facilitate permeation of Der p 1 and 
other inhaled allergens across the epithelial barrier thereby allowing interaction with 
dendritic antigen presenting cells residing underneath the epithelium which 
subsequently may trigger an allergic sensitisation. In addition to Der p 1, cigarette 
smoke which is known to cause airway inflammation has been shown to increase 
permeability of different markers across the airway epithelium both in vitro and in vivo 
[280-282]. Rusznak et al has also demonstrated that not only did exposure to cigarette 
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smoke decrease transepithelial resistance leading to increased permeability but it also 
enhanced  Der p 1-induced increase in permeability across bronchial epithelial cells in 
vitro [277]. 
 
4.1.3 Different classes of tight junction openers increase viral airway gene 
transfer  
Transfection of polarised respiratory epithelial cells has proven difficult as the airway 
epithelium has evolved specifically to resist uptake of inhaled particles and has 
developed mechanisms to clear these from both lower and upper airways (see Section 
1.4.3). However, different approaches have been assessed with the aim of increasing the 
low airway transfection efficiency. The concept of opening tight junctions to allow 
access of viral gene transfer agents to the basolateral memebrane domain and thereby 
increase gene transfer to airway epithelial cells has been explored in the context of 
adenovirus-mediated gene transfer in vitro and in vivo. As mentioned above, the CAR 
receptor, needed for entry of the commonly used adenovirus serotypes 2 and 5 into 
AECs, has been identified as one of the four transmembrane tight junctional proteins 
and is, therefore, not directly accessible after topical administration of the virus leading 
to low transfection efficiency. Pre-administration of various tight junction openers has 
enhanced access of adenovirus to its receptor and improved gene transfer in preclinical 
models [140,212]. Interestingly, Waddington et al have recently shown that the CAR 
receptor is not needed for liver transduction following intravascular delivery of 
adenovirus serotype 5 [142]. Instead, coagulation factor X binds directly to the 
adenovirus capsid protein, hexon, and thereby „bridges‟ the virus to alternative receptors 
in the liver. Additionally, the study showed a substantial reduction in hepatic gene 
transfer in mice transfected with a mutant adenovirus serotype 5 lacking the specific 
hexon binding region (hexon hypervariable region) for coagulation factor X compared 
to mice transfected with wild-type adenovirus serotype 5.  
 
 
The classes of tight junction and adherens junction openers, which have been shown to 
increase airway viral gene transfer by increasing junctional permeability, include Ca
2+
-
chelating agents, medium chain fatty acids (MCFA), occludin peptides, E-cadherin 
antibodies and detergents (see below). It is believed that Ca
2+
-chelating agents and 
medium chain fatty acids, via different mechanisms, trigger phosphorylation of MLC, 
which results in the classical myosin-actin cross bridging pulling the transmembrane 
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molecules inwards and increasing paracellular permeability (see Section 4.2.1 and 5.1.1 
for more details). In contrast to Ca
2+
-chelating agents and medium chain fatty acids, 
occludin peptides and E-cadherin antibodies exhibit their effect on paracellular 
permeability via direct interference with junctional transmembrane proteins whereas the 
mechanisms by which detergents affect tight junctional permeability are currently not 
fully understood. However, it has been suggested that detergents affect MLC 
phosphorylation as described for Ca
2+
-chelating agents and medium chain fatty acids 
(see Section 6.1.1 for more details). 
 
Ca
2+
-chelating agents and medium chain fatty acids 
Most research assessing the effect of tight junction openers on junctional permeability 
in airway epithelial cells has been carried out using the more conventional openers such 
as Ca
2+
-chelating agents and medium chain fatty acids (e.g. capric acid and lauric acid) 
to increase adenovirus-mediated gene transfer to airway epithelium. Johnson et al 
assessed the effect of sodium caprate (C10), sodium laurate (C12) and EGTA on 
adenovirus-mediated gene transfer [212]. This study showed a significant increase in 
gene transfer in murine trachea in vivo after pre-administration of C10 and C12 and co-
administration of EGTA and vector together. However, Johnson et al failed to show an 
increase in luminal albumin concentration, as a read-out of in vivo paracellular 
permeability, even though EGTA, C10 and C12 have previously been shown to increase 
paracellular permeability to large solutes in a human airway ex vivo model [283,284]. A 
significant increase in adenovirus-mediated gene transfer efficiency in murine airways 
in vivo after pre-treatment with EGTA and C10 was also reported by Gregory et al 
[141]. Transepithelial permeability was assessed by Wang et al in vivo measuring 
voltage across the epithelium. They reported a fall in voltage in rabbit tracheal and 
human nasal epithelial cells after treatment with EGTA indicating an opening of tight 
junctions and, in addition, they showed that EGTA increased retrovirus- and 
adenovirus-mediated gene transfer to rabbit tracheas [214]. 
 
Occludin peptides, claudin peptides and E-cadherin antibody 
In contrast to EGTA and medium chain fatty acids which are likely to indirectly affect 
the actin cytoskeleton, thereby increasing junctional permeability, a number of tight 
junction openers have been identified that exhibit their effect via direct interaction with 
the transmembrane spanning proteins in the junctional complex. Occludin peptides, 
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which are homologous to various sections of the extracellular loops in occludin, have 
been shown to change the distribution of occludin resulting in decreased transepithelial 
resistance, increased permeability and increased adenovirus-mediated gene transfer in 
vitro. However, the exact mechanism is not known [285,286]. 
 
Further, Coyne et al have shown that binding of the C-terminal fragment of Clostridium 
perfringens enterotoxin (C-CPE) to claudin 4, which is expressed in the airway and 
intestinal epithelium, enhanced absorption of high molecular weight molecules. When 
compared to C10, C-CPE proved 400-fold more potent without showing any evidence 
of toxicity in the rat jejunum [287]. However, C-CPE has not yet been assessed in the 
context of gene transfer. 
 
Finally E-cadherin antibody which blocks the function of E-cadherin, one of the 
transmembrane spanning proteins in the adherens junction, by direct binding, has been 
shown to affect junctional integrity and increase paracellular flux following apical 
exposure in a human bronchial epithelial cell line and in primary bronchial cells in vitro. 
This was accompanied by an increase in adenovirus-mediated gene transfer [288]. In 
contrast to this, other studies have indicated that E-cadherin antibodies were only 
effective after depletion of extracellular Ca
2+
 or after adding the antibody to the 
basolateral surface [289,290] which suggests that E-cadherin antibodies alone were not 
sufficient to disrupt the integrity of the tight junction, the most apical component in the 
junctional complex.  
 
Detergents 
Finally, both synthetic and biologic detergents have been shown to decrease the tight 
junctional barrier function. Pre-administration of polidocanol (synthetic detergent) and 
lysophosphatidylcholine (LPC) (biologic detergent) have resulted in increased virus-
mediated gene transfer to the nasal epithelium of mice in vivo [213,291]. However, 
direct comparison of the two detergents resulted in significantly higher numbers of 
transfected nasal epithelial cells (approximately 20 per mouse) when LPC was 
administered prior to lentivirus pseudotyped with vesicular stomatitis virus envelope 
glycoprotein (VSV-G) in vivo [291] indicating that a „natural‟ detergent may be more 
effective than synthetical detergents.  
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The above mentioned classes of tight junction openers have, by increasing paracellular 
permeability, enhanced viral gene transfer efficiency to the airway epithelium. 
However, other compounds such as chitosan, cyclodextrins and cytokines, which have 
also been shown to have an effect on paracellular permeability, have yet to be assessed 
in the context of enhancing gene transfer to the airways.   
 
4.1.4 Tight junction openers may increase non-viral airway gene transfer  
As for viral vectors, the extracellular barriers of the airway epithelium evolved to resist 
uptake of inhaled particles have also made non-viral gene transfer into polarised airway 
epithelial cells difficult and resulted in low gene transfer efficiency. Increasing gene 
transfer efficiency by allowing the vector access to the basolateral membrane domain 
using tight junction openers is easy to understand in the context of adenonvirus-
mediated gene transfer as the CAR receptor is located basolaterally. This strategy 
becomes harder to understand when talking about non-viral vectors as possible specific 
receptors for these agents are still not identified. However, it is generally believed that 
non-viral gene transfer agents enter cells via endocytosis and this process may be more 
efficient at the baselateral membrane domain compared to the apical thereby explaining 
the possible rationale for using tight junction openers to enhance non-viral gene transfer 
[215,216]. Proof-of-principle that allowing non-viral vectors access to the basolateral 
membrane domain of AECs increases gene transfer has been established.  
 
A small number of studies have assessed the effect of EGTA in the context of non-viral 
gene transfer. Chu et al demonstrated that pre-treatment with EGTA and Ca
2+
-free 
medium resulted in increased cationic lipid-mediated gene transfer in polarised 
bronchial cells maintained under air-liquid interface conditions in vitro. Additionally, 
the study showed that the increase in gene transfer was not dependent on cell 
proliferation as the relative cell proliferation did not change. Therefore, the increase was 
believed to be due to enhanced paracellular permeability and increased uptake of the 
non-viral vector via the basolateral membrane [215]. In addition, Meng et al has shown 
that intratracheal delivery of EGTA increases gene transfer in mice using the non-viral 
vector LID [217]. Rudolph et al showed that nebulisation of EGTA and polidocanol 
failed to enhance PEI-mediated gene transfer to the murine lung [187]. However, no 
optimisation of the dose of the tight junction openers delivered and the nebulisation 
time was carried out and furthermore, numbers were low (n=4). These studies have 
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shown some proof-of-principle that increased paracellular permeability enhances non-
viral gene transfer. However, further research is needed to understand the effect of tight 
junction openers on non-viral gene transfer to polarised airway epithelial cells 
 
Non-viral GTAs are known to enter cells mainly by endocytosis [292,293]. However, 
the exact mechanisms and cell surface molecules that trigger endocytosis are still 
undefined. Several studies have shown that binding and internalisation of cationic 
liposome-DNA complexes was significantly reduced in more differentiated compared to 
less differentiated airway epithelial cells in vitro [215,294]. However, Chu et al has 
demonstrated that this could be overcome by treatment with the tight junction opener 
EGTA leading to increased uptake of cationic liposomes into differentiated airway 
epithelial cells [215]. These results indicate that the relatively inefficient binding and 
internalisation of non-viral complexes by the apical membrane of polarised cells can be 
improved by exposure to the basolateral membrane domain. The authors also suggest 
that the enhanced endocytosis may be facilitated by receptors present at the basolateral 
membrane, however, no studies were carried out to assess this hypothesis.  
 
Proteoglycans (PGs) such as heparin sulphate PGs have been suggested to act as 
receptors for cationic liposome-DNA complexes. Proteoglycans, shown to be 
sequestered at the basolateral surfaces of polarised epithelial cells [296,297], are 
macromolecules consisting of a protein core with covalently attached linear, poly-
sulphated and, thereby, negatively charged poly-saccharide chains named 
glycosaminoglycan (GAG). Heparan sulphate is one of a number of negatively charged 
GAGs [295] (Figure 29). Interestingly, Mounkes et al have shown that proteoglycans 
mediate cationic lipid mediated gene delivery in vitro and in vivo. In vitro, cells stably 
transfected with a proteoglycan were efficiently transfected by cationic lipoplexes. In 
contrast, lipid-mediated gene transfer was not observed in cells not expressing the 
proteoglycan. In vivo, heparinase, which specifically cleaves the GAG heparan sulphate 
from cell surface proteoglycans, was given intravenously to mice prior to i.v. delivery 
of cationic lipoplexes. Interestingly, heparinase completely blocked cationic lipid-
mediated gene transfer to organs such as heart, spleen and lung [298]. These results 
have been supported by Mislick et al, who demonstrated that heparinase reduced 
cationic lipid-mediated gene transfer in vitro [299].  
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Figure 29: Heparan sulphate proteoglycan 
Heparan sulphate proteoglycan is attached to the cellular membrane. It is a macromolecule 
consisting of a protein core with covalently attached linear, heparan sulphate (HS) chains. The 
backbone structure of HS consists of N-acetylglucosamine (GlcNAc)-glucoronic acid (GlcA) 
disaccharides, which are modified by the addition of sulphate groups at various positions. The 
figure is taken from Belting et al [295]. 
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In addition, the presence of heparan sulphate PGs and GAGs in the extracellular media 
has been shown to decrease transfection efficiency of lipoplexes in vitro via binding of 
the non-viral vector in the extracellular space [295,299,300]. These results provide 
evidence that heparan sulphate PGs play a significant role in cationic liposome-
mediated gene transfer. However, the exact role is yet to be determined especially 
following publication of a study showing that although GAGs facilitate endocytosis of 
cationic lipoplexes the positive effect on gene transfer efficiency was disputed in vitro 
[216]. In this study two different cell lines (CHO cells and smooth muscle cells) were 
treated with different GAGs prior to transfection with lipoplexes. The effect of GAGs 
on uptake and reporter gene expression was then assessed. Interestingly, the study 
highlights that the findings are likely to be cell line dependent, which makes it hard to 
transfer these results to, for example, airway epithelial cells and additionally, it suggests 
the importance of continuing these studies in vivo.     
 
In this thesis the following tight junction openers were chosen to assess the effect on 
cationic liposome-mediated gene transfer to the airway epithelium in vivo and ex vivo; 
EGTA, C10 and C12 and LPC. These tight junction openers represent different classes 
of openers (Ca
2+
-chelators, medium chain fatty acids and detergents), which act on the 
tight junction via different mechanisms. The reasons for choosing these tight junction 
openers will be discussed in the relevant chapters.  
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4.2 Introduction to EGTA tight junction opener 
 
To assess the effect of a tight junction opener on GL67-mediated gene transfer to the 
airways, the Ca
2+
-chelator EGTA was chosen (Figure 30). There are several reasons for 
assessing this tight junction opener; it has a documented effect on paracellular 
permeability and has been shown to increase viral gene transfer to the airways. 
Moreover, it is the only tight junction opener that has shown proof-of-principle that 
allowing a non-viral vector access to the basolateral membrane domain of AECs 
increases gene transfer. Finally, clinical use of EGTA and ethylenediaminetetraacetic 
acid (EDTA), another Ca
2+
-chelator, did not result in side-effects, which is an important 
finding as the overall aim would be to translate the research to the clinic. These points 
will be discussed in more details below. 
 
4.2.1 Mechanisms by which EGTA regulates tight junctional permeability 
Several studies have shown that extracellular Ca
2+
 plays a crucial role in regulating tight 
junctional permeability in vitro. The exposure of MDCK epithelial cells for example to 
low Ca
2+
 (achieved by incubation in Ca
2+ 
free media containing the Ca
2+
-chelating agent 
EGTA) prevented the formation of TJs [301]. Importantly, TJ polarity and 
transepithelial resistance were restored after, raising the extracellular Ca
2+ 
concentration 
[302,303]. Although the effect of extracellular Ca
2+
 on tight junction barrier function is 
well known the intracellular mechanisms involved following, modulation of 
extracellular Ca
2+
, have not been fully understood. As previously mentioned it has been 
suggested that Ca
2+
-chelators such as EGTA, EDTA and 1,2-bis(o-
aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), as well as Ca
2+
-free media 
indirectly trigger activation of Ca
2+
-calmodulin dependent MLC kinase leading to 
phosphorylation of MLC, which result in myosin-actin cross bridging and thereby 
contraction of the actin-myosin filaments. The contractile force generated may result in 
retraction of the tight junctional transmembrane proteins leading to increased 
paracellular permeability [304]. However, the exact mechanism by which EGTA and 
other Ca
2+
-chelators activate MLC kinase as well as the link between depletion of 
extracellular Ca
2+
 and intracellular Ca
2+ 
levels remain unclear. EGTA and low 
extracellular Ca
2+ 
concentrations have also been shown to modulate junctional integrity 
leading to increased paracellular permeability via activation of PKC [305,306]. 
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Figure 30: EGTA formula and structure 
The figure show the formula and structure of ethyleneglycol-bis-(β-aminoethyl ether)-N,N‟-
tetraacetic acid (EGTA). The figure is taken from www.sigmaaldrich.com. 
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Although the exact mechanism is not fully elucidated it has been suggested that 
activation of PKC is mediated by cadherins, which are transmembrane spanning Ca
2+
-
dependent adhesion molecules belonging to the adherens junction. As cadherins bind 
Ca
2+
 directly through their extracellular domain, calcium may simply act by linking 
adhesion molecules on adjacent cells together. However, removal of extracellular Ca
2+ 
from the Ca
2+
 binding site is unlikely just to result in reduced adhesion between 
opposing cadherin proteins but may also cause conformational changes within the 
intracellular domain which may lead to activation of PKC [306]. PKC activation may 
then result in reorganisation of the cytoskeleton leading to internalisation of 
transmembrane spanning proteins, thereby increasing the paracellular permeability.  
 
4.2.2 EGTA enhances viral and non-viral airway gene transfer  
Although tight junctional integrity following administration of Ca
2+
-chelators has been 
widely studied, a limited number of studies have assessed the effect of Ca
2+
-chelators on 
gene transfer and in particular airway epithelial gene transfer.  
 
The majority of research has focussed on enhancing virus-mediated gene transfer 
efficiency to polarised airway epithelial cells ex vivo and in vivo using mainly EGTA. 
Adenovirus-mediated gene transfer to airway epithelial cells is relatively inefficient due 
to the lack of the CAR receptor on the apical membrane of AECs [307]. The CAR 
receptor is as previously mentioned one of four transmembrane tight junctional proteins 
and opening of the tight junctions following administration of EGTA has consistently 
enhanced adenovirus-mediated gene transfer to tracheal and lung airway epithelium in 
vivo by allowing the vector access to the basolateral membrane [140,141,212,214]. 
 
The effect of EGTA on adenovirus-mediated gene transfer in vivo was associated with 
mild lung inflammation, detected via histopathological analysis, neutrophilia and an 
increase in proinflammatory cytokines, which correlated with the increase in neutrophils 
measured in the lumen. In contrast, EGTA had no effect on lactate dehydrogenase 
(LDH) release, lung oedema or airway responsiveness suggesting that changes in 
paracellular permeability to enhance airway gene transfer can be achieved with relative 
minimal toxicity [212].  
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Other viral vectors such as the feline immunodeficiency virus (FIV), murine leukaemia 
virus (MuLV) and AAV serotype 2 have been shown to transduce polarised airway 
epithelium inefficiently when applied to the apical surface which may be due to the 
presence of their native receptors on the basolateral cell surface of polarised AECs. In 
contrast, AAV serotype 5, 6 and 9 have shown efficient uptake when applied apically to 
differentiated human airway epithelium ex vivo and in vivo suggesting that receptors for 
these AAV serotypes are present on the apical membrane [152,308]. Treatment with 
EGTA significantly enhanced gene transfer efficiency of FIV, MuLV and AAV 
serotype 2 in human polarised airway epithelial cells ex vivo and in tracheal airway 
epithelium in vivo [309-311]. Furthermore, the chloride transport defect was corrected 
in CF airway epithelia ex vivo when EGTA was administered together with FIV and 
MuLV based vectors encoding the CFTR cDNA [309,311]. 
 
As previously mentioned a limited number of studies have assessed the effect of EGTA 
on non-viral gene transfer to AECs. Importantly, EGTA was shown to increase cationic 
lipid GL67-mediated gene transfer in polarised bronchial epithelial cells ex vivo [215]. 
In contrast, nebulisation of EGTA failed to enhance PEI-mediated gene transfer to the 
murine lung in vivo [187]. However, as previously stated no optimisation of the dose of 
the tight junction openers delivered and the nebulisation time was carried out and 
furthermore, numbers were low. Further studies will, therefore, be needed to fully 
understand the effect of tight junction openers in the context of non-viral gene transfer.   
 
4.2.3 The use of EGTA clinically 
As the overall aim is to carry out translational research and hereby discover 
interventions that can be used clinically, the safety of EGTA has to be considered to 
determine whether this tight junction opener can be used to enhance airway gene 
transfer in CF patients. To date no published information is available about the use of 
EGTA in human lung. However, EDTA which has a chemical structure similar to 
EGTA and is therefore believed to have similar toxicity profile has been used in clinical 
trials to treat Pseudomonas aeruginosa infection in patients with CF [312,313]. The 
effect of EDTA on Pseudomonas aeruginosa seems to be due to a loss of magnesium 
from the culture medium caused by EDTA‟s chelating effect, since this cation is vital 
for maintenance of the bacterial cell wall integrity. Brown et al reported no adverse 
effects when CF children were treated twice daily with an aerosol of 0.05 M EDTA 
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over a 3 months period [312]. Similar, Hillmann et al have shown that in an attempt to 
treat Pseudomonas aeruginosa infection, tracheal injection and nebulisation of 0.05 M 
and 0.005 M EDTA, respectively, once a day for three days in adult patients caused no 
side-effects [313].  
 
Wang et al administered 0.01 M EDTA and EGTA to the nasal epithelium of healthy 
volunteers and reported a fall in electrical voltage, thus demonstrating increased 
paracellular permeability. Importantly, no adverse effects were seen [214]. 
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4.3 Aims 
 
The aim of the work described in this chapter was to assess the effect of EGTA on 
GL67-mediated gene transfer in mouse lung in vivo. Briefly, the non-viral gene transfer 
agent GL67 was delivered to the murine airways by nebulisation, a delivery method 
used clinically Various doses of EGTA were delivered to the murine lung by either  
nasal instillation or nebulisation to assess the effect of different delivery methods on 
gene transfer efficiency and toxicity. In addition, the effect of pre-administration or co-
administration of EGTA and vector were assessed. Finally, an attempt was made to 
assess whether EGTA disrupted the TJs between airway epithelial cells in vivo using a 
transmission electron microscopy (TEM) based technique.   
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4.4 Materials and Methods  
 
4.4.1 EGTA stock solutions 
A 0.2 M EGTA tetrasodium salt (Sigma-Aldrich Com. Ltd., Poole, UK) stock solution 
was made by dissolving 0.9366 g in 8 ml WFI, adjusting pH to 7.4 with concentrated 
hydrochloric acid (HCl) (Sigma-Aldrich Com. Ltd., Poole, UK) and then bringing the 
final volume to 10 ml with WFI. For higher concentrations of EGTA a 1 M stock 
solution was generated using acidic EGTA (Sigma-Aldrich Com. Ltd., Poole, UK); 3.81 
g was re-suspended in 6 ml WFI, the solid was dissolved by adjusting pH to 
approximately pH 9 using sodium hydroxide pellets (~ 10 pellets) and pH was then 
adjusted to pH 7.4 with concentrated HCl before adding WFI to a final volume of 10 
ml. 
 
4.4.2 EGTA nasal instillation prior to GL67-mediated gene transfer in mouse 
lung and nose 
25 µl or 50 µl EGTA (0.05 M to 0.4 M) were instilled, as previously described in 
Section 2.4.2, into the nose of C57Bl/6 mice (approximately 12 weeks old females, 
n=8/group). Control groups receiving WFI or no pre-treatment were included. 30 min 
after EGTA delivery, mice were placed in the nebulisation box and transfected with 10 
ml GL67 complexed to pCIKLux at a molar ratio of 6:8 by whole body nebulisation as 
described in Section 2.4.3. 24 hrs after transfection all mice were culled. The nasal 
epithelium and the right lung were harvested, snap-frozen in liquid nitrogen and stored 
at -80ºC for detection of luciferase activity (Section 2.5.1 and 2.5.2). The left lung was 
harvested and fixed in 10% formalin (Sigma-Aldrich Com. Ltd., Poole, UK) for 
histological assessment.  
 
4.4.3 Co-administration of EGTA and GL67/pCIKLux complexes in vitro 
293T cells were cultured in DMEM supplemented with 10% heat-inactivated FBS and 
1% penicillin/streptomycin and maintained at 37ºC in a 5% CO2 atmosphere. 24 hrs 
prior to transfection cells were seeded in 96-well plates at a density of 8000 cells/well. 
GL67 was complexed to pCIKLux as described in Section 2.1.2 at a molar ratio of 6:8 
and equal volumes of the complex and EGTA stock solutions ranging from 0.1 M to 1 
M were mixed. 16 µl of the generated complex (GL67/pCIKLux/EGTA) was diluted in 
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a total volume of 5 ml Opti-MEM   and 50 µl of this solution containing 2 µg pCIKLux 
and EGTA doses ranging from 8x10
-9
 mol to 8x10
-8
 mol, was then added to each well 
for 5 hrs at 37ºC (n=6/group). The medium was then removed and the cells were 
washed three times in DMEM prior to further incubation in complete medium. Control 
groups received medium and GL67/pCIKLux without EGTA. 48 hrs after transfection, 
cells were washed, processed and assayed for luciferase activity as described in Section 
2.5.1 and 2.5.2.  
 
4.4.4 Co-nebulisation of EGTA and GL67/pCIKLux complexes in mouse lung 
and nose 
C57Bl/6 mice (approximately 12 weeks old females, n=8/group) were nebulised for 30 
min, 1 hr and 2 hrs with a mixture of GL67/pCIKLux and 1 M EGTA (1:1, v:v). A total 
of 5 ml, 10 ml and 20 ml GL67/pCIKLux/EGTA were nebulised, corresponding to 30 
min, 1 hr and 2 hrs. Control mice received GL67/pCIKLux mixed with WFI (1:1, v:v). 
After 24 hrs the mice were culled and the right lung harvested for detection of luciferase 
activity and the left lung for histological assessment.  
 
4.4.5 EGTA nebulisation prior and subsequent to GL67-mediated gene transfer 
in mouse lung and nose 
C57Bl/6 mice (approximately 12 weeks old females, n=8/group) were transfected for 30 
min with GL67 complexed to pCIKLux by whole body nebulisation as described in 
Section 2.4.3, followed by nebulisation of 1 M EGTA and GL67/pCIKLux for 1 hr and 
30 min, respectively. During the experiment cohorts of mice (n=8/group) were added to 
the nebulisation box prior to starting each round of nebulisation to gain appropriate 
controls. To control for EGTA delivered, mice were nebulised as above but received 
WFI instead. 24 hrs post transfection the nasal epithelium and the right lung were 
harvested and luciferase activity determined.  
 
4.4.6 Histological assessment of mouse lung 
Following fixation of the left lung in 10% formalin, the tissue was embedded in paraffin 
(Medim Wax, South Godstone, UK) and transverse sections from the middle center of 
the lung were cut (M3500, Bright Instrument Co. Ltd., Huntingdon, UK) and stained 
with haematoxylin and eosin (H&E) by a technician (N. Cornish, Department of Gene 
Therapy, Imperial College, London, UK). The tissue was then scored semi-
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quantitatively for degree and area of haemorrhage and inflammation (1 section/lung). 
The scoring was carried out blinded by a pathologist (J. Zhu, Department of Lung 
Pathology, Imperial College London, UK) as it was believed a more experienced person 
was needed for this task. An arbitrary scoring system was used and scores were 
assigned as follows: 0.5 = area affected < ¼ of the section (patchy distribution), 1 = area 
affected between ¼ and ⅓ of the section (localized distribution) and the alveolar septa 
(wall) were slightly thicker, 2 = area affected between ⅓ and ⅔ of the section (diffused 
distribution) and the alveolar septa were obviously thicker but alveolar spaces still exist, 
3 = area affected > ⅔ of the section (diffused distribution) and the alveolar septa were 
obviously thicker but alveolar spaces still exist. Sections were scored using a light 
microscope (Leitz Dialux 20) equipped with a 10-40x objective. 
 
4.4.7 Assessment of tight junction permeability using lanthanum hydroxide 
Lanthanum hydroxide stock solutions 
4% and 8% stock solutions of lanthanum hydroxide were made up as follows: 4 g and 8 
g of lanthanum nitrate (TAAB Laboratories Equipment Ltd., Aldermaston, UK) was 
dissolved in 50 ml deionised water by adjusting pH to 7.8 with 0.1 M sodium hydroxide 
(NaOH) (Sigma-Aldrich Com. Ltd., Poole, UK) while stirring vigorously. The addition 
of NaOH was carried out gradually to avoid precipitation of lanthanum hydroxide. The 
final volume was then brought to 100 ml with water. The stock solutions were prepared 
fresh immediately before use and cooling of the solutions (<10ºC) was avoided as 
lanthanum hydroxide precipitates when cold [314,315]. 
 
Electron microscopical assessment of tight junctional permeability in mouse lung 
C57Bl/6 mice (approximately 12 weeks old females, n=3/group) were treated via nasal 
instillation with 50 µl or 25 µl EGTA at a concentration of 0.05 M and 0.4 M, 
respectively. Control mice did not receive any treatment. 30 min post treatment mice 
were exsanguinated using Hypnorm/Hypnovel (see also Section 2.3). The lungs were 
inflated in situ with glutaraldehyde (2.5%)-lanthanum hydroxide (1% and 4% final 
concentrations)-sodium cacodylate buffer (0.1 M, pH 7.4) (Sigma-Aldrich Com. Ltd., 
Poole, UK) through the trachea using a cannula (22 gauge, 32 mm). To avoid 
precipitation of lanthanum hydroxide at the higher concentration, lanthanum stock 
solution and buffer solution were both kept heated (25ºC) and mixed to obtain the right 
concentrations immediately before inflation of the lungs. The inflated lungs were then 
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removed and immersed in the same buffered fixative for 1 hr before rinsing in 
lanthanum hydroxide (1%, 4% as above) in phosphate buffer (0.1 M, pH 7.4) for 16 hrs 
at 4ºC. Subsequently, the tissue was post-fixed for 4 hrs in lanthanum hydroxide (1% 
and 4% final concentrations)-osmium tetroxide (1%) (TAAB Ltd., Aldermaston, UK) in 
sodium cacodylate buffer (0.1 M, pH 7.4) and then rinsed again in the same buffer but 
without osmium tetroxide for 16 hrs. The left lobe was then cut into 3 pieces to allow 
for embedding and dehydrated in graded series of ethanol (70-100%) for 30 min under 
rotation (2 rotations/min). The tissue pieces were immersed in 100% propylene oxide 
(VWR International Ltd., Leicester, UK), a mixture of propylene oxide and araldite 
(1:1) (Agar Scientific Ltd., Stansted, UK) and 100% araldite and rotated for 60 min, 16 
hrs and 8 hrs, respectively. This was followed by embedding in 100% araldite and 
polymerization of the resin at 60 ºC for 2-3 days. Ultrathin sections (~1 µm, 1 
section/lobe) were cut (Ultracut E, Reichert-Jung, Leica, Milton Keynes, UK) and 
assessed, while blinded, using TEM (Hitachi 7000, Nissei Sangyo Co. Ltd., Tokyo, 
Japan). Lanthanum dense tight junctions in 1-2 airways per mouse were counted and 
images captured under low magnification (0.1x1000) and subsequently developed. To 
standardise the results the length of the airways assessed was measured in pixels 
(3x/airway) using computer software (GIMPPortable, www.PortableApps.com). 
 
4.4.8 Statistical analysis 
Data was compared using ANOVA plus a Bonferroni or Dunnett correction or 
independent sample t-test where appropriate. Where necessary, raw data were log10 
transformed to ensure normal distribution (Kolmogorov-Smirnov normality test was 
performed) and equal variances between groups. A non-parametric Mann Whitney test 
or a Kruskal-Wallis with Dunn‟s correction was carried out when the assumptions were 
not met after transformations. The null hypothesis was rejected at p<0.05.   
150 
 
4.5 Results  
 
4.5.1 EGTA was soluble at 1 M 
The tetrasodium salt of EGTA was initially used to assess the effect of EGTA and the 
tetrasodium salt of EGTA was easily dissolved at concentrations up to 0.5 M. For 
subsequent studies a 1 M EGTA stock solution was required. However, it proved 
impossible to dissolve EGTA tetrasodium salt to this concentration at physiological pH 
(pH 7.4) and acidic EGTA was therefore used instead as described in Section 4.4.1. 
 
4.5.2 Nasal instillation of EGTA did not increase GL67-mediated gene transfer in 
mouse lung 
To assess if the TJ-opener EGTA increases non-viral gene transfer in the murine airway 
epithelium, mice were pre-treated with 50 µl EGTA intra-nasally using concentrations 
of 0.05 M, 0.2 M and 0.4 M (delivering doses of 2.5 µmol, 10 µmol and 20
 
µmol, 
respectively) 30 min prior to whole body nebulisation of GL67 complexed to pCIKLux. 
The doses and pre-treatment time (time between delivering TJ-opener and GTA) used 
were based on relevant literature assessing the effect of EGTA on viral and non-viral 
gene transfer efficiency in the airway epithelium in vivo [140,141,187]. All mice (n=4) 
receiving the highest dose (20 µmol, which had not previously been assessed in the 
literature), died while still anaesthetised. 24 hrs post transfection the remaining mice 
were culled and the right lung harvested for detection of luciferase activity. All 
transfected mice had significantly (p<0.05) higher gene expression than untransfected 
controls (Figure 31). Pre-administration of water to the lungs did not alter gene 
expression. However, luciferase expression was significantly (p<0.001) reduced in mice 
pre-treated with EGTA at both doses which suggests that EGTA may have a toxic effect 
on cells in vivo which negatively affects transfection efficiency. 
 
4.5.3 Increasing the concentration of EGTA did not increase GL67-mediated 
gene transfer in mouse lung  
In addition to the total dose delivered, the concentration of EGTA may affect gene 
expression. In the next experiment the concentration of EGTA was raised from 0.2 M 
(assessed in the previous experiment) to 0.4 M and the effect on gene expression was 
assessed.  
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Figure 31: Luciferase expression in mouse lung after EGTA nasal instillation  
Mice were pre-treated with 50 µl 0.05 M or 0.2 M EGTA or WFI by nasal instillation 30 min 
prior to whole body nebulisation with GL67/pCIKLux complexes. 24 hrs post transfection the 
right lung was harvested and assessed for luciferase expression. Mice receiving no pre-treatment 
before transfection and mice left untransfected (UT) were used as controls. Data are expressed 
as mean ± SEM (n=8/group), * = p<0.05 UT compared to all other groups, *** = p<0.001 
EGTA compared to WFI. 
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Only 25 µl 0.4 M (10
 
µmol) were delivered intra-nasally to mice 30 min prior to 
nebulisation of GL67/pCIKLux as mice receiving 50 µl 0.4 M EGTA died in the 
previous experiment (Table 1). For comparison, mice were also pre-treated with 50 µl 
0.2 M (10
 
µmol) prior to GL67/pCIKLux nebulisation as in the previous experiment. 
The dose delivered in both groups of mice was thereby identical. In addition, the high 
concentration (0.4 M) and corresponding volume (25 µl) delivered matched previously 
published data [140]. Mice were culled 24 hrs post transfection and the right lung and 
the nasal epithelium harvested and assayed for luciferase activity. As shown in Figure 
32, all transfected mice had significantly (p<0.05) higher gene expression in the lung 
than untransfected controls and again pre-administration of water to the lungs did not 
alter gene expression. EGTA pre-treatment again lead to significantly (p<0.05) reduced 
GL67-mediated lux expression in the lung. Hence, increasing the concentration of 
EGTA from 0.2 M to 0.4 M did not increase gene transfer efficiency.  
 
 
 
 
 
 Volume 
instilled 
EGTA 
concentration 
EGTA 
dose 
Comment 
Experiment 1 50 µl 0.05 M 2.5 µmol  
 50 µl 0.2 M 10 µmol  
 50 µl 0.4 M 20 µmol All mice died 
Experiment 2 50  µl 0.2 M 10 µmol  
 25 µl 0.4 M 10 µmol  
Published data by Chu et al 25 µl 0.4 M 10 µmol  
 
Table 1: EGTA volumes, concentrations and doses 
In two separate experiments (experiment 1 and 2) mice were treated intra-nasally with EGTA at 
the volumes, concentrations and doses listed in the table 30 min prior to whole body 
nebulisation with GL67/pCIKLux complexes. Previous published data by Chu et al list the 
maximum EGTA concentration, dose and volume instilled intra-nasally in mice [140].  
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Figure 32: Luciferase expression in mouse lung after nasal instillation of high 
concentration EGTA  
Mice were pre-treated with 50 µl 0.2 M or 25 µl 0.4 M EGTA or WFI by nasal instillation 30 
min prior to nebulisation of GL67/pCIKLux complexes. 24 hrs post transfection the right lung 
was harvested and assessed for luciferase expression. Mice receiving no pre-treatment before 
transfection and mice left untransfected (UT) were used as controls.  Data are expressed as 
mean ± SEM (n=8/group), * = p<0.05 UT compared to all other groups, * = p<0.05 EGTA 
compared to WFI. 
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4.5.4 Nasal instillation of EGTA did not increase GL67-mediated gene transfer in 
mouse nose  
I and others have shown that whole body nebulisation of GL67/DNA complexes 
transfect mouse lung tissue, but to date transfection of nasal epithelium after whole 
body nebulisation had not been assessed [316]. Interestingly, nebulisation led to 
significant (p<0.01) levels of GL67-mediated gene transfer in mouse nasal epithelium 
(Figure 33a). These results offered the option to also assess the effects of TJ-openers in 
nasal epithelium. Importantly, in contrast to whole lung tissue which consists of airway 
and alveolar epithelium the nasal epithelium is predominantly airway epithelium and, 
therefore, a good model for pulmonary airways.  
 
EGTA did not increase efficiency gene transfer in mouse nose (Figure 33b). 
Interestingly, however, EGTA did not decrease gene expression in the mouse nose 
implying a different susceptibility of nasal and lung tissue to the drug. As a negative 
control, mice were treated with WFI, which significantly decreased luciferase activity in 
the nose.  
 
4.5.5 Nasal instillation of EGTA did not lead to histologically visible alterations 
in mouse lung 
To assess if the decreased gene expression after administration of EGTA can be 
explained by morphological changes in the lung mice were treated with EGTA and 
GL67/pCIKLux as described in the previous section (Section 4.5.4) and the left lung 
was harvested for histological assessment. The tissue sections were analysed semi-
quantitatively for degree and area of haemorrhage and inflammation as these are the key 
components of lung injury. Figure 34 shows representative examples of lung tissue 
scored as 1, 2 and 3 based on the semi-quantitative point scoring system devised for this 
study. As shown in Figure 35, there were no differences between any of the groups. 
These results, therefore, suggest that administration of GL67/DNA complexes by 
nebulisation with or without EGTA pre-treatment does not cause haemorrhage or 
inflammation. In addition, the lung sections were assessed for damage within the 
respiratory epithelium. However, there was no evidence of epithelial damage after 
treatment with either 0.2 M or 0.4 M EGTA (Figure 36).  
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Figure 33: Luciferase expression in mouse nose after nasal instillation of high 
concentration EGTA  
a: Mice were nebulised with GL67/pCIKLux complexes or remained untransfected (UT). 24 hrs 
post transfection the nasal epithelium was harvested and assessed for luciferase expression. Data 
are expressed as a dot plot with mean, **= p<0.01 UT compared to transfected group. b: Mice 
were pre-treated with 50 µl 0.2 M or 25 µl 0.4 M EGTA or WFI by nasal instillation 30 min 
prior to nebulisation of GL67/pCIKLux complexes. 24 hrs post transfection the nasal epithelium 
was harvested and assessed for luciferase expression. Mice receiving no pre-treatment before 
transfection and mice left untransfected (UT) were used as controls. Data are expressed as mean 
± SEM (n=8/group), * = p<0.05 UT compared to all other groups, * = p<0.05 no pre-treatment 
compared to WFI.  
a 
b 
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Figure 34: Examples of lung sections with different degree of histological damage  
The left lung of mice were harvested and processed for histological assessment. Sections were 
scored semi-quantitatively for degree and area of haemorrhage and inflammation. Image a, b 
and c is representative of lung sections corresponding to score 1, 2 and 3, respectively (Original 
magnification: x10). Arrows indicate thickening of the alveolar wall and arrow heads 
haemorrhage.  
a 
c 
b 
c 
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Figure 35: Histological assessment of mouse lung after EGTA nasal instillation  
Mice were pre-treated with 50 µl 0.2 M or 25µl 0.4 M EGTA or WFI by nasal instillation 30 
min prior to nebulisation of GL67/pCIKLux complexes. Mice receiving no pre-treatment before 
transfection and mice left untransfected (UT) were used as controls. 24 hrs post transfection the 
left lung was harvested for histological assessment. Sections were scored semi-quantitatively for 
degree and area of haemorrhage and inflammation. Each symbol represent one animal, with the 
mean score of the group shown as a horizontal line (n=8-9/group). 
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Figure 36: Respiratory epithelium of mouse lung after EGTA nasal instillation  
Mice were pre-treated with 25µl 0.2 M or 0.4 M EGTA or WFI by nasal instillation 30 min 
prior to nebulisation of GL67/pCIKLux complexes. 24 hrs post transfection the left lung was 
harvested for histological assessment. Sections were assessed for respiratory epithelial damage. 
A naïve control group receiving no treatment was also included. a: EGTA 0.4 M, b: EGTA 0.2 
M, c: WFI and d: negative control. Representative images are shown (Original magnification: 
x10). Arrows indicate airway lumen and arrow heads indicate respiratory airway epithelium.  
 
 
 
a b 
c d 
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4.5.6 Co-administration of EGTA and GL67/pCIKLux complexes did not alter 
transfection efficiency in vitro 
As pre-treatment with EGTA had no effect on GL67-mediated gene transfer, I wanted 
to assess if co-delivery of the TJ-opener and the gene transfer agent could enhance gene 
transfer efficiency in vivo. To assess if the addition of EGTA to the GL67/pCIKLux 
complexes alters the capacity to transfect cells, I first transfected 293T cells with 
GL67/pCIKLux complexes to which equal volumes of EGTA ranging from 0.1 M to 1 
M had been added, leading to final concentrations of 0.05 M to 0.5 M EGTA. 48 hrs 
after transfection the cells were harvested and luciferase activity was measured. 
Importantly, the appearance of the lipid/DNA mixture did not change after addition of 
up to 0.05 M EGTA, i.e. there was no obvious precipitation. As shown in Figure 37, 
GL67-mediated transfection lead to significant (p<0.01) gene expression in all groups 
when compared to untransfected controls. Importantly the addition of EGTA did not 
change the transfection efficiency of the complexes and co-delivery into mouse lungs 
appeared feasible.  
 
4.5.7 Co-nebulisation of EGTA and GL67/pCIKLux complexes did not result in 
gene expression in mouse lung 
In an attempt to determine if co-delivery of the TJ-opener and the GTA would enhance 
gene transfer in vivo, mice were nebulised with GL67/pCIKLux complexes containing 
EGTA (final concentration 0.5 M) (1:1 v:v ratio) for 30 min, 1 hr and 2 hrs. 
GL67/pCIKLux complexes mixed with water for injection were included as controls. 
As the most concentrated EGTA stock solution feasible was 1 M, a final concentration 
of 0.5 M EGTA delivered was the highest feasible concentration delivered via 
nebulisation, when EGTA and GL67/pCIKLux complexes were mixed in a 1:1 ratio 
(v:v). Although, the physical impact on the mice during nebulisation was minimal, long 
term nebulisation would leave them wet and cold and I, therefore, decided not to exceed 
a maximum nebulisation time of 2 hrs. 24 hrs post transfection mice were culled and the 
right lung harvested for quantification of luciferase activity. Mice treated with 
GL67/pCIKLux complexes mixed with water for injection showed a nebulisation-time 
dependent significant (p<0.001) increase in luciferase expression. Surprisingly however, 
mice treated with GL67/pCIKLux complexes mixed with EGTA did not express 
luciferase at any of the nebulisation times (Figure 38).  
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Figure 37: Luciferase expression in vitro after co-administration of EGTA and 
GL67/pCIKLux  
293T cells were transfected with GL67/pCIKLux complexes containing 0.05 M to 0.5 M 
EGTA. Untransfected cells (UT) and cells transfected without addition of EGTA (0 M) were 
included as controls. 48 hrs post transfection cells were harvested and luciferase activity was 
measured. Data are expressed as mean ± SEM (n=6/group), **= p<0.01UT compared to all 
other groups. 
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Figure 38: Luciferase expression in mouse lung after co-nebulisation of EGTA and 
GL67/pCIKLux  
Mice were nebulised with GL67/pCIKLux complexes containing EGTA (final concentration 0.5 
M) for 30 min, 1 hr and 2 hrs. A naive control group (UT) or a group receiving GL67/pCIKLux 
complexes mixed with appropriate amounts of WFI were included as controls.  24 hrs post 
transfection the right lung was harvested and luciferase expression was measured. Data are 
expressed as mean ± SEM (n=8/group), * =p<0.05 UT compared to WFI + GL67/pCIKLux, 
*** = p<0.001 2 hrs nebulisation comapared to 30 min nebulisation.  
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4.5.8 Nebulisation of EGTA did not lead to histologically visible alterations in 
mouse lung 
To assess lung damage following nebulisation of EGTA, the left lung of treated mice 
was harvested for histological assessment and haemorrhage and inflammation were 
scored semi-quantitatively. The degree and area of haemorrhage and inflammation in 
mice treated with GL67/pCIKLux mixed with EGTA or GL67/pCIKLux mixed with 
water for up to 2 hours were similar to untransfected controls (Figure 39). In addition 
the respiratory epithelium remained unaltered compared to untransfected controls in all 
groups.  
 
4.5.9 Nebulisation of EGTA did not increase GL67-mediated gene transfer in 
mouse lung 
It was then determined if nebulisation of 1 M EGTA would enhance gene transfer 
efficiency. In contrast to the previous nasal instillation of EGTA, nebulisation will 
result in less EGTA to be delivered to the airways, but the contact time between drug 
and the target tissue may be longer, because of the longer nebulisation time. Mice were 
nebulised with GL67/pCIKLux for 30 min, followed by nebulisation of EGTA (1 M) 
for 1 hr, followed by nebulisation with GL67/pCIKLux for an additional 30 min (Figure 
40a). Additional mice were nebulised with EGTA followed by GL67/pCIKLux or only 
GL67/pCIKLux. A control group receiving water for injection instead of EGTA and 
untransfected mice were also included. 24 hrs post transfection the nasal epithelium and 
the right lung were harvested and luciferase expression determined. As shown in Figure 
40b all groups transfected with GL67/pCIKLux had significantly (p<0.05) increased 
gene expression compared to untransfected controls. Interestingly, lux expression was 
nebulisation time-dependent and gene expression levels were approximately 2-fold 
higher (p<0.01) in mice nebulised for two times 30 min (GTA-GTA) compared to mice 
nebulised for only 30 min (GTA). Pre-administration of either water for injection or 
EGTA before GL67/pCIKLux nebulisation did not increase gene expression compared 
to no pre-treatment. Mice treated with GL67/pCIKLux complexes, followed by EGTA 
and finally GL67/pCIKLux (GTA-EGTA-GTA) complexes could not be directly 
compared to mice receiving WFI instead of EGTA (GTA-WFI-GTA) as nebulisation of 
the non-viral vector in these two groups were performed with different vials of GL67.  
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Figure 39: Histological assessment of mouse lung after co-nebulisation of EGTA and 
GL67/pCIKLux 
Mice were nebulised with GL67/pCIKLux complexes containing EGTA (final concentration 0.5 
M) for 30 min, 1 hr and 2 hrs. A naive control group (UT) or a group receiving GL67/pCIKLux 
complexes mixed with appropriate amounts of WFI were included as controls. 24 hrs post 
transfection the left lung was harvested for histological assessment. Sections were scored semi-
quantitatively for degree and area of haemorrhage and inflammation. Each symbol represent one 
animal, with the mean score of the group shown as a horizontal line (n=8/group).  
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Figure 40: Luciferase expression in mouse lung after EGTA nebulisation   
Mice were nebulised with GL67/pCIKLux (GTA) for 30 min, followed by nebulisation with 
EGTA (1 M), followed by nebulisation with GL67/pCIKLux for 30 min (a). Additional mice 
were nebulised with EGTA followed by the GTA (EGTA-GTA) or only GTA. A control group 
receiving WFI instead of EGTA and untransfected mice (UT) were also included as controls. 24 
hrs post transfection the right lung was harvested and luciferase expression (b). Data are 
expressed as mean ± SEM (n=8/group) * = p<0.05 UT compared to all other groups, * = p<0.05 
GTA compared GTA. 
  Nebulisation   Nebulisation            Nebulisation   
GL67/pCIKLux      EGTA                     GL67/pCIKLux                   
0                             30                             60                            90                            120  min 
a 
b 
Figure 40a corresponds to 
the bar to the far right on 
figure 40b 
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However, mice treated with GL67/pCIKLux, followed by EGTA or WFI and finally 
GL67/pCIKLux (GTA-EGTA-GTA or GTA-WFI-GTA) showed approximately 2-fold 
increase in gene expression compared to mice nebulised once with the same vial of 
GL67/pCIKLux (GTA). The 2-fold increase was a result of extending the nebulisation 
time for GL67/pCIKLux from 30 min to 60 min and as gene expression levels in mice 
treated with EGTA (GTA-EGTA-GTA) were not increased above 2-fold (compared to 
GTA-GTA), these results strongly suggest that EGTA did not have an effect on gene 
transfer efficiency.  
 
Importantly, the EGTA solution progressively became more concentrated in the 
nebuliser reservoir during the nebulisation. 
 
4.5.10 Tight junctional permeability was unaltered in mouse lung following EGTA 
treatment 
In an attempt to understand further the in vivo transfection data, I wanted to assess 
whether EGTA disrupted the TJs between airway epithelial cells. Utilizing transmission 
electron microscopy (TEM) the electron-dense tracer lanthanum was used to assess tight 
junctional permeability. The lanthanum cation (La
3+
) possesses electron scattering 
power sufficiently high to produce contrast under TEM and, therefore, appears as an 
electron-dense precipitate on electron microscope images. At pH 7.2 to 8 lanthanum 
does not penetrate intact plasma membranes and the subsequent precipitation of 
lanthanum, which is caused by rinsing the tissue in cold phosphate buffer, is, therefore, 
limited to the extracellular space [317]. However, leaky or disrupted TJs will allow the 
tracer to fill the intercellular space between airway epithelia, whereas intact TJs are 
impermeable and exclude lanthanum. 
 
Briefly, mice were exsanguinated 30 min after nasal instillation of 0.05 M EGTA (50 
µl/mouse) (2.5 µmol). 0.05 M EGTA was chosen initial to assess the effect on tight 
junctional permeability and if no effect was observed the concentration and dose would 
be raised. Control mice receiving no treatment were included. The lungs were inflated 
in situ with a buffered 1% lanthanum solution, then removed and processed before 
embedding. Ultrathin sections were cut and 1 to 2 airways in the left lobe were analysed 
by TEM (n=3/group). Tissue morphology was good in the majority of mice the nuclei 
and other cellular components were visible in airway epithelial cells (Figure 41).  
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Figure 41: Representative TEM image of respiratory epithelium of mouse lung (1st 
experiment) 
Mice were treated by nasal instillation with 0.05 M EGTA (50 µl/mouse) or received no 
treatment. 30 min post treatment, the mice were exsanguinated and the lungs inflated in situ 
with a buffered 1% lanthanum solution and processed for TEM. 1 to 2 airways originating from 
the centre of the left lobe were analysed per mouse (n=3 mice/group). Images are representative 
for respiratory airway epithelium in all 6 mice. Left image: Short arrow indicates cilia, long 
arrow indicates nucleus and arrowhead indicates the basement membrane.  
x2500 
x5000 
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On gross observation there was no difference in morphology in EGTA or control mice. 
However, it proved difficult to visualise non-stained TJs and it was therefore not 
possible to count the total number of tight junctions assessed for each mouse. The total 
number of tight junctions assessed was meant to have been used to standardise the 
number of stained TJs observed in each mouse, which would have made it possible to 
compare EGTA treated mice to controls. As this was not feasible, the number of stained 
TJs observed was standardised by the length (presented in pixels) of airways assessed 
for each mouse. 
 
Two out of the three EGTA treated mice had no lanthanum-dense TJs (~8000 
pixels/mouse were assessed).  However, in one EGTA-treated mouse a stained junction 
was visible (Figure 42a). Control mice did not have stained TJs (~9000 pixels/mouse 
were assessed) (Figure 42b). In both cohorts of mice lanthanum precipitate was present 
on the apical membrane, suggesting that the lanthanum based precipitation technique 
had worked to a certain extent. 
 
In an attempt to optimise further the staining a 4% lanthanum solution was used, as this 
concentration has previously been used by Weiss et al [318]. To achieve a final 
lanthanum concentration of 4% I had to make a 16% lanthanum stock solution, as the 
protocol stated that lanthanum was diluted 1:4 with buffer [314,315]. Unfortunately 
lanthanum tends to precipitate at higher concentrations, and although titration with 
sodium hydroxide was carried out gradually over a 2 hr time period to obtain the 
required pH, lanthanum precipitated. I next made an 8% stock solution and diluted 1:2 
with buffer to a final concentration of 4%. To avoid precipitation when mixing with the 
buffer, both solutions had to be kept heated and could only be mixed to obtain the right 
concentrations, immediately before inflation of the lungs.  
 
In an attempt to see an effect of EGTA on tight junctional permeability the 
concentration and dose were raised. Mice were treated via nasal instillation with 0.4 M 
EGTA (0.4 M, (25 µl/mouse) (10 µmol). The total volume instilled in this experiment 
was reduced from 50 µl to 25 µl, as all mice had previously died, when treated with 50 
µl 0.4 M EGTA. Control mice receiving no treatment were included. Following 
exsanguination, the lungs were inflated in situ with a buffered 4% lanthanum solution, 
processed and embedded.  
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Figure 42: Stained and unstained TJ in respiratory epithelium of mouse lung 
Mice were treated by nasal instillation with 0.05 M EGTA (50 µl/mouse) or received no 
treatment. 30 min post treatment, the mice were exsanguinated and the lungs inflated in situ 
with a buffered 1% lanthanum solution and processed for TEM. 1 to 2 airways originating from 
the centre of the left lobe were assessed per mouse (n=3 mice/group). a: TJ stained with 
lanthanum precipitate (EGTA treated mouse). Only one stained TJs were identified in one 
EGTA treated mice. The remaining 5 mice showed no stained tight junctions. Short arrow 
indicates cilia, long arrow indicates nucleus and arrowheads stained TJ. b: TJ without 
lanthanum precipitate (control mouse). Short arrow indicates cilia, long arrow indicates the 
basement membrane and arrowheads indicate non-stained TJ.  
x7000 x20 000 
x4000 x20 000 
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Sections were cut and TEM used to assess either 1 or 2 airways from the left lobe of 
each mouse. In contrast to the first experiment tissue morphology in the majority of 
mice was poor; nuclei, cellular components and non-stained TJs were not readily visible 
(Figure 43). 0, 1 and 3 lanthanum-dense TJs were located in the 3 EGTA treated mice 
(~8000-9000 pixels/mouse were assessed) (Figure 44). Control mice showed no stained 
TJs (n=3, ~7000-8000 pixels/mouse). Although a higher concentration of lanthanum 
was used to stain the TJs in the second experiment, lanthanum precipitate was not 
present in higher abundance on the apical membrane compared to the previous 
experiment (Figure 45). 
 
The poor morphology observed in the second experiment makes the findings hard to 
interpret and a conclusive result was not obtained. However, these experiments do 
suggest that raising the concentration of lanthanum from 1% to 4% has no impact on the 
overall staining pattern and the lack of stained tight junctions in EGTA treated mice 
may, therefore not be due to suboptimal lanthanum concentration. Furthermore, EGTA, 
even at the higher concentration and dose used, did not seem effectively to disrupt TJs 
and allow for positively stained junctions.  
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Figure 43: Representative TEM image of respiratory epithelium of mouse lung (2nd 
experiment) 
Mice were treated by nasal instillation with 0.4 M EGTA (25 µl/mouse) or received no 
treatment. 30 min post treatment, the mice were exsanguinated and the lungs inflated in situ 
with a buffered 4% lanthanum solution and processed for TEM. 1 to 2 airways originating from 
the centre of the left lobe were assessed per mouse (n=3 mice/group). Images are representative 
of the respiratory airway epithelium in all 6 mice. Short arrow indicates cilia, long arrow 
indicates the basement membrane. 
x2500 
x5000 
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Figure 44: Stained TJ in respiratory epithelium of mouse lung 
Mice were treated by nasal instillation with 0.4 M EGTA (25 µl/mouse) or received no 
treatment. 30 min post treatment, the mice were exsanguinated and the lungs inflated in situ 
with a buffered 4% lanthanum solution and processed for TEM. 1 to 2 airways originating from 
the centre of the left lobe were assessed per mouse (n=3 mice/group). TJ stained with lanthanum 
precipitate (EGTA treated mouse) is indicated by arrowheads. Image is representative of stained 
TJs located in the respiratory airway epithelium of EGTA treated mice. 
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Figure 45: Lanthanum precipitate present on the apical membrane  
Mice were treated by nasal instillation with 0.05 M EGTA or received no treatment. 30 min post 
treatment, the mice were exsanguinated and the lungs inflated in situ with a buffered 1% 
lanthanum solution and processed for TEM. Image is representative of lanthanum precipitate 
present on the apical membrane of airway epithelial cells (n=6 mice). Arrowheads indicate 
lanthanum precipitate present on the apical membrane.  
x7000 
 
173 
 
4.6 Discussion  
 
The effect of the well characterised tight junction opener EGTA on cationic liposome 
GL67-mediated gene transfer was assessed in mice in vivo. EGTA was delivered via 
nasal instillation or nebulisation to the murine lung and transfection was carried out by 
nebulisation of GL67 complexed to a plasmid encoding the luciferase reporter gene. In 
addition, attempts were made to assess if EGTA disrupted the tight junctions between 
airway epithelial cells in the murine lung using a TEM-based technique to detect 
accumulation of lanthanum in the intercellular spaces.  EGTA treatment did not increase 
GL67-mediated gene transfer in vivo and, importantly, EGTA did not visibly disrupt the 
TJs in vivo.  
 
The effects of EGTA and other Ca
2+
-chelators on tight junctional integrity and 
paracellular permeability have been widely studied. More recently, mainly EGTA has 
been used to enhance virus-mediated gene transfer to airway epithelial cells ex vivo and 
in vivo. Viruses such as AdV and AAV serotype 2 enter AECs more efficiently from the 
basolateral compared to the apical surface as viral receptors are more abundant on the 
basolateral surface [139,150]. Although it is generally believed that non-viral vectors, 
including cationic liposomes, are taken up by cells via endocytosis the exact mechanism 
is still unclear [292,293]. Studies have suggested that endocytosis of non-viral vectors is 
generally more efficient from the basolateral membrane domain in polarised cells which 
may be due to receptors, believed to be proteoglycans, present on the basolateral 
membrane [215,296,297]. Opening of tight junctions would therefore allow the cationic 
liposome, used in this study, access to potential receptors on the basolateral membrane 
thereby enhancing uptake and gene transfer efficiency.    
 
First EGTA was delivered by nasal instillation („sniffing‟) to assess the effect on GL67-
mediated gene transfer in the murine lung. The nasal instillation method was chosen as 
this method has been widely used to deliver both viral and non-viral vectors to the 
murine lung [164,225] and it is known to be rapid, non-invasive and generally well 
tolerated. In addition, Gregory et al and Chu et al used this method to demonstrate an 
increase in adenovirus-mediated gene transfer in the murine trachea and main bronchi 
following administration of EGTA [140,141]. Secondly, and in contrast to previous 
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studies, GL67/pCIKLux complexes were delivered to the murine airways via 
nebulisation as this delivery method is used clinically and is likely to lead to increased 
contact time between the vector and the airway epithelium compared to nasal 
instillation. The doses and the time interval chosen between delivering EGTA and GL67 
(pre-treatment time) were based on relevant literature assessing the effect of EGTA on 
gene transfer efficiency in the airway epithelium in vivo [140,141]. More precisely, Chu 
et al has shown an increased effect of AdV-mediated gene transfer to the murine trachea 
and upper airways following nasal instillation of 0.05 M, 0.1 M, 0.2 M and 0.4 M 
EGTA and determined the optimal pre-treatment time to be 30 minutes and these results 
were repeated by Gregory et al [140,141]. 
 
Surprisingly, EGTA pre-treatment, via nasal instillation, had no effect on GL67-
mediated gene transfer in the murine lung; in fact gene transfer efficiency was reduced, 
which may be due to cellular toxicity in the lung (see below). Unacceptable mortality 
restricted the use of higher doses of EGTA. Toxicity is likely to be due to the Ca
2+
-
chelating effect of EGTA, which may have an impact on skeletal and cardiac muscle 
functions. Although, not directly comparable these results are in contrast to data 
published by Chu et al who showed that EGTA treatment significantly enhanced GL67-
mediated gene transfer ex vivo [215]. The reasons for these discrepant results are 
unknown, but nasal instillation of EGTA may lead to pooling of the liquid in the 
alveolar region, allowing minimal contact time between the tight junction opener and 
the airway epithelial cells. Interestingly, the data are consistent with those reported by 
Chu et al and Gregory et al showing that EGTA, delivered via nasal instillation, did not 
have an effect on adenovirus-mediated gene transfer in the murine lung [140,141]. 
Finally, EGTA treatment may cause cellular toxicity even at the lower doses which 
would explain the reduced gene transfer efficiency observed. However, in contrast to 
data published by Johnson et al which showed mild lung inflammation following EGTA 
treatment, histological assessment in this study did not reveal any increased 
haemorrhage or inflammation due to the tight junction opener. Although the same strain 
of mice and time point for analysis were employed in the two studies, the difference in 
results may be explained by the different delivery methods used. While Johnson et al 
delivered a lower dose of EGTA (0.0005 µmol) compared to the dose used for nasal 
instillation of EGTA in my experiment, they used tracheobronchial instillation [212]. It 
is also possible that EGTA administration may lead to subtle cellular effects at a 
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molecular level, which cannot be observed by standard histological assessment. More 
sensitive assays such as microarrays and proteomics may be useful to study these effects 
in more detail. 
 
A review of the relevant literature did not clearly indicate if concentration of EGTA or 
the total dose is the key variable. In an attempt to enhance gene transfer efficiency the 
concentration of EGTA was, therefore, increased from 0.2 M to 0.4 M without changing 
the total dose delivered to the mouse. However, increasing the EGTA concentration had 
no effect on GL67-mediated gene transfer efficiency in the murine lung. Data cannot be 
compared to published reports, because this variable has not been studied previously. 
 
Previously it has been shown that GL67/pDNA complexes delivered via whole body 
nebulisation to the mouse lung transfect the murine lung tissue [316]. Interestingly, the 
experiments in this thesis are the first to show that whole body nebulisation with 
GL67/pCIKLux also transfect the mouse nasal epithelium. This consists predominately 
of ciliated airway epithelial cells, which are the target cell for CF gene therapy. The cell 
composition of this tissue is more similar to the human respiratory epithelium than the 
mouse lung and may therefore be a better model when it comes to gene therapy for CF. 
The observed result made it possible to assess the effect of EGTA in a tissue with a 
cellular composition similar to the human respiratory epithelium. As for the lung, 
EGTA did not increase GL67-mediated gene transfer. However, EGTA did not reduce 
gene expressions levels either, which had previously been seen after EGTA treatment in 
the lung. Following nasal installation, EGTA bolus accumulates in the alveolar region 
and the alveoli may be more susceptible to the toxic effect of EGTA compared to the 
ciliated respiratory cells, which dominate the murine nasal epithelium. Interestingly, 
control mice pre-treated with WFI, showed significantly decreased luciferase 
expressions levels in the mouse nose. As WFI is deionised, my observation is in 
contrast to a study by Lemoine et al showing that cationic lipid resuspended in saline or 
PBS significantly reduced gene transfer efficiency compared to resuspension in 
deionised water in the murine nasal epithelium in vivo [319]. Administration of 
deionised water causes a hypotonic shock, initially resulting in cell swelling, which 
stimulates exocytosis of intracellular vesicles. By fusing with the membrane, these 
vesicles allow the membrane to expand. The second consequence of a hypotonic shock 
is the internalization of the excess membrane from both the apical and the basolateral 
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sides to reform the lost intracellular vesicles. This process forces the membrane to 
undergo extensive endocytosis leading to increased uptake of, for example non-viral 
vectors [319]. It is unclear, why WFI injection caused decreased rather than increased 
gene expression, in my hands and may warrant further follow up.  
 
As pre-treatment of EGTA via nasal instillation had no effect on GL67-mediated gene 
transfer, I assessed if co-administration of the TJ-opener and the non-viral vector could 
enhance gene transfer efficiency in vivo. Although several studies had determined the 
optimal pre-treatment time for maximal gene transfer efficiency to be 30 minutes 
[140,141,212], Johnson et al have shown in a direct comparison that co-administration 
of EGTA together with adenovirus mediated more efficient gene transfer than EGTA 
pre-treatment [212]. Compared to pre-administration, co-administration may ensure that 
the effects of EGTA administration have not disappeared by the time GL67 is delivered. 
Prior to assessing the effect of co-administration of EGTA and GL67/pCIKLux in vivo, 
it was important to determine if addition of EGTA would reduce the transfection 
efficiency of GL67/pCIKLux. Therefore, transfection efficiency of the combined 
complex was determined in vitro. GL67 interacts with pDNA via charge, which can 
easily be disturbed by addition of other compounds. For example Xenariou et al have 
shown that the addition of magnetic particles to GL67/pDNA complexes resulted in 
precipitation of the complex when perfused onto the mouse nasal epithelium [209]. 
Importantly, the in vitro data showed that EGTA and GL67/pCIKLux can be 
administered together without loss of transfection efficiency and led me to proceed to in 
vivo experiments.  However, co-nebulisation of EGTA and GL67/pCIKLux surprisingly 
abolished gene transfer in vivo completely. Nebulisation of GL67/pCIKLux when 
mixed with EGTA may cause changes in the size or the stability of the complex, which 
may have a negative impact on gene transfer efficiency. Alternatively, nebulisation of 
EGTA may result in more pronounced cellular toxicity. To address the latter, lungs of 
mice nebulised with EGTA were assessed histologically and compared to mice 
nebulised with WFI. However, EGTA did not increase the degree of haemorrhage and 
inflammation. As previously mentioned EGTA may cause subtle cellular effects at a 
molecular level, which cannot be observed by standard histological assessment. 
  
As co-nebulisation of EGTA and GL67 may have altered the GTA complex leading to 
reduction in gene transfer efficiency, an attempt was made to deliver EGTA by 
177 
 
nebulisation (approximately 22 µmol EGTA was delivered to each mouse, when 10 ml 
EGTA (1 M) was nebulised). When nebulised for 1 hr (10 ml) the contact time between 
the drug and the airway epithelium is likely to be longer, which may increase gene 
transfer to the airway epithelium. Increasing the contact time between vector and target 
tissue by prolonging the time a constant dose of vector was delivered via nasal 
perfusion, has previously been shown to enhance gene transfer efficiency to the murine 
nasal epithelium [320] To maximise the effect of EGTA on the epithelium, the highest 
possible concentration of EGTA (1 M), which could be made-up without causing EGTA 
precipitation, was delivered in vivo. Furthermore, the mice were nebulised for a 
maximum of two hours to avoid them getting too wet and cold, consistent with advice 
from veterinarians. To maximise my chances of observing an effect, mice were first 
nebulised with GL67/pCIKLux, followed by EGTA, followed by a second dose of 
nebulised GL67/DNA. Vector and tight junction opener were delivered in this way to 
allow the vector to be present when EGTA „hits‟ the target cells. Had vector delivery 
only been carried out after 1 hour of EGTA nebulisation the full effect of EGTA might 
have diminished by the time GL67/pCIKLux was nebulised. Unfortunately, EGTA 
nebulisation did not enhance GL67-mediated gene transfer to the lung in vivo possibly 
due to insufficient EGTA being delivered by inhalation. However, I did not determine 
the EGTA concentration in the aerosol and, therefore, the exact dose delivered to each 
individual mouse could not be calculated.   
 
In this experiment two different vials of lipid were used to nebulise the EGTA and WFI 
treated cohorts of mice, respectively. Although, the vials of lipid originated from the 
same batch and the two sets of nebulisations were performed simultaneously (i.e. one 
gas cylinder was employed to ensure that the nebulising pressure during each of the two 
nebulisations was exactly the same) with mice from the same batch, gene expression 
levels varied between the vials and, therefore, EGTA treated mice could not be 
compared directly to mice receiving WFI. The reasons for this are unclear, but may be 
related to subtle differences in lipid/DNA complex formation. Importantly, I learned 
from the set-up of this experiment. In future experiments, the number of groups was 
reduced to allow all mice to fit into one nebulisation box. Thereby, all mice are 
nebulised with the same vial of lipid/DNA complexes and a direct comparison between 
mice treated with a TJ opener and vehicle-treated mice is feasible.  Importantly, I also 
observed that the EGTA solution progressively became more concentrated in the 
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nebuliser reservoir. This is a classical phenomenon when nebulising water-based 
solutions, because during early stages of the nebulisation process the water diluent is 
nebulised at a higher rate leading to increased concentration of EGTA in the reservoir.  
 
I was also interested in assessing whether EGTA disrupted the TJs between the airway 
epithelial cells in the mouse lung in an attempt to understand further the in vivo 
transfection data generated.  The effect of tight junction openers on paracellular 
permeability can relatively easily be assessed in vitro by measuring transepithelial 
resistance or the flux of high molecular weight molecules such as albumin across the 
epithelium. However, assessment of the effect of EGTA and other compounds on tight 
junctional permeability in the lung in vivo has proven much harder. Johnson et al failed 
to show an increase in luminal albumin (serum protein) concentration, as a read-out for 
paracellular permeability in the murine lung following treatment with EGTA, C10 or 
C12, which is likely to reflect the lack of sensitivity of the enzyme-linked 
immunosorbent assay (ELISA) to detect small changes in murine albumin 
concentrations in the lumen [212]. Furthermore, this assay will not discriminate 
between the effect of the TJ opener on paracellular permeability in the respiratory 
airway epithelium and the alveolar epithelium. An increase in luminal albumin could be 
a result of increased permeability of the alveolar epithelium only and, therefore, this 
assay would not be suitable for assessing paracellular permeability in the murine 
respiratory airway epithelium.  
 
Other assays have been described in the literature to assess airway permeability. The 
concentration of radioactive-labelled albumin has, for example, been determined in the 
blood following tracheal instillation of the compound in rats [321]. However, as 
described previously, this assay will not allow us to discriminate between increased 
paracellular permeability in the respiratory epithelium and the alveolar epithelium and 
would, therefore, not be suitable to address the question I posed. Finally, enhanced 
levels of bronchoalveolar permeability have been shown to raise the concentration of a 
secreted Clara cell-specific protein (CC16) in the blood of rats [322,323]. However, 
again this assay will not discriminate between opening of tight junctions in the 
respiratory and alveolar epithelium. Moreover, the anti-CC16 antibody used to 
determine the concentration of CC16 is not commercial available. 
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I thus decided to use a TEM-based technique in an attempt to detect accumulation of the 
electron-dense tracer lanthanum in the intercellular spaces between airway epithelial 
cells in the murine lung following treatment with EGTA. Using this assay I could focus 
on the effect of EGTA on paracellular permeability in the respiratory epithelium. In 
addition, other studies have previously used this technique successfully to assess tight 
junctional permeability in the murine trachea and lung in vivo after treatment with a 
perfluorochemical (PFC) liquid and sulfur dioxide (SO2) [318,324]. In one of these 
studies EGTA was used as a positive control when assessing tight junctional 
permeability [318]. Following treatment with EGTA I first inflated lungs in situ with a 
buffered 1% lanthanum solution as this concentration was recommended in the 
literature [314,315,324,325]. One to two airways in the left lobe were analysed by 
TEM. The comparatively limited number of airways assessed was due to the fact that 
processing and TEM analysis is an extremely time consuming process. Although, an 
optimised protocol was used, in which the tissue was exposed to cold phosphate buffer 
to enhance precipitation of lanthanum, I did not observe efficient lanthanum deposition 
in paracellular spaces [315]. This may be due to either the delivered dose of EGTA not 
being effective in mouse airways or due to technical reasons.  
 
Importantly, EGTA does not only chelate divalent cations such as Ca
2+
 but also has an 
affinity for trivalent cations such as lanthanum. Binding of lanthanum to EGTA may 
prevent Ca
2+
 binding, thereby abolishing the effect of EGTA on tight junctional 
permeability. However, lanthanum has previously been used in combination with 
EGTA and resulted in stained tight junctions (see below) [318]. In an attempt to 
improve the method I talked to an expert who had previously used this technique (L. 
Johnson, Cystic Fibrosis/Pulmonary Research and Treatment Center, University of 
North Carolina at Chapel Hill, USA). Interestingly, in contrast to the published work, a 
verbal communication with Dr. Johnson revealed that he and other research groups had 
also encountered difficulties when using lanthanum staining including inefficient and 
unconvincing deposition of lanthanum in paracellular spaces.  
 
In a final attempt to optimise staining, the lanthanum concentration was increased from 
1% to 4% lanthanum. This concentration has previously been used successfully by 
Weiss et al [318]. The authors successfully managed to stain tight junctions with 
lanthanum following intratracheal instillation of EGTA (0.3 µmol) in mice using the 
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same protocol. Importantly, the preparation of a 4% lanthanum solution is not trivial, 
because lanthanum easily precipitates at higher concentrations. However, after careful 
optimisation of a number of steps I was able to overcome this problem. In addition to 
using a 4% lanthanum solution, I administered the highest feasible EGTA dose (10 
µmol) to maximise the effect of EGTA in this experiment. However, poor tissue 
morphology, likely due to the fixation method, complicated analysis and as for the 
previous experiment the higher concentration of both lanthanum and EGTA did not 
result in a significant number of stained TJs. 
 
The poor morphology observed in the last experiment made the findings hard to 
interpret and a conclusive result was not obtained. Overall, the assay proved technically 
very difficult and extremely labour extensive. Furthermore, consulting various experts 
identified no additional modification, which could have optimised the lanthanum 
staining further and resulted in better morphology. I, therefore, decided not to repeat 
these experiments. I was unable to identify another assay that would conclusively proof 
loosening of TJ between airway epithelial cells in the mouse lung in vivo and, therefore, 
reluctantly suspended this line of experiments. Alternatively, I could have established 
proof-of-principle that EGTA increases tight junctional permeability in airway epithelial 
cells ex vivo. However, several studies have previously convincingly demonstrated this 
by measuring transepithelial resistance or the flux of high molecular weight molecules 
across the epithelium and I did, therefore, not see the need to repeat these published 
data, because ultimately they will not inform us about the effect of EGTA in vivo 
[212,214,283]. 
 
Although, EGTA did not increase GL67-mediated gene transfer to the airways, the tight 
junction opener may have an effect on other non-viral gene transfer agents. For 
example, the size of DNA nanoparticles is smaller compared to GL67/pDNA 
complexes, which may allow this non-viral vector easier access to the basolateral 
membrane through the tight junctions. In addition to size, the overall charge of each 
non-viral vector is likely to affect access to and migration through the tight junction. 
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4.7 Summary 
 
In summary, EGTA delivered via nasal instillation or nebulisation to the murine lung 
did not enhance GL67-mediated transfection efficiency. It is currently, unclear, if this is 
due to inefficient opening of TJ, resulting in GL67/pDNA complexes being unable to 
enter opened TJ in vivo or due to GL67/pDNA complexes not being efficiency 
endocytosed via the basolateral membrane of airway epithelial cells in vivo. In an 
attempt to address these points I next studied an alternative TJ-opener (see Chapter 5).  
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Chapter 5: The effect of the medium chain fatty acids C10 and C12 on 
lipid-mediated gene transfer in vivo 
 
 
5.1 Introduction to C10 and C12 tight junction openers 
 
Administration of EGTA to the mouse nose and lung in vivo had not answered the 
question whether opening of the tight junctions in the airway epithelium leads to 
increased GL67-mediated gene transfer. I therefore decided to assess another class of 
tight junction openers, medium chain fatty acids (MCFA). The sodium salt of several 
medium chain fatty acids, but particularly C10 and C12 (Figure 46), has been shown to 
increase oral and rectal drug absorption by causing alternations in intestinal TJ 
permeability [284]. In addition to having a well documented effect on paracellular 
permeability in a number of different cell types via a different mechanism from EGTA, 
C10 and C12 have also been shown to increase paracellular permeability and enhance 
viral gene transfer in the airway epithelium in ex vivo and in vivo models 
[141,212,283,284]. However, the effects of these well documented tight junction opener 
on non-viral gene transfer, has not yet been assessed. Interestingly, C10 is currently the 
only tight junction opener used as an intestinal absorption enhancer in a drug product 
marketed in Japan, Denmark and Sweden [326]. These points will be discussed in more 
details below. 
 
5.1.1 Mechanisms by which C10 and C12 regulate tight junctional permeability 
The mechanisms of the effects of sodium salts of medium chain fatty acids on 
paracellular permeability have mainly focussed on C10. Studies in Caco-2 cells 
assessed the long-term effect (up to 60 min) of exposure and suggested that the effect of 
C10 on tight junctional permeability is a result of increased intracellular Ca
2+ 
concentrations via activation of phospholipase C (PLC) [305,326,327]. Activated PLC 
in the cellular membrane cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) to the 
two intracellular mediators DAG and IP3 of which the latter mobilises Ca
2+ 
from 
intracellular stores thereby increasing the intracellular Ca
2+
 concentration. An increase 
in intracellular Ca
2+ 
triggers binding of Ca
2+ 
to calmodulin and the calcium-calmodulin 
complex then activates MLC kinase resulting in phosphorylation of MLC.  
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Figure 46: C10 and C12 formulae and structures 
The figures show the formulae and structures of sodium caprate (C10) (a) and sodium laurate 
(C12) (b). The figures are taken from www.sigmaaldrich.com. 
 
 
 
a 
b 
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Finally, phosphorylation leads to the classical myosin-actin cross bridging which 
generates a contractile force pulling the tight junctional transmembrane proteins 
inwards thereby increasing the paracellular permeability [326,327] (Figure 47). The 
second product of PLC-induced cleavage of PIP2 is DAG which together with 
intracellular calcium has been shown to activate PKC which may result in 
phosphorylation of tight junction proteins leading to changes in paracellular 
permeability. The effect of PKC activation on permeability is complex and varies with 
different experimental setting and cell types [328]. Lindmark et al have shown that PKC 
activation down-regulates the effect of both C10 and C12 on paracellular permeability 
in Caco-2 cells [326] where as a study conducted by Tomita et al using the same cell 
line indicated that PKC activation had no overall effect on the C10-mediated increase in 
paracellular permeability [327]. These results highlight that further research is needed to 
fully understand the effect of PKC activation on paracellular permeability.  
 
Although C12 is structural very similar to C10 the exact mechanism by which the long-
term effect of C12 increases tight junctional permeability remains unclear. It has been 
suggested that this may as for C10, relate to a rise in the intracellular Ca
2+
 concentration 
via activation of PLC leading to phosphorylation of MLC by Ca
2+
-calmodulin 
dependent MLC kinase and eventually contraction of the actin-myosin filaments [326]. 
However, other studies have shown that C12 has little effect on the intracellular Ca
2+
 
concentration and causes no redistribution of the cytoskeleton [284,329,330] suggesting 
different mechanisms of action for structural similar MCFAs. 
 
Studies assessing the short-term effect (up to 12 min) of C10 and C12 have indicated 
that this is mediated via Ca
2+
-independent mechanisms of action which are likely to be 
similar for the two MCFAs [284,326]. Coyne et al have shown that both C10 and C12 
cause reorganisation of JAM, claudin-1 and -4 in human airway epithelial cells ex vivo, 
suggesting that both MCFAs exert their effect on the TJ via direct or indirect effects on 
these transmembrane proteins [284]. Claudins are cell adhesion molecules which 
function independently of Ca
2+ 
[331] and the reorganisation of claudin-1 and -4 which is 
likely to lead to increased paracellular permeability may, therefore, account for the 
short-term effect of C10 and C12. 
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Figure 47: Proposed mechanism by which C10 regulates tight junctional permeability 
C10 is believed to activate phospholipase C (LPC) in the cellular membrane resulting in 
cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) to the two intracellular mediators 
diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3) of which the latter mobilises Ca
2+ 
from intracellular stores hereby increasing the intracellular Ca
2+
 concentration. An increase in 
intracellular Ca
2+ 
triggers binding of Ca
2+ 
to calmodulin (CaM) and the calcium-calmodulin 
complex then activates myosin light chain kinase (MLCK) resulting in phosphorylation of 
myosin light chain. Phosphorylation leads to the classical myosin (My)-actin (Ac) cross 
bridging which generates a contractile force pulling the tight junctional transmembrane proteins 
inwards thereby increasing the paracellular permeability. The figure is adapted from Hayashi et 
al [336]. 
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Both MCFAs and Ca
2+
-chelators have an effect on tight junctional permeability via 
activation of the Ca
2+
-calmodulin dependent MLC kinase leading to phosphorylation of 
MLC, which result in myosin-actin cross bridging and thereby contraction of the actin-
myosin filaments, pulling the tight junctional transmembrane inwards. In contrast to 
MCFAs, which activates Ca
2+
-calmodulin dependent MLC kinase via PLC and the 
second messenger IP3, the exact mechanism by which Ca
2+
-chelators activate Ca
2+
-
calmodulin dependent MLC kinase, as well as the link between depletion of 
extracellular Ca
2+
 and intracellular Ca
2+ 
levels  remain unclear. Furthermore, it has been 
suggested that both MCFAs and Ca
2+
-chelators have an effect on paracellular 
permeability via activation of PKC. For both tight junction openers this mechanism is 
not fully understood, but it is not likely to be identical. For example, PKC is activated 
via the second messenger DAG, which may result in phosphorylation of tight junctional 
proteins, whereas Ca
2+
-chelators are believed to activate PKC via cadherins. Cadherins 
are transmembrane spanning Ca
2+
-dependent adhesion molecules, and removal of Ca
2+ 
is likely to cause conformational changes within the intracellular domain which may 
lead to activation of PKC. As outlined here, the mechanisms by which the two different 
classes of tight junction openers mediate their effect on paracellular permeability are, 
although not fully elucidated, not identical.   
 
5.1.2 C10 and C12 enhance viral airway gene transfer 
MCFAs may be attractive to enhance absorption of gene transfer vectors. A limited 
number of studies have assessed the effect of C10 and C12 on airway gene transfer.  
Coyne et al directly compared EGTA and C10 and have shown that both compounds 
reduced transepithelial resistance to similar levels in polarised human airway epithelial 
cells ex vivo. However compared to EGTA, C10 caused a greater increase in 
paracellular permeability of both a small molecule, mannitol (MW = 182 kD), and large 
molecule, dextran (MW = 2000 kD) whose molecular weight approximates that of 
adenovirus molecules. These data also translated into a more pronounced effect on 
adenovirus-mediated gene transfer (4-fold increase) in comparison to EGTA. Thus, C10 
may be a good choice for enhancement of airway gene transfer [283]. 
 
Ex vivo polarised human airway epithelial cells have also been used to assess the effect 
of C12 [284]. Both C12 and C10 induced a similar reduction in transepithelial 
resistance and a similar increase in paracellular permeability of small and large dextran 
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(10 kD and 2000 kD). Furthermore an approximately 1000-fold increase in adenovirus-
mediated gene transfer was observed after treatment with both C10 and C12 compared 
to controls. However, when assessing toxicity C12 treatment resulted in intermittent 
breaks in the epithelial layer and raised LDH levels, whereas C10 had no impact on 
these measures. Gregory et al have demonstrated an increase in adenovirus-mediated 
gene transfer in both upper (25-fold) and lower (3-fold) murine airways after nasal 
instillation of C10. Furthermore, the authors assessed whether mice treated with C10 
followed by adenovirus would develop an acute inflammatory response due to the 
increased cellular virus uptake; no changes were found [141]. When comparing the 
effect of both C10 and C12 to EGTA in the murine trachea following tracheobronchial 
instillation, Johnson et al have shown that MCFAs enhance adenovirus-mediated gene 
transfer to the murine trachea more efficiently compared to EGTA (less than 2-fold) and 
in line with data published by Gregory et al C10 treatment showed no significant 
increase in the total number of a variety of inflammatory cells [212]. In contrast, C12 
treated mice showed a small increase in neutrophils, which was likely to be related to 
the moderate inflammation in the lungs observed after histological assessment. 
Furthermore, C12 treatment resulted in an increase in LDH release, which was not seen 
for C10. Based on these studies C10 and C12 seem to increase adenovirus-mediated 
gene transfer efficiency to a similar extent in airway epithelial cells, but C10 appears 
generally to be less toxic.  
 
5.1.3 The use of C10 and C12 clinically 
The effect of C10 and C12 on paracellular permeability has mainly been studied with 
the aim of increasing the bioavailability of therapeutic drugs. Oral drug administration 
of more complex drugs such as hormones and proteins is often followed by poor 
intestinal absorption, mainly due to the physicochemical characteristics of these 
compounds. Increasing paracellular permeability via manipulation of the tight 
junctional complex with agents like C10 and C12 has significantly enhanced intestinal 
drug absorption and, although further research is needed, appears to be an appealing 
solution for enhancing bioavailability of complex drugs without having to manipulate 
the physiochemical features to ameliorate intestinal drug absorption via the transcellular 
route [332]. Several medium chain fatty acids, including C10 and C12 have been tested 
in clinical trials as absorption enhancer following oral and rectal delivery of different 
drugs [333-335]. Currently, C10 is used to enhance absorption of the antibiotic 
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ampicillin in an approved rectal drug product (Doktacillin
TM
) in several countries, 
including Japan, Denmark and Sweden [326]. To my knowledge the Doktacillin
TM
 
suppository is the only example of an approved drug product that contains an absorption 
enhancer.  
 
As previously mentioned safety as well as efficiency has to be considered when 
assessing the overall effect of tight junction openers on gene transfer to the airways, 
because of the overall aim is to translate this research into the clinic. To date no 
investigations have been published regarding the use of C10 or C12 in the human lung; 
however, the use of medium chain fatty acids in oral and rectal formulations without 
noticeable side-effects is promising.  
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5.2 Aims 
 
This work was carried out to determine the effect of medium chain fatty acids (C10 and 
C12) TJ-openers on GL67-mediated gene transfer in mouse nose and lung in vivo. The 
non-viral gene transfer agent GL67 complexed to an eukaryotic expression plasmid was 
again delivered to the murine airways via nebulisation. C10 and C12 were administered 
by either nasal instillation or nebulisation. Importantly, concentration and time interval 
between delivery of the TJ-opener and vector (pre-treatment time) were carefully 
optimised in an attempt to maximise the effect of the TJ-opener on GL67-mediated gene 
transfer.  
 
 
 
 
 
 
190 
 
5.3 Materials and Methods  
 
5.3.1 C10 and C12 stock solutions 
C10: A 0.5 M sodium caprate (C10) (Sigma-Aldrich Com. Ltd., Poole, UK) stock 
solution was made by dissolving 2.4275 g in a total of 25 ml sterile phosphate buffered 
saline (PBS) (-CaCl2/-MgCl2) (pH 9.1). pH was not adjusted to physiological pH as C10 
would precipitate during the process.  
 
C12: Two separate sodium laurate (C12) (Sigma-Aldrich Com. Ltd., Poole, UK) stock 
solutions were made (0.05 M and 0.2 M). 0.1120 g and 0.2223 g C12 were re-
suspended in a total of 10 ml and 5 ml WFI to make the 0.05 M and 0.2 M stock 
solutions, respectively. The solutions were vortexed for approximately 1 hr at 2400 rpm 
(DVX-2500 Multi-Tube Vortexer, VWR International, Lutterworth, UK) to completely 
dissolve the fatty acids. pH in the final stock solutions was pH 9.3 and pH 9.5. pH was 
not adjusted as C12 would precipitate.  
 
5.3.2 Maximum tolerable concentration of C10 and C12 for nasal instillation  
To assess the maximal tolerable concentration of C10 and C12 for nasal instillation, 
C57Bl/6 mice (approximately 12 weeks old females) were treated with C10 at 
concentrations of 0.05 M (pH 7.7), 0.2 M (pH 8.8), 0.25 M (pH 8.9) and 0.5 M (25 
µl/mouse) and with C12 at concentrations of 0.05 M and 0.2 M (25 µl/mouse) via nasal 
instillation as described in Section 2.4.2 (n=3 mice/group). The mice were monitored 
carefully for the next 24 hrs. At signs of side-effects the mouse would be culled and the 
internal organs stomach, intestine, spleen, liver, lung and kidney harvested, fixed in 
10% formalin and embedded in paraffin. Transverse sections were cut (n=3 
sections/organ), stained with H&E and assessed for toxicity by a pathologist (J. Zhu, 
Department of Lung Pathology, Imperial College, London, UK) using a light 
microscope (Leitz Dialux 20) equipped with a 10-40x objective. As controls, mice 
receiving PBS (n=3) were harvested and processed as described.  
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5.3.3 C10 and C12 nasal instillation prior to GL67-mediated gene transfer in 
mouse lung and nose 
To assess the effect of C10 and C12 on gene transfer efficiency, C57Bl/6 mice 
(approximately 12 weeks old females, n=6-10/group) were pre-treated with 25 µl C10 
or C12 at concentrations ranging from 0.01 M to 0.2 M between 10 min and 4 hrs prior 
to whole body nebulisation with 10 ml GL67/pCIKLux (molar ratio 6:8). To control for 
C10 and C12 treatment mice received PBS and WFI, respectively. 24 hrs after 
transfection all mice were culled. The nasal epithelium and the right lung were 
harvested, snap-frozen in liquid nitrogen and stored at -80ºC for detection of luciferase 
activity. The left lung was harvested and fixed in 10% formalin for histological 
assessment.  
 
5.3.4 C10 nebulisation prior and subsequent to GL67-mediated gene transfer in 
mouse lung and nose 
The effect of C10 nebulisation on gene transfer efficiency was assessed. C57Bl/6 mice 
(approximately 12 weeks old females, n=6-10/group) were nebulised for 30 min with 
GL67/pCIKLux, followed by nebulisation of 0.05 M C10 (pH 7.7) for 1 hr and a final 
nebulisation with GL67/pCIKLux for 30 min. During the experiment cohorts of mice 
(n=6-10/group) were added to the nebulisation box prior to starting each round of 
nebulisation to gain appropriate controls. In addition, nebulisation with PBS was carried 
out as a control. All transfections with GL67/pCIKLux were carried out in the same 
nebulisation box to allow for direct comparison between C10 and vehicle treated mice. 
24 hrs post transfection, mice were culled and the nasal epithelium and the right lung 
harvested for determination of luciferase expression. 
 
In a second experiment, C57Bl/6 mice (approximately 12 weeks old females, 
n=10/group) were placed in a nebulisation box and nebulised for 4 hrs with 0.05 M C10 
(pH 7.7) followed by nebulisation with 10 ml GL67/pCIKLux. The mice were dried 
individually and paper towels lining the bottom of the box were changes twice during 
the course of nebulisation. 24 hrs post transfection, mice were culled and the right lung 
and nasal epithelium were harvested and assayed for luciferase expression.  
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5.3.5 Histological assessment of mouse lung   
The left lung was processed and histological assessment carried out as described in 
Section 4.4.6. 
 
5.3.6 Statistical analysis 
Data were compared using ANOVA plus a Bonferroni correction or independent sample 
t-test where appropriate. Where necessary, raw data were log10 transformed to ensure 
normal distribution (Kolmogorov-Smirnov normality test was performed) and equal 
variances between groups. A non-parametric Mann Whitney test or a Kruskal-Wallis 
with Dunn‟s correction was carried out when the assumptions were not met after 
transformations. The null hypothesis was rejected at p<0.05. Histological data are 
presented as dot plots. Each dot represents one animal with the mean score of the group 
shown as a horizontal line. Data were compared using a Kruskal-Wallis test with 
Dunn‟s correction. Again, the null hypothesis was rejected at p<0.05 
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5.4 C10 results  
 
5.4.1 C10 was soluble at 0.5 M 
Both capric acid and the sodium salt of capric acid are commercially available. I chose 
the sodium salt of capric acid (C10) as literature assessing the effect of C10 on gene 
transfer efficiency used the alkaline version of the drug [141,212,284]. The commercial 
supplier states that C10 is soluble at 100 mg/ml, equivalent to 0.5 M. However, no 
detailed protocols on how to dissolve C10 at physiological pH were available in the 
literature or from the commercial supplier and, therefore, had to be developed. First, 
C10 was dissolved in WFI (0.5 M, pH 9.1) but precipitated when pH was adjusted to 
7.4. Then attempts were made to dissolve C10 in HEPES Krebs buffer containing 
MgCl2 and CaCl2. HEPES Krebs is effective as a buffer at pH 6.8 to 8.2 and was, 
therefore, expected to stabilise the C10 solution at a pH closer to physiological pH. 
However, C10 (0.5 M) was not soluble in HEPES Krebs buffer containing MgCl2 and 
CaCl2, but did dissolve when the buffer was made up without magnesium and calcium 
(pH 9.1). Similar to previous results, C10 precipitated when pH was adjusted. As a last 
attempt to dissolve C10 at physiological pH, PBS (without CaCl2 and MgCl2) was used, 
which is effective as a buffer at pH 7.4. C10 was soluble in PBS, however pH was not 
maintained at pH 7.4, but rose to pH 9.1 and again could not be adjusted without 
causing C10 to precipitate. Based on these results it was decided to conduct the 
experiments using C10 dissolved in PBS (-CaCl2/-MgCl2) without adjusting pH. Whilst 
ideally, I would have preferred not to use an alkaline solution, Johnson et al had 
previously instilled an alkaline (~ pH 8.5) solution of 0.1 M C10 in aqueous solution 
into the nose of mice [212]. Importantly, no side-effects were reported following nasal 
instillation of C10 in this study. WFI was not chosen to dissolve C10 as previous data 
(Section 4.5.4) indicated that pre-treatment with water had a negative effect on gene 
transfer efficiency in the mouse nose.  
 
5.4.2 Nebulisation of C10 did not increase GL67-mediated gene transfer in mouse 
lung and nose 
First, I assessed if nebulisation of 0.5 M C10 was feasible in a nebuliser. Delivery via 
nebulisation was chosen because it is a clinically applicable delivery method. I first 
tried to nebulise the highest possible concentration of C10 (0.5 M) to allow for a 
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maximal effect of C10. However, this resulted in precipitation of the drug and blocked 
the nebuliser within 10 min. In contrast, 0.05 M C10 could easily be nebulised and this 
concentration was subsequently used in the mice. As for the nebulisation of EGTA, 
mice were nebulised for 30 min with GL67/pCIKLux complexes, followed by C10 
(0.05 M) nebulisation for 1 hr and a final nebulisation with GL67/pCIKLux for 30 min 
(Figure 48). Vector and tight junction opener were delivered in this way to allow the 
vector to be present when C10 was delivered. Had vector delivery only been carried out 
after 1 hour of C10 nebulisation the full effect of C10 might have diminished by the 
time GL67/pCIKLux was nebulised. Additional mice were nebulised with C10 followed 
by GL67/pCIKLux or only GL67/pCIKLux. PBS treated mice were included as controls 
and, importantly, all transfections with GL67/pCIKLux were carried out in the same 
nebulisation box to allow for direct comparison between C10 and vehicle treated mice. 
24 hrs post transfection the nasal epithelium and the right lung were harvested and 
luciferase expression was quantified.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48: Schematic drawing of nebulisation of C10 and vector 
Mice were nebulised with GL67/pCIKLux complexes for 30 min, followed by nebulisation of 
0.05M C10 or PBS and GL67/pCIKLux complexes (GTA) for 1 hr and 30 min, respectively. 
  Nebulisation   Nebulisation            Nebulisation   
GL67/pCIKLux  C10 or PBS                     GL67/pCIKLux                   
0                             30                             60                            90                            120  min 
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As part of experiments described in the previous chapter (Chapter 4), I had already 
demonstrated that significant levels of luciferase expression were detectable in the 
mouse nasal epithelium following nebulisation of GL67/pCIKLux. All animals 
receiving GL67/pCIKLux complexes had significantly (p<0.05) increased lux 
expression in lung and nose compared to untransfected controls (Figure 49a+b). In the 
lung lux expression was nebulisation time-dependent and significantly (p<0.01) higher 
in mice nebulised for 2 times 30 min (GTA-GTA) compared to mice nebulised for only 
30 min (GTA) (Figure 49a). The administration of PBS did not decrease transfection 
efficiency in either the PBS-GTA or GTA-PBS-GTA group (Figure 49a). Similarly, 
nebulisation of WFI did not decrease efficiency in the lung in the previous experiment 
in which EGTA was assessed. C10 nebulisation resulted in a trend towards increased 
lux expression in the GTA-C10-GTA group, but this did not reach significance. 
However, in mice receiving C10 before GTA (C10-GTA) lux expression was 
significantly (p<0.01) increased when compared to the appropriate PBS control group 
(Figure 49a). In contrast, C10 treatment reduced GL67-mediated gene transfer in the 
GTA-C10-GTA group in the nasal epithelium. However, this reduction was not 
significantly different from the control group (GTA-PBS-GTA). This trend was also 
observed in the C10-GTA group when compared to their respective control (Figure 
49b).  
 
To confirm the above results and to increase n numbers, I repeated the experiment 
(n=10/group). Again, all animals receiving GL67/pCIKLux complexes showed 
significantly (p<0.05) increased lux expression in the lung and nose compared to 
untransfected controls and the level of expression was similar to the previous 
experiment (Figure 50a+b). However, in this experiment C10 treatment did not increase 
luciferase expression in the lung (Figure 50a). In the nose lux expression was again 
decreased in C10 treated mice and in contrast to the previous experiment PBS treatment 
also resulted in decreased expression level (Figure 50b). 
 
5.4.3 Increased nebulisation of C10 did not increase GL67-mediated gene 
transfer in mouse lung and nose 
I next increased the C10 dose inhaled by the mice by nebulising C10 for 4 hrs instead of 
1 hr. Previously, the maximum nebulisation time was set to 2 hrs as the mice became 
wet and cold during the procedure (Section 4.5.7). 
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Figure 49: Luciferase expression in mouse lung and nose after C10 nebulisation   
Mice were nebulised with GL67/pCIKLux complexes (GTA) for 30 min, followed by 
nebulisation of 0.05 M C10 or PBS and GL67/pCIKLux complexes (GTA) for 1 hr and 30 min, 
respectively or remained untransfected (UT). Additional mice were nebulised with C10 or 
PBS followed by GL67/pCIKLux or only GL67/pCIKLux. 24 hrs post transfection the 
right lung (a) and the nasal epithelium (b) were harvested and luciferase expression determined. 
Data are expressed as mean ± SEM (n=6/group), * = p<0.05 UT compared to all other groups, 
** = p<0.01 C10-GTA compared to PBS-GTA, ** = p<0.01 GTA-GTA (nebulisation for 1 hr) 
compared to GTA (nebulisation for 30 min). 
a 
b 
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Figure 50: Luciferase expression in the mouse lung and nose after C10 nebulisation 
(repeat) 
Mice were nebulised with GL67/pCIKLux complexes (GTA) for 30 min, followed by 
nebulisation of 0.05 M C10 or PBS and GL67/pCIKLux complexes (GTA) for 1 hr and 30 min, 
respectively or remained untransfected (UT). 24 hrs post transfection the right lung (a) and the 
nasal epithelium (b) were harvested and assayed for luciferase activity. Data are expressed as 
mean ± SEM (n=10/group), * = p<0.05 UT compared to all other groups.  
b 
a 
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However, by keeping mice dry and warm, as best as feasible, I was able to extend the 
nebulisation time to a total of 5 hours. Each mouse was dried individually during the 
course of nebulisation and paper towels lining the bottom of the box were changed 
regularly. In brief, mice were nebulised with C10 for 4 hrs followed by 1 hr 
GL67/pCIKLux nebulisation. 24 hrs post transfection the nasal epithelium and the right 
lung were harvested and luciferase activity determined.  
 
The transfection efficiency of GL67/pCIKLux in nose and lung was similar to previous 
experiments and significantly (p<0.05) increased lux expression compared to 
untransfected (Figure 51a+b). Prolonged C10 nebulisation, however, significantly 
(p<0.05) decreased lux expression compared to PBS controls in lung and nose (Figure 
51a+b). Interestingly, 4 hrs nebulisation with PBS decreased gene transfer efficiency in 
the mouse nasal epithelium and increased efficiency in the lung. However, these 
changes were not significant compared to the appropriate controls.  
 
I concluded that despite increasing the dose to the maximum feasible, C10 nebulisation 
did not increase GL67-mediated gene transfer in the lung or nose of mice. 
 
5.4.4 0.2 M C10 was the maximum tolerable concentration for nasal instillation  
C10 nebulisation to the airway epithelium had no effect on gene transfer efficiency in 
mouse lung or nose. Although the maximum feasible concentration and nebulisation 
time was used, the amount delivered may have been too small. The effect of C10 was, 
therefore, assessed following delivery by nasal instillation. In preparation for these 
experiments, I first determined the maximum tolerable dose of C10 when delivered by 
this route. Mice received 25 µl of C10 at concentrations ranging from 0.05 M to 0.5 M 
and were monitored carefully for the next 24 hrs (n=3/group). All three mice receiving 
the highest C10 concentration (0.5 M) did not recover after the anaesthetic. They 
showed respiratory distress, nasal bleeding and within approximately 2 hrs of treatment 
the abdomen appeared hard and swollen. The mice were culled immediately and 
harvesting of internal organs revealed gas in both stomach and intestine (Figure 52a+b).   
Organs were subsequently processed for histological assessment (see Section 5.4.5). 
The same side-effects were encountered in mice treated with 0.25 M C10, although 
swelling of the abdomen occurred approximately 6 hrs post treatment. 
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Figure 51: Luciferase expression in mouse lung and nose after 4 hrs C10 nebulisation 
Mice were nebulised with C10 (0.05 M) or PBS for 4 hrs followed by nebulisation of GL67/ 
pCIKLux complexes of 1 hr or remained untransfected (UT). 24 hrs post transfection the right 
lung (a) and the nasal epithelium (b) were harvested and luciferase activity determined. Data are 
expressed as mean ± SEM (n=10/group), * = p<0.05 UT compared to other groups. * = p<0.05 
C10 compared to PBS. 
 
 
a 
b 
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Figure 52: Gas-filled stomach and intestine after nasal instillation of 0.5 M C10  
Mice were treated with 25 µl of 0.5 M C10 by nasal instillation. Approximately 2 hrs post 
treatment the mice (n=3) were culled due to abdominal swelling. Harvesting of the internal 
organs revealed gas in stomach (a) and intestine (b). All three mice receiving the highest C10 
concentration did not recover after the anaesthetic.  
a 
b 
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Mice receiving 0.05 M and 0.2 M C10 were slightly hunched immediately after 
treatment but otherwise showed no signs of illness. However, it took several hours 
before the mice had recovered completely. 0.05 M and 0.2 M C10 concentrations were 
used for subsequent experiments.  
 
5.4.5 Histological assessment of internal organs revealed no changes after nasal 
instillation of 0.5 M C10 
As described above, mice (n=3) received 25 µl of 0.5 M C10 by nasal instillation to 
determine the highest tolerable dose. However, all three mice showed respiratory 
distress, nasal bleeding and within approximately 2 hrs of treatment the abdomen 
appeared hard and swollen. They were culled immediately and stomach, intestine, 
spleen, liver, lung and kidney were harvested, processed and assessed for toxicity in an 
attempt to explain the observations. Mice (n=3) receiving PBS were included as 
controls.  
 
I was particularly interested in the histological assessment of the stomach and intestine 
as harvesting had revealed trapped gas in these organs. However, none of the mice 
treated with either C10 or PBS showed signs of morphological changes in the stomach, 
intestine kidney or liver (Figure 53+54). Interestingly, a degree of interstitial lung 
inflammation leading to alveolar wall thickening was observed in the lung of all mice 
treated with both C10 and PBS indicating that the mice may have had an underlying 
infection (Figure 55a+b). This was further confirmed by the presence of macrophages in 
the spleen of the mice. 
 
5.4.6 Nasal instillation of C10 increased GL67-mediated gene transfer in mouse 
lung and nose, but the increase was dependent on pre-treatment time 
To assess if nasal instillation of C10 increased gene transfer to the airway epithelium in 
vivo, mice received 25 µl of 0.05 M C10 or PBS by nasal instillation 10 min, 1 hr, 2 hrs 
or 4 hrs before whole body nebulisation of GL67/pCIKLux. An additional control group 
received no pre-treatment before nebulisation. The C10 concentration and volume 
chosen for these experiments were based on the previously toxicity data generated and 
relevant literature assessing the effect of C10 on viral-mediated gene transfer to the 
airways [141]. 
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Figure 53: Mouse intestine and stomach after nasal instillation of 0.5 M C10 
Mice were treated with 25 µl of 0.5 M C10 by nasal instillation. Approximately 2 hrs post 
treatment the mice were culled due to abdominal swelling. The intestine and stomach were 
harvested for histological assessment. Mice treated with PBS were included as controls. a: 
intestine, C10 treated, b: intestine, PBS treated, c: stomach, C10 treated and d: stomach, PBS 
treated. Representative images are shown (Original magnification: x20). 
 
 
 
 
lumen 
lumen 
c d 
b a 
203 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
Figure 54: Mouse kidney and liver after nasal instillation of 0.5 M C10 
Mice were treated with 25 µl of 0.5 M C10 by nasal instillation. Approximately 2 hrs post 
treatment the mice were culled due to abdominal swelling. The kidney and liver were harvested 
for histological assessment. Mice treated with PBS were included as controls. a: kidney, C10 
treated, b: kidney, PBS treated, c: liver, C10 treated and d: liver, PBS treated. Representative 
images are shown (Original magnification: x20). 
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Figure 55: Mouse lung and spleen after nasal instillation of 0.5 M C10 
Mice were treated with 25 µl of 0.5 M C10 by nasal instillation. Approximately 2 hrs post 
treatment the mice were culled due to abdominal swelling. The lung and spleen were harvested 
for histological assessment. Mice treated with PBS were included as controls. a: lung, C10 
treated, b: lung, PBS treated, c: spleen, C10 treated and d: spleen, PBS treated. Representative 
images are shown (Original magnification: x20). Arrow heads indicate interstitial lung 
inflammation with alveolar wall thickening.  
a 
c d 
b 
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A range of pre-treatment times were assessed as the literature revealed conflicting 
results when assessing the optimal time between delivering the TJ-opener and the GTA 
[141,212]. 24 hrs post transfection, mice were culled and the nasal epithelium and the 
right lung were harvested for detection of luciferase activity.  
 
GL67-mediated gene transfer worked satisfactorily with similar levels of gene 
expression to the previous experiments in both lung and nose (Figure 56a+b). 
Interestingly, nasal instillation of C10 did lead to a significant (p<0.05) increase in 
GL67-mediated gene transfer in both lung and nose, but the magnitude of the increase 
was dependent on the pre-treatment time employed (Figure 56a+b). In both lung and 
nose, pre-treating the mice with C10 2 hrs prior to delivering the GTA increased gene 
transfer efficiency most effectively (Lung: C10: 20.36 RLU/mg protein ± 3.64 RLU/mg 
protein, PBS: 6.78 RLU/mg protein ± 1.19 RLU/mg protein, p<0.05) (Nose: C10: 13.57 
RLU/mg protein ± 2.20 RLU/mg protein, PBS: 0.34 RLU/mg protein ± 0.16 RLU/mg 
protein, p<0.001) (n=10/group). However, no correlation was observed between lux 
expression in the mouse lung and nose when C10 was instilled 2 hrs prior to delivering 
the GTA (p=0.0668, r
2
=0.2585) (Figure 57). As observed for PBS nebulisation, nasal 
instillation of PBS 1 hr and 2 hrs prior to delivery of GL67/pCIKLux significantly 
(p<0.05) decreased gene transfer efficiency in the nose. The optimal pre-treatment time 
was 2 hrs, which resulted in a 3-fold increase in the murine lung and a 40-fold increase 
in the murine nose. This time was used in subsequent experiments. 
 
5.4.7 Increasing the concentration of C10 increased GL67-mediated gene 
transfer in mouse nose but not lung  
In an attempt to increase gene transfer even further, mice were pre-treated with the 
highest tolerable C10 concentration (0.2 M). For comparison, and to reproduce the 
above results, a cohort of mice receiving 0.05 M was also included.  Briefly, mice were 
treated with 25 µl of 0.05 M or 0.2 M C10 or PBS 2 hrs prior to GL67/pCIKLux 
nebulisation. The nasal epithelium and the right lung were harvested 24 hrs post 
transfection and assayed for luciferase activity. The transfection efficiency of 
GL67/pCIKLux in nose and lung was similar to previous experiments and significantly 
(p<0.05) increased lux expression compared to untransfected animals (Figure 58a+b). 
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Figure 56: Luciferase expression in mouse lung and nose after C10 nasal instillation - 
assessing pre-treatment time 
Mice were pre-treated with 25 µl of 0.05 M C10 or PBS by nasal instillation 10 min, 1 hr, 2 hrs 
or 4 hrs prior to nebulisation with GL67/pCIKLux complexes. Mice receiving no pre-treatment 
were included as controls. 24 hrs post transfection the right lung (a) and the nasal epithelium (b) 
were harvested and assayed for luciferase activity. Data are expressed as mean ± SEM (n=6-
10/group), * = p<0.05, ** = p<0.01 and *** = p<0.001.   
a 
b 
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Figure 57: Correlation between luciferase expression in mouse lung and nose 
Mice were pre-treated with 25 µl of 0.05 M C10 by nasal instillation 2 hrs prior to nebulisation 
with GL67/pCIKLux complexes. 24 hrs post transfection the right lung and the nasal epithelium 
were harvested and assayed for luciferase activity. Each dot represents one mouse. p=0.07, 
r
2
=0.26.  
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Figure 58: Luciferase expression in mouse lung and nose after nasal instillation of high 
concentration C10  
Mice were pre-treated with 25 µl 0.05 M or 0.2 M C10 or PBS by nasal instillation 2 hrs prior to 
nebulisation of GL67/pCIKLux complexes. A control group receiving no pre-treatment and 
untransfected (UT) mice were also included. 24 hrs post transfection the right lung (a) and the 
nasal epithelium (b) were harvested and assayed for luciferase activity. Data are expressed as 
mean ± SEM (n=8/group), * = p<0.05 UT compared to other groups, * = p<0.05 C10 0.05 M 
compared to PBS and C10 0.2 M, ** = p<0.01 C10 0.05 M compared to 0.2 M C10 and *** = 
p<0.001 C10 0.2 M compared to PBS.  
a 
b 
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In the lung, 0.05 M C10 pre-treatment resulted in an approximately 3-fold increase in 
gene expression (p<0.05), which was similar to the increase observed in the previous 
experiment (Figure 58a). A significant increase in gene transfer efficiency was also 
observed in the nose after 0.05 M C10 pre-treatment (p<0.05) (Figure 58b). However, 
the increase (18-fold) was not as great as the increase observed in the previous 
experiment (40-fold). Overall, repeating the previous experiment assured us that 0.05 M 
C10 does increase gene transfer efficiency to the mouse lung and nose. 
 
Increasing the C10 concentration and thereby the dose 5-fold, did not increase gene 
expression in the lung. Expression levels were similar to PBS controls and significantly 
(p<0.05) lower than compared to mice treated with 0.05 M (Figure 58a). Interestingly, 
in the nasal samples 0.2 M C10 lead to a significant (p<0.01) increase in lux expression 
(200-fold) compared to the lower C10 concentration of 0.05 M (Figure 58b).  
 
These results suggest that to obtain maximal gene transfer in the lung and nose C10 
should be delivered by nasal instillation at concentrations of 0.05 M and 0.2 M, 
respectively. 
 
5.4.8 Nasal instillation of C10 did not lead to histologically visible alterations in 
mouse lung 
To assess if nasal instillation of C10 caused toxicity in the lung, mice were treated with 
0.05 M and 0.2 M C10 or PBS followed by GL67/pCIKLux nebulisation, received no 
pre-treatment or remained untransfected as described in the previous section (Section 
5.4.7). The left lung was processed for histological examination and tissue was analysed 
for degree and area of haemorrhage and inflammation using a semi-quantitative scoring 
system (Figure 59). Haemorrhage and inflammation were assessed as these are the key 
components of lung injury. Haemorrhage and inflammation were similar in all groups. 
Pre-administration of C10 or PBS did not increase histological changes compared to 
untransfected mice or mice receiving no pre-treatment before nebulisation of 
GL67/pCIKLux. 
 
In the first instance untransfected mice (UT) were scored again to determine the validity 
of the results, as haemorrhage and inflammation were unexpectedly high in these mice. 
Normally the score obtained for an untransfected mouse is approximately 1.  
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Figure 59: Histological assessment of mouse lung after C10 nasal instillation  
Mice were pre-treated with 25 µl 0.05 M or 0.2 M C10 or PBS by nasal instillation 2 hrs prior to 
nebulisation of GL67/pCIKLux complexes. A control group receiving no pre-treatment and 
untransfected (UT) mice were also included. 24 hrs post transfection the left lung was harvested 
for histological assessment. Sections were scored for degree and area of haemorrhage and 
inflammation. Each dot represents one animal with the mean score of the group shown as a 
horizontal line (n = 8/group). 
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Redoing the scoring of the samples (n=8) resulted in exactly the same score for each 
individual sample and I, therefore, did not find it necessary to redo the scoring for the 
remaining samples (Figure 60). In addition, further assessment showed that the high 
scoring obtained in these samples was mainly due to inflammation and not 
haemorrhage, as macrophages were present in large numbers.  
 
In addition to inflammation and haemorrhage, the respiratory epithelium was also 
assessed for any signs of damage following treatment with C10. As shown in Figure 61, 
the respiratory epithelium was intact and there was no evidence of damage with either 
of the C10 concentrations (0.05 M and 0.2 M) tested.  
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Figure 60: Repeated histological assessment of mouse lung  
The left lung of untransfected mice (UT) was harvested for histological assessment. Sections 
were scored for degree and area of haemorrhage and inflammation. The same untransfected 
samples were rescored (UT (Rescored)). Each dot represents one animal (n=8/group). 
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Figure 61: Respiratory epithelium of mouse lung after C10 nasal instillation  
Mice were pre-treated with 25 µl 0.05 M or 0.2 M C10 or PBS by nasal instillation 2 hrs prior to 
nebulisation of GL67/pCIKLux complexes. Untransfected (UT) mice were also included. 24 hrs 
post transfection the left lung was harvested for histological assessment. Sections were assessed 
for respiratory epithelial damage. a: 0.2 M C10, b: 0.05 M C10, c: PBS and d: UT. All images 
are representative of the respiratory epithelium in the lung for each group (Original 
magnification: x20). Arrows indicate the airways and arrowheads indicate the respiratory 
airway epithelium.  
 
 
 
 
 
 
 
 
a 
c d 
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5.5 C12 results  
 
5.5.1 C12 was soluble at 0.2 M but not at 0.5 M  
In the following studies the sodium salt of lauric acid (C12) was used to assess the 
effect on gene transfer efficiency. The alkaline version of the drug had previously been 
described in relevant literature [212,284] but - as was the case for C10 - no detailed 
description of solubility at physiological pH could be found. The commercial supplier 
does not state the solubility in aqueous solution. However, Johnson et al reports that 
C12 cannot easily be dissolved at concentration in excess of 0.01 M in aqueous solution 
[212]. First attempts were therefore made to dissolve C12 to a concentration of 0.01 M 
in PBS (without CaCl2 and MgCl2), because PBS had previously been used successfully 
to dissolve C10. In contrast to C10, however, 0.01 M C12 was not soluble in PBS. I 
next attempted to dissolve C12 in WFI. 0.01 M C12 easily dissolved in WFI (pH 8.5) 
and in addition, I was able successfully to dissolve the compound to 0.2 M (pH 9.5) 
although this required prolonged vortexing for approximately one hr. Attempts to adjust 
the pH to 7.4, however, caused the solutions to precipitate. 0.5 M C12 also went into 
solution, but precipitated within 1 hr when stored at room temperature. C12 stock 
solutions (0.05 M and 0.2 M) were made up in WFI for all subsequent experiments. I 
would have preferred not to use alkaline C12 solutions for my experiments; however, 
Johnson et al had previously treated mice by nasal instillation with alkaline C12 without 
reporting side-effects [212] and I therefore decided to go forward with these solutions.   
 
5.5.2 0.2 M C12 was the maximum tolerable concentration for nasal instillation  
In preparation for experiments assessing the effect of C12 on gene transfer efficiency 
following delivery by nasal instillation the maximum tolerated dose was determined. 
Mice received 25 µl 0.05 M and 0.2 M C12 (n=3/group) by nasal instillation and were 
monitored carefully for the next 24 hrs. Immediately after treatment mice receiving 0.05 
M C12 were hunched and inactive, which was more severe than normally observed after 
nasal instillation of PBS. Although, still fairly inactive they showed no other signs of 
illness 5 hrs post treatment. The mice were culled 24 hrs post treatment and the internal 
organs assessed; all organs including the stomach and intestine looked normal on gross 
observation with no signs of gas trapping. Following treatment with 0.2 M C12 all mice 
appeared hunched and inactive similar to the lower dose. Over the next 24 hrs the mice 
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recovered, but were more inactive compared to PBS-treated controls. There were no 
external signs of abdominal swelling. The mice were culled 24 hrs post treatment and 
organs harvested and processed for histological assessment. One out of the three mice 
had a slightly inflated stomach and intestine, however, the swelling was not as severe as 
previously observed in C10 treated mice. Due to the gas trapped in the stomach and 
intestine of one mouse treated with 0.2 M C12, this dose was considered the highest 
tolerated. Histological assessment of the harvested organs was initially only carried out 
on mice treated with the highest concentration of C12 (0.2 M) as this process was very 
time consuming. If changes were apparent mice treated with 0.05 M C12 would be 
assessed. 0.05 M and 0.2 M C12 were used in subsequent experiments and all animals 
were carefully monitored for any signs of abdominal swelling and discomfort.  
 
5.5.3 Histological assessment of internal organs revealed no changes after nasal 
instillation of 0.2 M C12 
To determine if mice (n=3) treated with 0.2 M C12 by nasal instillation showed signs of 
toxicity internal organs (stomach, intestine, spleen, liver, lung and kidney) were 
harvested 24 hrs post treatment and processed for histological assessment. As controls 
PBS treated mice were included. 
 
As in the previous experiment, morphological changes were not observed in any of the 
organs assessed in mice treated with either C12 or PBS (Figure 62+63+64). However, I 
again observed moderate lung inflammation and the presence of macrophages in the 
spleen in both C12 treated mice and controls suggesting that the mice were infected 
(Figure 64a+b).  
 
5.5.4 Nasal instillation of C12 increased GL67-mediated gene transfer in mouse 
lung and nose 
As C10 pre-treatment by nasal instillation had previously shown to enhance GL67-
mediated gene transfer to both the lung and nose in vivo, the effect of C12 was assessed 
using the same route of delivery. First, the effects of 0.01 M and 0.05 M C12 were 
assessed. 0.01 M C12 was included as the effect of this concentration had previously 
been assessed in the context of adenovirus-mediated gene transfer [212]. The mice 
received 0.01 M and 0.05 M C12 by nasal instillation 2 hrs prior to nebulising 
GL67/pCIKLux complexes. 
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Figure 62: Mouse intestine and stomach after nasal instillation of 0.2 M C12 
Mice were treated with 25 µl of 0.2 M C12 by nasal instillation. 24 hrs post treatment the mice 
were culled. The intestine and stomach were harvested for histological assessment. Mice treated 
with PBS were included as controls. a: intestine, C12 treated, b: intestine, PBS treated, c: 
stomach, C12 treated and d: stomach, PBS treated. Representative images are shown (Original 
magnification: x20). 
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Figure 63: Mouse kidney and liver after nasal instillation of 0.2 M C12 
Mice were treated with 25 µl of 0.2 M C12 by nasal instillation. 24 hrs post treatment the mice 
were culled. The kidney and liver were harvested for histological assessment. Mice treated with 
PBS were included as controls. a: kidney, C12 treated, b: kidney, PBS treated, c: liver, C12 
treated and d: liver, PBS treated. Representative images are shown (Original magnification: 
x20). 
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Figure 64: Mouse lung and spleen after nasal instillation of 0.2 M C12 
Mice were treated with 25 µl of 0.2 M C12 by nasal instillation. 24 hrs post treatment the mice 
were culled. The lung and spleen were harvested for histological assessment. Mice treated with 
PBS were included as controls. a: lung, C12 treated, b: lung, PBS treated, c: spleen, C12 treated 
and d: spleen, PBS treated. Representative images are shown (Original magnification: x20). 
Arrow heads indicate interstitial lung inflammation with alveolar wall thickening.  
a b 
c d 
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A pre-treatment time of 2 hrs was based on results obtained for C10 for which pre-
treatment times ranging from 10 min to 4 hrs were assessed (Section 5.4.6). Mice 
receiving WFI or no pre-treatment, as well as untransfected mice were included as 
controls. 24 hrs post transfection the mice were culled and the right lung and the nasal 
epithelium harvested for detection of luciferase activity.  
 
All mice treated with GL67/pCIKLux complexes expressed significant (p<0.05) levels 
compared to untransfected controls. The level of gene expression in the lung was 
similar to the previous experiments, whereas a slightly higher gene transfer level was 
observed in the nose compared to previously (Figure 65a+b). Administration of WFI 2 
hrs before gene transfer did not affect efficiency in the lung, but significantly (p<0.01) 
reduced gene expression in the nose (Figure 65a+b), which was also observed in the 
previous experiments when mice were pre-treated with WFI or PBS. Administration of 
0.01 M C12 had no effect on gene transfer in lung and nose, whereas 0.05 M C12 
significantly (p<0.05) increased gene expression by 40-fold in the nose compared to 
WFI controls. In the lung 0.05 M C12 also resulted in a trend towards increased 
expression (2-fold), but this did not reach significance.  
 
In an attempt to increase further gene transfer in vivo, the effect of 0.2 M C12, the 
highest tolerable dose, was assessed. As part of this experiment I also repeated 
treatment with 0.05 M C12 to ensure that previously obtained results were reproducible. 
Mice were pre-treated with 0.05 M and 0.2 M C12 by nasal instillation 2 hrs prior to 
GL67/pCIKLux nebulisation. Mice receiving 0.05 M C12 were hunched and inactive 
during treatment. However, they recovered within 5-6 hours post treatment. In contrast, 
3 out of 8 mice receiving 0.2 M C12 were culled immediately after GL67/pCIKLux 
nebulisation as the abdomen appeared hard and swollen. Assessment of the internal 
organs revealed gas in both stomach and intestine in all 3 mice. The remaining mice 
were culled 24 hrs post transfection and the right lung and nasal epithelium were 
harvested and luciferase activity assayed.  
 
As for all other experiments lux expression was significantly (p<0.05) higher in all mice 
receiving GL67/pCIKLux, demonstrating the high reproducibility of this non-viral gene 
transfer agent (Figure 66a+b).  
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Figure 65: Luciferase expression in mouse lung and nose after C12 nasal instillation  
Mice were pre-treated with 25 µl 0.01 M or 0.05 M C12 or WFI by nasal instillation 2 hrs prior 
to nebulisation of GL67/pCIKLux complexes. A control group receiving no pre-treatment and 
untransfected (UT) mice were also included. 24 hrs post transfection the right lung (a) and the 
nasal epithelium (b) were harvested and assayed for luciferase activity. Data are expressed as 
mean ± SEM (n=8/group), * = p<0.05 UT compared to all other groups, ** = p<0.01 no 
pretreamtment compared to WFI and *** = p<0.001 C12 0.05 M compared to WFI.  
b 
a 
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Figure 66: Luciferase expression in mouse lung and nose after nasal instillation of high 
concentration C12  
Mice were pre-treated with 25 µl 0.05 M or 0.2 M C12 or WFI by nasal instillation 2 hrs prior 
to nebulisation of GL67/pCIKLux complexes. A control group receiving no pre-treatment and 
untransfected (UT) mice were also included. 24 hrs post transfection the right lung (a) and the 
nasal epithelium (b) were harvested and assayed for luciferase activity. Data are expressed as 
mean ± SEM (n=5-9/group), * = p<0.05 UT compared to all other groups, * = p<0.05 C12 0.05 
M compared to WFI and C12 0.2 M and *** = p<0.001 C12 0.2 M compared to WFI. 
a 
a 
b 
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Similar to the previous lung experiment, pre-administration of WFI had no effect 
compared to controls receiving no pre-treatment. In contrast, there was a trend towards 
reduced gene transfer in the nose after pre-treatment with WFI (Figure 66a+b), but this 
decrease did not reach significance. Administration of 0.05 M C12 again significantly 
(p<0.001) increased gene expression in the nose (35-fold) and, additionally, there was a 
trend towards increased gene expression in the lung (2-fold), but this increase did not 
reach significance. These results show the reproducibility of the effect (Figure 66a+b). 
Increasing the concentration to 0.2 M C12 did not lead to an increase in lux expression 
compared to WFI controls in the lung. Importantly, gene expression was significantly 
(p<0.05) decreased compared to mice treated with 0.05 M. In the nasal epithelium, 
however, 0.2 M C12 further increased gene expression compared to 0.05 M C12 
(p<0.05) leading to a 90-fold increase compared to controls (p<0.001) (Figure 66a+b).  
 
5.5.5 Nasal instillation of C12 did not lead to histologically visible alterations in 
mouse lung 
Toxicity in the lung was assessed following nasal instillation of C12. Mice were pre-
treated with 0.05 M and 0.2 M C12 followed by nebulisation of GL67/pCIKLux as 
described in the previous section (Section 5.5.4). The left lung was harvested 24 hrs 
post transfection, paraffin embedded and sections were cut and scored for degree and 
area of haemorrhage and inflammation.  
 
Interestingly, the scores obtained for untransfected mice in this experiment were within 
the range normally expected, which further highlights that the scores previously 
obtained were unusual high (Section 5.4.8). Similar levels of haemorrhage and 
inflammation were obtained in control groups and mice treated with C12 0.2 M 
compared to untransfected mice. However, mice receiving 0.05 M C12 had a 
significantly (p<0.05) lower score compared to untransfected mice, which is likely to be 
due to a variation in scores between mice (Figure 67). 
 
Similar to C10, assessment of the respiratory epithelium revealed no signs of damage in 
any treated mice compared to untreated controls (Figure 68).  
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Figure 67: Histological assessment of mouse lung after C12 nasal instillation  
Mice were pre-treated with 25 µl 0.05 M or 0.2 M C12 or WFI by nasal instillation 2 hrs prior 
to nebulisation of GL67/pCIKLux complexes. A control group receiving no pre-treatment and 
untransfected (UT) mice were also included. 24 hrs post transfection the left lung was harvested 
for histological assessment. Sections were scored semi-quantitatively for degree and area of 
haemorrhage and inflammation. Each dot represents one animal with the mean score of the 
group shown as a horizontal line (n = 5-9/group), * = p<0.05 C12 0.05 M compared to UT. 
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Figure 68: Respiratory epithelium of mouse lung after C12 nasal instillation  
Mice were pre-treated with 25 µl 0.05 M or 0.2 M C12 or WFI by nasal instillation 2 hrs prior 
to nebulisation of GL67/pCIKLux complexes. Untransfected (UT) mice were also included. 24 
hrs post transfection the left lung was harvested for histological assessment. Sections were 
assessed for respiratory epithelial damage. a: 0.2 M C12, b: 0.05 M C12, c: WFI and d: UT. All 
images are representative of the respiratory epithelium in the lung for each group (Original 
magnification: x20). Arrows indicate the airways and arrowheads indicate the respiratory 
airway epithelium.  
b a 
c d 
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5.5.6 Summary: C10 was chosen as the lead candidate for subsequent studies  
The above experiments have shown that both C10 and C12 enhance GL67-mediated 
gene transfer in vivo. However, when analysing the data more carefully C10 treatment 
resulted in a slightly higher fold increase in lux expression in both lung and nasal 
samples compared to C12 (Table 2). Based on these results and the fact that C10 at the 
highest tested concentration (0.2 M) caused less severe side-effects, C10 was the chosen 
as the lead candidate for any subsequent studies.   
 
 
Lung 
TJ-opener Volume 
instilled 
[TJ-opener] Controls Fold increase in lux 
expression 
C10 25 µl 0.05 M PBS 
PBS 
 
No pre-treatment 
No pre-treatment 
3.0 (Fig. 56) 
3.3 (Fig. 58)  
 
~ 10 (Fig. 56) 
3.0 (Fig. 58) 
C12 25 µl 0.05 M WFI 
WFI 
 
No pre-treatment 
No pre-treatment 
2.4 (Fig. 65) 
1.8 (Fig. 66) 
 
2.9 (Fig. 65) 
1.8 (Fig. 66) 
 
 
 
Nose 
TJ-opener Volume 
instilled 
[TJ-opener] Controls Fold increase in lux 
expression 
C10 25 µl 0.2 M PBS 
 
No pre-treatment 
~ 200 (Fig. 58) 
 
~ 45 (Fig. 58) 
C12 25 µl 0.2 M WFI 
 
No pre-treatment 
~ 90 (Fig. 66) 
 
~ 30 (Fig. 66) 
 
 
 
Table 2: Fold increase in GL67-mediated gene transfer in mouse lung and nose after 
C10 or C12 nasal instillation  
The tables summarise fold increase in GL67-mediated gene transfer in the lung and nose 
following nasal instillation of the TJ-opener. The mean lux expression in mice pre-treated with 
the TJ-opener at 0.05 M and 0.2 M (25 µl/mouse) was compared to mice receiving vehicle (PBS 
or WFI) or no pre-treatment. 
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5.6 Discussion  
 
In Chapter 4 I described that EGTA did not enhance non-viral mediated gene transfer to 
the murine lung and nose. Here, I assessed the effect of the two alternative well 
established absorption enhancers and tight junction openers sodium caprate (C10) and 
sodium laurate (C12), on cationic liposome GL67-mediated gene transfer in vivo. C10 
and C12 were delivered via nasal instillation or nebulisation to the murine airways and 
transfection was carried out by nebulisation of GL67 complexed to a luciferase reporter 
plasmid. Nebulisation of GL67 was chosen as this delivery method is compatible with 
clinical use and, in contrast to bolus administration by nasal instillation, causes less lung 
inflammation. Although, nebulisation of C10 did not increase gene transfer efficiency to 
the mouse lung or nose, interestingly, delivering C10 and C12 via nasal instillation 
resulted in increased levels of gene expression in both organs compared to appropriate 
controls. Overall, C10 treatment resulted in a higher fold increase in luciferase 
expression in both lung and nose compared to C12 and, importantly, caused less severe 
side-effects. C10 was therefore chosen as the lead candidate for any subsequent studies.  
 
Although published data are limited, C10 and C12 have been shown to enhance 
paracellular permeability and increase viral-mediated gene transfer to airway epithelial 
cells in ex vivo and in vivo models [141,212,284]. In addition, the effect on adenovirus-
mediated gene transfer was more pronounced after C10 and C12 pre-treatment 
compared to EGTA ex vivo (4-fold) and in vivo (approximately 2-fold) suggesting that 
this class of TJ-openers may be better at enhancing airway gene transfer [212,283]. I 
hypothesised that opening of the tight junctions by treatment with C10 or C12 may not 
just allow viral vectors access to their basolateral receptors and increase gene transfer 
efficiency, but may also benefit non-viral vectors as these vectors are believed to enter 
polarised cells more efficiently from the basolateral membrane. 
 
I first assessed C10, as the documented effect of this tight junction opener on 
paracellular permeability and viral-mediated gene transfer in AECs has been studied in 
more detail compared to C12 both ex vivo and in vivo. In addition, C10 is currently used 
as a rectal absorption enhancer in a marketed drug.  
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Initially, I attempted to dissolve C10 at physiological pH at concentrations, which had 
previously been used in other studies. Importantly, none of these studies or the 
commercial supplier stated detailed protocols on how to dissolve C10 at this pH. C10 
was soluble in WFI, which previously had been used successfully to dissolve EGTA, 
but precipitated when the alkaline solution was adjusted to physiological pH. The 
reason for this is that capric acid (the corresponding acid of C10) forms when the pH is 
adjusted, which has a lower solubility compared to C10 (sodium salt of capric acid). In 
an attempt to stabilise the C10 solution at a pH closer to physiological pH, C10 was 
made up in HEPES Krebs buffer or PBS containing MgCl2 and CaCl2. C10 was not 
soluble in buffers containing MgCl2 and CaCl2, but interestingly, dissolved when the 
buffers were made up without these ions. I did not investigate the effects of MgCl2 and 
CaCl2 in detail, but magnesium and calcium are divalent cations and, therefore, require 
two C10 molecules to compensate their charges which may cause precipitation of the 
compound. The buffers did not stabilise pH closer to physiological pH and attempts at 
adjusting pH resulted in precipitation of C10. It was decided to dissolve C10 in PBS for 
subsequent studies as previous experiments had indicated that pre-treatment with WFI 
had a negative effect on gene transfer efficiency in the mouse nose. Overall, I cannot 
exclude that the pH in the C10 solution - as this was raised compared to physiological 
pH - had an effect on cell physiology and tight junction integrity. However, to assses if 
the raised pH in the C10 solution had an effect on cell physiology and tight junction 
integrity, the effect on gene transfer of pre-treatment with PBS at raised pH (pH 8.8) 
could have been compared to pre-treatment with PBS at physiological pH and C10. 
 
As part of experiments described in the previous chapter (Chapter 4), I had already 
demonstrated that significant levels of luciferase expression were detectable in the 
mouse nose following nebulisation of GL67/pCIKLux. In this set of experiments I 
further confirmed these results and in addition, I showed that similar levels of gene 
expression were obtained in individual experiment in both lung and nose indicating 
relatively little variation between different in vivo experiments. 
 
C10 was initially delivered to the airway epithelium via nebulisation. This delivery 
method was chosen as TJ-openers would, like the non-viral vector, be delivered via 
nebulisation in the clinic to target the polarised airway epithelium. The highest possible 
C10 concentration (0.5 M) was first nebulised to allow for a maximised effect of C10. 
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However, precipitation occurred during nebulisation indicating changes in the stability 
of the drug likely due to the shear stress of nebulisation. Generally, drugs in solution 
become more concentrated during nebulisation as water nebulises first and should the 
drug solution become too concentrated, precipitation will eventually occur [173]. This 
may also explain why 0.5 M C10 precipitated during the nebulisation process. In 
contrast, a less concentrated C10 solution (0.05 M) could easily be nebulised. 
 
As previously described for EGTA, C10 was nebulised in between two rounds of GL67 
nebulisation to allow the vector to be present when the TJ-opener was delivered. Had 
vector delivery only been carried out after 1 hour of C10 nebulisation the full effect of 
C10 might have diminished by the time GL67 complexed to pCIKLux was nebulised. 
PBS treated mice were included as controls and, importantly, all transfections with 
GL67/pCIKLux were carried out in the same nebulisation box to allow for direct 
comparison between C10 and vehicle treated mice. In the previous chapter, in which 
nebulisation of the tight junction opener EGTA was assessed, mice treated with EGTA 
and vehicle were nebulised in separate nebulisation boxes with two different vials of the 
lipid. Different levels of gene expression were obtained from the two vials of lipid, 
despite the fact that they came from the same batch, and EGTA and vehicle treated mice 
could, therefore, not be directly compared, which made it difficult to draw final 
conclusions. I designed this experiment so all cohorts of mice fitted into one 
nebulisation box and thereby the same vial of lipid could be used for all cohorts. 
Interestingly, the experiment showed that prolonging nebulisation time significantly 
increased gene transfer efficiency. This result suggests, that the vector should be 
nebulised for as long as is feasible in a clinical trial in order to maximise gene transfer. 
In the lung, C10 nebulisation increased gene transfer efficiency compared to controls, 
although this did not reach significance in all groups. More specifically, in mice 
nebulised with vector followed by C10 and then vector again (GTA-C10-GTA) the 
increase did not reach significance. In contrast, nebulisation of C10 followed by vector 
(C10-GTA) resulted in a significant increase. It is likely that this difference in 
significance between the two C10 treated groups is due to numbers being comparatively 
low (n=6/group), which means that a possible significant difference between the GTA-
C10-GTA group and the control group may not be picked up. Importantly, power 
calculations revealed that the experiment only had 32% power to pick up a significant 
difference and I would have had to include n=18 mice per group to achieve 80% power.  
229 
 
 
As variability is often seen in in vivo experiments it was very important to repeat the 
experiment to determine if the increase in gene transfer efficiency observed in the lung 
was reproducible. I, therefore, repeated this experiment with significantly higher 
numbers. Three groups were included in the experiment; C10 and PBS treated mice and 
an additional group, which received just vector treatment. Ideally, I would assess 18 
mice per group based on the previous power calculations; however, 10 mice per group 
were assessed as 30 was the maximum number of mice, which could fit simultaneously 
into the nebulisation box. Importantly, GL67-mediated gene transfer to both mouse lung 
and nose worked as expected with similar levels of gene expression compared to the 
previous experiment. In contrast to the above, no increase in reporter gene expression 
was observed in the lung. The reasons for the contradictory results obtained in these two 
experiments are unknown, but it is likely that the results from the previous experiment 
are false positives due to the natural variability in in vivo experiments. Again, C10 
nebulisation resulted in reduced levels of gene expression.  
 
In an attempt to enhance the effect of the tight junction openers on gene transfer 
efficiency, the C10 dose inhaled by the mice was increased by extending the 
nebulisation time from 1 hour to 4 hours. However, this had no effect on GL67-
mediated gene transfer. In fact, C10 treatment resulted in significantly lower levels of 
gene transfer expression in the lung and nasal epithelium compared to control mice 
which is likely to be related to toxicity caused by C10 when a larger dose was inhaled. 
These results indicate that although the contact time between the airway epithelium and 
the TJ-opener following nebulisation of C10 was relatively long (up to 4 hours) the 
actual dose inhaled may still be too small to have a significant impact on gene transfer 
efficiency. However, as the concentration of C10 in the aerosol is not easily determined 
the actual dose delivered to each individual mouse was not established. To support the 
theory that a small dose is inhaled during nebulisation, my group has estimated that 
approximately 5 to 10 µg DNA are deposited in the lung during a one hour nebulisation 
period, compared to 80 µg delivery by nasal instillation (U. Griesenbach, Department of 
Gene Therapy, Imperial College London, UK - personal communication). This result 
strongly suggests that the dose inhaled is significantly smaller following nebulisation. 
Alternatively, opening of tight junctions may not enhance cationic liposome-mediated 
gene transfer to the airways.  
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As nebulisation of C10 had no impact on GL67-mediated gene transfer the TJ-opener 
was delivered to the murine airway epithelium via nasal instillation. Gregory et al have 
previously shown that C10 instilled into the airways increased adenovirus-mediated 
gene transfer to both the upper and lower airways and it was, therefore, important to 
assess this delivery method [141]. In preparation for these experiments the maximum 
tolerable dose of the TJ-openers was determined. Nasal instillation of high 
concentration C10 (0.5 M) resulted in abdominal swelling due to gas accumulation in 
both stomach and intestine. This is likely to be caused by C10 inhibiting gut mobility, 
which then results in accumulation of swallowed air (J. Zhu, Department of Lung 
Pathology, Imperial College London, UK - personal communication). Interestingly, 
histological assessment of the stomach and intestine of mice treated with 0.5 M C10 
compared to controls revealed no morphological changes, which could explain the 
accumulation of air in these organs. Furthermore, additional organs (lung, kidney, 
spleen) were assessed, but no morphological changes were found in these organs either. 
Moderate inflammation was observed in the lung of all mice treated with both C10 and 
vehicle and, additionally, macrophages were present in the spleen of all mice suggesting 
that these mice were infected. Mice were bred under specific pathogen conditions 
(SPC), however, they were not maintained under SPC at the animal facility at Imperial 
College London and may, therefore, have picked up an infection. However, sentinels 
are regularly checked for infections at the animal facility and importantly, no 
unexpected pathogens were identified during the period when the experiments were 
carried out. It remains, therefore, unclear why the mice used in this experiment showed 
signs of pathogen infection in the spleen. 
 
Nasal instillation of C10 increased GL67-mediated gene transfer to airway epithelium in 
vivo in a time-dependent manner. The optimal time interval between delivering C10 and 
the non-viral vector was 2 hours for both lung and nose. The peak in expression levels 
after a time interval of 2 hours is likely to be due to the time it takes for C10 to exhibit 
its effect on the intracellular mediators DAG and IP3. By 4 hours the effect of C10 may 
have diminished, which would explain the return towards baseline expression levels 
observed at this time interval. The optimal time interval observed was not consistent 
with published literature, which has shown that either 10 minutes or 1 hour pre-
treatment time should be adopted to maximise the enhancement of adenovirus-mediated 
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gene transfer [141,212]. However, these studies were conducted ex vivo and in vivo by 
delivery of the TJ-opener via a double tracheostomy technique thereby targeting the 
murine trachea, and the results obtained may, therefore, not be directly comparable. 
Importantly, Johnson et al, who determined the optimal pre-treatment time to be 1 hour 
in vivo, did not assess any later time-points. High luciferase expression level in the lung 
of a mouse did not correlate with high expression level in the nose, indicating that both 
organs respond to the drug in an independent fashion. 
 
The increase in GL67-mediated gene transfer was not just time-dependent but was also 
dependent on the C10 dose delivered. In two independent experiments 0.05 M C10 
delivered by nasal instillation resulted in a 3-fold increase in gene expression compared 
to controls. Gene transfer efficiency was also increased in the nose in both of these 
experiments; however the relative increase varied from 18 to 40-fold, likely to be 
related to the variability often seen in in vivo experiments. In an attempt to increase 
further gene transfer efficiency, the highest possible dose of C10 was delivered (0.2 M, 
25 µl/mouse) via nasal instillation. 0.2 M C10 significantly enhanced gene expression in 
the mouse nose compared to 0.05 M C10. However, in the lung expression levels were 
significantly reduced, which is likely to be related to toxicity following pooling of high 
concentration C10. Therefore, to obtain maximal increase in gene transfer in mouse 
lung and nose C10 had to be delivered at concentrations of 0.05 M and 0.2 M, 
respectively.  
 
Gene transfer efficiency in both lung and nose may be further improved by delivering 
C10 in between two rounds of vector nebulisation, which had previously been assessed 
for C10 nebulisation. This strategy allows the vector to be present when the tight 
junction opener is delivered, which may have a positive impact on gene transfer. 
Secondly, the volume of C10 delivered via nasal instillation could be increased in an 
attempt to further improve gene transfer efficiency. However, this was not practically 
feasible. The relative low C10 volume used in these experiments (25 µl), was not 
instilled into the mouse nose as easily as was PBS. Increasing the C10 volume delivered 
would, therefore, further complicate the instillation process and thereby make it very 
difficult to ensure instillation of the complete volume. Furthermore, increasing the 
volume would mean increasing the dose, which would probably cause severe side- 
effects in the form of respiratory distress and inflated stomach and lungs.   
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Histological assessment of the lung revealed that pre-administration of C10 or PBS did 
not increase the degree of inflammation and haemorrhage compared to untransfected 
mice or mice receiving no pre-treatment before nebulisation of GL67/pCIKlux. These 
observations were in contrast to data published by Johnson et al showing mild lung 
inflammation after C10 treatment in the same strain of mice and at the same time point 
for analysis [212]. However, in contrast to my study Johnson et al delivered the TJ-
opener via tracheobronchial instillation and the volume reaching the lung is, therefore, 
likely to be greater compared to nasal instillation, hereby causing greater toxicity.  
 
The unexpectedly high score observed in untransfected mice prompted us to reassess 
the scoring. Rescoring the samples obtained from untransfected mice resulted in the 
exact same score for each individual mouse, which strongly indicated that the results 
obtained were valid. I, therefore, did not find it necessary to rescore the remaining 
samples as this process is extremely time consuming. Interestingly, the rescoring 
revealed that the high scores obtained in the untransfected samples were mainly due to 
inflammation and not haemorrhage. It is likely that an infection acquired during housing 
in the non-SPC animal facility is causing the inflammation observed. Importantly, 
infection leads to inflammation causing the release of cytokines, which are known to 
affect barrier function [337]. For example pro-inflammatory cytokines resulted in 
increased tight junctional permeability in airway epithelial cells ex vivo [338]. This may 
have affected the results described here. Although, infected mice in retrospect should 
not have been used, additional opening of tight junctions due to cytokine release was 
likely to have made the effect of C10 on lipid-mediated gene transfer in the mouse lung 
and nose less pronounced.  I did not think it was necessary to repeat the experiments in 
non-infected mice as cytokine release in infected mice would only have underestimated 
the increase in lipid-mediated gene transfer observed following treatment with C10. 
 
As previously mentioned, nasal instillation of TJ-openers may lead to pooling of the 
liquid in the alveolar region of the lung and the increase in GL67-mediated gene 
transfer observed in this study may, therefore, be due to enhanced transfection of the 
parenchyma and not the respiratory epithelium. This may explain why 0.2 M C10 had 
no impact on gene transfer efficiency in the lung, as pooling of high concentration C10 
in the parenchyma may cause toxicity, thereby impairing gene transfer to this region of 
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the lung. I considered using immunohistochemistry (IHC) to reveal which cells were 
transfected in the lung. However, colleagues within the CF Gene Therapy Consortium 
have previously documented that expressions levels following GL67-mediated gene 
transfer are too low to detect with IHC and, importantly, I did not believe that the 3-fold 
increase in gene expression previously observed in the lung following C10 treatment 
would raise expression levels above the detection limit. To determine more conclusive 
if C10 has increased transfection in AECs a larger animal model such as sheep would 
have to be employed. This model would allow for collection of AEC enriched samples 
through brushings and biopsies and reporter gene expression could subsequently be 
determined.  
 
As C10 did enhance lipid-mediated gene transfer to mouse lung and nose, I decided to 
assess the effect of C12, which has also been shown to increase tight junctional 
permeability and adenovirus-mediated gene transfer to airway epithelial cells ex vivo 
and in vivo. First, attempts were made to dissolve 0.01 M C12 in PBS without CaCl2 
and MgCl2, as PBS had successfully been used to dissolve C10. A concentration of 0.01 
M was based on a publication by Johnson et al, who successfully dissolved C12 at this 
concentration in aqueous solution [212]. Interestingly, C12 was not soluble in PBS but 
easily dissolved in WFI. The reason for this may be that PBS contains more ions 
compared to water resulting in higher ionic strength and polarity, which ultimately 
makes non-polar compounds like C12 less soluble in PBS compared to water. To 
determine the maximum tolerable dose of C12, mice were treated with 0.05 M and 0.2 
M C12 by nasal instillation. Mice treated with 0.2 M C12 showed no external signs of 
abdominal swelling, however early signs of gas trapping in stomach and intestine was 
observed in one mouse, when the organs were assessed internally. These side-effects 
were previously observed for C10, but at a higher concentration (0.5 M), suggesting that 
C12 has a more severe toxicity profile compared to C10. Importantly, these findings are 
supported by Johnson et al, who have previously reported that C12 is generally more 
toxic compared to C10 when assessing LDH release, cytokine production and histology 
in murine lung in vivo [212]. However, as observed for C10, no morphological changes 
were observed in stomach, intestine or any other organs assessed in mice treated with 
0.2 M C12.  
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Nasal instillation of C12 also increased GL67-mediated gene transfer in lung and nose 
in vivo. For these experiments a pre-treatment time of 2 hours was employed as this 
time interval was optimal for C10. Considering that C10 and C12 may have a similar 
mode of action, I felt it was reasonable to assume that C12 may also require a 2 hrs pre-
treatment time interval. I cannot, however, exclude that more careful optimisation of 
C12 pre-treatment times may lead to further increases in gene transfer.   
 
0.05 M C12 increased GL67-mediated gene transfer to mouse lung and nose, although 
the increase did not reach significance in the lung. In contrast, the lower concentration 
of 0.01 M had no effect on GL67-mediated gene transfer efficiency in either organ. The 
lower concentration chosen was based on data published by Johnson et al showing that 
0.01 M C12 significantly enhanced adenovirus-mediated gene transfer to the murine 
trachea [212]. The discrepancy between the results obtained by Johnson et al and the 
findings in this study may simply be due to the fact that different vectors were assessed 
in the two studies. However, the actual dose delivered to the airways was likely to be 
lower in my study compared to the published data as C12 was delivered via a double 
tracheostomy to the trachea. Furthermore, it is possible that different regions of the 
respiratory tree (trachea v lung) have different susceptibilities to TJ-openers [339]. It 
has previously been estimated that only 5% of the volume delivered by nasal instillation 
reaches the lung [340]. The remaining volume is either swallowed or lost in and around 
the nasal cavity. 
 
C12 was also delivered at a concentration of 0.2 M in an attempt to enhance gene 
transfer efficiency further. However, 3 out of 8 mice receiving 0.2 M C12 were culled 
immediately after GL67/pCIKLux nebulisation as the abdomen appeared hard and 
swollen. Gas accumulation was observed in both stomach and intestine. These 
observations were in contrast to data described above where mice (same strain/sex/age) 
treated with 0.2 M C12 had shown no external signs of gas accumulation. It is likely 
that these side-effects increased in severity due to GL67/pCIKLux nebulisation, 
however, the exact way GL67/pCIKLux contributed is unknown. Interestingly, C12 
treatment resulted in the same dose-response profile in both lung and nose as observed 
for C10. 0.2 M C12 significantly decreased gene transfer efficiency in the lung 
compared to the lower concentration (0.05 M). In contrast, 0.2 M C12 significantly 
increased gene expression in the nose compared to 0.05 M. The lack of effect in the 
235 
 
lung after pre-treatment with high concentration C12 (0.2 M) may be due to pooling of 
the tight junction opener in the lung following delivery by nasal instillation. Pooling of 
high concentrations of C12 may lead to toxicity thereby impairing gene transfer 
efficiency. However, the degree of inflammation or haemorrhage observed in lungs of 
mice treated with 0.2 M C12 was not more pronounced compared to untransfected mice 
or mice receiving 0.05 M C12 or vehicle. It is possible that C12, as well as C10, may 
cause subtle cellular effects at a molecular level, which cannot be observed by standard 
histological assessment. This may explain the reduction in gene transfer efficiency 
observed in the lung with a high concentration of the tight junction opener.  
 
In the previous chapter WFI had been shown to decreased lipid-mediated gene transfer 
efficiency in the murine nose. In these sets of experiment, WFI and PBS used to treat 
controls mice continued to reduce gene transfer efficiency in the mouse nose. 
Interestingly, vehicle-treated mice did not show reduced gene expression levels in the 
lung following delivery of the non-viral vector. It may be that pre-treatment with WFI 
and PBS causes swelling of the cells, thereby impairing vector uptake. The ciliated 
respiratory cells, which dominate the murine nasal epithelium, may be more susceptible 
to this effect compared to the lung tissue, which consists predominately of alveoli and 
this could be the explanation for the reduced gene transfer level in the nose. 
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5.7 Summary 
 
In summary, C10 and C12 significantly increased GL67-mediated gene transfer to the 
murine lung and nose in vivo. In agreement with previously published data assessing 
viral gene transfer, MCFAs are more efficient at enhancing non-viral gene transfer to 
the lungs and nose than EGTA [212,283]. However, when the potency of C10 and C12 
were compared, C10 pre-treatment resulted in a slightly higher increase in gene transfer 
efficiency and, importantly, at the optimal concentrations C10 caused less severe side- 
effects. C10 was, therefore, chosen as the lead candidate for subsequent studies.  
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Chapter 6: The effect of detergent LPC on lipid-mediated gene 
transfer in vivo 
 
 
6.1 Introduction to LPC tight junction opener 
 
Pre-administration of C10 and C12 increased lipid-mediated gene transfer in murine 
lung and nose. I decided to assess a final class of tight junction openers to determine if 
gene transfer efficiency could be enhanced further than previously observed for C10 
and C12. Detergents, such as lysophosphatidylcholine (LPC) and polidocanol, also have 
a well documented effect on paracellular permeability and are believed to work via a 
different mechanism from Ca
2+
-chelators and medium chain fatty acids. Additionally, 
they have increased virus-mediated gene transfer to airway epithelial cells ex vivo and in 
vivo. I chose to assess the biological detergent LPC (containing palmitic acid) (Figure 
69) as, in contrast to the synthetic detergent polidocanol, it converts into a non-toxic 
compound in vivo thereby minimising the risk of side-effects. Furthermore, the effect of 
LPC on viral gene transfer efficiency had proven more pronounced compared to 
polidocanol in vivo. These points will be discussed in more detail below.  
 
6.1.1 Mechanisms by which LPC regulates tight junctional permeability 
The exact mechanisms by which detergents such as LPC and polidocanol affect tight 
junctional permeability are currently not fully understood and data published on this 
subject are very limited. Huang et al have shown that LPC impaired endothelial barrier 
function by activation of PKC and RhoA, one of several Rho-GTPases in cells [341]. It 
has been suggested that junctional transmembrane proteins such as occludin may be 
direct targets of Rho-GTPases [342]. Furthermore, RhoA has been shown to enhance 
MLC phosphorylation and inhibit MLC phosphatases both via activation of Rho-kinase 
leading to increased overall phosphorylation of MLC. MLC phosphorylation results, as 
previously mentioned, in the classical myosin-actin cross bridging leading to 
contraction of the actin-myosin filaments and subsequently increased paracellular 
permeability [343,344]. Thus, LPC induced activation of PKC may result in 1) 
reorganisation of the cytoskeleton leading to internalisation of transmembrane spanning 
proteins leading to increased paracellular permeability or 
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R-COO-CH2-CH(OH)-CH2-HPO4-CH2-CH2-N-(CH3)3 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 69: LPC formula and structure 
The figure shows the formula and structure of lysophosphatidylcholine (LPC). LPC used in this 
thesis contained the fatty acid palmitic acid (R: CH3(CH2)14-). The figure is taken from 
www.wikipedia.org. 
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2) phophorylation of tight junction proteins which may affect paracellular permeability. 
Although PKC and RhoA have been suggested as possible mediators in the regulation 
of the LPC-induced increase in tight junctional permeability, the signal transduction 
cascade through which LPC activates these mediators has yet to be identified. 
 
6.1.2 LPC enhances viral airway gene transfer 
In the past, detergents have mainly been used to enhance nasal drug absorption leading 
to improved bioavailability of the drug of interest [345-347]. However, more recently 
data have shown that both LPC, classified as a biological detergent, and the synthetic 
detergent polidocanol significantly enhanced virus-mediated airway gene transfer in 
vivo (see below) [213,291,348]. Importantly, the biological detergent LPC has been 
shown to rapidly convert into the non-toxic phosphatidylcholine, a primary component 
of biologic membranes, when administered to cell systems in vitro and in vivo 
[349,350]. In addition, Chen et al have shown that LPC is a naturally occurring airway 
detergent [351]. The metabolism of LPC into a non-toxic compound is an advantageous 
feature not seen for other TJ-openers and, may minimise the risk side-effects in clinical 
trials. 
 
Limberis et al compared the effect of LPC and polidocanol pre-treatment on VSV-G 
pseudotyed lentivirus-mediated gene transfer to the murine nasal epithelium [291]. The 
study showed that LPC (4-fold) pre-treatment increased gene transfer more efficiently 
than polidocanol (1-fold) when the same dose of detergent (1%) was administered to the 
nasal epithelium (4 µl/mouse). Cmielewski et al have also demonstrated an increase in 
VSV-G pseudotyed lentivirus-mediated gene transfer to the murine nasal epithelium 
following pre-treatment with 0.1%, 0.3%, 1% and 2% LPC (4 µl/mouse). The study 
revealed exfoliation of the epithelium after treatment with 1% and 2% LPC, however, 
no damage to the epithelium was observed with 0.3% LPC and unexpectedly this dose 
resulted in the same level of gene transfer compared to 1% LPC [352]. In addition to 
these studies preliminary data by Aarbiou et al have shown a dose-dependent increase 
in VSV-G pseudotyped lentivirus-mediated gene transfer ex vivo following treatment 
with LPC. ALI cultures of human bronchial epithelial cells treated with LPC at 
0.0075% and 0.03% resulted in 40-50% and 50-60% GFP positive cells, respectively. 
However, 0.03% LPC caused shedding of cilia, but no loss of cell numbers was 
observed [353]. 
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Parsons et al assessed the effect of the synthetic detergent polidocanol on adenovirus-
mediated gene transfer to the murine nasal epithelium [213]. Mice were instilled with 
0.1% and 1% polidocanol (4 µl/mouse). In contrast to treatment with the lower 
concentration, 1% polidocanol produced damage to regions of the nasal epithelium. 
Interestingly, pre-treatment with 0.1% polidoconol resulted in a significant increase in 
transfected ciliated cells (2.2% of cells) compared to mice receiving PBS. Importantly, 
CF mice pre-treated with polidocaonol followed by adenovirus-mediated CFTR gene 
transfer also showed a significantly change in CFTR function (assessed by measuring 
the potential difference across the airway epithelium) towards wild-type values. 
 
As mentioned above, VSV-G pseudotyped lentivirus and adenovirus have been 
employed to assess the effect of detergents on airway gene transfer, as the receptors for 
these viruses are situated on the basolateral membrane of airway epithelial cells. 
Opening of tight junctions would allow the viruses access to their receptors and thereby 
increase vector uptake and ultimately gene transfer efficiency. Interestingly Rudolph et 
al have recently assessed the effect of polidocanol on PEI-mediated gene transfer in 
vivo [187]. In this study pre-nebulisation of polidocanol (0.1%) did not influence gene 
transfer efficiency of the non-viral vector to the murine lungs. However, only one 
polidocanol concentration was assessed and furthermore, numbers were low (n = 4). 
Increasing the concentration and/or extending the nebulisation time may have an impact 
on tight junctional permeability and thereby gene transfer efficiency. Further research is 
clearly needed to elucidate fully the effect of detergents on non-viral airway gene 
transfer in the lung. 
 
6.1.3 The use of LPC clinically  
To date no studies have been published describing the use of LPC in the human lung. 
The safety profile of this TJ opener is, therefore, not known. However, the metabolism 
of LPC into a non-toxic compound is likely to minimise the risk of side-effects. 
Interestingly, the synthetic detergent polidocanol has been used to enhance insulin 
bioavailability in diabetes patients when administered together with insulin via 
intranasal aerosolisation. Some nasal irritation was observed, which was related to the 
concentration of the detergent, but otherwise there were no side-effects [354]. 
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6.2 Aims 
 
The final TJ-opener assessed in this thesis was LPC as this has shown a greater effect 
on virus-mediated gene transfer compared to polidocanol. Additionally the potential 
side-effects from LPC are likely to be milder, as LPC converts into a non-toxic 
compound in vivo. The effect of LPC on GL67-mediated gene transfer was determined 
in mice in vivo. Similar to studies described in previous chapters the non-viral gene 
transfer agent GL67 was delivered to the murine airways via nebulisation and LPC was 
administered via nasal instillation. The LPC concentration and pre-treatment time were 
optimised in an attempt to enhance the effect of the TJ-opener on GL67-mediated gene 
transfer.  
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6.3 Materials and Methods  
 
6.3.1 LPC stock solutions 
1% and 2% L-α-LPC (Sigma-Aldrich Com. Ltd., Poole, UK) stock solutions were made 
up by dissolving 0.1 g in a total of 10 ml and 5 ml PBS (without CaCl2 and MgCl2), 
respectively. pH in the final stock solutions was then adjusted to physiological pH (pH 
7.4) with 0.1 M sodium hydroxide. 
 
6.3.2 Maximum tolerable concentration of LPC for nasal instillation  
To assess the maximal tolerable concentration of LPC following nasal instillation of the 
drug, C57Bl/6 mice received  25 µl of 0.1%, 0.3%, 1%, or 2% LPC by nasal instillation 
as described in Section 2.3.2 (n=3/group). For the following 24 hrs the mice were 
monitored carefully and culled if side-effects appeared; if so the mouse would be culled 
and internal organs (lung, liver, intestine, spleen, stomach, kidney) were harvested, 
fixed in 10% formalin and paraffin embedded. Transverse sections were cut (n=3 
sections/organ), stained with H&E and assessed for signs of toxicity by a pathologist (J. 
Zhu, Department of Lung Pathology, Imperial College, London, UK) using a light 
microscope (Leitz Dialux 20) equipped with a 10-40x objective. As controls, mice 
receiving PBS (n=3) were harvested and processed as described.  
 
6.3.3 LPC nasal instillation prior to GL67-mediated gene transfer in mouse lung 
and nose 
The effect of LPC on gene transfer efficiency was assessed by pre-treating C57Bl/6 
mice (approximately 12 weeks old females, n=6-10/group) with 25 µl of 0.1%, 0.3% or  
1% LPC 10 min, 1 hr or  2 hrs prior to whole body nebulisation with 10 ml GL67 
complexed to pCIKLux (molar ratio 6:8). Control mice receiving PBS or no pre-
treatment were included. Mice were culled 24 hrs post transfection and the nasal 
epithelium and the right lung were harvested, snap-frozen in liquid nitrogen and stored 
at -80ºC for detection of luciferase activity. The left lung was harvested and fixed in 
10% formalin for histological assessment.  
 
6.3.4 Histological assessment of mouse lung   
The left lung was processed and histological assessment carried out as described in 
Section 4.4.6. 
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6.3.5 Statistical analysis 
Gene expression data are expressed as mean ± SEM. Data was compared using 
ANOVA plus a Bonferroni correction or independent sample t-test where appropriate. 
Where necessary, raw data were log10 transformed to ensure normal distribution 
(Kolmogorov-Smirnov normality test was performed) and equal variances between 
groups. A non-parametric Mann Whitney test or a Kruskal-Wallis with Dunn‟s 
correction was carried out when the assumptions were not met after transformation. The 
null hypothesis was rejected at p<0.05. Histological data are presented as dot plots. Data 
were compared using a Kruskal-Wallis test with Dunn‟s correction. The null hypothesis 
was rejected at p<0.05. 
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6.4 Results  
 
6.4.1 1% LPC was the maximum tolerable concentration for nasal instillation  
Prior to assessing the effect of LPC on GL67-mediated gene transfer, the maximum 
tolerable dose following nasal instillation of LPC was determined. Briefly, mice 
received 25 µl of 0.1%, 0.3%, 1% or 2% LPC (n=3/group) by nasal instillation and were 
monitored carefully for the following 24 hrs. One mouse treated with 2% LPC was 
culled approximately 2 hrs post treatment because the animal did not move when 
touched.  Harvesting of the organs for histological assessment revealed discolouring of 
the lungs and a slightly inflated stomach. The remaining 2 mice treated with 2% LPC 
and mice receiving 0.3% and 1% LPC all appeared hunched and inactive during the first 
2-3 hours after treatment. In contrast, mice treated with the lowest concentration (0.1%) 
showed no adverse outward effect after treatment. 24 hrs post treatment mice receiving 
0.3%, 1% and 2% had recovered significantly. However, 1% and 2% LPC treated mice 
appeared less active compared to the group receiving 0.3%. Mice treated with 0.1%, 
0.3% and 1% were used in subsequent experiments as signs of treatment (inactivity and 
hunched appearance) was found to be acceptable. All mice were culled and organs were 
harvested for histological assessment from the 2 remaining mice treated with 2% LPC. 
Based on gross observation the organs did not show any abnormalities. Initially, only 
organs from mice treated with 2% LPC were assessed histological. If histological 
assessment revealed morphological changes, mice treated with the lower concentrations 
of LPC would be assessed. 
 
6.4.2 Histological assessment of internal organs revealed no changes after nasal 
instillation of 2% LPC 
In order to further assess the toxic effect of LPC transverse sections of the lung, liver, 
intestine, spleen, stomach and kidney of mice treated with 2% LPC were assessed 
histologically and compared to tissue obtained from mice treated with PBS. As shown 
in Figure 70 the intestine and stomach of LPC treated mice did not show any 
abnormalities when compared to PBS controls. However, autolysis (destruction of cells 
by the cells own enzymes) was sporadically observed in both groups which could be 
due to food residues in the intestine and stomach, or as a result of poor fixative 
penetration of the solid organs.  
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Figure 70: Mouse intestine and stomach after nasal instillation of 2% LPC  
Mice were treated with 25 µl 2% LPC or PBS by nasal instillation (n=3/group). Stomach and 
intestine were harvested, fixed in 10% formalin and paraffin embedded. Transverse sections 
were cut, stained with H&E and assessed for signs of toxicity. a: intestine, LPC treated, b: 
intestine, PBS treated, c: stomach, LPC treated and d: stomach, PBS treated. All images are 
representative of the tissue for each group (Original magnification: x20).  
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The remaining organs also showed no abnormalities (Figure 71+72). However, both 
groups had higher than normal levels of macrophages in the lung and spleen, which 
suggests that the mice may have been infected. Overall, no morphological changes were 
observed in any of the LPC treated mice, which would have explained the gross 
appearance observed (discolouring of the lung and inflated stomach) in one of the mice 
treated with 2% LPC. 
 
6.4.3 Nasal instillation of LPC increased GL67-mediated gene transfer in mouse 
lung and nose  
The effect of LPC on GL67-mediated gene transfer was assessed in vivo. Nasal 
instillation was chosen as route for delivery as this delivery method had previously 
shown promising results with both C10 and C12. Mice received 25 µl of 0.3% and 1% 
LPC by nasal instillation 1 hr prior to nebulisation with GL67 complexed to pCIKLux. 
The concentrations and pre-treatment time chosen for this experiment were based on 
personal communication with Dr. David Parsons (Department of Pulmonary Medicine, 
Women‟s and Children‟s Hospital, North Adelaide, Australia) who has previously 
studied the effects of LPC on viral gene transfer and literature published by his group 
[291]. In addition to the right lung, the nasal epithelium was also harvested as previous 
experiments had shown reasonable levels of luciferase activity in this tissue. Harvesting 
was carried out 24 hrs post transfection and tissue samples assayed for luciferase 
activity. As observed in previous chapters, all animals receiving GL67/pCIKLux 
complexes had significantly (p<0.05) increased lux expression in lung and nose 
compared to untransfected controls (Figure 73a+b). In the lung, there was a trend 
towards increased lux expression in mice pre-treated with 0.3% LPC compared to PBS-
treated mice, but this increase did not reach significance (p>0.05). In contrast, 1% LPC 
had no effect on gene transfer efficiency in the lung (Figure 73a). As shown in Figure 
73b, pre-treatment with both LPC concentrations resulted in increased levels of lux 
expression in the nose when compared to control mice (p<0.001). In addition, there was 
a trend towards increased levels of gene expression in mice treated with 0.3% LPC 
compared to mice treated with 1% LPC. In conclusion, lower concentrations of LPC 
appear to be more effective in increasing gene transfer.    
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Figure 71: Mouse kidney and liver after nasal instillation of 2% LPC  
Mice were treated with 25 µl 2% LPC or PBS by nasal instillation (n=3/group). Kidney and 
liver were harvested, fixed in 10% formalin and paraffin embedded. Transverse sections were 
cut, stained with H&E and assessed for signs of toxicity. a: kidney, LPC treated, b: kidney, PBS 
treated, c: liver, LPC treated and d: liver, PBS treated. All images are representative of the 
tissue for each group (Original magnification: x20).  
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Figure 72: Mouse lung and spleen after nasal instillation of 2% LPC  
Mice were treated with 25 µl 2% LPC or PBS by nasal instillation (n=3/group). Lung and 
spleen were harvested, fixed in 10% formalin and paraffin embedded. Transverse sections were 
cut, stained with H&E and assessed for signs of toxicity. a: lung, PBS treated, b: lung, LPC 
treated, c: spleen, PBS treated and d: spleen, LPC treated. All images are representative of the 
tissue for each group (Original magnification: x20).  
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Figure 73: Luciferase expression in mouse lung and nose after LPC nasal instillation  
Mice were pre-treated with 25 µl of 0.3% or 1% LPC or PBS by nasal instillation 1 hr prior to 
nebulisation of GL67/pCIKLux complexes. A control group receiving no pre-treatment and 
untransfected (UT) mice were also included. 24 hrs post transfection the right lung (a) and the 
nasal epithelium (b) were harvested and assayed for luciferase activity. Data are expressed as 
mean ± SEM (n=10/group), * = p<0.05 UT compared to all other groups, *** = p<0.001 LPC 
compared to PBS. 
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6.4.4 Lowering the concentration of LPC or extending the pre-treatment time did 
not enhance GL67-mediated gene transfer in mouse lung and nose 
As the lower concentration of LPC (0.3%) resulted in increased gene transfer efficiency 
in both lung and nose in the previous experiment, the concentration of LPC was further 
reduced to 0.1%. This concentration had previously been assessed by Limberis et al. 
and resulted in increased levels of gene expression following virus-mediated gene 
transfer [291]. In addition to lowering the concentration of LPC the pre-treatment time 
was extended to 2 hrs. C10 and LPC are not directly comparable as they fall into two 
different classes of TJ-openers. However, extending the pre-treatment time for C10 
from 1 hr to 2 hrs significantly enhanced GL67-mediated gene transfer efficiency. I, 
therefore, decided to assess the effect of LPC following 2 hrs pre-treatment. Briefly, 
mice were pre-treated with 0.1% and 0.3% LPC 2 hrs prior to whole body nebulisation 
with GL67/pCIKLux. 24 hrs post transfection mice were culled and the right lung and 
nasal epithelium harvested and assayed for luciferase activity. All groups nebulised with 
GL67/pCIKLux complexes showed increased lux expression in the mouse lung and 
nose compared to untransfected controls (p<0.05) (Figure 74a+b). As shown in Figure 
74a, pre-treatment with 0.1% LPC did not further increase gene transfer compared to 
0.3% LPC in the lung. In fact, similar levels of lux expression was observed in mice 
pre-treated with both LPC concentrations compared to controls (0.1%: p>0.05, 0.3%: 
p>0.05). The trend towards increased gene transfer efficiency in the mouse lung 
following treatment with 0.3% LPC observed in the previous experiment was not 
reproduced in this experiment 
 
In contrast, lux expression in nasal samples from mice treated with 0.1% and 0.3% LPC 
was significantly increased (0.1%: p<0.05, 0.3%: p<0.001) compared to PBS treated 
mice (Figure 74b). Mice receiving no pre-treatment showed similar levels of lux 
expression compared to the previous experiment, however, the increase in gene transfer 
efficiency in the nose following 0.3% LPC was approximately 10-fold lower in this 
experiment compared with the previous experiment. There was a trend towards 
increased gene expression in mice treated with 0.3% LPC compared to treatment with 
0.1%, but this increase did not reach significance. However, it does suggest a bell-
shaped dose response curve in the nose peaking after administration of 0.3%. 
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Figure 74: Luciferase expression in mouse lung and nose after nasal instillation of lower 
concentration LPC - extended pre-treatment time 
Mice were pre-treated with 25 µl 0.1% or 0.3% LPC or PBS by nasal instillation 2 hrs prior to 
nebulisation of GL67/pCIKLux complexes. A control group receiving no pre-treatment and 
untransfected (UT) mice were also included. 24 hrs post transfection the right lung (a) and the 
nasal epithelium (b) were harvested and assayed for luciferase activity. Data are expressed as 
mean ± SEM (n=8/group), * = p<0.05 UT compared to all other groups, * = p<0.05 LPC 0.1% 
compared to PBS and *** = p<0.001 LPC 0.3% compared to PBS. 
a 
b 
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As mentioned above, I did not observe a significant increase in gene transfer efficiency 
following treatment with 0.3% LPC in the lung. This result indicates that extending the 
time between pre-treating the mice with LPC and starting nebulisation of 
GL67/pCIKLux from 1 hr to 2 hrs had no further impact on gene transfer efficiency. In 
the nose, treatment with 0.3% LPC resulted in a significant increase in gene expression. 
However, as mentioned the increase was 10-fold lower compared to the previous 
experiment. Extending the time interval from 1 hr to 2 hrs did not, therefore, further 
increase gene transfer efficiency in the nose either. 
 
6.4.5 Reducing the pre-treatment time did not enhance GL67-mediated gene 
transfer in mouse lung and nose 
In a final attempt to increase further gene transfer efficiency to the airway epithelium in 
vivo, the pre-treatment time was reduced to 10 min. Briefly, mice received 25 µl of 
0.3% LPC by nasal instillation 10 min and 1 hr prior to nebulisation with 
GL67/pCIKLux. Mice receiving treatment 1 hr prior to nebulisation were included to 
assess if the positive, but not significant trend, observed previously in the lung (Section 
6.4.3) was reproducible. 24 hrs post transfection mice were culled and the right lung and 
nasal epithelium harvested and assayed for luciferase activity. Again, all mice nebulised 
with GL67/pCIKLux complexes showed a significant increase (p<0.05) in lux 
expression compared to untransfected controls (Figure 75a+b).  
 
Figure 75a shows that reducing the pre-treatment time to 10 min offered no additional 
effect in the lung. The positive trend observed previously with 0.3% LPC in the lung 
(Section 6.4.3) was still present although not as pronounced as in the previous 
experiment (p>0.05). Data obtained in this experiment were pooled with data from the 
previous experiment carried out (see Section 6.4.3). More precisely, lux expression in 
mice treated with 0.3% LPC 1 hr prior to nebulisation with GL67/pCIKLux was pooled 
(Section 6.4.3 and 6.4.5) and compared to lux expression in pooled PBS controls 
(n=18/group). However, even with these numbers the increase in gene transfer 
efficiency following treatment with 0.3% LPC still did not reach significance.    
 
In the nose, similar levels of lux expression were observed in mice pre-treated 10 min 
and 1 hr prior to nebulisation and both conditions led to increased (10 min: p<0.01, 1 hr: 
p<0.001) gene expression compared to controls (Figure 75b).  
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Figure 75: Luciferase expression in mouse lung and nose after LPC nasal instillation - 
reduced pre-treatment time 
Mice were pre-treated with 25 µl 0.3% LPC or PBS by nasal instillation 10 min and 1 hr prior to 
nebulisation of GL67/pCIKLux. A control group receiving no pre-treatment and untransfected 
(UT) mice were also included. 24 hrs post transfection the right lung (a) and the nasal 
epithelium (b) were harvested and assayed for luciferase activity. Data are expressed as mean ± 
SEM (n=6-8/group), * = p<0.05 UT compared to all other groups, ** = p<0.01 LPC (10 min) 
compared to PBS (10 min) and *** = p<0.001 LPC (1 hr) compared to PBS (1 hr). 
 
a 
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Reducing the pre-treatment time did not, therefore, result in an additional increase in 
gene transfer efficiency. Although, pre-treating the mice 1 hr prior to nebulisation 
resulted in a significant (p<0.001) increase in gene transfer as observed in the previous 
experiment (Section 6.4.3), the fold increase (~32-fold) was considerably lower than 
previously observed (~200-fold). 
 
6.4.6 Nasal instillation of LPC did not lead to histologically visible alterations in 
mouse lung  
Although 2% LPC had not resulted in any morphological changes in the lung (Section 
6.4.2), a more careful analysis of the lung was performed to assess if 0.3% and 1% LPC, 
shown to increase gene transfer efficiency, caused toxicity in the lung. Briefly, mice 
were pre-treated with 0.3% and 1% LPC followed by nebulisation of GL67/pCIKLux 
complexes as described in Section 6.4.3. 24 hrs post transfection the left lung was 
harvested, fixed in formalin and paraffin embedded. Sections were scored semi-
quantitatively for degree and area of haemorrhage and inflammation. The level of 
haemorrhage and inflammation in mice receiving LPC treatment was similar to mice 
receiving PBS and untransfected mice (Figure 76).  
 
Assessment of the respiratory epithelium in the lung revealed no signs of damage 
following treatment with LPC at 0.3% and 1% (Figure 77). 
 
6.4.7 Summary: C10 remained the lead candidate for subsequent studies  
To determine which of the assessed tight junction openers was the lead candidate for 
subsequent studies, I compared gene transfer efficiency obtained with LPC to the 
efficiency obtained for C10 in the previous chapter.   
 
Although LPC has enhanced GL67-mediated gene transfer to airway epithelium in vivo, 
the positive trend observed in the lung, the main target following nebulisation of the 
GTA, proved not to be significant. Furthermore, the actual fold increase in lux 
expression in both lung and nose was less than that observed for C10 (Table 3). Both 
TJ-openers caused the same level of toxicity following nasal instillation, and C10, 
therefore, remained the lead candidate for subsequent studies.   
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Figure 76: Histological assessment of mouse lung after LPC nasal instillation  
Mice were pre-treated with 25 µl 0.3% or 1% LPC or PBS by nasal instillation 1 hr prior to 
nebulisation of GL67/pCIKLux complexes. A control group receiving no pre-treatment and 
untransfected (UT) mice were also included. 24 hrs post transfection the left lung was harvested 
for histological assessment. Sections were scored semi-quantitatively for degree and area of 
haemorrhage and inflammation. Each dot represent one animal, with the mean score of the 
group shown as a horizontal line (n = 10/group). 
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Figure 77: Respiratory epithelium of mouse lung after LPC nasal instillation 
Mice were pre-treated with 25 µl 0.3% or 1% LPC or PBS by nasal instillation 1 hr prior to 
nebulisation of GL67/pCIKLux complexes. Untransfected (UT) mice were also included. 24 hrs 
post transfection the left lung was harvested for histological assessment. Sections were assessed 
for respiratory epithelial damage. a: 1% LPC, b: 0.3% LPC, c: PBS and d: UT. All images are 
representative of the respiratory epithelium in the lung for each group. Arrows indicate the 
airways and arrowheads indicate the respiratory airway epithelium (Original magnification: 
x20). 
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Lung 
TJ-opener Volume 
instilled 
[TJ-opener] Controls Fold increase in lux 
expression 
C10 25 µl 0.05 M PBS 
PBS 
 
No pre-treatment 
No pre-treatment 
3.0 (Fig. 56) 
3.3 (Fig. 58)  
 
~ 10 (Fig. 56) 
3.0 (Fig. 58) 
LPC 25 µl 0.3% PBS 
PBS 
 
No pre-treatment 
No pre-treatment 
3.1 (Fig. 73) 
1.9 (Fig. 75) 
 
2.8 (Fig. 73) 
1.3 (Fig. 75) 
 
 
 
Nose 
TJ-opener Volume 
instilled 
[TJ-opener] Controls Fold increase in lux 
expression 
C10 25 µl 0.2 M PBS 
 
No pre-treatment 
~ 200 (Fig. 58) 
 
~ 45 (Fig. 58) 
LPC 25 µl 0.3% PBS 
PBS 
 
No pre-treatment 
No pre-treatment 
~ 218 (Fig. 73) 
~ 32 (Fig. 75) 
 
~ 40 (Fig. 73) 
~ 12 (Fig. 75) 
 
 
 
Table 3: Fold increase in GL67-mediated gene transfer in mouse lung and nose after 
LPC nasal instillation  
The tables summarise the fold increase in GL67-mediated gene transfer in the lung and nose 
following nasal instillation of the TJ-opener. The mean lux expression in mice pre-treated (25 
µl) with the TJ-opener (0.3%, 0.05 M and 0.2 M) was compared to mice receiving vehicle 
(PBS) and no pre-treatment. 
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6.5 Discussion 
 
Although C10 and C12 were shown to increase non-viral mediated gene transfer to the 
murine lung and nose (see Chapter 5) the effect of the absorption enhancer 
lysophosphatidylcholine (LPC) on cationic liposome GL67-mediated gene transfer was 
assessed in vivo in an attempt to increase gene transfer efficiency even further. As LPC 
belongs to a different class of tight junction openers compared to C10 and C12 and has 
a different mode of action, there is a possibility that LPC may have a greater impact on 
gene transfer efficiency compared to the medium chain fatty acids. Here, LPC was 
delivered via nasal instillation as this delivery method had previously given promising 
results with both C10 and C12. Transfection was carried out by nebulisation of GL67 
complexed to a plasmid encoding the luciferase reporter gene. 
 
Published research assessing the effect of the biological detergent LPC on airway gene 
transfer is limited. Generally detergents have been used as absorption enhancers to 
increase uptake and bioavailability of small molecule drugs, which is believed to occur 
via manipulation of the tight junctional complex resulting in increased paracellular 
permeability. The research published to date has mainly focussed on the use of LPC to 
enhance viral gene transfer to the respiratory epithelium using VSV-G pseudotyped 
lentiviral vectors [291,348,353]. VSV-G pseudotyped lentiviral vectors transduce 
airway epithelium via receptors located predominantly on the basolateral surface of the 
cell. Effective transduction, therefore, requires the use of a TJ-opener to disrupt the tight 
junctions to allow the vector access to its basolateral receptors. Although LPC has not 
previously been shown to enhance non-viral gene transfer to the airway epithelium, pre-
treatment with the TJ-opener may also allow cationic liposome GL67 access to possible 
receptors on the basolateal membrane domain. In addition, LPC has been shown to act 
as a mucolytic agent [355] and may also decrease mucocilary clearance by acting as a 
cilia static agent [356], both of which may increase non-viral vector delivery and 
residence time resulting in enhanced gene transfer efficiency. 
 
First, LPC was delivered to the murine airway epithelium via nasal instillation and the 
effect on GL67-mediated gene transfer was assessed. Although not clinical applicable 
this delivery method was, as previously mentioned, chosen as C10 and C12 pre-
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treatment had resulted in enhancement of GL67-medaited gene transfer when 
administered via nasal instillation. In addition, several studies have shown that nasal 
instillation of LPC increased virus-mediated gene transfer to the murine nasal 
epithelium [291,348,357]. However, compared to my work the volume delivered to the 
murine airways via nasal instillation was significantly smaller in the studies mentioned 
above (4 µl/mouse). It is likely, that the TJ-opener was only inhaled into the nasal 
airways whereas inhalation of a larger volume, such as the volume used in my work (25 
µl/mouse), also reaches the lungs.  
 
In preparation for these experiments the maximum tolerable dose of the TJ-opener was 
determined. One out of three mice treated with the highest LPC concentration (2%) was 
culled as it remained unresponsive a few hours after treatment. The organs from the 
remaining two mice which initially appeared hunched and inactive were harvested for 
histological assessment 24 hrs post treatment. Although, the stomach of one mouse 
treated with LPC was partially inflated and the lungs were discoloured too, no 
histological changes were observed in that mouse or the two other mice treated with 
LPC. The changes in gross appearance observed (discolouring of the lung and inflation 
of the stomach) in the LPC treated mouse did, therefore, not translate to visible 
histological changes. The inflation of the stomach may be due to an effect of LPC on 
gut mobility resulting in accumulation of swallowed air in stomach and intestine, as 
previously observed for both C10 and C12 (Chapter 5). Discolouring of the lungs is 
likely to be due to haemorrhage. Interestingly, no signs of haemorrhage were observed 
when the lungs were assessed histologically, which may be because only a small 
number (n=s sections) of lung sections were assessed.  
 
Consistent with the data described in the previous two chapters (Chapter 4 and 5), here I 
showed that luciferase expression in both lung and nose was significantly raised in mice 
nebulised with GL67/pCIKLux complexes compared to untransfected controls. Again 
similar levels of gene expression were observed in each individual experiment 
indicating relatively little variation between different in vivo experiments. 
 
Consistent with published studies assessing the effect of 0.3% LPC on virus-mediated 
gene transfer to the murine nasal epithelium, I showed that nasal instillation of 0.3% 
LPC increased GL67-mediated gene transfer to both the murine lung and nose 
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[352,357]. However, compared to control mice the observed increase in gene transfer 
efficiency was only significantly different in the nasal epithelium. This may be due to 
pooling of the tight junction opener in the lung parenchyma following nasal instillation 
causing toxicity and thereby impairing gene transfer to the lung. However, when the 
lung was assessed histologically after 0.3% LPC treatment, no morphological changes 
or increased inflammation or haemorrhage was observed. It is possible that LPC may 
cause subtle cellular effects at a molecular level, which cannot be observed by standard 
histological assessment, but would explain the lower levels of gene transfer in the lung. 
Delivery of the maximum tolerable LPC concentration (1%) had no additional 
beneficial effect on gene transfer efficiency in neither the lung nor nose which was 
likely to be due to toxicity caused at the higher concentration. This finding is in 
consistence with published data by Stocker et al, who have shown that 1% LPC did not 
result in additional cells transduced following virus-mediated gene transfer the murine 
nose compared to 0.3% LPC [357].  
 
LPC is a detergent and higher concentrations may alter the cell membrane and reduce 
vector uptake or may cause cell shedding. Interestingly, shedding of the nasal 
epithelium has been reported when this tissue was treated with LPC via nasal instillation 
(4 µl/mouse) at high concentrations (1% and 2%) (D. Parsons, Department of 
Pulmonary Medicine, Women‟s and Children‟s Hospital, North Adelaide, Australia - 
personal communication) [352]. I delivered 1% LPC at a volume which is significantly 
larger than that previously reported and shedding of the epithelium in both nose and 
lung could, therefore, be expected. However, assessment of the respiratory epithelium in 
the lung revealed no signs of cell shedding following 1% LPC, which would explain the 
lack of effect on gene transfer efficiency observed. In addition, scoring the lung tissue 
for haemorrhage and inflammation revealed no differences between mice treated with 
1% and 0.3% LPC. Interestingly, several groups reported that 1% LPC can increase 
gene transfer in the mouse nose despite proof that the detergent at this concentration 
causes epithelial cell shedding [291,352,357]. This may be due to partial destruction of 
the epithelium in the nasal cavity or cells other than AEC being transfected.  
 
No studies have assessed the effect of LPC on non-viral gene transfer prior to my work. 
However, Rudolph et al have recently determined the effect of polidocanol on PEI-
mediated gene transfer in vivo [187]. Polidocanol is a detergent and therefore belongs to 
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the same class of tight junction openers as LPC, but in contrast to LPC does not convert 
into a non-toxic compound in vivo. In this study, 0.1% polidocanol was nebulised for 30 
min prior to nebulisation of PEI to the murine lung. Polidocanol was found to have no 
effect on gene transfer efficiency in the mouse lung. However, polidocanol was only 
nebulised for 30 min at a concentration of 0.1% in this study. Further optimisation of 
both concentration and length of nebulisation may, therefore, increase PEI-mediated 
gene transfer as these two variables have been found to have an impact on gene transfer 
efficiency in my work.  
 
In an attempt to increase further gene transfer efficiency, the LPC concentration was 
lowered from 0.3% to 0.1%. This concentration has previously been shown to increase 
lentiviral gene transfer in nasal epithelium in vivo [291]. Lowering the concentration of 
LPC may increase gene transfer efficiency further in the lung as a relatively low 
concentration of C10 and C12 was found to enhance gene expression levels most 
efficiently in this organ in the previous chapter (Chapter 5). In addition, I was interested 
to assess if lowering the concentration of LPC would result in a bell-shaped dose-
response curve as previously observed following C10 and C12 pre-treatment in the 
murine lung. However, lowering the concentration of LPC did not increase gene 
transfer in the lung compared to controls and in contrast to the previous experiment, the 
trend towards increased expression levels in the mouse lung following treatment with 
0.3% LPC was not reproduced. This is likely to be due to the extended time (2 hours 
versus 1 hour in the previous experiment) between delivering the TJ-opener and the 
GTA adopted in this experiment (see below). The peak in expression levels after a time 
interval of 1 hour is likely to reflect the time it takes for LPC to exhibit its effect on 
mediators such as PKC and RhoA, which have been suggested to mediate the effect of 
LPC.  
 
In the nasal epithelium, a significant increase in gene transfer was reproducibly 
observed in this experiment following treatment with 0.3% LPC, but the increase was 
approximately 10-fold lower compared to the previous experiment, which suggests that 
the effect of LPC is starting to diminish when the time interval between delivering LPC 
and the vector is extended from 1 hour to 2 hours. 0.1% LPC also increased gene 
transfer efficiency significantly in the mouse nose. However, there was a trend toward 
increased gene transfer following treatment with 0.3% compared to 0.1% LPC 
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suggesting that the lower dose may not be as efficient at disrupting tight junctions in the 
nose. These findings are supported by data published by Cmielewski et al, Limberis et 
al and Stocker et al [291,352,357] showing that delivery of 0.1% LPC to the murine 
nasal epithelium resulted in a significantly smaller VSV-G pseudotyped lentivirus-
mediated increase in gene transfer efficiency compared to 0.3% and 1% LPC, 
respectively.  
 
In an attempt to increase gene transfer efficiency further, I optimised the time interval 
between delivering LPC and nebulising the vector. In the previous chapter, I had found 
that the duration of this interval had an impact on gene expression following C10 
treatment and, as briefly mentioned above, the time interval between delivery of LPC 
and vector also affected gene expression indicating that the effect on tight junctional 
permeability is transient. Furthermore, personal communication with Dr. David Parsons 
(Department of Pulmonary Medicine, Women‟s and Children‟s Hospital, North 
Adelaide, Australia) revealed that optimisation of the time interval was essential in 
order to maximise the effect of LPC on adenovirus-mediated gene transfer efficiency in 
the murine nose. Importantly, optimisation by Dr. David Parsons and colleagues had led 
to maximum levels of gene expressions when LPC was delivered to the murine nasal 
epithelium 1 hour prior to administration of the viral vector [357]. 
 
As mentioned above, I first extended the time interval time from 1 hour, originally 
recommended by Dr. David Parsons based on his research, to 2 hours. However, the 
trend towards increased gene transfer in the lung previously seen following treatment 
with 0.3% LPC was not observed. Although significantly increased, gene expression 
levels were 10-fold lower in the nose after extension of the time interval to 2 hours. The 
increase in transfection efficiency observed in the nose maybe due to a higher dose of 
the tight junction opener reaching the nasal epithelium compared to the lung, thereby 
having an effect even though a sub-optimal time interval was employed. As the surface 
area of the nose is smaller compared to that of the lung, the dose reaching the nasal 
epithelium following nasal instillation of the tight junction opener is likely to be higher. 
Furthermore, it has previously been estimated that only 5% of the volume delivered by 
nasal instillation reaches the lung [340]. The remaining volume is either swallowed or 
lost in and around the nasal cavity, which further highlights that the actual dose 
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delivered to the pulmonary epithelium was likely to be lower compared to the dose 
delivered to the nasal epithelium. 
 
Finally, a time interval of 10 minutes was employed to assess if a shorter time period 
between delivery of LPC and the vector would increase gene transfer efficiency further. 
Similar levels of gene expression were obtained using a time interval of 10 minutes and 
1 hour. This result indicates that the effect of LPC on tight junctional permeability via 
intracellular mediators is optimal within 10 minutes. The fact that gene transfer 
efficiency observed is similar when the vector is delivered 1 hour after LPC could imply 
that the concentration of LPC does not diminish significantly during the first hour after 
delivery or that tight junctional permeability is increased for at least 1 hour after tight 
junctions are exposed to LPC even though the concentration of LPC diminishes. In vitro 
studies using cigarette smoke as a tight junction opener have shown that tight junctional 
permeability is increased for hours after exposure to cigarette smoke has ended 
depending on the experimental conditions [277,358]. These findings strongly suggest 
that tight junctions do not reform immediately after exposure to the tight junction 
opener has ended and, therefore, it is most likely that the effect of LPC on tight 
junctional permeability continues after the concentration has diminished.  
 
The positive trend observed previously when 0.3% LPC was delivered to the lung 1 
hour prior to vector administration was reproduced in the final experiment. To 
determine if the experiments had been underpowered, lux expression data from both 
experiments were pooled and compared to PBS controls. However, the increased gene 
transfer efficiency following treatment with 0.3% LPC did still not reach significance. 
Repeating the previous experiment by delivering 0.3% LPC 1 hour prior to the vector 
resulted again in a significant increase in gene expression levels in the nose. However, 
the fold increase was significantly lower this time, which is likely to be due to animal 
variability. Overall, these results highlight the importance of reproducing results in 
independent experiments, before drawing firm conclusions.   
  
Murine nasal tight junctional permeability was not assessed following treatment with 
LPC as this is a difficult and time consuming process. Instead as time was limited, I 
prioritised the assessment of the effect of my lead candidate (C10) on tight junctional 
permeability in the nose (see next chapter). These experiments were expected to show, 
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as proof-of-principle, that tight junctional integrity could be disrupted by a treatment 
with a tight junction opener.  
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6.6 Summary 
 
After careful optimisation the biological detergent LPC increased GL67-mediated gene 
transfer to the murine lung and nose in vivo. However, compared to C10 (see Chapter 5) 
LPC pre-treatment was less efficient resulting in a smaller increase in gene transfer at 
the optimal concentration. C10 was, therefore, selected as the lead candidate for 
additional experiments, aimed at assessing the effect of the tight junction opener on 
CFTR gene transfer and correction of the ion transport defect in CF knockout mice.  
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Chapter 7: The effect of the medium chain fatty acid C10 on lipid-            
mediated gene transfer in CF knockout mice 
 
 
7.1 Introduction  
 
Based on the previous assessment of the effect of EGTA, C10, C12 and LPC on GL67-
mediated gene transfer to the murine lung and nose, C10 was selected as the lead 
candidate as this tight junction opener had proven to be the most effective at enhancing 
gene transfer to the murine lung and nose. Here, I assessed if C10 treatment prior to 
GL67-mediated gene transfer could increase CFTR gene transfer to the murine nasal 
epithelium and correct the ion transport defect seen in CF knockout mice.  
 
7.1.1 CF mouse models  
Three years after cloning of the human CFTR gene in 1989 mouse models for CF were 
reported. CF knockout mice were generated using gene targeting in mouse embryonic 
stem cells [359]. Table 4 lists the mouse models created and divides them into the type 
of CF mutation they carry. Most CF mice have intestinal disease similar to CF patients 
often leading to malabsorption and intestinal obstruction with high pre- and post-
weaning mortality [359]. However, special fiber-free diets and administration of 
laxatives have helped to improve survival of the mice, although breeding and working 
with these fragile animals is difficult.   
 
Zhou et al corrected the intestinal abnormalities by using the rat intestinal fatty acid-
binding protein (FABp) promoter to express human CFTR in intestinal epithelial cells 
[231]. These double-transgenic CF mice are healthy and have a normal life expectancy. 
In contrast to standard female CF mice, which are generally infertile, the double-
transgenic mice described by Zhou et al have normal fertility. Homozygote CF mice 
can, therefore, breed and 100% of pubs are CF knockouts. This eliminates the need for 
genotyping and significantly reduces the cost of breeding.  
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Mouse Mutation Survival 
Gene knockouts   
Cftr
tm1Unc 
Exon 10 replacement <5% to maturity 
Cftr
tm1Cam
 Exon 10 replacement <5% to maturity 
Cftr
tm3Bay 
Exon 2 replacement 40% at 1 month 
Cftr
tm1Hsc
 Exon 1 replacement 25% to maturity 
Cftr
tm1Bay 
Exon 3 insertional mutagenesis 40% by day 7 
Cftr
tm1Hgu 
Exon 10 insertional mutagenesis  No significant reduction 
Cftr
tm1Hgu
/Cftr
tm1Unc
 Exon 10 insertional mutagenesis No significant reduction 
   
Introducing human 
mutations 
  
Cftr
tm2Cam ∆508 in exon 10 - replacement <5% to maturity 
Cftr
tm1Kth ∆508 in exon 10 - replacement 40% to maturity 
Cftr
tm1G551D 
G551D in exon 11 - replacement 27-67% by day 35 
Cftr
tm2Uth 
 R117H in exon 4 - replacement No significant reduction 
Cftr
tm3Uth 
Y122X in exon 4 - replacement 24% to maturity 
Cftr
tm2Hgu ∆508 in exon 10 - „hit and run‟ No significant reduction 
Cftr
tm2Hgu 
G480C in exon 10 - „hit and run‟ No significant reduction 
 
 
Table 4: CF mouse models 
Adapted from Dorin et al [359]. 
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Lung disease is the primary concern of CF individuals, physicians and research 
scientists. Therefore, the value of CF models in understanding the disease pathogenesis 
and in developing novel therapies is largely dependent upon the extent to which the 
models mimic lung disease seen in CF individuals. However, in general CF mice do not 
exhibit the characteristic features of human CF lung disease. Characterisation of the 
mouse models revealed little evidence of pulmonary abnormalities such as mucus 
plugging, neutrophil accumulation and bronchiectasis [360]. Furthermore, CF mice do 
not naturally become chronically infected with Pseudomonas aeruginosa, which is a 
key feature of human CF lung disease contributing to the overall lung inflammation 
observed. 
 
Although, CF mice generally do not mimic human CF lung disease, a mild human-like 
CF lung phenotype has been described in some CF mouse strains at baseline and after 
challenge with bacteria [360-362]. By challenging CF mice with Pseudomonas 
aeruginosa-laden agarose beads, mild chronic lung infection and host inflammatory 
responses can be achieved lasting approximately one month [362,363]. Interestingly, 
van Heeckeren et al have assessed whether CFTR gene transfer can improve survival 
and decrease host inflammatory response to lung infection with Pseudomonas 
aeruginosa, thereby correcting the lung phenotype [364]. In this study, CFTR was 
delivered to the murine CF airways by an adenoviral vector and 2 weeks later CF mice 
received intratracheal inoculation of Pseudomonas aeruginosa-laden agarose beads to 
establish chronic infection. Cytokine responses were similar in CFTR transfected mice 
and control groups. However, survival was significantly higher in mice pre-treated with 
adenovirus/CFTR or empty adenovirus compared to a controls group indicating that the 
inflammatory response to adenovirus itself contributes to the survival advantage.   
 
The lack of lung disease in CF mice is likely due to expression of alternative Ca
2+
-
activated chloride channels, which compensate for the lack of CFTR expression in the 
conducting airways [365]. Furthermore, the cell composition in mouse and human lung 
is different, which is likely to contribute to the difference in lung phenotype. Airway 
submucosal glands, for example, in the mouse are localised in the trachea whereas these 
glands extend into the bronchi in humans [360]. They are likely to play a role in the 
pathogenesis of human CF lung disease as the serous cells of the glands are the site of 
the highest levels of CFTR expression in the human airways and abnormalities of these 
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glands are one of the earliest findings in CF lung pathology [360,366]. Another striking 
difference is that the murine lung is predominately composed of non-ciliated columnar 
cells named Clara cells, whereas the human lung is lined by pseudostratified columnar 
epithelium consisting of ciliated and non-ciliated cells columnar cells, goblet cells and 
basal cells (Figure 78) [367,368]. 
 
Importantly, the murine nasal epithelium is also lined by pseudostratified columnar 
epithelium like the human lung and is, therefore, more comparable to human lung, than 
the mouse lung, which is an important aspect when selecting appropriate models for the 
development of CF gene therapy [360,367,369]. Furthermore, electrophysiological 
analysis of the nasal epithelium in CF mouse models has shown this tissue accurately 
replicates the defects observed in human CF airways; increased sodium absorption, 
reduced/absent CFTR-mediated chloride transport and no significant contribution to 
chloride transport by the alternative Ca
2+
-activated chloride channels (see Section 7.1.2 
below) [370]. The CF murine nasal epithelium, therefore, appears to be a good model 
for CF gene therapy studies.  
 
In addition to the described electrophysiological changes in the nasal epithelium, CF 
mice also show a reduction in periciliary liquid (PCL) height, which is likely to be 
central to CF pathophysiology (see Section 1.4.3) [372,373]. Depletion of PCL in CF 
allows the viscous mucus layer present on top of the PCL layer to collapse onto the cilia 
resulting in impaired mucociliary clearance of potential pathogens. This scenario 
ultimately results in mucus obstruction and chronic infection, the characteristics of CF 
lung disease. Furthermore, adherence of Pseudomonas aeruginosa to ciliated nasal 
epithelial cells of CF mice is increased compared to wild-type mice, which is also 
observed in humans [63,374]. Interestingly, Griesenbach et al assessed whether GL67-
mediated CFTR gene transfer was sufficient to correct these CF-related abnormalities in 
the mouse nasal epithelium [175]. The study showed no changes in PCL height at day 
14 post transfection and no reduction in bacterial adherence. However, at day 1 post 
transfection PCL height increased by approximately 60% towards control values. 
Interestingly, power calculations revealed that the experiment had only 15% power to 
determine whether this difference was significant and to achieve the generally accepted 
power of 80%, group sizes of >100 mice would have been required.  
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Figure 78: Respiratory epithelium of human lung, mouse nose and mouse lung 
Schematic drawing of pseudostratified respiratory epithelium containing ciliated and non-
ciliated cells, goblet cells and basal cells (a). Human pseudostratified respiratory epithelium 
from lung biopsy (b), mouse nasal pseudostratified respiratory epithelium (c) and mouse lung 
respiratory epithelium consisting primarily of non-ciliated columnar cells (d). The arrows 
indicate non-ciliated columnar cells. The schematic drawing is adapted from Dahl et al [371]. 
Non-ciliated 
cell 
Goblet cell 
Ciliated cell 
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Although there are significant differences between CF human and CF mouse, the mouse 
nasal epithelium has, for reasons described above, been widely used for CFTR gene 
therapy studies (see Section 7.1.3 below). The gut-corrected CF knockout mouse (FABp 
mouse) is often the preferred CF mouse model to work with as the characteristic 
intestinal disease has been circumvented and the mouse, therefore, is healthy and has a 
normal lifespan [231]. Importantly, the characteristic electrophysiological differences in 
the nasal epithelium, which are also observed in CF patients, are retained in these mice 
[370]. 
 
7.1.2 Nasal potential difference measurements 
As previously mentioned CF knockout mice show the characteristic CF ion transport 
defect across the nasal epithelium which means they have absent or low chloride 
secretion and a high sodium absorption. Correction of these ion transport differences 
may, therefore, be a good readout to assess efficacy of CFTR gene transfer.  
 
Nasal potential difference (NPD) measurements are used to assess the ion transport, i.e. 
the voltage, across the nasal epithelium and are a valuable and reliable assay to 
discriminate between CF and non-CF mice [375,376]. In addition, it can be used as an 
endpoint assay to determine the functional effect of CFTR following CFTR gene 
transfer to the murine nasal epithelium. To assess NPD in mice, a solution containing 
the ENaC channel blocker amiloride is perfused into the nasal cavity, which leads to a 
drop in NPD in both CF and non-CF mice. Compared to non-CF mice, the drop is more 
pronounced in CF mice as these mice display a higher baseline NPD due to increased 
sodium absorption (Figure 79). Subsequently, the nasal epithelium is perfused with a 
low chloride solution containing amiloride generating a driving force for chloride 
secretion through the CFTR channel in non-CF mice. This is visible by 
hyperpolarisation of the NPD, which is not observed in CF mice. Amiloride is added to 
the low chloride solution to assure that the described hyperpolarisation seen in non-CF 
mice is due to chloride secretion and not sodium absorption through ENaC channel 
[129]. 
 
The technique developed to measure NPD in mice is similar to the method used in 
humans and as ion transport is similar in the two species, the same profile is created in 
humans as described above for mice.  
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Figure 79: Nasal potential difference measurements in CF and non-CF mouse nasal 
epithelium  
Following measurement of basal NPD (BL - baseline), a solution containing amiloride (Am) is 
perfused into the nasal cavity, which leads to a drop in NPD in CF and non-CF mice. 
Subsequently the nasal epithelium is perfused with a low chloride solution (LC), which 
generates a driving force for chloride secretion and increased NPD in non-CF but not in CF 
mice. The figure is taken from Griesenbach et al [129]. 
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As for mice, the measurements discriminate easily between CF and non-CF subjects due 
to development of robust protocols [377,378]. In CF patients, potential difference (PD) 
measurements are performed in the nose for diagnostic purposes. In addition, PD 
measurements in both nose and lung are used as endpoints in clinical trials assessing the 
effect of CFTR gene therapy.  
 
PD measurements in the mouse nose are challenging and technically difficult even for 
an experienced operator as small movements of the catheter, used to perfuse the 
solutions into the nasal cavity, markedly influence the recording. Furthermore, 
measurements are sensitive to epithelial damage, which can easily occur, especially for 
the non-experienced operator, when inserting the catheter into the nose. To be able to 
interpret the NPD measurements, high quality traces are crucial. Interestingly, a study 
has found that only 80% of traces were interpretable for the low chloride response in CF 
mice whereas this number was close to 100% in wild-type mice [370]. This was likely 
to be due to the fact that an increase in chloride secretion is easy to recognize in wild-
type mice, whereas the precise point of change of the CF PD is harder to see, especially 
if the trace is slightly noisy. In addition to obtaining high quality traces, accurate 
scoring of the responses is also important. The above study also found that both intra- 
and inter-operator variability for scoring baseline PD was extremely low. In contrast, 
both intra- and inter-operator variability for the low chloride response was markedly 
higher despite using experienced operators and strict scoring guidelines, which possibly 
reflects the difficulty interpreting the low chloride response in CF mice [370].  
 
Finally, power calculations indicate that large animal numbers are required to detect 
small changes in baseline PD and low chloride response [370]. NPD measurements 
may, therefore, have limited value when assessing therapies with anticipated small 
treatment effects. As large animal numbers are not always practical, small changes in 
measurements are likely to remain undetected, which is a concern as low levels of 
CFTR function may ameliorate CF lung disease [25,124,125]. 
 
7.1.3 Clinical and pre-clinical studies using potential difference as an endpoint 
Clinical and pre-clinical CFTR gene therapy studies using PD as an endpoint are 
described below. 
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In clinical trials NPD measurements have been used as the most important endpoint 
assay after CFTR gene transfer. The majority of gene transfer studies in CF patients 
have employed viral vectors and partial correction of the chloride transport defect has 
been observed in some of these studies [133,379] while others have not been able to 
detect any restoration of the ion transport [377,380,381]. Similarly variable results were 
obtained in studies assessing non-viral vectors. However, the two studies, in which 
GL67 was delivered to the nasal epithelium via infusion and aerosol, respectively, both 
showed a statistical significant correction of the chloride transport [176,379]. 
Interestingly, GL67-mediated gene transfer to the lungs of CF patients resulted in about 
25% restoration of the chloride transport, which was significantly different from the 
placebo group [176]. 
 
In pre-clinical studies, partial correction of the chloride transport defect has been 
observed following treatment with viral vectors such as recombinant Sendai virus, 
lentivirus and adenovirus carrying the CFTR transgene [213,291,382]. A limited 
number of studies have reported correction of the chloride ion transport defect in CF 
mice after non-viral gene transfer. Alton et al showed partial correction of the chloride 
response in murine nasal and tracheal epithelium in 5 out of 6 and 5 out of 7 mice, 
respectively, when pCFTR complexed to cationic liposome DC-Chol/DOPE was 
delivered by nebulisation. However, the change in chloride response observed proved 
not to be significant [170]. These findings were supported by Hyde et al, who also 
showed partial, but non-significant, correction of the chloride transport in the CF 
murine tracheal epithelium following tracheal instillation of DC-Chol/DOPE complexed 
to pCFTR [169]. Interestingly, partial correction of the chloride transport in nasal 
epithelium of CF mice has also been observed following transfection with pCFTR 
complexed to a peptide ligand, which is known to target the serpin-enzyme complex 
receptor (sec-R) located on the apical surface of airway epithelial cells [201]. In 
contrast, Griesenbach et al have not been able to detect changes in the low chloride 
response in the nasal epithelium of CF knockout mice after gene transfer with GL67 
complexed to pCFTR [175]. However, the assay was only powered to detect changes of 
more than 30% towards wild-type.  
 
A likely reason why the above mentioned studies did not show significant partial 
correction of the chloride transport after non-viral-mediated CFTR gene transfer is 
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insufficient gene transfer efficiency. Tight junction openers may increase non-viral gene 
transfer efficiency and thereby allow partial correction of the chloride transport defect in 
CF mice following non-viral gene transfer. However, the few studies assessing the 
effect of tight junction openers on non-viral gene transfer in vivo did not determine the 
functional effect post CFTR gene transfer.  
 
Importantly, the negative functional data obtained by Griesenbach et al following 
GL67-mediated CFTR gene transfer are inconsistent with experience in humans, where 
transfection with this non-viral vector has lead to partial correction of the nasal chloride 
transport [175,176,379]. These data suggest possible species-specific differences in 
response to GL67 and the CF knockout mouse may therefore not be a representative 
model in which to assess gene transfer efficiency to human airway epithelial cells. 
However, as this model is the only readily available CF knockout model it still is a 
valuable tool as long as its limitations are recognised.   
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7.2 Aims 
 
To assess if increased gene transfer achieved after C10 pre-treatment in nasal 
epithelium (Chapter 5) is sufficient to allow correction of ion transport defect in CF 
mouse nasal epithelium.  
 
For this purpose delivery of the tight junction opener to the nasal epithelium was first 
optimised and baseline NPD measurements were carried out to assess the effect of C10 
treatment on tight junction permeability. In addition, histological assessment of the 
nasal respiratory epithelium was performed. Importantly, I assessed if the previously 
observed increase in gene expression following C10 treatment would allow correction 
of the CF ion transport defect and increase vector-specific CFTR mRNA expression 
levels in CF knockout mice. Finally, an attempt was made to determine which types of 
cells were transfected after non-viral gene transfer 
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7.3 Materials and Methods  
 
7.3.1 C10 stock solutions 
0.05 M and 0.2 M sodium caprate (C10) stock solutions were made up by dissolving 
0.0971 g and 0.3884 g in a total of 10 ml sterile PBS (-CaCl2/-MgCl2). The pH in the 
final stock solutions was pH 7.7 and pH 8.8, respectively. As previously described 
(Section 5.4.1), stock solutions could not be adjusted to physiological pH without 
causing precipitation of C10 (data not shown). Stock solutions were diluted with PBS (-
CaCl2/-MgCl2) to final concentrations as indicated below.  
 
7.3.2 Maximum tolerable concentration of C10 for nasal perfusion  
To assess the maximum tolerable concentration of C10 following perfusion of the TJ 
opener, FABp mice (approximately 12 weeks old females/males, n=3/group) were 
perfused for 15 min (100 µl/mouse) with 0.0125 M (pH 7.1), 0.05 M or 0.2 M C10 or 
PBS as described in Section 2.4.1. Appropriate doses of Ketaset/Domitor were used to 
anaesthetise the mice during the procedure (see Section 2.3). All mice were monitored 
carefully for the following 24 hrs and culled if signs of side-effects appeared.  
 
7.3.3 GL67/pDNA delivery by nebulisation or nasal perfusion 
GL67 was delivered to the nasal epithelium by nasal perfusion or nebulisation to assess 
the effect of different delivery methods on gene transfer efficiency. As described in 
Section 2.4.1 and 2.4.3, C57Bl/6 mice (approximately 12 weeks old females and males, 
n=16-30/group) were nebulised for 1 hr with GL67/pCIKLux complexes (10 ml, 2.5 
mg/ml) or perfused for 15 min with GL67/pCIKLux complexes (100 µl/mouse, 0.8 
mg/ml). Untransfected mice were included. For nasal perfusion Ketaset/Domitor was 
used as an anaesthetic and immediately after the procedure the antidote was given (see 
Section 2.3). 24 hrs post transfection mice were culled and the nasal epithelium was 
harvested as described in Section 2.5.1, snap-frozen in liquid nitrogen and stored at -
80ºC for detection of luciferase activity. 
  
7.3.4 C10 delivery by nasal instillation or nasal perfusion  
Delivery of C10 to the nasal epithelium by nasal instillation was compared to delivery 
by nasal perfusion. Briefly, FABp mice (approximately 12 weeks old females and 
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males, n=8/group) were perfused with C10 at 0.0125 M or 0.05 M for 1 hr (400 
µl/mouse) and 15 min (100 µl/mouse), respectively. For comparison, FABp mice 
(approximately 12 weeks old females and males, n=8/group) were treated with 25 µl 0.2 
M C10 or PBS (-CaCl2/-MgCl2) via nasal instillation. 2 hrs after delivering C10 or PBS, 
GL67/pCIKLux was delivered to all mice via nasal perfusion for 15 min (100 µl/mouse, 
0.8 mg/ml) (see Section 2.4.1). Mice were anesthetised with Ketaset/Domitor and the 
antidote given at the end of the procedure as described in Section 2.3. Mice pre-treated 
with C10 via nasal perfusion received no antidote in between perfusions. 24 hrs post 
transfection mice were culled and the nasal epithelium harvested for detection of 
luciferase activity (see Section 2.5.1 and 2.5.2). 
 
7.3.5 C10 nasal instillation prior to GL67-mediated reporter gene transfer in 
mouse nose  
FABp mice or C57Bl/6 mice (approximately 12 weeks old females and males) were 
pre-treated via nasal instillation with 25 µl C10 (0.05 M or 0.2 M) or PBS. 2 hrs post 
treatment mice were anesthetised with pentobarbital (see Section 2.3 for details) and the 
nasal epithelium was perfused with GL67 complexed to pCIKLux (n=8-10/group) or 
pEGFP-N1 (n=4/group) for 15 min (100 µl/mouse, 0.8 mg/ml) and 1 hr (400 µl/mouse, 
0.2 mg/ml), respectively (see Section 2.4.1 for details). 24 hrs or 48 hrs post transfection 
mice were culled or exsanguinated using Hypnorm/Hypnovel as described in Section 
2.3. The left nostril was brushed for mRNA analysis as described in Section 7.3.10 and 
the remaining nasal epithelium was harvested and either assayed for luciferase activity 
or assessed for GFP fluorescence via direct visualisation as described in Section 7.3.12. 
Control mice pre-treated with 0.2 M C10 or PBS was also perfused with GL67 
complexed to the control plasmid pCIKempty for 1 hr (400 µl/mouse, 0.2 mg/ml). 
 
7.3.6 Tight junction permeability in mouse nose after C10 nasal instillation 
To assess the effect of C10 treatment on tight junction permeability in the nasal 
epithelium in vivo, mice were treated with C10 and baseline NPD measurements carried 
out (see Sections 7.3.9 for details). First, pre-treatment baseline NPD measurements 
were performed on FABp mice (approximately 12 weeks old females and males, n=4-
8/group) as described in Section 7.3.9. The day after mice were treated with 25 µl C10 
(0.05 M or 0.2 M) or PBS by nasal instillation and baseline NPD measurements were 
again performed at the following time points post treatment; 30 min, 2 hrs, 4 hrs, 24 hrs, 
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48 hrs, 5 days and 14 days. Mice receiving C10 and PBS treatment were exsanguinated 
using Hypnorm/Hypnovel (see Section 2.3) immediately after measuring baseline NPD 
at 2 hrs, 48 hrs and 14 days post treatment. The nose was harvested and processed for 
histological assessment as described in Section 7.3.11 (n=4/group). Untreated mice 
were included as controls. All other mice were culled immediately after the final 
baseline NPD measurement. 
 
7.3.7 C10 nasal instillation prior to GL67-mediated CFTR gene transfer in mouse 
nose  
To assess if the increase in gene expression observed after C10 treatment would 
increase CFTR gene transfer efficiency, FABp mice (approximately 12 weeks old 
females and males, n=8-11/group) were pre-treated via nasal instillation with 25 µl C10 
(0.05 M or 0.2 M) or PBS 2 hrs prior to perfusion with GL67 complexed to pCIKCFTR, 
pCIKempty or pGM169 for 1 hr (400 µl/mouse, 0.2 mg/ml) (see Section 2.1.1 for 
details on plasmids). During the procedure mice were anesthetised with Pentobarbital 
(see Section 2.3) and 48 hrs post transfection NPD measurements were carried out on 
mice treated with 0.05 M C10 as described in Section 7.3.9. Immediately after the mice 
were exsanguinated using Hypnorm/Hypnovel (see Section 2.3) and the left nostrils 
brushed for mRNA analysis as described in Section 7.3.10. To control for potential 
changes in mRNA levels due to the preceding NPD measurement a group of treated 
mice were only brushed for mRNA analysis. Mice receiving 0.2 M C10 treatment were 
exsanguinated 14 days post transfection and the left nostrils brushed for mRNA 
analysis. Untransfected mice were included as negative controls.  
 
7.3.8 Reporter gene expression from long lasting CEFI promoter/enhancer in 
mouse nose 
To assess gene expression from the long lasting CEFI promoter/enhancer (see Section 
2.1.1 for details) in the murine nose, C57Bl/6 mice (approximately 12 weeks old 
females and males, n=8/group) were anesthetised with Hypnorm/Hypnovel (1:1:4) and 
perfused as described in Section 2.4.1 with GL67 complexed to pGM144 (see Section 
2.1.1 for details about plasmids) for 15 min (100 µl/mouse, 0.8 mg/ml). Immediately 
after the procedure mice were given the appropriate antidote (see Section 2.3). Control 
mice were perfused with GL67/pCIKLux as described in Section 2.4.1. 24 hrs, 7 days 
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and 14 days post transfection all mice were culled and the nasal epithelium harvested 
for detection of luciferase activity.  
 
7.3.9 Mouse nasal potential difference measurements  
All murine NPD measurements were performed by a technician (R. Farley, Department 
of Gene Therapy, Imperial College London, UK) as previously described [370]. FABp 
mice were anesthetised with Hypnorm/Hypnovel (1:1:2) (see Section 2.3 for details) 
and placed on a heated board in the supine position. NPD measurements were made 
using a double-lumen polythene catheter (total outer diameter 0.5 mm). One lumen, 
filled with HEPES Krebs buffer (140 mM NaCl, 6 mM KCl, 1 mM MgCl2, 2 mM 
CaCl2, 10 mM glucose, 10 mM HEPES, pH 7.4) throughout the procedure, served as the 
measuring electrode. It was connected via a calomel electrode to an analogue to digital 
converter (Logan Research Ltd, Rochester, UK) which, in turn, was connected to a 
computer. The second lumen containing the appropriate perfusate was connected to a 
peristaltic pump set at a rate of 25 µl/min (Pharmacia, Cambridge, UK). As a reference 
electrode a Venflon catheter (20 gauge) filled with HEPES Krebs buffer was inserted 
i.p. To test the circuit a buccal PD was obtained by inserting the double lumen catheter 
filled with HEPES Krebs buffer into the mouth (acceptable values; -10 to -20 mV). The 
catheter was then inserted 3 mm into the mouse‟s nostril. Baseline NPD measurements 
were measured and recorded as a mean value after the PD had stabilised for at least 30 
sec. After measuring the baseline NPD, HEPES Krebs buffer containing 0.1 mM 
amiloride (HKA) was perfused onto the nasal epithelium for 5 min. The difference 
between baseline NPD and post amiloride NPD was defined as the amiloride response 
(expressed as delta NPD (mV)). Importantly, the catheter lumen was primed to the tip 
with HKA and no lag period was therefore observed from starting perfusion to 
observing a response. For measuring low chloride NDP, the perfusate was changed to a 
low chloride HKA solution (1 mM MgCl2, 2 mM CaCl2, 10 mM glucose, 10 mM 
HEPES, 0.1 mM amiloride, 140 mM sodium gluconate, 6 mM potassium gluconate) 
and perfused for 8 min. A response was observed after approximately 2 min, the time it 
took the solution to pass through the catheter and reach the nasal epithelium. The 
difference between the amiloride response and the maximal stable low chloride NPD 
was defined as the low chloride response (expressed as delta NPD (mV)). Recovery 
mice were placed in a box on a heat board until fully recovered. Otherwise, mice were 
culled immediately after the procedure. 
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7.3.10 mRNA analysis in mouse nose (Real-time RT-PCR) 
First, the facial skin was removed to slice off the cartilage at the tip of the nose. To 
harvest the nasal respiratory epithelium an inter-dental brush (Curaprox CPS 07, Dent-
o-Care Ltd., London, UK) was inserted 2 mm into the left nasal cavity and then rolled 
along the septum. The cells were resuspended in 350 µl RLT buffer (Qiagen Ltd., West 
Sussex, UK) containing 1% β-mercaptoethanol (Sigma-Aldrich Com. Ltd., Poole, UK) 
and spun through a QIAshredder spin column (Qiagen Ltd., West Sussex, UK) for 2 
min (13 793 g, 4ºC). RNA extraction was carried out using the Qiagen RNeasy Mini kit 
(Qiagen Ltd., West Sussex, UK) with „on column‟ DNAse digestion. Briefly, 350 µl 
70% ethanol was added to the lysate and the mixture transferred to the RNeasy mini 
column followed by centrifugation for 15 sec at 9875 g (4ºC). The column was then 
washed with 350 µl RW1 buffer by centrifugation for 15 sec at 9875 g (4ºC) followed 
by addition of 80 µl DNase I incubation mix (10 µl DNase I + 70 µl Buffer RDD) for 30 
min at room temperature. Another wash step was carried out prior to adding 2 x 500 µl 
RPE buffer and centrifuge for 15 sec and 2 min, respectively (9875 g, 4ºC). Finally, 30 
µl RNase-free water was added directly on to the silica membrane prior to 
centrifugation for 1 min at 9875 g (4ºC). The eluate was then added back onto the 
membrane and an additional centrifugation was carried out. Further, „in solution‟ DNase 
treatment was performed on all RNA extracted samples using the Ambion DNA-free
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kit (Ambion Ltd., Huntingdon, UK). Briefly, 5 µl rDNase mastermix (3 µl 10x DNase I 
buffer + 2 µl rDNase) was added to the eluate containing the extracted RNA and 
incubated for 30 min at 37ºC. 5 µl resuspended DNase inactivation reagent was then 
added prior to incubation for 2 min at room temperature. Finally, the mixture was 
centrifuged for 1.5 min (13 793 g, 4ºC) and the supernatant subsequently quantified for 
levels of endogenous and vector-specific CFTR mRNA by real-time quantitative 
multiplex TaqMan reverse transcriptase polymerase chain reaction (RT-PCR) using the 
ABI PRISM 7700 Sequence Detection System and Sequence Detector v1.6.3 software 
(Applied Biosystems, Warrington, Cheshire, UK).  
 
The TaqMan analysis was performed by a collaborator (S. Sumner-Jones, Gene 
Medicine Group, University of Oxford, UK) as previously described by Griesenbach et 
al [370]. Briefly, levels of endogenous and vector-specific CFTR mRNA were 
quantified by real-time quantitative TaqMan RT-PCR. The following primers were 
designed and used (F, R, P refer to forward, reverse and fluorogenic probe oligos; where 
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a separate primer was used for cDNA synthesis, this is indicated as R2); murine Cftr F 
(5'-AGC CAG CTT TAT CTC CAA ACT CTT C-3'), murine Cftr R (5'-GCT GTC 
TGT ACC CTT TCC TCA AA-3'), fluorogenic murine Cftr P (5'-VIC-TCA GCT GGA 
GCA CAG C-3'), pGM169 R2 (5'- CCA GCT GAA GAA CAG CTT GCT–3'), 
pGM169 F (5'-TCT CCC TCC TGT GAG TTT GGT T-3'), pGM169 R (5'-GCT CAC 
CAC AGA GGC CTT CT-3'), fluorogenic pGM169 P (5'-FAM-CCA GCT GAA GAA 
CAG CTT GCT-TAMRA-3'), pCIKCFTR R2 (5'-GCT CGT CGT ATT AAG TAC 
TCT AGC-3'), pCIKCFTR F (5'-TGA GGC ACT GGG CAG GTG T-3'), pCIKCFTR R 
(5'-GTC GTA TTA AGT ACT CTA GCC TTA AGA-3') and fluorogenic pCIKCFTR P 
(5'-FAM-CCA CTC CCA GTT CAA TTA CAG C-3'). Ribonucleic acid (RNA) was 
reverse-transcribed and triplicate PCR (polymerase chain reaction) reactions were 
carried out for each sample. In vitro transcribed synthetic RNA fragments 
corresponding to the fully spliced mRNA were quantified and used to generate standard 
curves prior to mRNA quantification [383]. 
 
Controls included no template control and no-reverse transcriptase (RT-) control, where 
total RNA or MultiScribe reverse transcriptase and RNase inhibitor were omitted from 
the reverse transcriptase reaction, respectively. 
 
The number of copies of plasmid-derived CFTR mRNA and endogenous Cftr mRNA 
were calculated from standard curves of in vitro transcribed RNA fragments that 
surrounded the amplified region [383]. The amount of plasmid-derived CFTR mRNA 
was expressed as a percentage of the endogenous Cftr mRNA detected, such that 
samples containing equivalent amounts of each mRNA are expressed as 100% 
vector/endogenous mRNA. Samples plotted as undetectable were 1) positive for 
endogenous Cftr mRNA and negative for vector-specific CFTR mRNA or 2) positive 
for endogenous Cftr mRNA and positive for vector-specific CFTR mRNA, but neither 
of the amounts was quantifiable.  
 
7.3.11 Histological assessment of mouse nose  
Following exsanguination, the facial skin, lower jaw and tongue were removed. The 
nose was then harvested by cutting down through the skull behind the eyes avoiding any 
crush injury. Fixation was carried out in 10% formalin for 2-3 days followed by 
decalcification in 10% formic acid (Sigma-Aldrich Com. Ltd., Poole, UK) for 4-5 days. 
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The cheeks, teeth and tissue behind the eyes were trimmed off before embedding the 
nose in paraffin. Sections were cut and stained by a technician (N. Cornish, Department 
of Gene Therapy, Imperial College London, UK) as follows; starting from the tip of the 
nose, approximately 5 sections (5 µm thick) were cut 250 µm apart (Shandon Finesse 
325 microtome, ThermoFisher Scientific, Waltham, USA) and stained with H&E. The 
sections corresponding to approximately 2.5 mm into the nose were assessed in a 
blinded fashion (1 section/mouse). In detail, the respiratory airway epithelium lining 
both sides of the nasal septum was scored semi-quantitatively for degree of denuded 
epithelium (0%, 25%, 50%, 75% and 100%) using a light microscope (Zeiss Axioskop 
2+, Zeiss, Welwyn Garden City, UK) equipped with x20 magnification objective.  
 
7.3.12 Direct visualisation of GFP fluorescence in mouse nose 
First, mice were exsanguinated using Hypnorm/Hypnovel. The nose was then harvested 
as described in the previous section and fixed in 4% paraformaldehyde (PFA) (Sigma-
Aldrich Com. Ltd., Poole, UK) for 2 days. Decalcification was carried out in 20% 
EDTA, pH 7.4 (Sigma-Aldrich Com. Ltd., Poole, UK) for 7 days followed by 
cryopreservation in 15% sucrose for 2 days at 4ºC. The cheeks, teeth and tissue behind 
the eyes were trimmed off before mounting the nose in optimal cutting temperature 
(OCT) compound (Bayer PLC, Newbury, UK). Sections were cut and stained by a 
technician (N. Cornish, Department of Gene Therapy, Imperial College London, UK) as 
follows; Approximately 7 µm sections were cut (Bright Cryostat OTF/AS/LT, Bright, 
Huntingdon, UK) at 5 levels into the nose. For each level 2 sections were cut; 1 section 
was stained with H&E and the other was mounted on to glass slides in Vectashield 
containing DAPI. All sections were examined for GFP expressing fluorescent cells 
using a Zeiss Microscope (Zeiss Axioskop 2+, Zeiss, Welwyn Garden City, UK) 
equipped with a FITC filter (excitation 490 nm, emission 565 nm) and x20 
magnification objective.  
 
7.3.13 Statistical analysis 
Results are presented as mean ± SEM and as dot plots with the mean of the group 
shown as a horizontal line. Data was compared using ANOVA plus a Bonferroni 
correction or independent sample t-test where appropriate. Where necessary, raw data 
were log10 transformed to ensure normal distribution (Kolmogorov-Smirnov normality 
test was performed) and equal variances between groups. A non-parametric Mann 
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Whitney test or a Kruskal-Wallis with Dunn‟s correction was carried out when the 
assumptions were not met after transformations. The null hypothesis was rejected at 
p<0.05.  
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7.4 Results  
 
In this chapter, I aimed to maximise further gene transfer to the mouse nasal epithelium 
by combining efficient delivery of C10 with the most efficient delivery of GL67/pDNA 
complexes. The optimal conditions were then used to assess correction of ion transport 
defects in nasal epithelium of CF knockout mice.   
 
7.4.1 Problems with anaesthesia were encountered  
In an attempt to maximise gene transfer to the murine nasal epithelium, GL67/pDNA 
complexes were administrated by nasal perfusion (see Section 7.4.2 below for details). 
Nasal perfusion is a standard GTA delivery method within my Department and we 
generally use the anaesthetic Ketaset/Domitor for nasal perfusion studies in both wild-
type and CF knockout mice because it is long lasting, well tolerated and an antidote, to 
ensure quick recovery from anaesthesia, is available. In contrast to other general 
anaesthetics, mice anaesthetised with Ketaset/Domitor show no twitching of the nose 
when the catheter, used for nasal perfusion, is inserted into the nasal cavity. Insertion of 
the catheter into the nasal cavity is thereby made easier for the operator, which greatly 
reduces the risk of damaging the nasal epithelium.  
 
The initial experiments, assessing the effect of C10 in the nose, were, therefore, carried 
out using Ketaset/Domitor. However, surprisingly approximately 25% of FABp mice 
anesthetised with Ketaset/Domitor showed signs of discomfort after the procedure. 24 
hrs post-treatment an orange coloured discharge from the intestine and a slightly 
inflated stomach were observed in the majority of the mice. 48 hrs after anaesthesia 
approximately 75% of FABp anaesthetised with Ketaset/Domitor had died. As mice 
pre-treated with C10 or PBS displayed these side-effects, C10 could not be the cause. In 
order to assess if the side-effect were due to the combination of Ketamine/Dormitor and 
Metofane, used to anaesthetise the mice with for nasal instillations, mice were 
subsequently anaesthetised without receiving additional pre-treatment. Side-effects 
were still encountered in mice receiving no pre-treatment and, therefore, I concluded 
that the side-effects were solely due to the anaesthetic Ketamine/Dormitor. The chief 
veterinarian at Imperial College London decided, in line with the UK Home Office 
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Animals Act 1986, that this anaesthetic could no longer be used on recovery FABp 
mice.  
 
Due to the side-effects, which occurred in FABp mice anaesthetised with 
Ketaset/Domitor, a new general anaesthetic had to be used for nasal perfusions. The 
anaesthetic Hypnorm/Hypnovel was, therefore, tested in FABp mice. This anaesthetic is 
routinely used in CF mice for the purpose of exsanguination. It had not previously been 
used to anesthetise the mice prior to performing nasal perfusions. Briefly, FABp mice 
were treated with C10 or PBS via nasal instillation prior to nasal perfusion of 
GL67/pDNA for 1 hr. For nasal instillation of C10, mice were anaesthetised with 
Metofane as described in Section 2.3. For nasal perfusion, Hypnorm/Hypnovel was 
mixed with water at a ratio of 1:1:4 as 25% of CF-knockout mice anesthetised with the 
standard ratio of 1:1:2 died before starting the perfusion. Approximately 30% of the 
mice pre-treated with C10 or PBS died during the perfusion due to respiratory 
difficulties and all remaining mice also showed respiratory distress.  
 
Although, the anaesthetic was topped up several times during the 1 hr perfusion severe 
twitching of the nose was observed resulting in loss of the nasal catheter used for 
perfusion. Interestingly, the degree of respiratory difficulties observed, was not seen to 
the same extend in FABp mice receiving no pre-treatment (i.e. nasal instillation of C10 
or PBS) prior to nasal perfusion of GL67/pDNA complexes, indicating that the 
combination of Metofane and Hypnorm/Hypnovel was causing the side-effects. To 
avoid these effects, I attempted to use Hypnorm/Hypnovel for nasal instillation of C10 
instead of Metofane. Interestingly, the degree of respiratory difficulties during nasal 
perfusion of GL67/pDNA complexes was markedly reduced. However, delivery of C10 
via nasal instillation using Hypnorm/Hypnovel was significantly impaired as respiratory 
function was suppressed making correct dosing of the mice difficult. Furthermore, 
twitching of the nose resulted repeatedly in loss of the catheter during the nasal 
perfusion procedure and additional administration of Hypnorm/Hypnovel did not avoid 
this happening.  
 
Due to the problems encountered with Hypnorm/Hypnovel, I decided to test a further 
anaesthetic Pentobarbital. An overdose of Pentobarbital is frequently used to cull 
animals (50 mg/ml, 200 µl administered per 20 g mouse), but when adjusted 
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appropriately (15 mg/ml, 80 µl administered per 12 g mouse) the anaesthetic is also 
suitable for recovery procedures (see Section 2.3 for details). Approximately 15-20% of 
FABp mice died either during the perfusion due to respiratory difficulties or within the 
15 hrs after anaesthesia. The majority of mice showed respiratory distress during the 
entire perfusion, however, this could be relieved by gentle massaging the chest. In 
contrast to Hypnorm/Hypnovel no twitching of the nose was observed when using 
Pentobarbital, which made insertion of the catheter into the nose easy and most 
importantly the catheter was maintained in the nasal cavity during the perfusion. 
Furthermore, the combination of Metofane for nasal instillation of C10 and 
Pentobarbital did not exacerbate the side-effects of Pentobarbital (respiratory 
difficulty/distress) as seen for Hypnorm/Hypnovel. Although, Pentobarbital was not the 
ideal choice of anaesthetic for nasal perfusions it was the best option available and was 
therefore used in subsequent experiments in this chapter.  
 
7.4.2 Nasal perfusion was the optimal delivery method for GL67/pDNA in mouse 
nose 
After selection of an appropriate anaesthetic the optimal delivery method to achieve 
highest gene expression in the nasal epithelium was determined. 
 
I decided to compare delivery of GL67/pDNA by nasal perfusion with delivery by 
whole body nebulisation. Nasal perfusion as well as whole body nebulisation both 
ensures comparatively long contact time between the nasal epithelium and the GTA. 
Delivery of the GTA by nasal instillation was not included in the comparison as this 
delivery method results in a relatively short contact time between the nasal epithelium 
and GTA. Additionally, historic data have shown that nasal perfusion of GTA results in 
higher levels of gene transfer in the mouse nose compared to nasal instillation (R. 
Farley, Department of Gene Therapy, Imperial College London, UK - personal 
communication).  
 
As shown in Figure 80 both methods led to a significant increase in gene expression 
compared to untreated controls (p<0.05). However, luciferase expression was 
significantly (p<0.001) higher (33-fold) after 15 min of nasal perfusion compared to 
nebulisation. In subsequent experiments GL67/pDNA was, therefore, delivered to the 
nasal epithelium via nasal perfusion.  
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Figure 80: Luciferase expression in mouse nose after nebulisation or nasal perfusion of 
GL67/pCIKLux complexes 
C57Bl/6 mice were nebulised for 1 hr or perfused onto the nasal epithelium for 15 min with 
GL67/pCIKLux complexes. Untransfected (UT) mice were included as controls. 24 hrs post 
transfection the nasal epithelium was harvested and assayed for luciferase activity. Data are 
expressed as mean ± SEM (n=16-30/group), * = p<0.05 UT compared to both other groups and 
***= p<0.001 nebulisation compared to nasal perfusion. 
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As gene transfer efficiency was significantly higher after nasal perfusion for 15 min 
compared to nebulisation for 1 hr, I did not find it necessary to compare 1 hr nasal 
perfusion to 1 hr nebulisation. 
 
7.4.3 0.05 M C10 was the maximum tolerable concentration for nasal perfusion 
Prior to assessing the effects of C10 on gene transfer, the optimal route for delivery as 
well as the maximum tolerable dose had to be established. To determine the maximum 
tolerable dose, FABp mice were anaesthetised with Ketaset/Domitor and perfused for 
15 min with various concentrations of C10 (0.0125 M, 0.05 M and 0.2 M) or PBS and 
monitored carefully for the following 24 hrs. As mentioned above (Section 7.4.1), 
Ketaset/Domitor was used for the initial experiments, including this experiment, before 
the cause of the side-effects was fully understood and Pentobarbital became the choice 
of anaesthetic for nasal perfusions in FABp mice.  
 
Mice perfused with 0.2 M C10 either died during the perfusion due to respiratory 
difficulties or were culled immediately after completion of the procedure because the 
abdomen became hard and swollen. Assessment of the internal organs revealed gas in 
both stomach and intestine as previously seen following treatment with high dose C10 
(see Section 5.4.4). In contrast, animals perfused with PBS showed no signs of these 
side-effects. Lowering the concentration of C10 to 0.05 M or 0.0125 M improved side-
effects, i.e. there were no signs of trapped gas in the stomach or intestine. However, the 
mean recovery time from anaesthesia was significantly longer than for PBS treated 
mice. Based on these findings, FABp mice were treated with a maximum of 0.05 M 
C10 in subsequent experiments.  
 
As mentioned above (Section 7.4.1), FABp mice anesthetised with Ketaset/Domitor 
showed signs of discomfort after the procedure and when culled 24 hrs post-treatment 
an orange coloured discharge from the intestine and a slightly inflated stomach were 
observed. These side-effects were due to the anaesthetic as previously described (see 
Section 7.4.1 for details). 
  
7.4.4 Nasal instillation was the optimal delivery method for C10 in mouse nose 
To allow ourselves the best possible chance of correcting the CF ion transport defect 
following C10 treatment, C10 had to be delivered to the nasal epithelium in a way that 
290 
 
generates the highest possible level of gene expression. I, therefore, assessed the effect 
of delivering C10 by two different delivery methods; nasal instillation and perfusion. 
The contact time between the drug and epithelium can easily be controlled and 
importantly extended when administered by nasal perfusion. Here, I compared 15 min 
nasal perfusion of 0.05 M C10 (100 µl/mouse) and nasal perfusion of 0.0125 M C10 for 
1 hr (400 µl/mouse) to administration of 0.2 M C10 (25 µl/mouse) by nasal instillation. 
Different concentrations of C10 was used for 15 min and 1 hr perfusions to allow for 
the same dose of C10 (5x10
-6
 mol) to be delivered. Importantly, the same dose of C10 
(5x10
-6
 mol) was delivered following administration of the maximum tolerable 
concentration of C10 (0.2 M) by nasal instillation, thereby allowing direct comparison 
between C10 nasal perfusions and nasal instillation. Due to animal ethics i.e. animal 
numbers, control mice received PBS only via nasal instillation. 2 hrs after initiation of 
the pre-treatment, GL67/pCIKLux was delivered to all FABp mice via nasal perfusion, 
the optimal procedure for high level gene transfer (as described in Section 7.4.2). The 
nasal epithelium was harvested 24 hrs post-transfection and assayed for luciferase 
activity. As shown in Figure 81, all mice treated with GL67/pCIKLux expressed 
significant higher levels of lux compared to untransfected controls (p<0.05). 
Interestingly, delivery of  the same dose of C10 via nasal instillation resulted in a 
significantly (p<0.01, 3-fold) higher level of lux expression compared to C10 nasal 
perfusion. Prolonging the contact time between the epithelium and the TJ-opener by 
extending the perfusion time from 15 min to 1 hr had no additional effect on gene 
transfer efficiency. Based on these results C10 was delivered to the nasal epithelium via 
nasal instillation in subsequent experiments.  
 
7.4.5 Nasal instillation of 0.2 M C10 increased GL67-mediated gene transfer in 
mouse nose - gene expression was higher in FABp than C57Bl/6 mice  
The initial experiments assessing the effect of C10 on gene transfer efficiency were 
carried out in inbred C57Bl/6 mice (Chapter 5). However, to assess correction of ion 
transport defects in CF mice I had to switch to outbred FABp mice. Gene transfer 
efficiency and the response to C10 was first compared in the two strains of mice 
(n=8/group). Mice were treated via nasal instillation with 25 µl 0.2 M C10 or PBS 
(n=8/group) 2 hrs prior to nasal perfusion of GL67/pCIKLux (15 min/mouse). 24 hrs 
post transfection the nasal epithelium was harvested and assayed for luciferase activity. 
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Figure 81: Luciferase expression in mouse nose after C10 nasal perfusion or instillation  
FABp mice were pre-treated with C10 via nasal instillation (0.2 M, 25 µl/mouse) or nasal 
perfusion for 15 min (0.05 M, 100 µl/mouse) or 1 hr (0.0125 M, 400 µl/mouse). 2 hrs after 
initiation of the pre-treatment, GL67/pCIKLux complexes were perfused onto the nasal 
epithelium for 15 min. Untransfected (UT) mice were included as controls. 24 hrs post-
transfection the nasal epithelium was harvested and luciferase activity determined. Data are 
expressed as mean ± SEM. (n=8/group), * = p<0.05 UT compared to all other groups, ** = 
p<0.01 nasal instillation compared to nasal perfusion. 
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All mice treated with GL67/pCIKLux expressed significant higher levels of lux 
compared to untransfected controls (p<0.05). Lux expression in mice pre-treated with 
C10 was significantly higher than for mice pre-treated with PBS (C57Bl/6: p<0.05, 
FABp: p<0.001). The two strains showed no significant difference in gene transfer 
levels after PBS pre-treatment. Surprisingly, luciferase expression in FABp mice was 
significantly (p<0.01) increased compared to C57Bl/6 mice after C10 pre-treatment 
(Figure 82). Given these data, all experiments were carried out using the CF mouse 
model as planned.  
 
7.4.6 Nasal instillation of 0.05 M C10 increased GL67-mediated gene transfer in 
mouse nose 
In Figure 82, I have shown that 0.2 M C10 increased gene transfer compared to PBS 
treatment when GL67/pCIKLux was delivered via nasal perfusion. However, before 
assessing if C10 treatment would allow correction of the ion transport defect in the 
nasal epithelium of FABp mice, I decided to determine if the increase in gene 
expression observed after pre-treatment with 0.2 M was reproducible. Furthermore, the 
effect of C10 on gene transfer efficiency at the lower concentration of 0.05 M was also 
assessed, as this concentration had also led to increased gene transfer in the mouse nose, 
when GL67/pCIKLux was delivered via whole body nebulisation.  
 
Briefly, mice were pre-treated via nasal instillation with 25 µl C10 (0.05 M or 0.2 M) or 
PBS. 2 hrs post treatment 15 min nasal perfusion with GL67/pCIKLux complexes was 
carried out (n=8/group). The nasal epithelium was harvested 24 hrs post transfection 
and assayed for luciferase activity. As shown in Figure 83, mice treated with 
GL67/pCIKLux expressed significant (p<0.05) higher levels of lux compared to 
untransfected controls and the level of expression was similar to the previous 
experiment indicating that GL67-mediated transfection efficiency in the murine nasal 
epithelium is reproducible. A significant (p<0.01, ~18-fold) increase in lux expression 
was observed in mice pre-treated with 0.2 M C10 compared to PBS. Importantly, the 
increase was similar to that observed in the previous experiment (~20-fold) (see Section 
7.4.5) demonstrating that the increase in gene expression after pre-treatment with 0.2 M 
is highly reproducible. 
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Figure 82: Luciferase expression in nose of C57Bl/6 and FABp mice after C10 nasal 
instillation   
C57Bl/6 mice and FABp mice were pre-treated with 25 µl of 0.2 M C10 or PBS by nasal 
instillation 2 hrs prior to nasal perfusion of GL67/pCIKLux for 15 min. Untransfected (UT) 
mice were included as controls. 24 hrs post transfection the nasal epithelium was harvested and 
assayed for luciferase activity. Data are expressed as mean ± SEM (n=8/group), * = p<0.05 UT 
compared to all other groups, * = p<0.05 C10 in C57Bl/6 compared to PBS in C57Bl/6, ** = 
p<0.01 C10 in C57Bl/6 compared to C10 in FABp and *** = p<0.001 C10 in FABp compared 
to PBS in FABp. 
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Figure 83: Luciferase expression in mouse nose after nasal instillation of 0.05 M or 0.2 M 
C10  
FABp mice were pre-treated with 25 µl C10 (0.05M or 0.2M) or PBS by nasal instillation 2 hrs 
prior to nasal perfusion of GL67/pCIKLux for 15 min. Untransfected (UT) mice were included 
as controls. 24 hrs post transfection the nasal epithelium was harvested and assayed for 
luciferase activity. Data are expressed as mean ± SEM (n=8/group), * = p<0.05 UT compared to 
all other groups and ** = p<0.01 C10 compared to PBS. 
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Pre-treatment with C10 at the lower concentration of 0.05 M also led to a significant 
(p<0.01) increase (6-fold) in lux expression compared to PBS treatment. Interestingly, 
the additional increase in gene expression after pre-treatment with 0.2 M C10 compared 
to 0.05 M C10 was not significant.  
 
7.4.7 Nasal instillation of C10 changed baseline nasal potential difference 
In an attempt to assess the effect of C10 treatment on tight junction permeability in vivo, 
mice were treated with C10 and baseline NPD measurements were carried out. Opening 
of tight junctions will alter sodium absorption across the epithelium and lower baseline 
NPD. I decided to assess the effect on tight junction permeability of not only 0.2 M 
C10, but also 0.05 M C10, as both of these concentrations significantly increased GL67-
mediated gene transfer to the mouse nose as shown in the previous section. First, a pre-
treatment baseline NPD measurement was recorded prior to C10 treatment. Mice were 
then treated with 25 µl C10 (0.05 M or 0.2 M) or PBS (n=4/group) and NPD 
measurements were again performed at various time points post treatment (30 min, 2 
hrs, 4 hrs, 24 hrs, 48 hrs and 5 days) to assess the time-course of increased trans-
epithelial permeability. Untreated mice were not included as significant amounts of data 
are already available in the Department.  
 
As shown in Figure 84a+b, PBS pre-treatment did not alter NDP at any of the time-
points assessed. However, NPD significantly decreased (0.05 M: p<0.01, 0.2 M: 
p<0.05) 30 min after treatment with both 0.05 M and 0.2 M C10 suggesting an increase 
in tight junction permeability. 24 hrs post treatment with 0.05 M C10 NPD had almost 
recovered to pre-treatment values and 48 hrs after C10 treatment no difference was 
observed between C10 treated and PBS treated mice (Figure 84a). In contrast, NPD in 
mice treated with 0.2 M C10 was still reduced 48 hrs after treatment, but had returned to 
pre-treatment values 5 days after C10 administration (Figure 84b).  
 
7.4.8 Nasal instillation of C10 caused epithelial damage 
Prior to assessing if the increase in gene expression following C10 treatment would 
allow correction of the ion transport defect, the effect of C10 on the nasal respiratory 
epithelium was assessed histologically. Briefly, FABp mice were treated with 25 µl C10 
(0.05 M or 0.2 M) or PBS (n=4/group) via nasal instillation. Untreated mice were 
included as controls. Mice were culled 2 hrs, 48 hrs and 14 days post-treatment. 
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Figure 84: Baseline NPD after C10 nasal instillation  
FABp mice were treated with 25 µl of 0.05 M C10 (a) or 0.2 M C10 (b) or PBS by nasal 
instillation. Pre- and post-treatment baseline nasal potential difference (NPD) measurements 
were performed at the indicated time points (m = min, h = hrs, d = days). Each dot represents 
one animal with the mean baseline NPD measurement of the group shown as a horizontal line. * 
= p<0.05 pre-treatment compared to 30 min post-treatment with C10 0.2 M and ** = p<0.01 
pre-treatment compared to 30 min post-treatment with C10 0.05 M. 
a 
b 
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The nose was harvested, processed and sections corresponding to approximately 2.5 
mm into the nose were assessed. When it became apparent that C10 treatment resulted 
in denudation of the nasal epithelium, sections were scored semi-quantitatively for 
degree of denuded epithelium. More precisely, the respiratory epithelium lining both 
sides of the nasal septum was assessed. This region was chosen as it was easy to define 
and, importantly, consisted entirely of ciliated airway epithelial cells, the target cells for 
CF gene therapy.    
 
As shown in Figure 85a+b, C10 treatment resulted in denudation of the nasal respiratory 
epithelium 2 hrs post treatment. In one out of the four PBS treated mice, the epithelium 
was in a few spots slightly torn, however, this was likely to be due to insertion of the 
catheter used for NPD measurements into the nasal cavity (Figure 86b). Unexpectedly, 
the NPD measurement in the PBS treated mouse was not affected by the slight tear. 
Untreated mice showed no signs of shredded respiratory epithelium. Semi-quantitative 
scoring of the nasal respiratory epithelium showed that denudation was dose-dependent. 
The respiratory epithelium of mice treated with 0.2 M C10 was almost 100% denuded 2 
hrs post treatment, whereas in mice treated with 0.05 M C10 only approximately 25% 
of the epithelium was denuded (Figure 87).  
 
I also asked how quickly the epithelium is repaired and analysed the nasal epithelium 
histologically 2 and 14 days after C10 exposure. Importantly, in 6 out of 6 mice the 
epithelium was completely restored 14 days after treatment, while denuded areas where 
still present 2 days after treatment, particularly in animals treated with 0.2 M C10 
(Figure 87). 
 
7.4.9 Time-course for epithelial repair coincided with time-course for restoration 
of nasal potential difference 
Before harvesting of nasal tissue for histological assessment I also took the opportunity 
to measure baseline NDP in these mice. NDP was significantly (p<0.001) decreased 2 
hrs after treatment with 0.05 M and 0.2 M C10, but not after PBS treatment (Figure 88). 
The results presented in Section 7.4.7 were, therefore, reproducible. The time-course for 
recovery of NPD coincided with repair of the epithelium with partial recovery 2 days 
post-treatment and complete recovery of both NDP and epithelial damage 14 days post-
treatment. 
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Figure 85: Mouse nose sections after C10 nasal instillation  
FABp mice were treated with 25 µl 0.05 M C10 (a) or 0.2 M C10 (b) by nasal instillation. 2 hrs 
post treatment the nose was harvested and processed and cross sections corresponding to 
approximately 2.5 mm into the nose were cut for histological assessment. Arrows indicate 
denuded epithelium due to C10 treatment. Representative images are shown (Original 
magnification: x2.5 and x20). 
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Figure 86: Mouse nose sections after PBS nasal instillation  
FABp mice remained untreated (a) or were treated with 25 µl PBS (b) by nasal instillation. 2 
hrs post treatment the nose was harvested and processed and cross sections corresponding to 
approximately 2.5 mm into the nose were cut for histological assessment. Arrow heads indicate 
denuded epithelium due to insertion of catheter into the nasal cavity for measurement of nasal 
potential difference (NPD). Representative images are shown (Original magnification: x2.5 and 
x20).  
b 
a 
300 
 
 
 
 
 
 
 
U
nt
re
at
ed
 (2
hr
s)
 
U
nt
re
at
ed
 (4
8h
rs
) 
U
nt
re
at
ed
 (1
4d
ay
s)
 
P
B
S
 (2
hr
s)
P
B
S
 (4
8h
rs
)
P
B
S
 (1
4d
ay
s)
C
10
 0
.0
5M
 (2
hr
s)
C
10
 0
.0
5M
 (4
8h
rs
)
C
10
 0
.0
5M
 (1
4d
ay
s)
C
10
.0
.2
M
 (2
hr
s)
C
10
.0
.2
M
 (4
8h
rs
)
C
10
.0
.2
M
 (1
4d
ay
s)
0
25
50
75
100
                           2h  48h  14d        2h   48h 14d         2h  48h  14d
     UT                     PBS                 C10 0.05M             C10 0.2M
%
 d
e
n
u
d
e
d
 r
e
s
p
ir
a
to
ry
 e
p
it
h
e
li
u
m
 
Figure 87: Histological assessment of mouse nasal respiratory epithelium after C10 nasal 
instillation  
FABp mice were treated with 25 µl C10 (0.05 M or 0.2 M) or PBS by nasal instillation. 2 hrs 
(h), 48 hrs (h) and 14 days (d) post treatment baseline nasal potential difference (NPD) 
measurements were performed prior to harvesting and processing the nose for histological 
assessment. Sections corresponding to approximately 2.5 mm into the nose were obtained and 
the respiratory epithelium lining both sides of the nasal septum was scored semi-quantitatively 
(%) for degree of denuded respiratory epithelium. Untreated mice (UT) were included as 
controls. Each dot represents one animal with the mean score of the group shown as a horizontal 
line. Red circled dots represent animals in which denuded epithelium were caused by insertion 
of the catheter for NPD measurements into the nasal cavity.  
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Figure 88: Baseline NPD up to 14 days after C10 nasal instillation  
FABp mice were treated with 25 µl of 0.05 M or 0.2 M C10 or PBS by nasal instillation. Pre- 
and post-treatment baseline nasal potential difference (NPD) measurements were performed at 
the indicated time points. Each dot represents one animal with the mean baseline NPD 
measurement of the group shown as a horizontal line. *** = p<0.001 pre-treatment compared to 
2 hrs post-treatment with C10. 
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7.4.10 Gene expression was similar in mouse nose harvested 24 hrs and 48 hrs 
after gene transfer  
Based on results described above, the earliest time-point suitable for assessment of 
correction of NPD after CFTR gene transfer is 48 hrs after transfection. At this time-
point NPD and tissue damage had almost recovered in mice treated with 0.05 M C10, 
which is essential for assessment of correction of NPD after CFTR gene transfer. The 
residual damage may in part be due to catheter-insertion during the NPD measurement 
and, therefore, unavoidable regardless what time-point is chosen. Importantly, the 
strongest and most widely used CMV promoter/enhancer generates highest level of 
gene expression 1 to 2 days after gene transfer, which match well with the earliest 
suitable time-point for assessment of correction of NPD after CFTR gene transfer (i.e. 
48 hrs). Therefore, I decided to use the 48 hr time-point (in addition to a 14 day time-
point) in subsequent studies.  
 
Up to this point all my nose gene transfer studies had focussed on analysing gene 
expression 24 hrs after CMV promoter/enhancer mediated gene transfer. Before moving 
forward I, therefore, first proved that C10-mediated increases in gene expression can 
also be observed 48 hrs after gene transfer. Briefly, mice were treated with 25 µl of 0.05 
M C10 or PBS (n=8/group) via nasal instillation 2 hrs prior to nasal perfusion (15 min) 
with GL67 complexed to pCIKLux. 24 hrs or 48 hrs post transfection mice were culled 
and the nasal epithelium harvested and assayed for luciferase activity. Figure 89 shows 
mice treated with C10 expressed higher levels (p<0.05) compared to PBS controls 
regardless if harvested 24 or 48 hrs after gene transfer. Importantly, there was no 
significant difference (p>0.05) in luciferase expression levels between mice culled 24 
hrs or 48 hrs after gene transfer. I, therefore, concluded that the 48 hr time-point was 
appropriate for subsequent studies.  
 
7.4.11 Nasal instillation of 0.05 M C10 did not correct the ion transport defect 
To assess if the increase in gene expression after 0.05 M C10 treatment would allow 
correction of the CF ion transport defect mice were perfused for 1 hr with GL67 
complexed to pCIKCFTR. I increased perfusion time from 15 min to 1 hr because I had 
to ensure that gene expression is maximised in these experiments. It has been previously 
shown that this increased gene expression by 6-fold in the mouse nose [320]. 
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Figure 89: Luciferase expression in mouse nose 24 hrs and 48 hrs after C10 nasal 
instillation  
C57Bl/6 mice were pre-treated with 25 µl of 0.05 M C10 or PBS by nasal instillation 2 hrs prior 
to nasal perfusion of GL67/pCIKLux for 15 min. Untransfected (UT) mice were included as 
controls. 24 hrs or 48 hrs post transfection mice were culled and the nasal epithelium harvested 
and assayed for luciferase activity. Data are expressed as mean ± SEM (n=8/group), * = p<0.05 
UT compared to all other groups and * = p<0.05 C10 compared to PBS. 
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FABp mice were pre-treated with 25 µl 0.05 M C10 or PBS 2 hrs prior to perfusion 
with GL67 complexed to pCIKCFTR or pCIKempty for 1 hr. 48 hrs post transfection 
NPD measurements were carried out. Briefly, an amiloride-containing solution was 
perfused into the nasal cavity, which led to a drop in NPD. The drop is more 
pronounced in CF mice compared to non-CF mice as they display a higher baseline 
NPD due to increased sodium absorption. The nasal epithelium was perfused with a low 
chloride solution, which would generate a driving force for chloride secretion through a 
potentially expressed CFTR channel in CFTR transfected FABp mice. CFTR expression 
in FABp mice would be visible by a hyperpolarisation of the NPD, not observed in 
untransfected mice. NPD values of wild-type mice were included as reference values. 
 
Figure 90a+b shows representative images of interpretable traces from a non-CF mouse 
and a FABp mouse. The difference between baseline NPD and post amiloride NPD is 
defined as the amiloride response and the difference between the amiloride response 
and the maximal stable low chloride NPD is defined as the low chloride response. 
 
Figure 91a+b show baseline NPD and the low chloride response in transfected and 
untransfected FABp mice. Baseline NPD measurements were within the range 
previously reported for CF-knockout mice and WT mice [370]. Baseline NPD in mice 
transfected with GL67/pCIKCFTR did not change in the absence of C10 consistent with 
previously published data [320]. However, baseline NPD also remained unchanged in 
mice pre-treated with C10 and was not different compared to untreated mice or mice 
transfected with pCIKempty. Similar to baseline NPD, quantification of low chloride 
response also showed that pre-treatment with C10 followed by transfection with 
GL67/pCIKCFTR did not lead to increased chloride transport. 
 
7.4.12 Nasal instillation of 0.05 M C10 did not increase CFTR mRNA 
I next assessed, if vector-specific CFTR mRNA was actually expressed after gene 
transfer. Mice were pre-treated with 25 µl 0.05 M C10 or PBS 2 hrs prior to perfusion 
with GL67 complexed to pCIKCFTR or pCIKempty for 1 hr (n=12-18/group). 48 hrs 
post transfection the nostrils were brushed for mRNA analysis. Prior to brushing the 
nostrils for mRNA analysis, NPD measurements were performed as described in the 
previous section.   
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Figure 90: Representative interpretable traces from a non-CF mouse and a FABp mouse 
Representative interpretable nasal potential difference (NPD) traces from a non-CF mouse (a) 
and a FABp mouse (b). The short arrow indicates start of perfusion with an amiloride 
containing solution and the long arrow indicates start of perfusion with a low chloride solution.  
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Figure 91: Baseline NPD and low chloride response 48 hrs after nasal instillation of 0.05 
M C10 
FABp mice were pre-treated with 25 µl of 0.05 M C10 or PBS by nasal instillation 2 hrs prior to 
nasal perfusion of GL67/pCIKCFTR or GL67/pCIKempty for 1 hr. 48 hrs post transfection 
mice were anesthetised and nasal potential difference (NPD) measurements carried out (a: 
baseline NPD, b: low chloride response). Each dot represents one animal with the mean NPD 
measurement of the group shown as a horizontal line. Wild-type (WT) mice were included for 
comparison.  
 
a 
b 
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As shown in Figure 92 vector-specific mRNA expression was detectable in all groups 
transfected with pCIKCFTR and in approximately 41% of all samples. C10 treatment 
had no effect on mRNA expression as similar levels of vector-specific mRNA 
expression were seen in PBS treated mice. Overall expression levels were comparable 
to approximately 20% of endogenous murine Cftr mRNA levels. Importantly, 
endogenous murine Cftr mRNA was detected in all samples demonstrating that 
harvesting and mRNA extraction methods were working satisfactorily and non-
responders were, therefore, not due to technical problems.  
 
The effect of the NPD measurements on mRNA expression is unknown. I, therefore, 
included a group of mice that were transfected with GL67/pCIKCFTR but did not 
undergo NPD measurements before cell harvest for mRNA extraction. mRNA levels in 
this cohort were similar to mice that had undergone NPD and I could conclude that the 
NPD measurement had not interfered with mRNA detection.  
 
7.4.13 Nasal instillation of 0.05 M C10 did not increase luciferase mRNA  
In an attempt to understand further why C10 pre-treatment did not lead to an increase in 
vector-specific mRNA expression after GL67/pCIKCFTR transfection, vector-specific 
mRNA was also quantified after GL67/pCIKLux transfection. Briefly, mice were 
treated with 25 µl of 0.05 M C10 or PBS (n=9/group) 2 hrs prior to nasal perfusion with 
GL67 complexed to pCIKLux. 48 hrs post transfection mice were culled and the nostrils 
brushed for mRNA analysis. As shown in Figure 93, the overall responder rate was 44% 
with a mean expression level of 15% of endogenous murine Cftr levels, similar to 
pCIKCFTR transfected mice. There was no difference between C10 and PBS treated 
mice. Considering that all pCIKLux-treated mice express luciferase protein (=100% 
responder rate) I conclude that the mRNA assay is less sensitive than the luminescent 
luciferase protein assay used. This may explain why the beneficial effects could only be 
observed when quantifying luciferase protein expression.  
 
7.4.14 pGM144 resulted in sustained gene expression in mouse nose 
Although the 48 hr time-point appeared appropriate for assessment of NPD after gene 
transfer, I cannot completely exclude that some C10-induced damage may persist and 
interfere with the assay. 
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Figure 92: CFTR mRNA expression 48 hrs after nasal instillation of 0.05 M C10 
FABp mice were pre-treated with 25 µl of 0.05 M C10 or PBS by nasal instillation 2 hrs prior to 
nasal perfusion of GL67/pCIKCFTR for 1 hr. Untransfected (UT) mice were included as 
controls. 48 hrs post transfection nasal potential difference (NPD) measurements were 
performed and mice were then culled and the left nostril brushed for mRNA analysis. Each dot 
represents one animal with the mean CFTR mRNA expression (expressed as vector-specific 
expression as % of endogenous murine Cftr mRNA) of the group shown as a horizontal line. 
Samples plotted as undetectable (UD) were positive for endogenous Cftr mRNA and then either 
negative for vector-specific CFTR mRNA or positive for vector-specific CFTR mRNA, but the 
amount was not quantifiable.  
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Figure 93: Luciferase mRNA expression 48 hrs after nasal instillation of 0.05 M C10 
FABp mice were pre-treated with 25 µl of 0.05 M C10 or PBS by nasal instillation 2 hrs prior to 
nasal perfusion of GL67/pCIKLux for 15 min. Untransfected (UT) mice were included as 
controls. 48 hrs post transfection mice were culled and the left nostril brushed for mRNA 
analysis. Each dot represents one animal with the mean luciferase mRNA expression (expressed 
as vector-specific expression as % of endogenous murine Cftr mRNA) of the group shown as a 
horizontal line. Samples plotted as undetectable (UD) were positive for endogenous Cftr mRNA 
and then either negative for luciferase mRNA or positive for luciferase mRNA, but the amount 
was not quantifiable. 
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I, therefore, decided to measure NPD responses 14 days post C10 administration and 
GL67/pCFTR gene transfer. Assessment at the later time-point allows the use of the 
higher concentration of C10 (0.2 M), thereby maximising the chance of increased gene 
transfer. However, the pCIKCFTR plasmid is not suitable for these experiments, 
because the short-acting CMV promoter/enhancer will not support gene expression for 2 
weeks [218]. 
 
The Consortium has developed longer-acting promoters and the elongation factor 1 
alpha (EF1α) promoter is the lead candidate. This promoter drives expression for >4 
weeks in the mouse lung but has not been assessed in the mouse nasal epithelium [218]. 
I first evaluated if the CEFI promoter/enhancer, consisting of the CMV enhancer 
coupled to the EF1α promoter, leads to prolonged luciferase expression in the mouse 
nose. Briefly, C57Bl/6 mice were perfused with GL67 complexed to pGM144 
(expressing luciferase under control of the CEFI promoter/enhancer) or pCIKLux for 15 
min (n=8/group). 24 hrs, 7 days and 14 days post transfection the nasal epithelium was 
harvested for detection of luciferase activity. As shown in Figure 94 both pGM144 and 
pCIKLux led to significant gene expression 24 hrs after transfection compared to 
untransfected controls (pGM144: p<0.001, pCIKLux: p<0.05) and the level of gene 
expression after transfection with pCIKLux was similar to previous experiments. 
Interestingly, pGM144 mediated expression was approximately 6-fold higher (p<0.05) 
than pCIKLux-mediated expression and persisted at stable levels for at least 14 days. 
The CEFI promoter/enhancer was, therefore, suitable for assessment of CFTR function 
14 days after transfection. 
 
7.4.15 Nasal instillation of 0.2 M C10 did not increase CFTR mRNA 14 days post 
transfection 
To assess CFTR expression under the control of the CEFI promoter/enhancer, FABp 
mice were transfected with GL67 complexed the pGM169. I first assessed if 0.2 M C10 
treatment would increase pGM169-specific mRNA expression. Mice were treated with 
25 µl of  0.2 M C10 or and PBS by nasal instillation 2 hrs prior to perfusion with GL67 
complexed to pGM169 for 1 hr. 14 days post transfection mice were exsanguinated and 
the left nostril brushed for mRNA analysis. As shown in Figure 95, vector-specific 
mRNA expression as a percentage of endogenous murine Cftr mRNA was detectable in 
48% of the samples, which was similar to that observed in the previous experiments. 
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Figure 94: Luciferase expression in mouse nose at 24 hrs, 7 days and 14 days after 
transfection with GL67/pGM144 complexes 
C57Bl/6 mice were treated with GL67/pGM144 or GL67/pCIKLux by nasal perfusion for 15 
min. Untransfected (UT) mice were included as controls. 24 hrs, 7 days and 14 days post 
transfection mice were culled and the nasal epithelium harvested and assayed for luciferase 
activity. Data are expressed as mean ± SEM (n=8/group), * = p<0.05 GL67/pCIKLux at day 1 
compared to UT, * = p<0.05 GL67/pGM144 at day 1 compared to GL67/pCIKLux at day 1 and 
*** = p<0.001 GL67/pGM144 at day 1 compared to UT. 
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Figure 95: CFTR mRNA expression 14 days after nasal instillation of 0.2 M C10  
FABp mice were pre-treated with 25 µl of 0.2 M C10 or PBS by nasal instillation 2 hrs prior to 
nasal perfusion of GL67/pGM169 for 1 hr. Untransfected (UT) mice were included as controls. 
14 days post transfection mice were culled and the left nostril brushed for mRNA analysis. Each 
dot represents one animal with the mean CFTR mRNA expression (expressed as vector-specific 
expression as % of endogenous murine Cftr mRNA) of the group shown as a horizontal line. 
Samples plotted as undetectable (UD) were positive for endogenous Cftr mRNA and then either 
negative for vector-specific CFTR mRNA or positive for vector-specific CFTR mRNA, but the 
amount was not quantifiable.  
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Overall expression levels were comparable to 3-17% of endogenous Cftr mRNA levels, 
which was slightly smaller than observed in the previous experiments. Similar to 
previous experiments C10 pre-treatment did not enhance mRNA expression compared 
to controls. Based on these results, I decided not to perform the planned NPD 
measurements, because pre-treatment with 0.2 M C10 did not improve gene expression 
levels, which would have been necessary to warrant a second lengthy, approximately 6-
8 week long, NPD experiment. 
 
7.4.16 Nasal instillation of C10 did not result in GFP-positive airway epithelial 
cells 
In an attempt to address which type of cells were transfected following gene transfer to 
the nasal epithelium, FABp mice were pre-treated with 25 µl PBS or C10 (0.05 M and 
0.2 M) 2 hrs prior to perfusion with GL67 complexed to pEGFP-N1 (GFP expression 
plasmid under the control of a CMV promoter/enhancer) or pCIKempty (n=4/group). 24 
hrs post transfection the nose was harvested, processed and cross sections were cut and 
stained with H&E and DAPI for visualisation of GFP fluorescence. As shown before 
(Section 7.4.8), H&E stained sections demonstrated dose-dependent denudation of the 
respiratory epithelium. Although 5 nasal cross sections were assessed per mouse, the 
vast majority of AECs and cells in the subepithelium in mice pre-treated with C10 
showed no GFP expression (Figure 96). However, one mouse instilled with 0.05 M C10 
followed by perfusion with GL67/pEGFP-N1 revealed two GFP expressing AECs at 
approximately 2 mm into the nose (level 1) (Figure 97). These results indicate lipid-
mediated gene transfer in the mouse nose was below the detection limit of this assay. I 
am, therefore, currently unable to determine which cells have been transfected in the 
presence and absence of C10.  
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Figure 96: Mouse nasal epithelium after C10 nasal instillation and GFP gene transfer  
FABp mice were pre-treated with 25 µl of C10 (0.05 M or 0.2 M) or PBS by nasal instillation 2 
hrs prior to nasal perfusion of GL67/pEGFP-N1 and GL67/pCIKempty for 1 hr. Untransfected 
mice were included as controls. 24 hrs post transfection the nose was harvested, processed and 
cross sections were cut and stained with DAPI for visualisation of green fluorescence protein 
(GFP). a: C10 0.2 M, GL67/pEGFP-N1, b: C10 0.05 M, GL67/pEGFP-N1, c: PBS, GL67/ 
pEGFP-N1 and d: untransfected negative control. All images are representative of the nasal 
epithelium for each group Arrows indicate the septum. Arrow heads indicate the respiratory 
epithelium (Original magnification: x20). 
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Figure 97: Mouse nasal epithelium after C10 nasal instillation and GFP gene transfer - 
GFP expressing cells present 
A FABp mouse was pre-treated with 25 µl of 0.05 M C10 by nasal instillation 2 hrs prior to 
nasal perfusion of GL67/pEGFP-N1 for 1 hr. 24 hrs post transfection the nose was harvested, 
processed and cross sections were cut and stained with DAPI for visualisation of green 
fluorescence protein (GFP). a: blue channel to visualise DAPI, b: green channel to visualise 
GFP, c: red channel to visualise auto fluorescence and d: overlay of all channels. Arrows 
indicate the septum. Arrow heads indicate GFP expressing cells (Original magnification: x10). 
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7.5 Discussion 
 
C10 was the most effective tight junction opener increasing gene transfer to lung and 
nose (see Chapter 6). Here, I optimised further C10-mediated gene transfer to nasal 
epithelium with the overall aim of assessing the effect on CFTR gene transfer in CF 
knockout mice. The murine nasal respiratory epithelium was chosen as a surrogate 
organ because it (a) consists of pseudostratified respiratory epithelium with cell 
composition similar to human lung and (b) has CFTR-mediated ion transport. The nasal 
epithelium of CF knockout mice displays the characteristic CF ion transport 
abnormalities and can, therefore, be used to assess efficacy of CFTR gene transfer.  
 
For administration of the gene transfer agent by nasal perfusion, and importantly for 
nasal potential difference measurements, animals have to be deeply anaesthetised. The 
combination of Ketaset and Domitor was the obvious choice because the Department 
had extensive experience using Ketaset/Dormitor in both wild-type and CF-knockout 
mice. In addition, published literature has confirmed that Ketaset/Domitor is producing 
chemical restraint in mice suitable for minor procedures and the availability of the 
antagonist Antisedan (α2-receptor antagonist) ensures fast recovery after completion of 
the procedures. This not only reduces observation time, but importantly reduces the risk 
of hypothermia often experienced in anaesthetised mice [384]. However, administration 
of Ketaset/Domitor resulted in intestinal discharge, inflated stomachs and death within 
48 hours in approximately 75% of FABp mice. Ketaset/Domitor was, therefore, 
excluded for future use in FABp mice by the chief veterinarian at Imperial College 
London.  
 
The reasons for the side-effects observed in the CF-knockout mice are unclear, but 
maybe related to the anaesthetic interfering with the CFTR channel in the murine 
intestinal epithelial cells, leading to re-occurrence of the CF-like intestinal pathology in 
the gut-corrected FABp-CF mice. Interestingly, Lam et al have shown that α2-receptor 
agonists, including Medetomidine (Domitor), inhibited CFTR-mediated chloride 
secretion in the murine colonic epithelium by acting on basolateral K
+
-channels [385]. 
The intestinal chloride secretion depends on the coordinated activity of apical Cl
-
-
channels as well as basolateral Na
+
-K
+
-2Cl
-
-cotransporters, Na
+
-K
+
-ATPases and K
+
-
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channels. Inhibition of one of these transport mechanisms leads to inhibition of chloride 
secretion, thereby explaining the effect of α2-receptor agonists.  
 
Ketamine/Dormitor did not cause side-effects in wild-type mice, possibly pointing to a 
threshold-effect on CFTR inhibition and highlighting that CFTR expression in gut-
corrected knockout mice, although sufficient to correct the phenotype in untreated mice, 
is insufficient to cope with pharmacological inhibition of CFTR function. FABp CF 
mice have been breed and treated with Ketamine/Dormitor in the laboratory for many 
years. The sudden occurrence of intestinal pathology after anaesthesia was, therefore, 
surprising and may be related to genetic drifts introduced through prolonged 
brother/sister mating.  
 
Hypnorm/Hypnovel was then assessed as an alternative anaesthetic for FABp mice. 
Although Hypnorm/Hypnovel was well tolerated in FABp mice when administered on 
its own, it proved fatal by impairing respiratory function in a large fraction of mice that 
had also received Metofane approximately 2 hours prior to Hypnorm/Hypnovel to 
administer C10 by nasal sniffing. However, the exact mechanism of interaction of 
Metofane and Hypnorm/Hypnovel in the FABp mice is unknown.  
 
To overcome this problem I decided to administer C10 and gene transfer agents using 
Hypnorm/Hypnovel. This strategy required mice to remain anaesthetised for the period 
between C10 and lipid/DNA administration (approximately 2 hours). However, 
although, mice tolerated anaesthetic regime well, it was less than ideal. C10 
administration by nasal sniffing was less efficient, because Hypnorm/Hypnovel causes a 
degree of respiratory suppression, which interferes with efficient delivery by nasal 
sniffing. Furthermore, the nasal epithelium remained sensitive despite deep anaesthesia 
of the animal, which caused excessive twitching of the mouse head on catheter insertion 
and required frequent re-insertion of the catheter into the nostrils. Frequent re-insertion 
of the perfusion catheter is known to cause epithelial damage which would interfere 
with gene transfer, but also with subsequent efficacy measurements.  
 
Pentobarbital, an alternative long-lasting anaesthetic, was then assessed. Although, 15-
20% of FABp mice died due to respiratory difficulties during or after the 1 hour 
perfusion, this anaesthetic was considered suitable for administration of the gene 
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transfer agent by nasal perfusion. Importantly, Pentobarbital caused no excessive 
twitching of the mouse head on catheter insertion, thereby, minimising the risk of 
causing epithelial damage. No mice died during the first 15 minutes of the nasal 
perfusion, highlighting the problems encountered when longer perfusions times (i.e. 1 
hour) are employed.  
 
The overall aim of this chapter was to assess if C10 pre-treatment would enhance non-
viral mediated CFTR gene transfer to the nasal epithelium of FABp mice and allow 
correction of the ion transport defect observed in these mice. To give ourselves the best 
possible chance to achieve this aim, the optimal delivery method for both tight junction 
opener and GTA leading to most efficient gene transfer, was first determined. Not 
surprisingly, nasal perfusion of the GTA, a delivery method optimised to deliver large 
quantities of GTA to the nasal epithelium and ensure prolonged contact time,  resulted 
in a significantly higher level of reporter gene expression compared to whole body 
nebulisation, performed in previous experiments, in which only a fraction of the 
compound is inhaled.  
 
Surprisingly, delivery of C10 by nasal instillation resulted in significantly higher levels 
of reporter gene expression compared to standard (15 min) and prolonged (1 hr) nasal 
perfusion. Interestingly, prolonging the contact time from 15 min to 1 hr had no 
additional effect on gene transfer levels. I cannot exclude that delivering the same dose 
over an even longer time period (e.g. 4 hours) would not have increased gene transfer 
levels further. However, due to animal welfare I decided not to put the mice through a 4 
hour nasal perfusion as Pentobarbital had caused severe respiratory difficulties during 1 
hour perfusion. The reasons for the higher levels of gene expression following nasal 
instillation of C10 are unclear, but may indicate that prolonged contact time between 
C10 and the nasal epithelium causes cellular changes that subsequently prevent efficient 
uptake and/or expression of the GTA. 
 
A combination of C10 nasal instillation (0.2 M) followed by nasal perfusion of GL67 
complexed to pCIKLux resulted in approximately 20-fold increase in reporter gene 
transfer which, although significant, was lower than the increase (approximately 45-
fold) observed in the nose when the GTA was delivered via whole body nebulisation in 
previous experiments. A possible explanation for this difference may be that droplets 
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generated during nebulisation allow easier migration of GTA through the opened tight 
junctions leading to higher levels of gene transfer.  
 
As variability is often seen in in vivo experiments it was very important to repeat the 
experiment to determine if the increase in gene transfer efficiency observed in the nose 
was reproducible. In addition to treating mice with 0.2 M C10, I included mice pre-
treated with 0.05 M C10 as this concentration had previously (Chapter 5) resulted in 
increased gene transfer in the mouse nose. Similar levels of gene expression were 
obtained in individual experiments from mice pre-treated with PBS followed by 
transfection with the non-viral vector via nasal perfusion, indicating relatively little 
variation between different in vivo experiments. Pre-treatment with both 0.05 M and 0.2 
M C10 lead to a significant increase in gene transfer compared to vehicle treated mice 
and, importantly, the 20-fold increase observed in the previous experiment after pre-
treatment with 0.2 M was reproduced.  
 
To assess correction of the ion transport defect in CF mice, I had to switch from inbred 
C57Bl/6 mice, used to assess the effect of C10 on gene transfer efficiency in previous 
chapters, to outbred FABp mice. First, I decided to compare gene transfer efficiency in 
the two strains. A previous study by Dames et al has shown that PEI-mediated aerosol 
gene transfer efficiency was mouse strain dependent [386]. Compared to NMRI and 
mixed 129/Sv x C57Bl/6 mice, lung gene expression in BALB/c mice was significantly 
higher. This mouse strain dependency could not be correlated with pDNA dose effects, 
as pDNA deposition rates in the lungs of mice were not significantly different between 
each of the mouse strains tested. The authors, therefore, suggest that genetic background 
variations may influence the level of gene expression. More precisely, one or more of 
the individual steps involved in the complex transfection process, comprising (1) vector 
uptake, (2) intracellular trafficking, (3) endosomal release, (4) nuclear pDNA uptake 
and (5) transcription and translation, may be affected by the genetic background of 
different mouse strains. I have showed here, that gene expression is significantly higher 
in FABp mice compared to C57Bl/6 mice after C10 pre-treatment. However, in contrast 
to the findings by Dames et al no difference was found between the two strains when 
mice were pre-treated with PBS. It is likely that the genetic background influences the 
susceptibility to C10, as has been suggested for gene transfer agents.  
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Ideally, I would have used an inbred CF mouse strain for these experiments, as these are 
identical, thereby reducing gene transfer variability. However, at the time of the 
experiment inbreed FABp mice were not available. Alternatively, non-FABp inbreed 
CF mouse strains could have been used. However, these are difficult to work with and 
maintain as, in contrast to FABp mice, they have intestinal disease leading to 
malabsorption and intestinal obstruction with high pre- and post-weaning mortality.  
 
Following determination of the optimal delivery method for both C10 and the GTA to 
the murine nasal epithelium the effect of C10 treatment on tight junction permeability 
was assessed. Several studies have shown that C10 alters tight junctional permeability 
ex vivo [283,284]. In addition, Johnson et al and Weiss et al have used a TEM-based 
technique, described in Section 4.5.10, to demonstrate increased paracellular 
permeability after SO2 and EGTA treatment in murine trachea and lung in vivo, 
respectively [318,324]. However, to date no studies have attempted to assess tight 
junction permeability in the murine nose after administration of a tight junction opener. 
Here, I assessed tight junction permeability by measuring baseline NPD. The magnitude 
of baseline NPD is largely a readout of Na
+
 absorption. It has been well described that 
Na
+
 absorption is disturbed, if tight junction integrity is compromised for example 
during pathogen-induced inflammation [387,388]. 
 
To ensure that a reduction in NPD could clearly be attributed to reduced tight junction 
integrity rather than procedure-related epithelial cell damage, I first confirmed that the 
repeated catheter insertion (required for NPD measurements) did not lead to a lowering 
of NPD. Baseline NPD values measured in untreated mice and in vehicle-treated mice 
were similar to those reported in the literature [370]. Administration of both low (0.05 
M) and high (0.2 M) concentration C10 significantly reduced baseline NPD. Due to 
practicality considerations numbers were low, but the results were reproduced in a 
second experiment. Baseline NPD had recovered to pre-treatment values approximately 
48 hrs after treatment with 0.05 M C10. In contrast, the time (minimum 5 days) required 
to completely recover baseline NPD following treatment with 0.2 M, was longer than 
expected considering that tight junction integrity generally recovers within 24 hrs after 
treatment in human airway culture models [283,284]. I, therefore, speculated that other 
tissue alterations, for example C10-induced epithelial cell shedding, may be responsible 
for the prolonged recovery time; histological assessment confirmed this hypothesis. C10 
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treatment had led to dose-dependent epithelial cell shedding and the NDP recovery time 
in animals treated with 0.2 M C10 coincided with complete recovery of the surface 
epithelium when observed histologically (day 14) and was also consistent with 
published “repair-time” of approximately 7 days reported for mouse nasal epithelium 
after denudation with detergents [389].  
 
Viral vectors have achieved at least partial correction of the chloride transport defect in 
CF knockout mice, but, interestingly, even a high expression viral vectors such as 
Sendai virus has only resulted in 20-25% correction of the chloride ion transport defect 
compared to non-CF values [162,213,390]. Understanding this phenomenon may help 
to improve development of new treatments for CF. In contrast to viral vectors, non-viral 
vectors including GL67 have been less successful [175]. It has generally been 
postulated that transfection efficiency achieved with non-viral vectors in the mouse 
nasal epithelium is too low to correct chloride transport. To study this hypothesis further 
I assessed if the observed increase in gene expression in the murine nasal epithelium 
following C10 treatment would allow correction of the CF ion transport defect. In this 
experiment I increased perfusion time with the non-viral vector from 15 min (standard) 
to 1 hr. 15 min perfusion is more manageable for the operator and the level of gene 
transfer obtained is normally sufficient to answer general questions regarding for 
example delivery methods. However, in order to correct the ion transport defect in CF 
mice a high level of gene transfer is needed and with the aim to obtain the highest 
possible level of gene transfer, GL67 was perfused for 1 hr instead of the standard 15 
min perfusion.  
 
Despite 0.05 M C10 having previously significantly increased luciferese gene transfer 
efficiency, I did not achieve an improvement in chloride transport in the nose of FABp 
mice following C10 treatment and CFTR gene transfer. The lack of a significant 
restoration of the nasal PD in FABp mice might be due to sequence differences between 
mouse and human CFTR as the two species only share 78% identity at the amino acid 
level [391]. However, in the context of virus-mediated gene transfer the human cDNA 
was able partially to correct chloride transport, which makes the above hypothesis 
unlikely [162,213], An alternative explanation may be that the threshold gene 
expression for correction of the CF ion transport abnormalities in the murine nose was 
not reached despite C10 pre-treatment. It is unclear how much recombinant CFTR 
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protein per cell and how many corrected cells would be required to correct NPD in 
mice, although in vitro cell mixing studies have shown that 5-20% of non-CF cells can 
correct chloride transport in CF cultures, whereas correction of the sodium transport 
abnormality required close to a 100% of non-CF cells to be present in cell mixture 
[125,126]. Interestingly, no studies have ever detected changes in sodium ion transport 
in CF mice following gene transfer, which is likely to be due to the high number of cells 
needed to be transfected in order to correct the sodium transport defect. 
 
A study by Grubb et al has recently questioned the usefulness of NPD measurements in 
CF mouse nasal epithelium as a model for assessing gene transfer to ciliated respiratory 
epithelial cells [390]. The authors suggest that bioelectric responses in the mouse nose 
are largely regulated by the olfactory epithelium rather than the respiratory epithelium, 
implying that the ion transport differences between wild-type and CF knockout mouse 
are also generated due to CFTR-specific changes in the olfactory epithelium. These 
results are supported by the work of Ostrowski et al, who failed to restore the NPD in 
double-transgenic CF knockout mice with the human CFTR cDNA under the control of 
the FOXJ1 promotor, known to drive expression specifically in ciliated cells [392]. 
These studies suggest that expression of recombinant CFTR in ciliated cells may not be 
sufficient to correct the CF-related ion transport abnormalities in mice. The fact, that 
several studies have reported partial correction of chloride transport in CF mice after 
virus-mediated CFTR gene transfer [213,393] may be linked to the fact that viral 
vectors such adenovirus and Sendai virus have been reported to transduce olfactory 
epithelium efficiently [394,395]. 
 
To ensure that the lack of NDP correction was not due to failed gene transfer I 
quantified vector-specific CFTR cDNA in mouse respiratory epithelium using real-time 
RT-PCR. I used a technique that allowed harvesting of cell populations consisting of 
more than 80% respiratory epithelial purity from the mouse nasal epithelium [396]. I 
detected significant levels of vector-specific CFTR mRNA (approximately 20% of 
endogenous Cftr). However, surprisingly C10 pre-treatment did not significantly 
increased vector-specific CFTR expression compared to controls. This may be due to 
the larger inter-animal variability of the real-time PCR compared to the luciferase 
reporter gene assay. Alternatively, the large number of non-responders (59% of all 
samples) may have meant that the assay was no longer sufficiently powered to detect a 
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6-fold difference, which was previously observed in the corresponding experiment 
assessing luciferase expression levels following C10 pre-treatment and pCIKLux gene 
transfer (Section 7.4.6). Furthermore, the effect of C10 on non-viral mediated gene 
transfer could be plasmid dependent. CFTR pDNA (8520 base pairs) is larger than lux 
pDNA (5632 base pairs) and, although unlikely, the overall size of GL67/pCIKCFTR 
complexes may be greater compared to GL67/pCIKLux complexes. This may affect 
migration of the complexes through tight junctions and, thereby, access to possible 
receptors present on the basolateral membrane of AECs.   
 
As mentioned above, cell mixing studies have shown that only 5-20% of non-CF cells 
can correct chloride transport in CF cultures. Taking these findings into account, I 
wondered why the level of vector-specific CFTR mRNA (20% of endogenous Cftr) 
obtained in my experiment was not enough to correct the chloride ion transport. It is 
likely, that the CFTR mRNA expression level obtained (20% of endogenous Cftr) 
originated from very few cells (< 5%) and this low number of transfected cells would 
not have been sufficient to correct the chloride transport.  
 
To exclude that the above results were specific to the CFTR cDNA in the pCIKCFTR 
expression plasmid, I also quantified vector-specific mRNA after transfection with 
pCIKLux. However, similar to above I was unable to detect a significant increase in 
mRNA expression after C10 pre-treatment. In addition to higher inter-animal variability 
the luciferase reporter gene and the real-time PCR assay use different cell populations. 
 
As mentioned above, the cell harvesting technique used to collect cells for the real-time 
PCR assay is highly enriched for respiratory epithelial cells, whereas tissue used for the 
luciferase assay is a more heterogeneous population consisting of respiratory and 
olfactory epithelium and subepithelium. It is, therefore, possible that the increased 
luciferase expression following C10 pre-treatment is due to transfection of non-
respiratory epithelial cells, which would not have been detected with the real-time PCR 
assay. To further assess this possibility and in an attempt to correlate luciferase mRNA 
levels with luciferase protein expression, the nasal tissue harvested for detection of 
lucifease expression following transfection with pCIKLux could have been quantified 
for vector-specific mRNA. Alternatively, I could have attempted to determine luciferase 
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expression in the respiratory epithelial cells obtained via the harvesting technique 
developed for collection of cells for the real-time PCR assay.  
 
In addition to assessing the effect of low concentration C10 on CFTR gene transfer the 
effect of high concentration C10 (0.2 M) was also determined. However, considering 
that complete restoration of NPD after 0.2 M C10 perfusion was only achieved 
minimum 5 days after gene transfer, an expression plasmid with a longer-lasting 
expression profile, i.e. the human elongation factor 1 alpha promoter (EF1α) coupled to 
the CMV enhancer (CEFI), was used for these studies. This CEFI promoter/enhancer 
has been shown to lead to long-lasting expression in mouse lung, but had not been 
assessed in mouse nose [218]. I confirmed that the CEFI promoter/enhancer also led to 
persistent luciferase expression (>14 days) in the mouse nasal epithelium and was, 
therefore, suitable for further assessment. Similar to results described above, 0.2 M C10 
pre-treatment did not lead to increased CFTR mRNA expression, determined at day 14, 
in mice transfected with a plasmid carrying the human CFTR cDNA under the control 
of the CEFI promoter/enhancer (pGM169). Interestingly, vector-specific CFTR mRNA 
was detectable in mice pre-treated with 0.2 M C10 at day 14 (5% of endogenous Cftr). 
This finding may imply that CFTR mRNA positive respiratory epithelial cells 
(harvested using the above mentioned technique) have been generated from transfected 
basal cells retained after 0.2 M C10 treatment, as this treatment has shown to result in 
complete denudation of the respiratory epithelial cells. However, from the histological 
assessment I cannot determine whether basal cells were retained after 0.2 M C10 
treatment or not. Basal cells have previously been suggested to function as stem cells 
and transfection of stem cells may result in generation of airway epithelial cells with a 
functional CFTR channel.   
 
Previous in-house experiments have shown that levels of vector-specific CFTR mRNA 
expression in the range of 90% of endogenous Cftr levels did not lead to correction of 
the ion transport abnormalities in CF mice [175]. Gene expression achieved in 
experiments conducted as part of this thesis did not exceed these level. This plus the 
fact that pre-treatment with 0.2 M C10 caused significant tissue damage argued against 
following this line of labour expensive and time consuming investigations.  
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Importantly, I attempted to address which types of cells were transfected following 
luciferase and CFTR gene transfer to the nasal epithelium. Immunohistochemistry-
based methods or direct visualisation of GFP reporter gene expression are commonly 
used to visualise recombinant protein in target cells. In mouse nasal epithelium these 
techniques have been successfully used in the context of virus-mediated gene transfer 
[389,397]. However, cell identification after non-viral gene transfer to airway 
epithelium is more difficult. To the best of my knowledge, there are no published 
reports assessing non-viral gene transfer in mouse nasal epithelium. However, Jenkins 
et al claim to have localised luciferase expression immunohistochemically in murine 
bronchial AECs after transfection with a non-viral LID vector [202]. Furthermore, 
Davies et al have shown that direct visualisation of GFP can be used to assess GL67-
mediated gene transfer in the murine lung [398]. However, the overall number of GFP 
positive cells in the lung was very low and most GFP positive cells were parenchymal 
cells rather than airway epithelium. Consistent with Lee et al, I was unable to identify 
GFP positive cells in the mouse nasal epithelium after GL67-mediated gene transfer, 
even if C10 was pre-administered. These data further confirms that luciferase is a more 
sensitive reporter than GFP, whose sensitivity is for example affected by the 
comparatively high auto-fluorescence in mouse airways. Overall, GL67-mediated gene 
transfer is likely to result in GFP expression, which is below the detection limit of the 
assay and yet techniques to assess low level transfection are not available.   
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7.6 Summary 
 
In summary, both low (0.05 M) and high (0.2 M) concentrations C10 significantly 
increased luciferase reporter gene transfer to the murine nose following determination 
of the optimal delivery method for both tight junction opener and GTA. Furthermore, 
histological assessment and NPD measurements indicated that low concentration C10 
had some effect on tight junction permeability. In contrast high concentration C10 
completely destroyed the nasal epithelium. However, pre-treatment with low 
concentration C10 did not allow correction of the ion transport defect in CF mice or 
enhanced CFTR mRNA expressions levels. Moreover, attempts at assessing which cell 
types were transfected following reporter gene transfer was not successful, due to 
comparatively low levels of gene expression achieved after non-viral gene transfer. 
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Chapter 8: The effect of the medium chain fatty acid C10 on lipid-
mediated gene transfer in a human airway epithelial cell model 
 
 
8.1 Introduction to a human airway epithelial cell model 
 
As previously described, the effect of different classes of tight junction openers on 
GL67-mediated gene transfer has been assessed in vivo. The medium chain fatty acid, 
C10 enhanced gene transfer to the murine lung and nose most effectively. To extend 
these data to human airways, I next assessed the effect of C10 on GL67-mediated gene 
transfer in an ex vivo human airway epithelial cell model.  
 
8.1.1 Cell lines and primary cell culture models for human airways 
A large number of human non-CF and CF immortalised airway epithelial cell lines 
exist, which have been used extensively in CF research as airway epithelial cells are the 
target cells for CF therapies. These include cell lines such as CFBE41o- (CF bronchial 
epithelial cells), CFTE29o- (CF tracheobronchial epithelial cells), 16HBE14o- (WT 
bronchial epithelial cells) and 9HTEo- (WT tracheobronchial epithelial cells) [399] 
Although, immortalised cell lines are generally easy to culture, have a long lifespan and 
high proliferation rates they do not mimic the morphology, biochemical characteristics 
and cellular responses of the lung and, importantly, certain cellular features such as cilia 
and extracellular mucus barriers are missing. Cell lines also lack the complex cell 
composition of airways and with a few exceptions do not form stable tight junctions 
(i.e.16HBE14o-) [400]. The use of immortalised cell lines in optimising airway 
epithelial cell gene transfer is, therefore, limited. Moreover, immortalised cell lines are 
generally inaccurate in predicting gene transfer efficiency in vivo (U. Griesenbach, 
Department of Gene Therapy, Imperial College London, UK - personal 
communication).  
 
Primary human airway epithelial cells can be obtained from brushing the nasal passages 
or bronchi. In contrast to immortalised cell lines, these brushings are composed of a 
mixture of goblet and basal cells, as well as columnar ciliated and non-ciliated cells and, 
therefore, closely mimic the cell population of airways. However, a number of 
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disadvantages are linked to the use of primary human airway epithelial cells. (1) A 
limited number of cells (typically ~10
6
) are obtained during a given harvesting 
procedure (e.g. nasal brushing). (2) Primary cells are difficult to culture, have a limited 
life expectancy, generally dying within one or two days in culture. (3) Cells are often 
contaminated with bacteria, particularly when derived from CF airways. (4) Most 
importantly, cells collected by nasal and bronchial brushings have been removed from 
their basement membrane. The basolateral membrane is, therefore, exposed and easily 
assessable, limiting the model for optimisation of airway gene transfer [230,401]. 
 
8.1.2 Airway air liquid interface cultures 
To address this issue, over the last 10 years air liquid interface (ALI) cultures have been 
developed as a model for human airway. Cells isolated from human airways are seeded 
on semi-permeable membranes. After initial expansion under submerged conditions the 
apical membrane is exposed to air, while the basolateral membrane is exposed to culture 
medium to provide nutrients. After a few weeks in culture the cells form a tight cell 
layer and become ciliated. Good quality ALI cultures resemble nature human airway 
epithelium with respect to structure and cell composition (see below) and if 
appropriately looked after, remain viable for several months [373,402]. It is currently 
unclear which cell type is mainly responsible for cell division and differentiation when 
in culture, but it has been suggested that basal cells, often referred to as progenitor cells 
may have a role in this process. 
 
Human non-CF and CF airway ALI cultures have been used as models to assess airway 
epithelium properties, i.e. ASL height, ion composition, transepithelial ion transport and 
disease pathogenesis. Importantly, the CF airway ALI cultures display the characteristic 
ion transport and ASL height defects as observed in CF subjects [45,373,402]. 
Additionally, the cultures have been utilised for drug testing and gene therapy studies 
[401,403-405]. Kobinger et al, for example, have shown that a spike envelope 
glycoprotein (originating from the severe acute respiratory syndrome coronavirus) 
pseudotyped HIV vector efficiently transfect human airway ALI cultures [403]. Liu et 
al compared the efficiency of AAV (serotype 2 and 5)-mediated gene transfer in human 
and monkey airway ALI cultures and showed that AAV transfected monkey airway ALI 
cultures more efficiently (400-fold) [404]. Moreover, Zhang et al recently used a human 
parainfluenza virus to deliver CFTR gene to CF airway ALI cultures [127]. The study 
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showed correction of ion transport defects and restoration of ASL height and mucus 
transport to levels approaching non-CF cultures. Interestingly, Pickles and colleagues 
also found that delivery of the CFTR gene to approximately 25% of surface epithelial 
cells was sufficient to restore ASL height and mucus transport suggesting that gene 
transfer to the entire respiratory airway epithelium is not needed in order to achieve 
clinical benefit.  
 
Although, the studies quoted above illustrate the potential power of ALI cultures for 
optimisation of airway gene transfer, good quality ALI cultures are difficult to grow and 
to maintain. Routine large scale culturing of ALI cultures is generally only achieved in a 
few specialised centres. However, recently human non-CF airway epithelial ALI 
cultures have become commercially available from Epithelix Sarl (Epithelix Sarl, 
Geneva, Switzerland) [230]. Briefly, cultures are generated by isolating human airway 
epithelial cells from nasal polyps of healthy volunteers, seeding them onto a semi-
permeable membrane and keeping them submerged for cells to proliferate and reach 
confluence as described above. After confluence is reached, differentiation is induced 
by removing the apical medium and exposing the apical membrane to air.  
 
These cultures are characterised by a pseudostratified appearance which closely 
resembles that observed in airways in vivo and as expected for differentiated airway 
epithelia express specific markers, such as occludin and CFTR. Furthermore, electrical 
resistance measurements performed in the Epithelix cultures, which assess cell 
confluence and tight junction integrity, were well within the range of previously 
published values for human AECs in primary cultures [406-408]. Short-circuit current 
studies displayed the characteristic non-CF flux of ions through the ENaC and CFTR 
channels when cultures were treated with amiloride and forskolin (forskolin increases 
cAMP levels by activation of adenylate cyclase, which leads to CFTR channel 
activation) respectively, indicating a normal functioning airway epithelia. Finally, ALIs 
consist of ciliated and non-ciliated epithelial cells, goblet cells and basal cells and, 
therefore, resemble the structure of human airways (Figure 98). 
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Figure 98: Human bronchial biopsy and human airway air liquid interface culture 
Human pseudostratified respiratory epithelium from lung biopsy (a) and air liquid interface 
culture (b). Long arrows indicate ciliated columnar cells, small arrows indicate basal cells and 
arrow heads indicate goblet cells (Original magnification x100). 
a 
b 
lumen 
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8.1.3 Non-viral gene transfer in airway air liquid interface cultures 
Although successful viral gene transfer into airway ALI cultures has been reported (see 
above), non-viral gene transfer into these cultures has been inefficient, which suggests 
that ALI cultures are a good model for airway gene transfer as non-viral gene transfer in 
humans is, in comparison to viral gene transfer, also inefficient.  
 
The UK Cystic Fibrosis Gene Therapy Consortium has attempted to transfect ALI 
cultures with various commonly used non-viral gene transfer agents including 
Lipofectamine 2000, PEI and the cationic lipid GL67 complexed to a Firefly luciferase 
reporter gene (S. Xenariou, Department of Gene Therapy, Imperial College London, 
UK - personal communication). However, despite careful optimisation members of the 
Consortium were initially unable to generate convincing evidence of gene transfer in 
this model. However, this problem has recently been overcome by switching from a 
Firefly luciferase reporter gene to a Gaussia luciferase gene (see below). 
 
8.1.4 Gaussia luciferase reporter gene 
Luciferases are the most widely used reporter genes. These reporter systems are very 
sensitive, cheap and fast to assay, which make them extremely popular, especially in 
experiments where signal intensity is expected to be low, such as non-viral gene 
therapy.  
 
Luciferases are bioluminescence proteins which act as enzymes to catalyze the reaction 
between the substrate luciferin (generic term) and oxygen resulting in oxidation of 
luciferin (oxy-luciferin) and light emission [409]. The most commonly used luciferase 
reporter gene is Firefly luciferase from the firefly Photinus pyralis, which is widely 
used as a gene therapy reporter gene [410,411]. However, various other types of 
luciferase reporter genes, such as the secreted Gaussia luciferase, have been identified.  
 
Gaussia princeps is a bioluminescent marine copepod, approximately 10 mm long, 
which when attacked, startle and temporarily distract predators by emitting light [412]. 
Gaussia luciferase from Gaussia princeps is a secreted protein, which catalyzes the 
oxidation of coelenterazine producing coelenteramide, CO2 and blue-green light with a 
peak emission at ~475 nm [413] (Figure 99).  
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Figure 99: Oxidation catalyzed by Gaussia luciferase 
Marine copepod Gaussia princeps secretes the protein Gaussia luciferase, which catalyzes the 
oxidation of coelenterazine producing coelenteramide, CO2 and blue-green light with a peak 
emission at ~475 nm. The figure is taken from www.neb.com. 
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Recent studies utilising Gaussia luciferase include, for example, analysis of secretory 
pathway mechanisms [414,415], in vivo imaging of tumours [416,417] and, in 
combination with other luciferases, in dual- and triple-luciferase assays [418,419]. 
 
Gaussia luciferase presents several advantages over other luciferases. (1) It is more 
sensitive in vitro and in vivo than Firefly luciferase due to a longer half-life. (2) The 
protein is secreted and, therefore, can be detected in cell medium [420], which is useful 
for long-term duration studies. (3) The protein itself is heat stable, resistant to 
acidic/basic conditions and, in contrast to Firefly luciferase, does not require co-factors 
such as ATP or Mg
2+
 for optimal function [420]. 
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8.2 Aims 
 
The aim of this chapter was to assess the effect of C10 on GL67-mediated gene transfer 
in a human airway ALI model. Commercially available non-CF airway ALI cultures 
(MucilAir
TM
) (Epithelix Sarl, Geneva, Switzerland) were used in the experiments. The 
effect of C10 on transepithelial resistance, a read-out of tight junction integrity, was first 
determined. Secondly, transfection conditions were optimised prior to assessing the 
effect of C10 on gene transfer with GL67 complexed to a plasmid carrying the reporter 
gene Gaussia luciferase.  
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8.3 Materials and Methods  
 
8.3.1 C10 stock solutions 
A 0.5 M sodium caprate (C10) stock solution was made by dissolving 0.4855 g in a 
total of 5 ml sterile PBS (-CaCl2/-MgCl2) (pH 9.1). pH was not adjusted to 
physiological pH as this would cause precipitation of C10.  
 
8.3.2 Short-circuit current   
In my experience the quality and maturity of purchased ALI cultures can vary from 
batch to batch. In order to validate the ALI cultures (MucilAir
TM
) prior to initiating gene 
transfer experiments the effect of amiloride and forskolin on short-circuit current in 
three cultures from each batch was determined upon arrival.  
 
These validation measurements were performed a technician (M. Chan, Department of 
Gene Therapy, Imperial College London, UK). ALI cultures (MucilAir
TM
) were placed 
in Ussing chambers (insert size 9 mm) under short-circuit conditions (Warner 
Instruments U2500, Harvard Apparatus Ltd., Kent, UK). After approximately 30 min 
equilibration period, 10 µM amiloride (Sigma-Aldrich Com. Ltd., Poole, UK) was 
added to the apical surface followed approximately 5 min later by addition of 10 µM 
forskolin (Sigma-Aldrich Com. Ltd., Poole, UK) to both apical and basolateral surfaces. 
Throughout the experiment short-circuit current (Isc) was measured using software 
(DVC-1000 Voltage-Current Clamp, World Precision Instruments, Stevenage, UK). 
Short-circuit current measurements (Isc) are expressed as µA/cm
2
. 
 
8.3.3 Maximum tolerable concentration of C10 in ALI cultures 
The effect of C10 on cell viability was assessed by adding 12 µl of 0.05 M (pH 7.6), 
0.25 M (pH 8.9), 0.5 M C10 or PBS (-CaCl2/-MgCl2) in 188 µl MucilAir
TM 
Culture 
Medium onto the apical surface of the ALI cultures (MucilAir
TM
) (n=3/group). These 
conditions corresponded to final C10 concentrations of 3 mM, 15 mM and 30 mM, 
respectively. After 30 min incubation at 37ºC, the apical medium was removed, the 
basolateral medium replaced with fresh medium and the cells washed three times in 
MucilAir
TM
 Culture Medium. The respiratory epithelium was monitored carefully for 
cilia beating and signs of toxicity for the following 24 hrs.  
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8.3.4 Transepithelial resistance  
To assess the effect of C10 treatment on tight junctional permeability ALI cultures 
(MucilAir
TM
) were treated with C10 and the transepithelial resistance (Rt) across the 
respiratory epithelium measured. Briefly, 188 µl and 900 µl MucilAir
TM
 Culture 
Medium was added to the apical and basolateral compartment, respectively, before 
leaving the inserts to stabilize for minimum 20 min at 37ºC. Pre-treatment Rt 
measurements were performed in triplicate using an ohmmeter (EVOM - Epithelial 
Voltohmeter, World Precision Instruments, Stevenage, UK). 12 µl 0.05 M C10 or PBS 
(-CaCl2/-MgCl2) was then added onto the apical surface of the ALI cultures 
(MucilAir
TM
) (n=4/group) and the ALI cultures were then exposed to C10 or PBS for 30 
min or 4 hrs. Rt measurements were carried out in triplicate at 10 min, 30 min and 4 hrs 
while ALI cultures were still exposed apically to C10 or PBS. After removal of C10 or 
PBS from the apical surface, the basolateral medium was replaced with fresh 
MucilAir
TM
 Culture Medium. Rt measurements were repeated in triplicate at 24 hrs and 
48 hrs post treatment. For these Rt measurements, medium was added to the apical (200 
µl) and basolateral compartment (900 µl) a minimum of 20 min prior to performing the 
measurements. Transepithelial resistance measurements are expressed as Rt (Ω) x 
surface area (cm
2
).  
 
8.3.5 GL67-mediated gene transfer in ALI cultures 
12 µl 0.05M C10 or PBS (-CaCl2/-MgCl2) in 188 µl MucilAir
TM
 Culture Medium was 
added onto the apical surface of the ALI cultures (MucilAir
TM
) (n=4-6/group). After 30 
min incubation at 37ºC the apical medium was removed, the basolateral medium 
replaced with 700 µl fresh MucilAir
TM
 Culture Medium and the cells washed three 
times in Opti-MEM. Transfections were carried out with 100 µl GL67 complexed to 10 
µg pCIKLux or pCMV-GLux at a molar ratio of 1:4 and 6:8 (see Section 2.1.2 for 
details). As positive controls, cells were transfected with 100 µl recombinant Sendai 
virus (see Section 2.1.3 for details) carrying Firefly luciferase (10
7
 pfu in 100 µl 
medium/culture) (SeV-lux) and 100 µl Lipofectamine 2000 complexed to pCMV-GLux. 
Briefly, 25 µl Lipofectamine 2000 (Invitrogen Ltd., Paisley, UK) and 10 µg pCMV-
GLux were diluted in 60 µl and 15 µl Opti-MEM, respectively, gently mixed and 
incubated for 20 min at room temperature before use. After 6 hrs, 2 x 6 hrs (24 hrs 
apart) and 24 hrs transfection incubation time at 37ºC, the apical medium was removed 
and the basolateral medium replaced with 700 µl fresh MucilAir
TM
 Culture Medium 
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prior to further incubation at 37ºC. 48 hrs post transfection cells transfected with 
GL67/pCIKLux and SeV-lux were harvested and assayed for Firefly luciferase activity 
as described in section (Section 2.5.1 and 2.5.2). For cells transfected with pCMV-
GLux, 100 µl MucilAir
TM
 Culture Medium was added to the apical surface 48 hrs post 
transfection to retrieve the secreted GLux protein. The ALI cultures were then incubated 
for 1 hr at 37ºC prior to harvesting the apical medium for detection of Gaussia 
luciferase as described in Section 2.5.3. 
 
8.3.6 Statistical analysis 
Results are presented as dot plots with the mean of the group shown as a horizontal line 
or as mean ± standard SEM. Data was analysed using ANOVA plus a Bonferroni 
correction or independent sample t-test where appropriate. Where necessary, raw data 
were log10 transformed to ensure normal distribution (Kolmogorov-Smirnov normality 
test was performed) and equal variances between groups. A non-parametric Mann 
Whitney test or a Kruskal-Wallis with Dunn‟s correction was carried out when the 
assumptions were not met after transformations. The null hypothesis was rejected at 
p<0.05. 
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8.4 Results  
 
In this chapter, I aimed to assess the effect of C10 on GL67-mediated gene transfer in a 
human ALI model. Prior to carrying out gene transfer experiments, proof-of-principle 
that C10 treatment altered tight junction barrier function was determined.  
 
8.4.1 ALI cultures responded appropriately to amiloride and forskolin 
In my experience the quality and maturity of purchased ALI cultures can vary from 
batch to batch. Therefore, three ALI cultures from each batch were validated by 
assessing the effect of amiloride and forskolin on short-circuit current prior to initiating 
gene transfer experiments. Short-circuit current measurements are a good read out of 
cell integrity and a tight epithelial cell layer. They are performed by placing the ALI 
culture in an Ussing chamber and then measure the ion transport after addition of 
amiloride and forskolin. The ENaC channel blocker amiloride results, as previously 
mentioned, in inhibition of sodium absorption through the ENaC channel and forskolin 
increases cAMP levels by activation of adenylate cyclase, which leads to chloride 
channel activation (including activation of CFTR) and increased chloride secretion. 
These changes in ion transport are representative of human airways and results in a 
characteristic short-circuit current trace.  
 
Figure 100 shows a representative trace from an ALI culture treated first with amiloride 
and then with forskolin. As expected a decrease in short-circuit current was observed in 
response to amiloride treatment due to inhibition of sodium absorption via ENaC. In 
addition, forskolin induced activation of chloride transport and increased the current. 
All cultures showed an appropriate response to drug treatment similar to human airways 
and I concluded that the cultures were electrically tight and, therefore, suitable for 
assessing the effects of C10 on gene transfer.   
 
8.4.2 3 mM C10 was the maximum tolerable concentration in ALI cultures 
Prior to assessing the effect of C10 on gene transfer efficiency and tight junction barrier 
function, the effect of different C10 concentrations on cell viability was assessed.  
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Figure 100: Short-circuit current trace in ALI culture 
ALI cultures (MucilAir
TM
) were placed in Ussing chambers under short-circuit conditions. After 
approximately 30 min equilibration period, 10 µM amiloride was added to the apical surface 
followed 5 min later by addition of 10 µM forskolin to both apical and basolateral surfaces. 
Short-circuit current measurements (Isc) are expressed as µA/cm
2
. Three ALI cultures were 
assessed per batch received. The above is a representative trace.  
Amiloride    Forskolin 
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These experiments were performed as C10 treatment might cause cell shedding, which 
would interfere with transepithelial resistance measurements and hereby the 
assessments of tight junction barrier function. 3 mM, 15 mM and 30 mM C10 was 
added onto the apical surface of ALI cultures (n=3/group) inserts for 30 min. The 
highest concentration tested (30 mM) was based on relevant literature assessing the 
effect of C10 treatment on adenovirus-mediated gene transfer into differentiated airway 
epithelial cells ex vivo [283,284]. In these studies, the transepithelial resistance dropped 
significantly when human airway ALI cultures were treated with 30 mM C10 and upon 
removal of C10 transepithelial resistance recovered to pre-treatment values. 
Furthermore, C10 treated cultures showed a significant increased in adenovirus-
mediated gene transfer compared to controls and, importantly, the effect of C10 was not 
associated with changes in the histological appearance of the epithelium or an increase 
in lactate dehydrogenase levels.  
 
As recommended by Epithelix Sarl cilia beating is a good indicator of “cell well-being”. 
The cultures were, therefore, monitored carefully at regular intervals for the next 24 hrs. 
As shown in Figure 101d, cells on inserts treated with 30 mM C10 were partly stripped 
off after 30 min incubation time and no cilia beating was observed on the remaining 
cells. A similar response was seen following treatment with 15 mM C10, although, on 
gross examination, fewer cells appeared to be stripped off compared to treatment with 
30 mM C10. In contrast, the 3 mM C10 caused no cell shedding and cilia were beating 
actively after 30 min incubation time (Figure 101c). Inserts treated with 3 mM C10 
were indistinguishable from control inserts treated with PBS (Figure 101b). 24 hrs post 
treatment the cilia were beating efficiently and there was no cell shedding. Again inserts 
treated with 3 mM C10 were indistinguishable from control inserts treated with PBS.  
Based on these observations the effect of 3 mM C10 on tight junctional permeability 
was assessed.  
 
8.4.3 C10 decreased transepithelial resistance in ALI cultures 
As proof-of-principle that C10 treatment altered tight junctional permeability, the 
transepithelial resistance across the respiratory epithelium was measured as a read-out 
of airway tight juntional integrity.  
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Figure 101: ALI cultures after treatment with different concentrations of C10  
The apical surface of ALI cultures (MucilAir
TM
) was either untreated (a) or exposed to PBS (b), 
3 mM C10 (c) or 30 mM C10 (d) for 30 min (n=3/group). The apical medium was then removed 
and representative images were taken (Original magnification: x20). 
 
 
 
 
 
 
b a 
c d 
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In a fully differentiated airway epithelium opening of tight junctions by addition of a 
tight junction opener will result in a significant drop in transepithelial resistance. Upon 
removal of the tight junction opener the tight junctions will reform and transepithelial 
resistance will return to pre-treatment values.  
 
Transepithelial resistance measurements (Rt) were carried out prior to adding C10 onto 
the apical surface of the ALI culture. Cultures were then exposed to C10 (3 mM) or 
PBS for 30 min (n=4/group). Rt measurements were performed after 10 min and 30 min 
incubation with C10 to monitor opening of tight junctions. The TJ opener was then 
removed and Rt measurements were repeated 24 hrs and 48 hrs after treatment to 
monitor reversal of the effect of the TJ opener. The time points chosen were base on 
relevant literature [283,284]. The ALI cultures are fragile and easily damaged with the 
electrodes required to perform the Rt measurements. I, therefore, restricted the number 
of post-treatment measurements to a minimum.   
 
As shown in Figure 102, 10 min incubation with C10 had no effect on Rt compared to 
PBS-treated control cultures. However, after 30 min Rt had decreased to approximately 
25% of pre-treatment values, whereas PBS treatment caused no change in Rt (p<0.05). 
Upon removal of C10, Rt increased over the next 24 hrs and returned to levels above 
pre-treatment values by 48 hrs, however, the Rt observed 48 hrs post-treatment was not 
significantly different from the pre-treatment value. Interestingly, a non-significant 
increase in Rt was also observed 48 hrs post PBS treatment.  
 
To maximise the effect of C10 on GL67-mediated gene transfer efficiency I attempted 
to reduce the transepithelial resistance further by increasing C10 incubation time to 4 
hrs. However, 4 hrs incubation with C10 did not further reduce Rt compared to 30 min 
incubation time. An incubation time of 30 min was, therefore, used in subsequent 
experiments.    
 
8.4.4 C10 did not increase GL67-mediated Firefly luciferase gene transfer in ALI 
cultures 
Attempts at transfecting the ALI cultures with GL67 or Lipofectamine 2000 complexed 
to pCIKLux, performed by various people in the Department, have to date been 
unsuccessful (manuscript in preparation). 
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Figure 102: Effect of C10 on transepithelial resistance (Rt) 
ALI cultures (MucilAir
TM
) were treated with 3 mM C10 or PBS on the apical surface for 30 
min. Triplicate transepithelial resistance (Rt) measurements were performed at 10 min, 30 min, 
24 hrs and 48 hrs. Data are expressed as mean ± SEM (n=4/group), * = p<0.05 C10 compared to 
PBS 30 min post-treatment. 
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I, therefore, assessed if opening of tight junctions though C10 pre-treatment would 
enhance GL67-mediated gene transfer efficiency of air liquid interface cultures.  
 
ALI cultures were treated with 3 mM C10 or PBS on the apical surface. After 30 min 
incubation time C10 and PBS (n=4-6/group) were removed and cultures were 
transfected with GL67 complexed to pCIKLux (10 µg/culture) using a 1:4 (lipid:DNA) 
molar ratio, which had previously been optimised, for 6 hrs or 24 hrs [173]. In addition, 
C10 or PBS pre-treated control cultures were transfected with recombinant Sendai virus 
carrying a luciferase reporter gene (SeV-lux). Negative control cultures remained 
untreated. 48 hrs post transfection the cells were harvested and assayed for luciferase 
activity. As shown in Figure 103, SeV-lux transfected ALI cultures efficiently (p<0.01) 
with expression levels being 22300-fold higher than the untransfected controls. 
Interestingly, C10 pre-treatment further significantly (p<0.01) increased expression by 
approximately 40-fold. As previously mentioned, GL67-mediated transfection did not 
lead to luciferase expression in culture pre-treated with PBS and transfection efficiency 
was not improved through pre-treatment with C10. This may have been due to 
transfection efficiency being below the detection limit of the assay.    
 
8.4.5 6:8 lipid/DNA ratio and 6 hrs transfection time were optimal conditions for 
GL67- mediated Gaussia luciferase gene transfer in ALI cultures 
During the course of the project various people in the Department evaluated a novel 
reporter gene, secreted Gaussia luciferase (GLux), for airway gene transfer and 
demonstrated that GLux was more sensitive than Firefly luciferase in various in vivo 
and ex vivo airway models (manuscript in preparation). GLux was, therefore, assessed 
in ALI cultures.  
 
ALI cultures were first transfected with pCMV-GLux (10 µg/culture) complexed to 
GL67 using the standard 1:4 lipid/DNA molar ratio or remained untransfected 
(n=6/group). 48 hrs post transfection medium was added to the apical surface and the 
cultures were incubated for 1 hr prior to harvesting the apical medium for detection of 
GLux. Significant (p<0.01) levels of GLux expression were detectable in the apical 
medium 48 hrs after transfection, indicating that GLux was a more sensitive reporter 
than Firefly luciferase in ALI cultures (Figure 104). 
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Figure 103: Firefly luciferase expression after C10 pre-treatment and transfection with 
GL67/pCIKLux 
ALI cultures (MucilAir
TM
) were treated with 3 mM C10 or PBS on the apical surface for 30 
min. PBS and C10 were then removed and cultures were transfected with GL67/pCIKLux (1:4 
molar ratio) for 6 hrs and 24 hrs. As a positive control cultures were transfected with 100 µl 
SeV-lux (10
7
 pfu/100 µl). Untransfected (UT) cultures were included as a negative control. 48 
hrs post transfection the epithelium was harvested and assayed for luciferase activity. Each dot 
represents one culture with the mean lux expression of the group shown as a horizontal line. ** 
= p<0.01 SeV-lux compared to UT and ** = p<0.01 no pre-treatment (SeV-lux) compared to 
C10 pre-treatment (SeV-lux). 
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Figure 104: Gaussia luciferase expression after transfection with GL67/pCMV-GLux at 
different molar ratios 
ALI cultures (MucilAir
TM
) were transfected with GL67/pCMV-GLux at molar ratios of 1:4 and 
6:8 for 6 hrs. Untransfected (UT) cultures were included as a negative control. 48 hrs post 
transfection medium was added to the apical surface and the cultures were incubated for 1 hr 
prior to harvesting the apical medium for detection of GLux activity. Each dot represents one 
culture with the mean GLux expression of the group shown as a horizontal line. ** = p<0.01 
GL67/pCMV-GLux 1:4 molar ratio compared to UT and ** = p<0.01 GL67/pCMV-GLux 1:4 
molar ratio compared to 6:8 molar ratio. 
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I also assessed if a 6:8 lipid/DNA molar ratio, which is generally used for nebulisation 
into human lung [173], would lead to an increased transfection efficiency compared to 
1:4 lipid/DNA molar ratio. GLux expression was significantly (p<0.01) higher using the 
6:8 compared to the 1:4 lipid/DNA ratio and the former was used for subsequent 
experiments (Figure 104). 
 
To assess the effect of transfection time, ALI cultures were transfected with 
GL67/pCMV-GLux (6:8 molar ratio) for 6 hrs, 2 x 6 hrs (24 apart) or 24 hrs 
(n=6/group). 48 hrs post transfection the apical medium was harvested and assayed for 
GLux activity. Figure 105 shows that transfection for 2 x 6 hrs (24 hrs apart), offered no 
additional increase in lux expression compared to the standard 6 hrs transfection 
(p>0.05). Transfection for 24 hrs reduced GLux expression to background levels, likely 
to be due to toxicity. Based on these results I concluded that GL67/pCMV-GLux led to 
transfection of ALI cultures and that a 6:8 molar ratio of lipid:DNA combined with a 6 
hr transfection time maximised levels of gene transfer. These conditions were used in 
subsequent experiment.  
 
8.4.6 C10 did not increase GL67-mediated Gaussia luciferase gene transfer in 
ALI cultures 
The improved sensitivity of GLux resulted in detection of GL67-mediated gene transfer 
into ALI cultures, therefore made it feasible to re-assess the effect of C10 treatment on 
non-viral gene transfer. 
 
The experiment was performed as described for Firefly luciferase studies described 
above. ALI cultures were treated with 3 mM C10 or PBS on the apical surface for 30 
min or remained untreated. Upon removal of C10 and PBS, cultures were transfected 
with GL67 complexed to pCMV-GLux (6:8 molar ratio) for 6 hrs. 48 hrs post 
transfection medium was added to the apical surface and the cultures were incubated for 
1 hr prior to harvesting the apical medium for detection of GLux.  
 
As shown in Figure 106, GL67-mediated gene transfer led to GLux expression in ALI 
cultures that were not pre-treated with C10 or PBS (p<0.05). Importantly, C10 did not 
increase GLux expression compared to PBS-treated controls. 
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Figure 105: Gaussia luciferase expression after transfection with GL67/pCMV-GLux at 
different lengths of time 
ALI cultures (MucilAir
TM
) were transfected with GL67/pCMV-GLux (6:8 molar ratio) for 6 hrs, 
2 x 6 hrs and 24 hrs. Untransfected (UT) cultures were included as a negative control. 48 hrs 
post transfection medium was added to the apical surface and the cultures were incubated for 1 
hr prior to harvesting the apical medium for detection of GLux activity. Each dot represents one 
culture with the mean GLux expression of the group shown as a horizontal line. 
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Figure 106: Gaussia luciferase expression after C10 pre-treatment and transfection with 
GL67/pCMV-GLux 
ALI cultures (MucilAir
TM
) were treated with 3 mM C10 or PBS on the apical surface for 30 
min. PBS and C10 were then removed and cultures were transfected with GL67/pCMV-GLux 
(6:8 molar ratio) for 6 hrs. Untransfected (UT) cultures were included as a negative control. 48 
hrs post transfection medium was added to the apical surface and the cultures were incubated 
for 1 hr prior to harvesting the apical medium for detection of GLux activity. Each dot 
represents one culture with the mean GLux expression of the group shown as a horizontal line. * 
= p<0.05 GL67/pCMV-GLux compared to UT. 
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Lipofectamine 2000 (LF2000) is a cationic lipid commonly used for in vitro studies and 
often more efficient then GL67 in ex vivo models. Before drawing a final conclusion I 
also assessed the effects of C10 on LF2000-mediated gene transfer in ALI cultures. As 
shown in Figure 107, LF2000 significantly increase GLux expression in transfected ALI 
cultures (p<0.01), but similarly to GL67 C10 had no beneficial effect on LF2000-
mediated gene expression in ALI cultures. 
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Figure 107: Gaussia luciferase expression after C10 pre-treatment and transfection with 
Lipo/pCMV-GLux 
ALI cultures (MucilAir
TM
) were treated with 3 mM C10 or PBS on the apical surface for 30 
min. PBS and C10 were then removed and cultures were transfected with Lipo/pCMV-GLux for 
6 hrs. Untransfected (UT) cultures were included as a negative control. 48 hrs post transfection 
medium was added to the apical surface and the cultures were incubated for 1 hr prior to 
harvesting the apical medium for detection of GLux activity. Each dot represents one culture 
with the mean GLux expression of the group shown as a horizontal line. ** = p<0.01 
Lipo/pCMV-GLux compared to UT. 
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8.5 Discussion   
 
Historically cell lines and mice have been used to screen and validate lung gene transfer 
agents and both models have pros and cons (see Section 8.1 and Chapter 7). More 
recently it has been recognised that human air liquid interface cultures are also a 
valuable model for validating gene transfer agents (see Section 8.1).  However, their use 
has not been very widespread because until recently good quality human ALI cultures 
could only be grown in a small number of specialised laboratories. More recently 
human airway ALI cultures have now become commercial available (for example from 
Epithelix Sarl, Geneva, Switzerland) and, although expensive, the more readily 
availability of the MucilAir
TM
 ALI cultures will allow for more widespread use of this 
model. However, airway ALI cultures are only a useful model if they are fully 
differentiated and have a cell composition which resembles the human airway. 
Importantly, MucilAir
TM 
ALI cultures fulfil these requirements.  
 
In addition to confirming the histological appearance of the MucilAir
TM 
ALI cultures, I 
showed that the electrophysiological ion transport characteristics, determined by short-
circuit current measurements, were representative of human airways and, thereby 
confirmed data previously published by Wiszniewski et al [230]. MucilAir
TM 
ALI 
cultures are currently generated from human nasal polyps but Liu et al have shown 
comparable short circuit current profiles in ALI cultures grown from tracheobronchial 
tissue [421], suggesting that the fact that the MucilAir
TM 
ALI cultures were grown from 
nasal polyps does not alter their electrophysiological responses. However, a long-term 
goal for Epithelix Sarl is to provide cultures generated from bronchial cells (i.e. 
bronchial brushings) and my Department and Epithelix Sarl have established a 
collaboration to achieve this.  In addition, CF airway ALI cultures will be needed to 
assess the effect of CFTR gene transfer. However, these are currently not available as it 
is difficult to obtain CF nasal polyp tissue on a regular basis. Again, my Department has 
established a collaboration with an ear nose throat (ENT) surgeon (due to start in 
summer 2010) to collect CF nasal polyps which will then be processed by Epithelix 
Sarl.  
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Prior to assessing the effect of C10 on tight junction barrier function the optimal C10 
concentration to ensure ALI cell viability was determined. Based on publications by 
Coyne et al 30 mM C10 has been shown to reduce transepithelial resistance and 
increase paracellular permeability significantly in human respiratory ALIs without 
affecting cell viability and without increasing lactate dehydrogenase levels [283,284]. 
However, here I have shown that 30 mM C10 partially stripped off the airway 
epithelium, and that the concentration had to be reduced to 3 mM C10 before the 
epithelium did not show gross signs of toxicity. The reasons for differences in culture 
susceptibility to C10 between my work and the previous studies are unknown, but may 
be related to the origin of the cells, the culture conditions, the inserts used and 
importantly age and differentiation status of the cultures. In contrast to my work Coyne 
et al isolated nasal or bronchial cells from surgical specimens and, although the cells 
were plated on inserts identical to ours, the exact culture conditions used differed (e.g. 
culture medium, time in culture, number of cell passages). Moreover, my ALI cultures 
were older at the time they were used for experiments compared to the published studies 
and it is likely that the differentiation state was, therefore, also different.  
 
Pre-treatment with 3 mM C10 reversible decreased transepithelial cell resistance, 
thereby indicating that C10 had an effect on tight junction integrity. This effect was 
transient and tight junction integrity had returned to baseline levels approximately 24 
hrs after treatment. The transient response to C10 treatment is encouraging from a 
clinical point of view as return of the tight junction integrity following treatment is 
important for normal physiological function. In my hands, transepithelial resistance 
decreased approximately 25% after treatment with C10 for 30 min, whereas Coyne et al 
showed a 90% decrease within a few minutes [283,284]. Exposing MucilAir
TM 
ALI 
cultures to C10 for 10 min resulted in only approximately 5% decrease. The reasons for 
these differences (i.e. % decrease and C10 exposure time) are unknown, but may, as 
described above, be due to the different cell types employed to grow the cultures and 
the age and differentiation status of the cultures. In addition, a 10-fold lower C10 
concentration was used in my work compared to Coyne et al, which can explain the 
actual difference in effect observed and the longer C10 exposure time necessary for the 
effect to become evident.  
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When the effect of C10 pre-treatment on GL67-mediated gene transfer was first 
assessed, ALI cultures transfected with SeV carrying Firefly luciferase were included as 
positive controls. SeV transfects airway epithelial cells very efficiently and in my 
experiment this control, therefore, assessed viability of the cultures reliably. 
Surprisingly, C10 pre-treatment significantly increased SeV-lux transfection efficiency. 
Opening of tight junctions following C10 treatment may allow the viral vector access to 
the basolateral membrane, which may further enhance virus entry into the cells. 
 
Using the common Firefly luciferase reporter gene, the effect of C10 pre-treatment on 
GL67-mediated gene transfer was assessed. Transfections with GL67 were carried out 
for either 6 hrs or 24 hrs. The longer exposure time (i.e. 24 hrs) was included to allow 
for maximal contact time between the vector and the epithelium, which may enhance 
vector uptake and thereby increase gene transfer efficiency. However, C10 pre-
treatment did not lead to detectable reporter gene expression after transfections with 
GL67 for 6 hrs or 24 hrs. I cannot exclude that C10 pre-treatment may have had an 
effect, but did not raise transfection efficiency above the detection limit of the assay.  
 
For comparison, Chu et al have previously shown that GL67-mediated gene transfer 
was significantly raised following EGTA pre-treatment of normal human bronchial 
epithelial (NHBE) cells grown and maintained under ALI conditions [215]. In this 
experiment secreted alkaline phosphatase was used as a reporter gene suggesting that 
this reporter gene may be more sensitive than Firefly luciferase thereby allowing 
detection of GL67-mediated gene transfer. Moreover, the ALI cultures employed by 
Chu et al were described as polarised cells with apical microvilli and closely apposed 
cell membranes, which was reflected by the high transepithelial resistance measured 
across the cultures. However, these cultures were not fully differentiated into a 
pseudostratified airway epithelium consisting of ciliated and non-ciliated cells, goblet 
cells and basal cells as found in MucilAir
TM 
ALI cultures. This could also explain the 
difference in gene transfer efficiency observed after pre-treatment with a tight junction 
opener in the study by Chu et al and my work. It is likely that confluent polarised 
NHBE cells are less tight compared to a fully differentiated airway epithelium and tight 
junction openers may therefore have a more pronounced effect on polarised NHBE cells 
resulting in a greater increase in gene transfer in these cells.  
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In a further attempt to assess non-viral gene transfer in human airway ALI cultures the 
highly sensitive Gaussia luciferase reporter gene assay was used. The increased assay 
sensitivity allowed detection of GL67-mediated gene transfer into human airway ALI 
cultures and allowed us to optimise transfection parameters. First, I determined the 
optimal transfection conditions for GL67/pCMV-GLux in order to allow for maximal 
expression of GLux. I showed that a lipid/DNA ratio of 6:8 resulted in significantly 
higher levels of gene transfer compared to a molar ratio of 1:4. A lipid/DNA ratio of 1:4 
was initially optimised for nasal instillation in the mouse whereas a ratio of 6:8 was 
optimised for nebulisation in mouse and human studies. Mixing lipid and DNA in 
different ratios results in different properties of the complexes due to a difference in 
surface charges, which is likely to influence the uptake of the complexes and thereby 
transfection efficiency. Moreover, a lipid/DNA ratio of 6:8 results in complexes which 
are more viscous compared to a 1:4 ratio. This property may prolong the contact time 
between vector and airway epithelium as beating cilia may take longer to remove the 
complexes from the apical surface of the cells possibly resulting in increased uptake and 
gene transfer.  
 
I also assessed the effect of various transfection times (6 hrs, 2 x 6 hrs (24 hrs apart) and 
24 hrs) on gene transfer. Transfection for 2 x 6 hrs (24 hrs apart) offered no additional 
increase in lux expression compared to the standard 6 hrs transfection. Importantly, no 
gross changes to the epithelium were observed. In contrast, exposing the cultures to the 
vector for 24 hrs resulted in epithelial damage and reduced cilia beating, explaining the 
lack of GLux expression in these cultures.  
 
The increased assay sensitivity allowed us to re-assess the effect of C10 on 
GL67/pCMV-GLux mediated gene transfer. Although, the numbers were comparatively 
low due to the high costs of the cultures (approximately €50 per culture), C10 treatment 
clearly did not enhance GL67-mediated gene transfer. Before drawing a final 
conclusion, the effect of C10 on Lipofectamine-mediated gene transfer was assessed, as 
it is a well validated and widely used cationic lipid for in vitro transfections 
(www.invitrogen.com). Similarly to GL67, C10 had no beneficial effect on 
Lipofectamine-mediated gene expression in ALI cultures. 
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Interestingly, PBS pre-treatment reduced GL67-mediated GLux expression back to 
background levels. This has previously been observed in the nasal epithelium of vehicle 
treated mice in vivo (see Chapter 5 and 6). It may be that pre-treatment with PBS causes 
swelling of the cells, thereby impairing vector uptake [319]. However, considering that 
Lipofectamine-mediated gene transfer was not reduced when cultures were pre-treated 
with PBS, it is likely that the overall numbers in the experiment were too low to 
determine conclusively the effect of PBS on gene transfer. However, considering, that 
opening of tight junctions clearly did not enhance gene transfer, I did not follow-up the 
PBS effect in more detail considering the high costs of the ALI cultures. 
  
In addition, my work shows that transfection efficiency into ALI cultures is highly 
variable. The magnitude of gene expression was dependent on the batch of ALIs used. 
The reasons for this are currently unknown, but may be linked to the age and 
differentiation of the cultures or the polyp donor. These finding are currently being 
further investigated in the Department. 
 
Coyne et al has, as previously mentioned, shown that adenovirus-mediated gene transfer 
into ALI cultures was significantly enhanced following pre-treatment with C10 
[283,284]. The size difference between viral and non-viral vectors is likely to play a 
role in the different C10 responses observed in the studies by Coyne et al and my work. 
Viral vectors have an average size of approximately 100 nm and in comparison 
GL67/DNA complexes measure 200-600 nm [225]. Viral vectors may, therefore, easily 
gain access to the basolateral membrane via the open tight junctions whereas non-viral 
vectors may be too bulky to pass through the junction. Furthermore, a 10-fold lower 
C10 concentration was used in my work compared to Coyne et al. The lower C10 
concentration used in my work may, therefore, not be adequate to open the tight 
junctions sufficiently to allow GL67 access to the basolateral membrane. However, as 
mentioned above it was not feasible to raise the concentration of C10 due to toxicity.  
 
I showed an increase in GL67-mediated gene transfer in the mouse nose and lung 
following pre-treatment with C10, which I have not been able to replicate in the human 
airway ALI cultures. The reasons for this are likely to be complex. In the mouse lung, 
delivery of C10 via nasal instillation is likely to lead to pooling of the tight junction 
opener in the parenchyma and the effect of C10 on tight junctional integrity may be 
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more pronounced in the parenchyma compared to the respiratory epithelium. This 
would result in an increase in gene transfer in the murine lung, which would not be 
reflected in the human airway ALI cultures which consist of human respiratory 
epithelium. In the mouse nose, the cell composition resembles the human airways and 
compared to the murine lung the nose is, therefore, considered a better model. However, 
other factors, such as the C10 dose delivered and delivery methods employed, are likely 
to affect gene transfer efficiency and may in part explain why gene transfer was not 
increased in ALI cultures after C10 pre-treatment. Although, the dose delivered was 
optimised separately in the two models (i.e. mouse nose and human airway ALI 
cultures), the murine nasal epithelium may be more robust, thereby allowing a 
comparatively higher dose of C10 to be added. Alternatively, different species may just 
react differently to the effect of C10 even though the epithelium targeted (i.e. 
differentiated respiratory epithelium) is the same. Taking the results and these 
considerations into account, the human airway ALI cultures may be a good model of the 
human airways.  
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8.6 Summary 
 
In summary, human airway ALI culture, exposed to C10 for 30 min, resulted in a 
significant decrease in transepithelial resistance, which returned to pre-treatment values 
24 hrs post treatment. The highly sensitive Gaussia luciferase reporter gene assay 
allowed us to detect GL67-mediated gene transfer into human airway ALI cultures, 
which meant transfection parameters could be optimised. However, C10 pre-treatment 
did not enhance GL67/pCMV-GLux mediated gene transfer into human airway ALI 
cultures.  
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Chapter 9: Summary and future directions for tight junction openers 
 
 
9.1 Summary  
 
This thesis assessed the effect of different classes of tight junction openers on GL67-
mediated gene transfer to the airway epithelium of mice. In summary, EGTA had no 
effect on GL67-mediated gene transfer and attempts assessing whether EGTA disrupted 
tight junctions between airway epithelial cells in vivo, using a TEM-based technique, 
were not successful. In contrast, pre-treatment with C10, C12 and LPC significantly 
enhanced gene transfer to both murine lung and nose after careful optimisation of drug 
doses and delivery. However, compared to C10, C12 and LPC pre-treatment proved less 
efficient resulting in a smaller increase in gene transfer in both murine lung and nose. 
C10 was, therefore, selected for additional experiments, aimed at assessing the effect of 
the tight junction opener on CFTR gene transfer and correction of the ion transport 
defect in the nose of CF knockout mice. Both low (0.05 M) and high (0.2 M) 
concentrations of C10 significantly increased reporter gene transfer to the nose 
following determination of the optimal delivery method for the tight junction opener 
and GTA. Furthermore, histological assessment and NPD measurements indicated that 
low concentration C10 altered tight junction permeability. However, pre-treatment with 
low concentration C10 did not allow correction of the ion transport defect in CF mice or 
enhanced CFTR mRNA expressions levels. CFTR mRNA expressions levels were not 
enhanced after pre-treatment with high concentration C10 either and, furthermore this 
concentration caused significant tissue damage. Finally, the effect of C10 on GL67-
mediated gene transfer in an ex vivo human airway epithelial cell model was assessed in 
order to extend the data from mouse to human airways. C10 pre-treatment resulted in a 
significant decrease in transepithelial resistance indicating an opening of tight junctions. 
Although, using the highly sensitive Gaussia luciferase reporter gene assay, C10 pre-
treatment did not enhance GL67-mediated gene transfer into human airway ALI 
cultures. Overall, C10 pre-treatment increased GL67-mediated reporter gene transfer to 
the murine nose and lung. However, the data highlighted a narrow toxicity-efficacy 
window, resulting in tissue damage at higher concentrations.  
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9.2 Future directions  
 
The data presented in this thesis may warrant assessing the effect of C10 on GL67-
mediated gene transfer in a larger animal model such as the sheep. In contrast to mouse 
models sheep have similar size lungs to man, which allows easy access to pulmonary 
airway epithelial cells and the tight junction opener and GTA can be nebulised 
individually to the sheep using a clinically relevant nebuliser, thereby mimicking 
delivery in humans. Furthermore, methods for harvesting of respiratory airway 
epithelial cells, the target for CF gene therapy, have been developed and in contrast to 
mice, these cells can easily be harvested via bronchial brushings or biopsies. These 
sampling methods, therefore, allow for assessment of gene transfer into the relevant 
pulmonary cells. As for the mouse, careful optimisation of C10 doses and the time 
interval between nebulising C10 and the GTA will be needed in order to avoid tissue 
damage and maximise the effect on gene transfer efficiency.  
 
The drawback of using a larger animal model to assess the effect of C10 on gene 
transfer efficiency is, of course, that a CF model is not yet available to the wider 
research community and importantly functional assays, such as correction of the ion 
transport defect can, therefore, not be employed to assess the effect of C10. The recent 
development of a CF pig may in the near future change this. Rogers et al chose pigs to 
generate a new CF model as pigs in terms of anatomy, biochemistry, physiology, size, 
life span and genetics are more similar to humans than mice [73]. Interestingly, the 
generated CFTR
-/-
 newborn pigs exhibited defective chloride transport and developed 
meconium ileus, pancreatic destruction and biliary cirrhosis, thereby, replicating 
abnormalities seen in newborn humans with CF [74,76]. Furthermore, CF pigs 
developed CF lung disease, including airway inflammation, mucus accumulation and 
infection within months of birth and, additionally, these pigs failed to eradicate bacteria 
effectively as wild-type controls [75]. The findings in the CF pig model are in stark 
contrast to CF mice models. Although, lung, intestinal and pancreatic abnormalities are 
seen in CF mice, the murine models do not exhibit lung disease, meconium ileus and 
pancreatic insufficieny as observed in CF patients. Importantly, gene transfer in CF pigs 
may help to answer the key question, if gene therapy can ameliorate clinically aspects of 
the CF lung disease. 
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Increasing tight junctional permeability in CF human airways causes some concern as 
this could potentially release bacteria to the basolateral surface and eventually the 
circulation. The potential consequences of this should be addressed before this strategy 
is used in clinical studies. Until CF pigs with CF-like bacterial lung infection are readily 
available, other bacterial infection models could be employed to determine the safety of 
tight junction openers in infected airways as opening of the tight junctions may allow 
bacteria in infected airways access to the systemic circulation. For example, tracheal 
delivery of Pseudomonas aeruginosa-laden agarose beads has been employed to 
generate a murine model of chronic bacterial lung infection [362,422]. However, 
clinically more relevant larger animal infection models have not yet been established. 
Therefore, development and characterisation of, for example, an ovine bacterial lung 
infection would be the first step towards addressing the concern regarding bacterial 
escape after administration of tight junction openers.  
 
Alternatively, the effect of C10 on other non-viral gene transfer agents, such as PEI and 
DNA nanoparticles, could be assessed [178,188]. The small size of DNA nanoparticles 
may ease the transport of this non-viral vector through the open tight junctions, thereby 
resulting in increased basolateral uptake and enhanced gene transfer efficiency. 
Although the size of GL67 and PEI is not markedly different, the overall charge of the 
two non-viral gene transfer agents when complexed to negatively charged DNA is 
likely to differ and this may influence the transport of the GTA through the tight 
junction and, thereby, affect access to the basolateral surface. Pre-treatment with C10 
may, therefore, result in a greater increase in PEI-mediated gene transfer efficiency 
compared to GL67.  
 
Although, Gregory et al have shown that the significant enhancement of adenovirus-
mediated gene transfer to the murine airways after pre-treatment with C10, is not further 
enhanced by pre-treating with a combination of C10 and EGTA, pre-treating mice with 
C10 combined with a different class of tight junction opener may result in increased 
GL67-mediated gene transfer [141]. 
 
As described different approaches can be pursued to assess further the effect of C10 on 
non-viral gene transfer to the airways. However, the data presented in this thesis do 
highlight a relatively narrow toxicity-efficacy window and the key question is whether 
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this narrow window will be sufficient to significantly improve airway gene transfer and 
lead to correction of clinically relevant endpoints in CF patients. The additional pre-
clinical experiments described above may, in part address this question, and help to 
decide, if assessment of tight junction openers in CF gene therapy clinical trials is 
warranted. 
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Appendix 1: Overview of in vivo experiments with TJ-openers 
 
TJ- 
opener 
Delivery method [TJ-opener] TJ-
opener 
volume 
Pre-
treatment 
time 
Nebulisation 
time 
Assessment  Figure 
No. 
EGTA 
EGTA nasal instillation 
GL67/pCIKLux nebulisation 
0.05 M 
0.2 M 
0.4 M 
50 µl 30 min 1 hr Lux expression (lung) 31 
EGTA 
EGTA nasal instillation 
GL67/pCIKLux nebulisation 
0.2 M 
0.4 M 
50 µl 
25 µl 
30 min 1 hr 
Lux expression (lung) 
Lux expression (nose) 
32 
33 
EGTA 
EGTA nasal instillation 
GL67/pCIKLux nebulisation 
0.2 M 
0.4 M 
50 µl 
25 µl 
30 min 1 hr Histology (lung) 
35 
36 
EGTA 
EGTA and GL67/pCIKLux  
co-administration  
0.05 - 0.5 M    Lux expression in vitro 37 
EGTA 
EGTA and GL67/pCIKLux  
co-nebulisation 
0.5 M   
30 min 
1 hr 
2 hrs 
Lux expression (lung) 
Histology (lung) 
38 
39 
EGTA  
GL67/pCIKLux nebulisation  
EGTA nebulisation 
GL67/pCIKLux nebulisation  
1 M 10 ml  
30 min 
1 hr 
30 min 
Lux expression (lung) 40 
EGTA EGTA nasal instillation 0.05 M 50 µl   TJ permeability (lung) 
41 
42 
EGTA EGTA nasal instillation 0.4 M 25 µl  
 
TJ permeability (lung) 
43 
44 
 
3
9
6
 
 
2 
 
 
TJ- 
opener 
Delivery method [TJ-opener ] TJ-
opener 
volume 
Pre-
treatment 
time 
Nebulisation 
time 
Assessment  Figure 
No. 
C10 
GL67/pCIKLux nebulisation  
C10 nebulisation 
GL67/pCIKLux nebulisation  
0.05 M 10 ml  
30 min 
1 hr 
30 min 
Lux expression (lung) 
Lux expression (nose) 
49 
50 
C10 
C10 nebulisation 
GL67/pCIKLux nebulisation 
0.05 M 40 ml  
4 hrs 
1 hr 
Lux expression (lung) 
Lux expression (nose) 
51 
C10 C10 nasal instillation 0.05 - 0.5 M 25 µl   Max. tolerable concentration  
C10 C10 nasal instillation 0.5 M 25 µl   Histology (internal organs)  
53 
54 
55 
C10  
C10 nasal instillation 
GL67/pCIKLux nebulisation 
0.05 M 25 µl 
10 min 
1 hr 
2 hrs 
4 hrs 
1 hr 
Lux expression (lung) 
Lux expression (nose) 
56 
C10  
C10 nasal instillation 
GL67/pCIKLux nebulisation 
0.05 M 
0.2 M 
25 µl  2 hrs 1 hr 
Lux expression (lung) 
Lux expression (nose) 
Histology (lung) 
58 
59 
61 
 
 
 
 
3
9
7
 
3 
 
TJ- 
opener 
Delivery method [TJ-opener ] TJ-
opener 
volume 
Pre-
treatment 
time 
Nebulisation 
time 
Assessment  Figure 
No. 
C12 C12 nasal instillation 
0.05 M 
0.2 M 
25 µl   Max. tolerable concentration  
C12 C12 nasal instillation 0.2 M 25 µl   Histology (internal organs) 
62 
63 
64 
C12 
C12 nasal instillation 
GL67/pCIKLux nebulisation 
0.01 M 
0.05 M 
25 µl 2 hrs 1 hr 
Lux expression (lung) 
Lux expression (nose) 
65 
C12 
C12 nasal instillation 
GL67/pCIKLux nebulisation 
0.05 M 
0.2 M 
25 µl 2 hrs 1 hr 
Lux expression (lung) 
Lux expression (nose) 
Histology (lung) 
66 
67 
68 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
9
8
 
4 
 
TJ- 
opener 
Delivery method [TJ-opener] TJ-
opener 
volume 
Pre-
treatment 
time 
Nebulisation 
time 
Assessment  Figure 
No. 
LPC LPC nasal instillation 
0.1% 
0.3% 
1% 
2% 
25 µl   Max. tolerable concentration  
LPC LPC nasal instillation 2% 25 µl   Histology (internal organs) 
70 
71  
72 
LPC 
LPC nasal instillation 
GL67/pCIKLux nebulisation 
0.3% 
1% 
25 µl 1 hr 1 hr 
Lux expression (lung) 
Lux expression (nose)  
Histology (lung) 
73 
76 
77 
LPC  
LPC nasal instillation 
GL67/pCIKLux nebulisation 
0.1% 
0.3% 
25 µl 2 hrs 1 hr 
Lux expression (lung) 
Lux expression (nose)  
74 
LPC 
LPC nasal instillation 
GL67/pCIKLux nebulisation 
0.3%  25 µl 
10 min 
1 hr 
1 hr 
Lux expression (lung) 
Lux expression (nose)  
75 
 
 
 
 
 
 
 
3
9
9
 
 
5 
 
TJ- 
opener 
Delivery method [TJ-
opener] 
TJ-
opener 
volume 
Pre-
treatment 
time 
Perfusion 
time 
Assessment  Figure 
No. 
 
GL67/pCIKLux nasal perfusion 
v 
GL67/pCIKLux nebulisation    
15 min Lux expression (nose) 80 
C10 C10 nasal perfusion 
0.0125 M 
0.05 M 
0.2 M 
100 µl  15 min Max. tolerable concentration  
C10 
C10 nasal instillation 
v 
C10 nasal perfusion 
 
 
 
GL67/pCIKLux nasal perfusion 
0.2 M 
 
0.05 M  
0.0125 M 
 
 
 
25 µl 
 
100 µl 
400 µl 
 
 
 
2 hrs 
 
2 hrs 
2 hrs 
 
 
 
 
 
15 min 
1 hr 
 
 
15 min 
Lux expression (nose) 81 
C10  
C10 nasal instillation 
GL67/pCIKLux nasal perfusion 
0.2 M 25 µl 2 hrs 15 min 
Lux expression (nose): 
FABp v C57Bl/6 
82 
C10 
C10 nasal instillation 
GL67/pCIKLux nasal perfusion 
0.05 M 
0.2 M 
25 µl 2 hrs 15 min Lux expression (nose) 83 
C10  C10 nasal instillation 
0.05 M 
0.2 M 
25 µl   NPD (30 min - 5 days) 84 
 
 
4
0
0
 
 
      
 
6 
 
TJ- 
opener 
Delivery method [ TJ-
opener ] 
TJ-
opener 
volume 
Pre-
treatment 
time 
Perfusion 
time 
Assessment  Figure 
No. 
C10  C10 nasal instillation 
0.05 M 
0.2 M 
25 µl   
Histology (2 hrs, 48 hrs, 14 days)  
NPD (2 hrs, 48 hrs, 14 days) 
87 
88 
C10  
C10 nasal instillation 
GL67/pCIKLux nasal perfusion 
0.05 M 25 µl 2 hrs 15 min 
Lux expression (nose): 
24 hrs v 48 hrs 
89 
C10  
C10 nasal instillation 
GL67/pCIKCFTR nasal perfusion 
0.05 M 25 µl 2 hrs 1 hr 
Baseline NPD 
Low chloride response 
91 
C10 
C10 nasal instillation 
GL67/pCIKCFTR nasal perfusion 
0.05 M 25 µl 2 hrs 1 hr CFTR mRNA (48 hrs) 92 
C10 
C10 nasal instillation 
GL67/pCIKLux nasal perfusion 
0.05 M 25 µl 2 hrs 15 min Luciferase mRNA (48 hrs) 93 
C10 GL67/pGM144 nasal perfusion    15 min Lux expression (1, 7, 14 days) 94 
C10  
C10 nasal instillation 
GL67/pGM169 nasal perfusion 
0.2 M 25 µl 2 hrs 1 hr CFTR mRNA (14 days) 95 
C10  
C10 nasal instillation 
GL67/pEGFP-N1 nasal perfusion 
0.05 M 
0.2 M 
25 µl 2 hrs 1 hr Histology (GFP expressing cells)  
96 
97 
 
 
 
4
0
1
 
 
